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2Abstract
Rheumatoid arthritis (RA) is a chronic inflammatory disease with a significant impact
on patients’ quality of life. One of the well-described features in RA is hypoxia. It has been
shown that both RA synovial fluid and synovial tissue are characterised by insufficient
amount of oxygen. Abnormality in hypoxia-inducible factor (HIF) expression is a marker of
decreased oxygen tension in RA and in other pathological conditions. HIFs, together with the
proteins which regulate their stabilisation and transactivation, namely prolyl hydroxylase
domain (PHD) enzymes and factor inhibiting HIF-1 (FIH-1), were the main focus of this
thesis.
The first aim of the study was to investigate the specific roles of HIF isoforms in RA
fibroblast-like synoviocytes (FLS), which are the key cells in RA pathogenesis. Expression of
HIF-1, HIF-2 and a panel of genes involved in angiogenesis (ANGPTL-4, ephrin-A3,
VEGF), glycolysis (GLUT-1, ENO-1), pH regulation (CA9) and apoptosis (BNIP-3) were
significantly increased by hypoxia. Successful silencing of both HIFs using short interfering
RNA (siRNA) was achieved in RA FLS, and was followed by examination of the HIF-
dependence of the candidate genes. The majority of these genes were found to be HIF-1-
dependent, whereas only ANGPTL-4 and VEGF were regulated by both HIF-1 and HIF-2.
Subsequently, the mRNA and protein expression of PHDs and FIH-1 in RA FLS, their
response to hypoxic conditions and their HIF-dependence were examined. Specific
knockdown of the hydroxylases was performed and the effects on HIFs and genes of interest
were assessed. The most significant changes were noticed after silencing PHD-2, which led to
HIF- stabilisation and upregulation of HIF-dependent genes. In addition, PHD-2 depletion
increased a number of pro-angiogenic genes and also contributed to new tubule formation in a
functional angiogenesis assay. Comparison of RA, osteoarthritis (OA) FLS and normal
human dermal fibroblasts (NHDF) revealed that PHD-2 has similar functions in promoting
neovascularisation in arthritic cells (RA and OA), but not in non-arthritic cells (NHDF).
Finally, the last chapter describes preliminary data on the expression of the least investigated
HIF-3 subunit and its negative splice variant, HIF-34, in RA FLS.
This research contributes to a better understanding of the upstream and downstream
regulation of HIF signalling in RA, showing that PHD-2 has a key role in regulating hypoxic
responses via HIFs in RA FLS. Because this pathway controls the expression of so many
genes relevant to the disease, it may be an important target for RA therapy. One of the most
critical challenges would be to target the correct HIF/PHDs molecule in the right tissue/cell,
ensuring that it will not affect angiogenesis in healthy tissues.
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TBP TATA-binding protein
TBS tris-buffered saline
TBST tris-buffered saline plus
Tween20
TGF transforming growth factor
Tm melting temperature
TMB 3,3’,5,5’-tetramethylbenzidine
TNF tumour necrosis factor
TNFR tumour necrosis factor receptor
t0 time zero
u unit
U untreated
uPAR urokinase plasminogen activator
receptor
UV ultra-violet
V volt
VCAM vascular cell adhesion molecule
VEGF vascular endothelial growth
Factor
VEGF-R VEGF receptor
VHL von Hippel-Lindau tumour
suppressor
XIAP X-linked inhibitor of apoptosis
protein
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1 INTRODUCTION
1.1 The rationale of the project
Rheumatoid arthritis (RA) is a chronic autoimmune systemic disease of unknown
aetiology. The current hypothesis of RA pathogenesis favours the interplay between genetic
factors, autoimmunity, environment, sex hormones and possibly an infectious agent. RA may
appear at any time of life but usually begins at the age of 30 and 50, and women are affected
three times as frequently as men. RA is characterised by inflammatory and destructive
features with pain and stiffness affecting multiple joints, most commonly those with the
highest ratio of synovium to articular cartilage. In addition, muscles near inflamed joints often
atrophy, which may lead to fatigue and weakness, whereas affected tendons and ligaments
account for tissue swelling due to tenosynovitis (Figure 1.1).
Figure 1.1 The hands of an RA patient
35-year old female with RA for 4 years shows swollen, red and inflamed joints.
The major demonstration of RA is in the synovial joints; however, it may involve a
wide range of organs. The systemic inflammation is manifested by increased rheumatoid
factor (RF), erythrocyte sedimentation rate (ESR) or acute phase markers such as C-reactive
protein (CRP). Other systemic symptoms include vasculitis, inflammation in lungs, anaemia
and weight loss. Cardiovascular manifestations such as pericarditis, ischemic heart disease
and myocardial infarction are the main reasons for elevated morbidity and mortality of RA
patients (Van Doornum et al 2006).
Several immune and inflammatory cell types are actively involved in the
pathogenesis of RA such as T cells and B cells, by secreting a variety of cytokines,
chemokines and antibodies. The attention, however, is also directed towards the residing
fibroblast-like synoviocytes (FLS). FLS maintain the homeostasis in the normal joint, provide
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components for synovial fluid and extracellular matrix, and create architecture of the synovial
membrane. In the affected RA synovium, FLS are potential initiators and perpetuators of
pathological hyperplasia, inflammation and angiogenesis. Moreover, FLS are able to attach
and invade articular cartilage contributing to the bone destruction observed in the RA joint.
In patients diagnosed with RA the first options of treatment are the classic disease
modifying anti-rheumatic drugs (DMARDs) for example methothrexate, sulfalazine and
leflunomide, with a dose of glucocorticoids (e.g. dexamethasone) or non-steroidal anti-
inflammatory drugs (NSAIDs) for instance ibuprofen, indomethacin, cyclooxygenase (COX)-
2 inhibitors (e.g. celecoxib). Alone or in combined therapy this management of RA
extinguishes inflammation and restrains disease progression. However, current treatment only
partially controls disease activity and by having adverse effects limits prolonged
administration.
The introduction of tumour necrosis factor- (TNF- blocking agents to clinical
practice by Maini and Feldmann (Maini et al 1999) was a milestone in RA therapy.
Monoclonal antibodies which block TNF-, namely infliximab, adalimumab, golimumab and
certolizumab, are approved for use in RA, together with TNFR2 fusion protein, etanercept.
This innovative approach of targeting RA induced an avalanche of a new class of biological
drugs, also called biological DMARDs (summarised in Table 1.1). However, the statistics
reveals a lack of or losing clinical responses in approximately 30% of patients receiving TNF-
 blockers, which are still the most effective treatment. It indicates that other TNF-
independent pathways existing in RA are involved in inflammation and joint destruction. In
addition, anti-TNF- treatment has been associated with adverse side effects including
increased risk of tuberculosis, usually by reactivation of latent infection (Hamilton 2004),
worsening of pre-existing heart conditions and skin lesions (Voulgari et al 2008).
In recent years therapeutic options with novel mechanisms of action have been
introduced in non-responders to anti-TNF- treatment. These include humanised monoclonal
antibody targeting interleukin (IL)-6 receptor (tocilizumab) and recombinant IL-1 receptor
antagonist (anakinra), with relatively high efficacy especially when combined with
methotrexate. Also immune cells that are crucial to the mechanisms of joint inflammation and
destruction have been targeted in RA therapy. Cytotoxic T lymphocyte associated antigen
(CTLA)-4 on T cells downregulates the immune response by binding to co-stimulatory
molecules on T cells (CD28) and on the antigen-presenting cells (APCs) such as CD80 and
CD86, thereby inhibiting T cell activation. Abatacept, developed as a CTLA-4Ig fusion
protein, which blocks the interaction between T cells and APCs, has proven successful. B
cells also contribute to inflammation by producing (auto)antibodies, cytokines and
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chemokines, as well as acting as central APCs. The monoclonal antibody, rituximab, directed
against the surface molecule on B cells (CD20) has been shown to reduce signs and
symptoms of RA through depletion of normal and malignant B cells (Andersson et al 2008).
Table 1.1 A summary of biological DMARDs used in RA
Biological
DMARDS
Trade name Company Description
Infliximab Remicade Centocor/
Schering-Plough
TNF inhibitor, a chimeric MoAb
Etanercept Enbrel Amgen/ Wyeth TNF inhibitor, a fusion protein
containing the ligand-binding portion
of the soluble TNFR2 (p75)
Adalimumab Humira Abbott TNF inhibitor, a fully human MoAb
Golimumab Simponi Centocor TNF inhibitor, a fully human MoAb
Certolizumab pegol Cimzia UCB TNF inhibitor, pegylated Fab’ fragment
lacking Fc
Anakinra Kineret Amgen IL-1 inhibitor, recombinant IL-1R
antagonist
Rituximab Rituxan Biogen-Idec/
Roche
A chimeric MoAb binding CD20
targeting B cells
Abatacept Orencia Bristol-Myers
Squibb
A fusion protein binding CD28
targeting T cells
Tocilizumab RoActemra Chugai/ Roche IL-6 inhibitor, a humanised MoAb
binding IL-6R
Abbreviations: DMARDs - disease-modifying anti-rheumatic drugs, MoAb – monoclonal antibody.
Depending on the therapy the efficacy is only seen in about half of the patients,
usually when at least two drugs are combined. The genetic background of RA together with
environmental influences determines which subset of patients belongs to TNF-dependent, B
cell-dependent, or T cell-dependent disease. It is crucial to identify the differences between
responders and non-responders to these treatments for instance by gene profiling studies.
Moreover, there is a constant search in every pathological aspect of RA involving different
cell types to find newer anti-rheumatic targets and eventually new therapies. There are a
number of agents awaiting therapeutic assessment such as kinases (including SYK and JAK),
RANK/RANKL inhibitors, metalloproteinases and adhesion molecules, all involved in the
development of RA.
Augmented and unstable vasculature is a prominent feature of RA joints. Synovial
angiogenesis may facilitate other pathological features of RA, including synovitis through
influx of inflammatory cells and molecules, and hyperplasia of synovial tissue, which as the
cell number expands the tissue requires more blood vessels. Angiogenesis is driven by the
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balance between angiogenic and angiostatic factors. Many pro-angiogenic growth factors are
produced in the synovium, including vascular endothelial growth factor (VEGF), fibroblast
growth factor (FGF), tumour necrosis factor (TGF), epidermal growth factor (EGF) and
platelet-derived growth factor (PDGF). Also molecules facilitating neovessel formation such
as chemokines, adhesion molecules and matrix metalloproteinases are found in the RA
synovium. RA together with other inflammatory diseases has been classified as an
angiogenesis-dependent disease (Folkman 2007). It is believed that angiogenesis inhibitors
could serve as a therapeutic approach, therefore many studies in arthritis models in mice and
rats have been performed. Gene therapy using viral vectors to deliver endostatin,
thrombospondin-1 or soluble Tie2 receptor inhibited disease onset and reduced the number of
vessels. Administration of anti-proliferative and anti-angiogenic methoxyestradiol reduced
synovial blood vessels and disease severity (Brahn et al 2008). Also blockade of VEGF has a
great potential in RA, since it has been demonstrated that targeting VEGF and VEGFR-1 (a
naturally occurring VEGF antagonist) with antibodies suppressed arthritis in established
murine collagen induced arthritis (CIA) model, reduced neovascularisation and the severity of
the symptoms (Choi et al 2009). In addition, the efficacy of bevacizumab (monoclonal anti-
VEGF antibody) in metastatic colorectal cancer is well described, and bevacizumab is now
also approved for certain types of lung, kidney and brain tumours (Thairu et al 2011). These
studies support the importance of angiogenesis in RA development (Westra et al 2010).
The third driving force of RA, next to angiogenesis and inflammation, is local tissue
hypoxia. Due to the hyperplastic tissue with insufficient perfusion, hypoxic feature of RA is
the rapid protein stabilisation and accumulation of hypoxia-inducible factor, HIF-1, which
when dimerised with HIF-1 creates a functional transcription factor (Semenza and Wang
1992). In addition to widely distributed HIF-1, two other members of this family, HIF-2
and HIF-3, have been identified with more restricted expression patternAccumulation of
HIF- appears at the range of oxygen tensions between 0 – 7% O2 (Jiang et al 1996),
concluding that the tolerance of HIFs to oxygen varies between the cell types and tissues.
HIFs protein is regulated by oxygen-dependent prolyl hydroxylase domain (PHD) and factor
inhibiting HIF-1 (FIH-1) enzymes, which activity decreases with declining oxygen tensions.
Thus hypoxia results in HIF- stabilisation, heterodimerisation, DNA binding and eventually
activation of target genes, including VEGF (Ivan et al 2001; Jaakkola et al 2001). Of the four
identified PHD enzymes, PHD-2 is thought to be the main oxygen sensor, since silencing
PHD-2 results in increased HIF accumulation (Berra et al 2003). The importance of PHD-2
has been highlighted in several recent studies demonstrating the importance in angiogenesis
of a tumour and vascular normalisation by the stromal cells such as endothelial cells (Chan
and Giaccia 2010).
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Immunohistochemical studies revealed that HIF-1 is associated with areas of
hypoxia in the RA joints (Hollander et al 2001) and that decreased oxygen tension correlates
with synovial proliferation (Lee et al 2007b), inflammation (Ng et al 2010) and angiogenesis
in RA (Kennedy et al 2010). Dysregulated tissue oxygenation and dysfunctional vasculature
in RA trigger hypoxia-reperfusion injury of the joints creating redox milieu, which can lead to
tissue damage caused by generated reactive oxygen species (Bonello et al 2007). The
literature demonstrating HIF- involvement in many different aspects of the disease
pathology is increasing (Gaber et al 2005), therefore this molecule is also considered a
potential target for RA intervention (Westra et al 2010).
Modulating HIF- can be achieved at multiple levels, mainly regulating HIFs
translation and transcriptional activity, employing small molecule drugs and chemical entities
(Rey and Semenza 2010). In the specific case of RA, promoting angiogenesis is suggested to
be the most important role of HIFs. RA FLS, which were transfected with lentiviruses
expressing siHIF-1 or treated with chetomin (a HIF inhibitor), or bevacizumab (monoclonal
antibody anti-VEGF) then re-suspended in Matrigel and injected into SCID mice, shown the
reduction in cell infiltration and vessel formation in the implants, and also decreased HIF-
and VEGF expression (Del Rey et al 2009). Cramer and colleagues have shown that
macrophages and neutrophils with post-natally disrupted HIF-1 (Cre-lox technique) in the
passively-induced mice model of arthritis have impaired inflammation response, reduced joint
swelling, cell infiltration, pannus formation and cartilage destruction (Cramer et al 2003). An
inhibitor of histone deacetylase (FK228) administrated intravenously in CIA model blocked
angiogenesis in synovial tissue, decreasing VEGF and HIF-1 (Manabe et al 2008). In
addition, another molecule (BP-1, synthetic benzophenone analogue) has been shown in vivo
in the AIA rat model to be anti-angiogenic and anti-inflammatory, reducing levels of HIF-1
and VEGF (Shankar et al 2009). Even more studies have been done on cancer models
investigating the outcome of inhibiting HIFs. Targeting HIF-1 expression with another
inhibitor, NCS-134754, in renal cell carcinoma (RCC)-4 reduced angiogenesis by decreasing
VEGF expression (Chau et al 2005). Small molecule inhibitors of the HIF-1 pathway, which
may have anti-angiogenic and anti-cancer activities, include the topoisomerase inhibitor
topotecan, which can repress HIF activity and inhibit transcription of well characterised HIF
target genes, including VEGF (Rapisarda et al 2002). A pilot clinical trial, the results of
which have just been published, has shown decreased levels of VEGF and GLUT-1, together
with a reduction in HIF-1, in patients with advanced solid tumours following oral topotecan
(Kummar et al 2011), and such approaches might also be useful in RA.
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In addition to targeting HIF molecules specifically, it would be possible to regulate
their actions via HIF upstream modifiers such as PHD, some of which are believed to be
involved in the negative feedback loop. It has been recently identified that PHD-2 is a potent
mediator of tumour angiogenesis (Chan et al 2009) and also an important contributor of
vessel normalisation (Mazzone et al 2009). However, the role of PHDs in RA has not been
defined yet.
Since angiogenesis is a part of the adaptive response of tissue to hypoxia and it
certainly contributes to RA, starving a tissue of blood vessels and as a consequence of oxygen
is a concept extrapolated from tumour biology. Therefore drugs, both endogenous inhibitors
and synthetic compounds, which were developed for targeting angiogenesis in cancer, are
now being widely examined in various in vivo models of RA. In addition, therapies currently
used in RA to control inflammation such as TNF- blockers, glucocorticoids and some
DMARDs have been already tested and shown to reduce VEGF, blood vessel formation and
the number of swollen joints (Taylor 2002). Moreover, HIF- inhibition has been
demonstrated to be effective in different in vivo models, decreasing inflammatory cell ingress
and disease severity (Cramer et al 2003), and reducing VEGF levels and angiogenesis (Del
Rey et al 2009). These facts of interdependence between angiogenesis, inflammation and
hypoxia further enhance the link between HIF and these pathological conditions.
By regulating genes involved in erythropoiesis, angiogenesis, proliferation and
metastasis, HIFs are believed to be involved in both physiology (development) and
pathophysiology (tumourigenesis), both of which are characterised by rapid cell proliferation
and thus hypoxia. It is crucial to carefully scrutinise contrasting or unite effects of HIF-1
and HIF-2 on target genes in the aspect of hypoxic diseases, since they may contribute to
progression or regression of disease.
RA is a complex disease itself being regulated by hundreds of mediators. Agents with
multiple actions such as PHD or HIF may be more effective in treatment than targeting a
single molecule. A combined therapy would be expected to be the most efficient by having
antiinflammatory, antiangiogenic and preferentially to some extent immunosuppressive
activities. From the literature presented above, it becomes apparent that HIF and the upstream
regulators, especially PHD-2, is undoubtedly an interesting and potential molecule to
manipulate in RA in order to gain a medical benefit. Therefore, a better understanding of
biology of the PHD-HIF axis may lead to the development of new therapies.
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1.2 Research objectives
The RA synovium is characterised by hypoxic and inflamed milieu, which drives
angiogenesis. RA FLS, which are at the edge of the invasive pannus, are believed to be
exposed to the greatest degree of hypoxia. The expression of both -subunits was clearly
demonstrated to be increased in these residing cells. RA FLS also secrete large amounts of
angiogenic factors and inflammatory cytokines, which together with hypoxia/HIF are
believed to induce the changes in the gene and protein profile of these cells.
It is well established that the HIF pathway coordinates the cellular responses to hypoxia
in RA pathogenesis and progression for instance via angiogenic response. The expression
pattern of both HIF- isoforms in RA joint differs slightly, forming the basis for the
suggestion that they may have distinct roles in RA. The first aim of my project was to
distinguish the roles between HIF-1 and HIF-2 in RA FLS, identifying unique and novel
HIF targets. To achieve it a specific HIF inhibition was performed applying siRNA approach.
The role of the least well-described HIF- subunit, HIF-3 was also examined.
The second part of the project aimed to examine the roles of upstream regulators of
HIFs, PHDs and FIH. It is well established that some of the dioxygenases, PHD-2 and PHD-
3, contain HRE and are HIF--dependent, and thus are involved in the negative feedback loop
of the HIF pathway. It was of interest to investigate hydroxylation specificity of these
enzymes towards -subunits and the effects downstream of HIF. In order to investigate the
cell specificity in the PHD-HIF regulation, FLS from RA patients, as well as OA FLS and
NHDF, were compared.
The hypothesis of this study was therefore that RA FLS may contribute to RA
pathogenesis and progression, partly as a consequence of hypoxia and thus PHD-HIF
pathway. The research planned within the framework of the project aimed to address the
following key questions:
1. Which HIF isoforms are responsible for controlling different biological responses, in
particular those relevant to angiogenesis, in RA FLS?
2. What is the role of individual HIF hydroxylases in the regulation hypoxic responses
in RA FLS?
3. Does silencing PHD-2 and PHD-3 have functional consequences in RA?
4. What are the differences in hypoxic responses between arthritic (OA and RA FLS)
and healthy, non-arthritis fibroblasts (NHDF)?
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2 BACKGROUND
2.1 Importance of oxygen in physiology and pathology
Oxygen is an inevitable component of life. Oxygen is the most abundant element by
mass in the Earth’s crust making up almost half of the crust’s mass (49.2%). The diatomic gas
with the formula O2 is by the volume the second major constituent of air (20.95%) after
nitrogen (N2; 78.09%). Oxygen is used in cellular respiration in the living organisms and
serves as a terminal electron acceptor in mitochondria to generate energy stored as adenosine
triphosphate (ATP) molecules. ATP synthesis is driven by an electrochemical gradient and is
maintained by oxidative metabolism of glucose and fatty acids in the mitochondria,
generating reducing molecules in the respiratory chain.
Most organisms including bacteria, yeast, invertebrates and vertebrates require
oxygen for survival. Extraction and distribution of oxygen has been conserved through
evolution by the development of specialised systems such as the respiratory and
cardiovascular system. Mammalian life is restricted to a narrow range of oxygen tensions and
breathing is the most significant limiting factor. People can survive without food for 40 days
and without water for approximately 4 days, but only for up to 4 minutes without oxygen.
Deprivation of an adequate oxygen supply is called hypoxia and in some cases it can be fatal.
Interestingly, during normal tissue growth such as embryogenesis mammals are relatively
resistant to a lowered oxygen percentages, where the only source of oxygen for the foetus is
via foetal haemoglobin, which has high affinity to oxygen acquired from the mother’s
erythrocytes. The embryo is not only resistant to hypoxia, but indeed a highly hypoxic
environment is required, as it regulates cellular differentiation (Morriss and New 1979).
Highlanders have a much higher capacity for oxygen absorption than lowlanders, since
their bodies have adapted to high altitudes for centuries. For instance, monks in Tibet or
shepherds in Nepal living on the Tibetan plateau (the world’s highest plateau), have increased
nitric oxide (NO), which vasodilates blood vessels and relaxes vascular smooth muscle cells
to increase the oxygen extraction from air. On the other hand, inhabitants of the Altiplano
plateau (in Andes, the second highest plateau in the world) are described as barrel-chested and
short in stature with big lungs to facilitate exchange of gases. In addition, muscles and heart
are able to endure oxygen deprivation by blocking some parts of the circulation system,
slowing down the cardiac rhythm and switching from aerobic to anaerobic metabolism.
Sustaining oxygen reduction for several hours or months is observed in some animals, which
substantially lower the intensity of metabolic rate during hibernation (hedgehogs, bats, mice,
bears) or aestivation (snails, frogs, crabs, crocodiles, lemurs).
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In addition, although water dissolves oxygen easily oxygen deprivation also occurs in
aquatic environments, which can be caused by humans or arise naturally. It happens for
instance due to pollution or the presence of excess nutrients in the water, which triggers
extensive growth of algae and plankton blooming (eutrophication), reducing the sunlight that
penetrates the water and decreasing the amount of dissolved oxygen. Moreover, overgrowth
of the organic matter is decomposed by bacteria, which consume available oxygen, thus
destroy the habitat of aquatic animals and plants. Gulf of Mexico is one of the well-
recognised regions in the world where the water near the sea floor is hypoxic.
An adult human in rest inhales 1.8 – 2.4 grams of oxygen per minute. However,
oxygen can have detrimental effect on our health when consumed in excess. An increased
oxygen content, termed hyperoxia, can lead to oxygen toxicity syndrome/oxygen poisoning.
Hyperoxia occurs in parallel with excessive angiogenesis in the organ or when inordinate
oxygen is delivered clinically to the patients. Hyperoxia is a concern for scuba divers,
astronauts, pre-mature newborns and people using hyperbaric oxygen therapy or recreational
oxygen cafeterias. Inspiring pure oxygen improperly dosed can lead to changes in the lungs,
eyes and brain. This is happening mainly due to increase in reactive oxygen species (ROS)
which destroy the molecular structure of cells and their membranes, resulting in the collapse
of the alveoli in the lungs or retinal detachment causing blindness.
2.2 Hypoxia
Oxygen tension is expressed as percentage of oxygen (% O2), which is the volume of
air that perfuses the aqueous solutions, or it is indicated as millimetre of mercury (mmHg)
defined as the pressure exerted at the base of the column of fluid exactly 1mm high, where the
density of fluid is 13.6g/cm3 at the place where acceleration of the gravity is 9.8m/s2.
Hypoxia is defined as an abnormal level of oxygen in the air, blood and tissue,
whenever oxygen demand exceeds oxygen supply. Oxygen tensions in physiological
conditions in mammals vary greatly and lie in the 1 - 15% O2 range. For instance, arterial
blood contains 15% O2 and venous blood 6% O2. Oxygen concentration in joint synovium
from healthy individuals ranges from 9 to 12% O2 (Sivakumar et al 2008). In the kidney
medulla, bone marrow niches, thymus or articular cartilage it can be even 1% O2 due to
atypical blood vessel networks (Simon et al 2008). Usually ex vivo studies describe normoxia
as 20 - 21% O2 (~150 mmHg), which is the ambient air oxygen concentration. Generally
hypoxic experiments in vitro are performed between 0.5 and 3% O2; however, as presented
above this oxygen percentage can be normoxic in physiological conditions in some organs
(Bertout et al 2008). Therefore for experimental purposes it is crucial to choose a proper
oxygen concentration.
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There are different kinds of hypoxia depending on the cause. (i) Ischemic hypoxia is a
result of shortage of the blood supply, i.e. a shortage of oxygen, to an organ due to a blockage
of the arteries or veins supplying it. (ii) Hypoxic hypoxia which causes hypoxemia (decreased
oxygen level in blood) is usually a result of lowered oxygen level in the air being breathed at
high altitudes, or because of the failure of ventilation by the lungs during for instance chronic
obstructive pulmonary disease. (iii) Anemic hypoxia refers to haemoglobin deficiency due to
inadequately circulating erythrocytes (anemia) or inability of haemoglobin to carry the
oxygen for instance during carbon monoxide (CO) poisoning, or because haemoglobin has
too ‘high affinity’ to oxygen deterring its release in the tissue (hemoglobinopathies). (iv)
Histotoxic hypoxia is the inability of tissue to accept and utilise oxygen from the bloodstream
resulting from tissue poisoning caused by alcohol, narcotics or cyanide, leading to the
cytochrome complexes failure. (v) Tissue hypoxia is present in highly metabolically active
tissue, such as that found in solid tumours and the expanding RA synovium.
Hypoxia is one of the most important features of solid tumours, and hypoxic cells are
three times more radioresistant than well-oxygenated cells. The knowledge about the
oxygenation status of the tumour using a simple clinical test can help predict the effectiveness
of radio- and chemotherapy, the optimisation of treatment and also patient survival prognosis
(Beasley et al 2002; Koukourakis et al 2002). The level of oxygenation can be assessed
indirectly by measuring vascular density (poor vascularisation is indicative of the level of
hypoxia in tumours) or intrinsic markers (oxygen-regulated proteins or mRNA, including
carbonic anhydrase, pyruvate kinase or lactate dehydrogenase). Other methods include P31-
signal measured by nuclear magnetic resonance spectroscopy and bioreductive chemical
probes metabolically activated, like pimonidazole (misonidazole), a nitroaromatic compound
which binds only to cells with decreased oxygen tension or the widely used ex vivo method,
cryospectrophotometric measurement of oxyhaemoglobin (Bertout et al 2008). The best
method so far is polarographic measurement with microelectrodes, which provides a direct
measurement of oxygen tension (Moeller et al 2007). However, even today scientists lack an
optimal direct tissue oxygen measurement method that is non-invasive, precise and
quantitative; therefore it is crucial to find a reliable method for measuring oxygen tension.
Anemia, hemorrhage and pneumonia belong to a group of so-called hypoxic diseases.
Hypoxia concerns also ‘modern’ ailments such as lung diseases related to smoking,
atherosclerotic cardiovascular disease, obesity and solid tumours, where the oxygen supply
cannot keep up with the intensively proliferating tissue mass. Additionally, hypoxia is a
feature of rheumatoid arthritis (RA) and is thought to contribute to the development and
maintenance of RA. Hypoxia and RA have been the main subjects of this thesis.
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2.2.1 TISSUE RESPONSES TO HYPOXIA
Lowland residents while ascending the mountains or during any sport exercise where
the altitude is a factor (e.g. skydiving) are exposed to non-physiological amounts of oxygen.
Already at 3,000m (10,000ft) or higher the body can respond very dramatically to bigger
demands of oxygen, resulting in hypoxia in the bloodstream. Some of the symptoms of
inadequate oxygenation include heart palpitations, shortness of breath, headache, dizziness,
distorted vision and rapid loss of consciousness, which can cause coma or death due to liquid
accumulation in the lungs and the brain. By regulating hematopoietic, respiratory, and
cardiovascular physiology both tissues and cells operate together to acclimatise and minimise
injury by restoring adequate oxygenation.
Decreased oxygen tension in the blood is sensed by the carotid bodies (a small cluster
of chemoreceptors), which are located at the bifurcation of the common carotid arteries,
activates the cardiovascular and respiratory centres in the central nervous system (CNS),
increasing ventilation and cardiac output (Kline et al 2002). Changes in oxygen concentration
are also detected by lungs, by specialised cells such as pulmonary neuroepithelial cells and
pulmonary artery myocytes. Tissue oxygenation is also sensed by the liver and kidneys,
which respond by producing erythropoietin (EPO) (Stockmann and Fandrey 2006),
accelerating erythropoiesis (also known as polycythaemia) and eventually increasing red-cell
mass (Bunn 2007). Higher number of erythrocytes maximises uptake and transport of oxygen
which in the long-term help to restore normal levels of oxygen.
2.2.2 CELLULAR RESPONSES TO HYPOXIA
Tissue hypoxia can lead to cellular dysfunction and ultimately to necrosis or death.
The cellular oxygenation state is sensed by mitochondria through ROS production, energy
state or cytosolic redox state The oxygen-sensing cascade includes (i) heme proteins such as
complex III and IV of the respiratory chain, (ii) isoforms of the NADPH oxidase, and (iii)
non-heme proteins like PHD enzymes or heme oxygenase (HO)-2 (Acker et al 2006). Cells
adapt to hypoxia through the expression of proteins that detect changes in oxygen
concentration and support cell survival.
A series of adaptive responses to hypoxia are mediated by increased expression and
activity of transcription factors such as activator protein (AP)-1, nuclear factor B (NFκB) 
and hypoxia-inducible factor (HIF) (Wang and Semenza 1996). HIF-1 and the downstream
genes make up a highly evolved system of protective physiology that is conserved across
aerobic organisms. The HIF pathway has been investigated in this thesis.
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2.3 Hypoxia-Inducible Factor
Induction of the potent HIF transcriptional complex is centrally involved in the oxygen
homeostasis by controlling transcription of a myriad of genes and triggers a series of
emergency responses to hypoxia. HIFs coordinate compensatory changes by ‘turning on’
energy saving pathways and ‘turning off’ processes that consume energy, and thus protect
against tissue damage and cell death.
By switching from aerobic to anaerobic metabolism HIFs allow for continued energy
production despite reduced oxygen availability. The oxidative phosphorylation produces 38
ATP molecules per mole of glucose oxidised, whereas anaerobic glycolysis produces 2 ATP
molecules. Under hypoxic conditions the rate of aerobic respiration and ATP synthesis is
decreased, which is then compensated by increased glucose uptake via glucose transporters,
such as GLUT-1, and the glucose catalysis by the activity of glycolytic pathway involving
enzymes, e.g. lactate dehydrogenase (LDH)-A. The oxygen supply in hypoxic tissue is
reimbursed by the induction of HIF-dependent genes, VEGF and EPO, which increase blood
vessel formation and erythrocyte production, respectively. HIFs stimulate production of
cytoprotective entities which prevent the release of harmful factors such as oxygen free
radicals, increase proliferation via survival factors such as insulin-like growth factor (IGF)-2,
and regulates apoptosis by means of apoptotic genes including Bcl2/adenovirus E1B 19kDa
protein-interacting protein (BNIP)-3. In addition, intracellular acidification is prevented by
upregulation of carbonic anhydrase (CA)-9, which helps to transport carbon dioxide out of
tissue (Figure 2.1).
Figure 2.1 Genes regulated by HIF
HIF transcription factor regulates a number of biological processes via genes such as VEGF (vascular
endothelial growth factor), EPO (erythropoietin), GLUT (glucose transporter)-1, SDF (stromal cell-
derived factor)-1, transferrin, CA (carbonic anhydrase)-9, BNIP (Bcl2/adenovirus E1B 19kDa protein-
interacting protein)-3 and IGF (insulin-like growth factor)-2.
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2.3.1 THE DISCOVERY OF HIFS
The HIF family was first discovered in 1992 by Semenza and Wang while dissecting
out a promoter region in the EPO gene. It was known before that this glycoprotein hormone,
which regulates red blood cell production, is increased by hypoxia and facilitate tissue oxygen
delivery. An electrophorectic mobility shift assay of hepatic cells (Hep3B) cultured in
hypoxia revealed a DNA/protein complex with reduced mobility. A nuclear factor which
bound to the EPO promoter was described and the DNA-binding activity of this factor was
found to be tightly regulated by cellular oxygen tension, therefore the protein was designated
hypoxia-inducible factor (HIF-1) (Semenza and Wang 1992). The studies also revealed the
core hypoxia-responsive element (HRE) or HIF-binding site (HBS) composed of the
consensus sequence 5’-(A/G)CGTG-3’, which determines HIF-1 transcriptional activity
(Semenza et al 1996). HIF-1 was believed to be the main oxygen sensor for nearly a decade
being maximally stabilised in HeLa cells exposed to 0.5% O2 (Jiang et al 1996), until the
discovery of the upstream regulators of HIF, known as prolyl hydroxylase, described later.
Subsequent purification studies revealed that HIF-1 was in fact a heterodimer
consisting of two subunits, including oxygen-regulated HIF-1 and constitutively expressed
nuclear protein HIF-1 (Wang and Semenza 1995). Studies on HIF-1, also known as the
aryl hydrocarbon receptor nuclear translocator (ARNT), revealed that this protein is expressed
in excess, is not altered by hypoxia and is also a component of other transcription factors
(Wang et al 1995; Jiang et al 1996). Soon after, two closely related proteins which also
dimerise with HIF-1 were identified in mice and termed HIF-2 (Tian et al 1997) and HIF-
3 (Gu et al 1998). It was reported that HIF-2protein, also known as endothelial PAS
domain protein (EPAS)-1, is a strong gene activator in hypoxia (Ema et al 1997; Tian et al
1997). HIF-3, described first as an inhibitory PAS protein (IPAS), was shown to be less
closely related to HIF-1 and HIF-2 and to be a less potent transcription factor (Gu et al
1998). Interestingly at least one of the HIF-3 splice variants, human HIF-34 or mouse
IPAS, is associated with a negative regulation of HIF-1 and HIF-2 (Hara et al 2001;
Makino et al 2001).
It was demonstrated that HIF-1 is continuously transcribed in cells and HIF-1
protein accumulates in hypoxia, but when the cells are reintroduced to normoxia, the protein
has a very short half-life of less than 5 minutes (Huang et al 1996; Yu et al 1998). HIF-1 is
rapidly degraded by the action of ubiquitin-proteasome system (Salceda and Caro 1997;
Huang et al 1998) through von Hippel-Lindau tumour suppressor protein (pVHL) (Maxwell
et al 1999). The importance of pVHL in HIF-1 protein degradation was found by studying
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RCC which constitutively express HIF-1 due to lack of the functional pVHL. Re-expression
of pVHL restored the ability of these cells to oxygen sensing (Maxwell et al 1999). It has
been verified that pVHL is a required component in the E3 ubiquitin ligase-mediated HIF-1
ubiquitination (Kamura et al 2000).
HIF-1 was successively found to bind to HRE in different cell lines (Maxwell et al
1993; Wang and Semenza 1993) activating a plethora of genes, to control intracellular
hypoxic responses throughout the body with a fundamental role in embryogenesis and in
human pathophysiology. The genes regulated by HIF-1 include those involved in
angiogenesis, apoptosis, vasomotor control, erythropoiesis and energy metabolism (Wenger
2000). High throughput screenings, such as microarray analysis, gradually revealed how
potent the HIF-1 transcription factor is. To date, it has been established that approximately
1% of all human genes are regulated by HIF-1; nonetheless, the HIF-1 transcriptome is
constantly growing.
2.3.2 HIF STRUCTURE
HIFs consist of four protein domains important for complete activation of gene
transcription. (1) A contiguous basic helix-loop-helix (bHLH) domain and (2) the Per-ARNT-
Sim (PAS) domain (divided into two subdomains PAS-A and PAS-B) create a functional
interface for HRE binding and -subunit dimerisation, respectively (Wang et al 1995). (3)
The oxygen-dependent degradation (ODD) domain, consisting of approximately 200 amino
acids in the central region of the molecule, regulates protein stability (Huang et al 1998) and
thus is potentially the most important sequence of HIF-. More accurately, the N-terminal
transactivation domain (N-TAD), which is an internal segment within the ODD domain, is
responsible for hypoxic stabilisation of -subunits. (4) Further downstream of the ODD
domain is the C-terminal TAD (C-TAD) (Jiang et al 1997; Pugh et al 1997), which when
hydroxylated inhibits the interaction with co-activators such as CBP (CREB-binding
protein)/p300 and thus silences HIF transcriptional activity (Hewitson et al 2002; Lando et al
2002b).
HIF-1 and HIF-2 are believed to be the main transcription factors as they contain
all 4 domains required for the absolute activity of gene activation. HIF-3 also belongs to the
bHLH-PAS family and consequently HIF-3 is able to dimerise with HIF-1 and HRE also
activating HIF target gene expression, but to less extent than HIF-1 and HIF-2. In addition,
at least some of the HIF-3 splice variants do not contain the C-TAD, indicating that they do
not have direct transcriptional activity. While HIF-1, although is a bHLH-PAS protein, it
does not contain the ODD domain, hence it is not regulated by hypoxia (Figure 2.2).
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Figure 2.2 Domain structures of the HIF transcription factors
Functional domains are illustrated as grey boxes. The percentages show the homology of amino acids
between HIF-1 and HIF-2, between indicated domains. Three human HIF- paralogues and HIF-1,
a common binding partner, all contain the bHLH and the PAS (PAS-A and PAS-B) domains, which
enable binding to HRE and heterodimerisation respectively. HIF-1 HIF-2 and HIF-3 contain a
domain responsible for protein stabilisation such as the ODD domain which encloses the N-TAD. The
ODD domain includes prolyl residues Pro402 and Pro564 in HIF-1, Pro405 and Pro531 in HIF-
2and Pro490 in HIF-3 which are targeted by PHDs. The C-TAD which includes the asparaginyl
residue (Asn813 in HIF-1 and Asn851 in HIF-2) is hydroxylated by FIH-1 and is required for
complete HIF-1 and HIF-2 transactivation (adapted from Lisy and Peet 2008).
2.3.3 HIF REGULATION
There are a number of steps necessary for HIF-1 and HIF-2 to become stable and
active transcription factors. HIF- protein predominantly undergoes hydroxylation and
ubiquitination, but also acetylation, S-nitrosylation and phosphorylation, all of which
determine HIF half-life and/or transcriptional activity (Brahimi-Horn et al 2005). HIF-
genes are regulated at the transcriptional, post-transcriptional, translational and post-
translational levels. However, the most studied regulatory mechanism occurs at the oxygen-
dependent post-translational level.
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2.3.3.1 Oxygen-dependent regulation of HIF
The most prominent post-translational modifications of HIF- subunits, including
those acting on stability and transactivity, are oxygen-dependent. It was shown that the rapid
turnover of HIF- protein is triggered by pVHL binding (Maxwell et al 1999) that is
dependent upon the hydroxylation of specific prolyl residues within the ODD domain of HIF-
 subunits (Ivan et al 2001; Jaakkola et al 2001; Yu et al 2001). This action initiates
polyubiquitination (tagging the lysine residues of a protein with multiple copies of a 76 amino
acid basic polypeptide, called ubiquitin) followed by the recruitment of E3 ubiquitin ligase
complex, which destines -subunits to proteasomal degradation by 26S proteasome (Salceda
and Caro 1997; Maxwell et al 1999). The hydroxylases responsible for the observed HIF-
protein instability were subsequently characterised and named HIF prolyl hydroxylase
domain (PHD)-containing enzymes and are the main regulators of HIF- oxygen-dependent
protein stabilisation (Bruick and McKnight 2001; Epstein et al 2001).
Factor inhibiting HIF-1 (FIH-1) is another oxygen-dependent hydroxylase which
appears to have supplementary role to that of the PHDs, exerting an additional level of a
negative control of HIF- protein that has escaped degradation. FIH-1-mediated
hydroxylation of asparaginyl residue (Asn) in HIF-1 and HIF-2 was shown to block the
binding of the two co-activators, p300 and CBP, to the -subunits and thus to inhibit HIF
transcriptional activity (Lando et al 2002a; McNeill et al 2002).
Small changes in oxygen tension cause significant changes in enzymatic catalysis of
PHDs and are very rapidly transduced to changes in HIF- protein levels (Epstein et al 2001;
Hirsila et al 2003). Under conditions where oxygen is limiting PHDs and FIH-1 activities
decrease and HIF- subunits accumulate, enter the nucleus where they bind to HIF-1 and
co-activators CBP/p300. The co-activators possess histone acetyltransferase activity to
remodel the chromatin structure and facilitate the recognition of HRE in the promoter regions
of genes by the transcriptional complex. Consequently HIF-/1 heterodimers bind to HRE
and direct the expression of HIF target genes. The HIF-VHL-PHD axis is firmly established
as the central regulator of the cellular oxygen homeostasis and is illustrated schematically in
Figure 2.3.
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Figure 2.3 Oxygen-dependent regulation of HIF-
In the presence of oxygen (normoxia), 2-OG (2-oxoglutarate), ascorbic acid and iron (Fe2+), PHDs and
FIH-1 hydroxylate specific amino acids residues, prolyl and asparaginyl, respectively. Hydroxyprolines
allow HIF- to interact with pVHL, which ubiquitinates and targets the protein for degradation by 26S
proteasome. Hydroxyasparagines limit HIF transactivation by reducing the binding affinity between -
subunit and CBP/p300 co-activators. When oxygen is a limiting factor (hypoxia), HIF- is stabilised
and activated due to decreased PHDs and FIH-1 hydroxylase activity. HIF-subunits accumulate and
translocate into the nucleus, dimerise with HIF-1, bind to CBP/p300 and finally to HRE (hypoxia-
responsive element) in the promoter sites of target genes to activate gene transcription.
2.3.3.2 Oxygen-independent regulation of HIF
Although HIF was originally described as a hypoxia-inducible factor, it is now clear
that HIF- is also induced by non-hypoxic stimuli (Table 2.1), which directly or indirectly
regulate HIF-in parallel to the oxygen-dependent pathway (Gaber et al 2005). It has been
reported that apart from its regulation by hypoxia, HIF is also regulated by (i) physical
factors, including mechanical stress (Pufe et al 2004), heat (Katschinski et al 2002), and low
pH (Mekhail et al 2004), and (ii) biochemical factors such as cytokines (Hellwig-Burgel et al
1999), growth factors (Richard et al 2000), hormones (Zelzer et al 1998), NO (Sandau et al
2001) and ROS (Haddad and Land 2001; Bonello et al 2007), and also by pathogens for
instance LPS (Blouin et al 2004) or hepatitis B virus (Moon et al 2004).
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Table 2.1 Repertoire of factors inducing HIF
Factors Inducers
Physical Hypoxia, heat, low pH, mechanical stress
Biochemical Cytokines (IL-1b, TNF-a)
Growth factors (bFGF, EGF, HGF, IGF-I, IGF-II, PDGF)
Hormones (insulin, thrombin, FSH, thyroid hormone, angiotensin II)
Bacterial and viral LPS, HBx
ROS
RNS
OH·, O2·
_
, H2O2, 1O2
NO, HNO2, NO2
Abbreviations: bFGF - basic fibroblast growth factor, EGF - epidermal growth factor, HGF -
hepatocyte growth factor, IGF - insulin-like growth factor, PDGF - platelet derived growth factor, FSH
- follicle stimulating hormone, LPS - lipopolysaccharide, HBx - hepatitis B virus protein X, ROS -
reactive oxygen species, RNS - reactive nitrogen species (summarised by Gaber et al 2005).
2.3.4 SIMILARITIES BETWEEN HIF-1 AND HIF-2
As briefly mentioned, three paralogues of the HIF- subunit have been described to
date, HIF-1, HIF-2 and HIF-3, and three paralogues of HIF-1(ARNT1, ARNT2 and
ARNT3) interacting with -subunits (Lisy and Peet 2008). Six transcript variants of HIF-1
(Gothie et al 2000; Chun et al 2002), one of HIF-2 (Tian et al 1997) and seven of HIF-3
(Pasanen et al 2010) have been identified. However, a considerable amount of research has
been carried out on HIF-1 and HIF-2, two the most closely related -subunits, showing
their fundamental roles as the mediators of transcriptional responses to hypoxia.
HIF-1 and HIF-2 share a number of similarities, including the genomic
organisation, regulation and their mode of action. They are both complementary in total
amino acid sequence of approximately 48% and they share identity up to 80% in nucleotide
sequence. In humans the homology in amino acids between HIF-1 and HIF-2 in the
modular protein structures, in particular domains such as bHLH, PAS-A, PAS-B, N-TAD and
C-TAD was shown to be 99%, 91%, 96%, 81% and 87%, respectively (Lisy and Peet 2008)
(Figure 2.2). Both HIF- contain two specific prolyl residues in the ODD domain and one
asparaginyl residue in the C-TAD. Both -subunits are modified in a similar manner by
oxygen-dependent HIF hydroxylases, PHDs and FIH-1, targeting their ODD and C-TAD
segments. In normoxia this action results in protein degradation via the pVHL ubiquitin-E3
ligase, whereas in hypoxia decrease in HIF hydroxylase’s enzymatic activity leads to HIF-
stabilisation (Salceda and Caro 1997; Maxwell et al 1999; Ivan et al 2001). The mechanism
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of action, meaning the transactivation of target genes by both HIF-1 and HIF-2, is also
alike and includes the ability to dimerise with HIF-1 via the PAS domain, DNA recognition
and binding to HRE in the gene promoters via the bHLH domain (Wang et al 1995).
Due to structural similarities it is believed that HIF-1 and HIF-2 are responsible
for analogous responses to hypoxia. Indeed they share some common target genes such as
VEGF and/or EPO, suggesting they may have similar role in regulating processes including
angiogenesis and/or erythropoiesis (Wang et al 1995; Hu et al 2003; Warnecke et al 2004;
Raval et al 2005; Hu et al 2006). Vessel formation using Matrigel assay revealed common
contribution of HIF-1 and HIF-2 with the most significant induction of angiogenesis when
endothelial cells were co-transfected with both HIFs (Ben-Shoshan et al 2008). However, it
was demonstrated that HIF-1 and HIF-2 may bind to different HRE in the same target
genes, for instance VEGF and GLUT-1, each of them having at least two potential HIF-
binding sites. It has been suggested that although -subunits can regulate common targets,
such as VEGF, they may still affect different stages of the same biological process. For
instance, HIF-1 is believed to be involved in vasculogenesis and angiogenesis (Carmeliet et
al 1998; Iyer et al 1998; Ryan et al 1998), whereas HIF-2 is important at the later stage of
vessel development which is vascular remodelling (Peng et al 2000).
2.3.5 DIFFERENCES BETWEEN HIF-1 AND HIF-2
However, there is growing evidence revealing differences between HIFs, implying
that the HIF- isoforms have distinct biological roles in different cell types. In brief,
differences between HIFs include embryonic deletion phenotype, unique tissue distribution,
exclusive targets, specific co-activator engagement and opposing effects on tumour growth
(Patel and Simon 2008).
One of the first distinctions between HIFs is the presence in organisms with HIF-1
being older evolutionally, existing from Caenorhabditis elegans (C. elegans) to humans,
whereas HIF-2 being present only in complex vertebrates, namely fish, mice, chicken, quails
and mammals (Hu et al 2003).
The first functional difference between HIF- subunits was shown in mouse models
revealing distinct phenotypes of HIF-1 and HIF-2 deletion in mice (Table 2.2). Both HIF-
 are inevitable during embryogenesis since both HIF-1 and HIF-2 knockout mice led to
embryonic lethality. However, the developmental expression profiles and pathology of HIF-
1-/- and HIF-2-/- mice were different. Mice lacking HIF-1 were arrested in their
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development by embryonic day (E) 8.5 and died by day E10.5 with cardiovascular defects
and impaired angiogenesis (Iyer et al 1998). In HIF-1-/- mice, initially and properly formed
vascular plexus subsequently degenerated and the mice developed both cardiac and vascular
malformations, suggesting that the first processes of vascular development, namely
vasculogenesis and angiogenesis, are dependent on HIF-1 (Carmeliet et al 1998; Iyer et al
1998; Ryan et al 1998). In three independent germ line murine HIF-2-/- strains, embryonic
(at E9.5 – E12.5) or perinatal lethality was manifested with vascular disorganisation in yolk
sac (Peng et al 2000) and severe vascular defects in embryo, including heart failure (Tian et al
1998), bradycardia, defective lung maturation (Compernolle et al 2002), impaired ROS
metabolism and mitochondrial homeostasis (Scortegagna et al 2003a). Interestingly, it is
suggested that the process following blood vessel formation, namely vascular remodeling, is
HIF-2-dependent, since HIF-2-/- mice undergo vasculogenesis with properly formed but
improperly fused vessels (Peng et al 2000).
Table 2.2 Description of HIF knockout mice and general functions of -subunits
Characteristic HIF-1a HIF-2a
KO mice Lethal
(Iyer et al 1998, Kotch et al 1999)
Lethal
(Tian et al 1998, Scortegagna et al 2003)
KO phenotype Cardiac malformation,
vascular regression
Heart failure, bradycardia, impaired
ROS metabolism
Specific genes GLUT-1, BNIP-3, CA9
(Iyer et al 1998, Greijer&van der Wall 2004,
Zhong et al 1999)
cyclin D, TGF-b, ANGPT2, VEGFR1
(Raval et al 2005, Aprelikova et al 2006,
Nagao et al 2011)
General function Metabolism, apoptosis, angiogenesis Vascular remodelling, hematopoiesis,
cancerogenesis
HIF-associated
diseases
Majority of cancers
(Zhong et al 1999, Semenza 2010)
RCC, polycythaemia
(Raval et al 2005, Ang et al 2002)
Abbreviation used in the table: GLUT-1, BNIP-3, CA9, TGF-- transforming growth factor beta,
ANGPT2 - angiopoietin 2, VEGFR1 - VEGF receptor 1, RCC - renal cell carcinoma, KO - knockout.
HIF-1 appears to be ubiquitously expressed, possessing a number of basic cell
functions, whereas HIF-2 seems to be more tissue restricted and thus is believed to play
more discrete roles. HIF-2 is primarily expressed in the embryo vasculature and in the lungs,
heart, kidney and liver (Ema et al 1997; Tian et al 1997). Particularly high levels of HIF-2
mRNA were found in renal cells, hepatocytes, epithelial cells, cardiomyocytes, astrocytes and
pneumocytes (Wiesener et al 2003). The fact that HIF-2 is expressed in some tissues and
cells, whereas HIF-1 is widely distributed in the organism, is mirrored by the number of
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HIF-regulated genes. For instance, hypoxic and adenoviral-mediated HIF-1 induction in
endothelial cells resulted in the induction of 245 genes and reduction of 325 genes by more
than 1.5-fold. Most of the genes increased by HIF-1 are cytokines, growth factors, receptors,
and other signalling proteins; whereas genes downregulated include those involved in
cytoskeleton formation, cell growth and DNA repair (Manalo et al 2005). It was reported
using short interfering RNA (siRNA) and Affymetrix gene analysis of hepatoma cells that 3%
of all genes are regulated by hypoxia, amongst which the vast majority of genes are HIF-1-
dependent (75% of upregulated genes and 62% of downregulated genes) and HIF-2 regulates
approximately 13% (36/271) of upregulated genes, and 17% of downregulated genes
(37/217), with the remainder apparently requiring both HIF-1 and HIF-2 (Warnecke et al
2008). Another study has shown that HIF-2 regulates approximately 5% of genes (14/270)
and HIF-1 targets more than 80% of all investigated HIF-dependent genes (Aprelikova et al
2006). A microarray analysis performed on MCF-7 breast cancer cell line by Elvidge and
colleagues revealed that of all hypoxia-inducible genes only 2% are HIF-2-dependent (5/246)
and 51% (127/246) are HIF-1-dependent (Elvidge et al 2006). Therefore due to the low
number of HIF-2-regulated genes, the significance of HIF-2 is controversial and it is
believed that it contributes relatively little to hypoxia responsiveness.
In the view of some researchers, HIF-2 is ascribed a unique function in comparison
to a broader and more general role of HIF-1, and is more widely expressed than originally
reported (Patel and Simon 2008). Some of the specific HIF-2 functions include promotion of
differentiation of adipocytes (Shimba et al 2004) and regulation of stem cell pluripotency
regulated by specific gene Oct-4 (Hu et al 2006). Hypoxic induction of the chondrocyte
phenotype was shown to be HIF-2-dependent by up-regulation of cartilage matrix genes and
the transcription factor SOX9 (Lafont et al 2007). Interestingly, HIF-2 is believed to be
involved in osteoarthritis (Saito et al 2010). It was reported that HIF-2 is also responsible
for hypoxia-induced motility and cell migration through activation of LOXL2 (up-regulated
in metastatic breast cancer cells), WISP2 (estrogen-stimulated cell proliferation) and
CBP/p300-interacting modulator (CITED)-2 (involved in cell proliferation) (Aprelikova et al
2006). HIF-2 regulates also uPAR (urokinase plasminogen activator receptor) and PAI
(plasminogen activator inhibitor)-1, which takes part in cell adhesion, signal transduction and
integrin-associated migration (Scortegagna et al 2003b; Carroll and Ashcroft 2006). Together
with the fact that HIF-2 was shown to be stabilised in RCC, it is stated that HIF-2 has a
special function in metastasis and oncogenesis. HIF-2 has a particular role in ROS
homeostasis by regulating antioxidant enzymes (Scortegagna et al 2003b) and in iron
metabolism by inducing transferring transcripts (Rolfs et al 1997; Rankin et al 2007). By
being the key regulator of EPO in kidneys and by modulating blood vessel dynamics via
Chapter 2
39
VEGF, HIF-2 contributes to systemic delivery of oxygen (Takeda et al 2004; Takeda et al
2008).
Some cells express only one -subunit, but most cells express both of them. In those
cell types expressing HIF-1 and HIF-2, it has been suggested that it is HIF-1 which plays
a pivotal role in cell response to hypoxic condition. It was shown that HIF-2 is less active
isoform than HIF-1 in vascular endothelial cells, even though it is broadly expressed in
those cells (Tian et al 1997). Hu and co-workers have shown that even in murine HIF-1-/-
endothelial stem cells HIF-2 is inactive, although there is elevated level of HIF-2 protein
(Hu et al 2006). Possibly HIF-2 has a specific transcriptional repressor or it lacks
transcriptional activator, since HIF-2 dimerises with HIF-1, interacts with HRE, but still
does not activate gene transcription in embryonic stem cells (Hu et al 2006). Some
researchers imply that the importance of HIF-2 is larger only in the absence of HIF-1 and
that HIF-1 is not required for HIF-2 activity. This is based on the experiments conducted
on human RCC with pVHL defect (50% of RCC constitute of these 768-O cells) which
express increased levels of HIF-2 and in which HIF-2 shows full activity (Hu et al 2003).
The differences between HIF-1 and HIF-2 concern also mRNA and protein
stability, with HIF-1 being transiently expressed, and HIF-2 being sustained in prolonged
hypoxia (Uchida et al 2004; Chen et al 2006; Li et al 2006). Cobalt chloride (CoCl2), which
inhibits hydroxylation of prolines, dramatically decreases mRNA half-life of HIF-1 from
19.3 hours in normoxia to 2.6 hours. Interestingly, HIF-2 is not changed by CoCl2 (18.2
hours in normoxia versus 17.2 hours), which means that sustained hypoxia decreases HIF-
1but not HIF-2, mRNA stability (Uchida et al 2004). Measuring the half-life of HIF-
mRNA in hypoxia-treated cells by inhibition of transcription after adding actinomycin D,
revealed again that HIF-1 is less stable compared to HIF-2 with the half-life of
approximately 160 minutes for HIF-1 mRNA, whereas HIF-2 mRNA remains relatively
unchanged (Li et al 2006; Dr Helene Larsen, unpublished data from our group). Different
RNA decay patterns in hypoxia could be caused by the structure of HIF-1 3’UTR which
contains instability motifs hidden in a hairpin structure (700 bases of AUUUA also called
AU-rich elements), which is not present in HIF-2 (Rossignol et al 2002). Binding of natural
antisense HIF (aHIF) (Thrash-Bingham and Tartof 1999) to HIF-1 possibly disrupts the
secondary hairpin structure and reveals AU-rich motifs, which leads to mRNA decay. Thus,
HIF-1, but not HIF-2, is subjected to this specific feedback loop mechanism. In terms of
protein stability, although in hypoxia HIF-1 protein is massively stabilised, the protein is
rapidly decayed with the half-life between 5 and 10 minutes during re-oxygenation (Wang et
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al 1995). HIF-2 protein half-life, on the other hand, was prolonged during re-oxygenation as
reported in macrophages (Elbarghati et al 2008). Therefore, HIF-1 protein is more sensitive,
whereas HIF-2 protein seems to be relatively resistant to degradation at oxygen levels that
normally lead to degradation of HIF-1 (Lofstedt et al 2007). It was therefore suggested that
if genes are changed in prolonged/chronic hypoxia, they are transactivated possibly by HIF-
2, and not HIF-1.
The difference between HIF-1 and HIF-2 also includes the employment of unique
co-factors which is driven mainly by the structure variations of the N-TAD and the C-TAD.
For instance, hepatic nuclear factor (HNF)-4 (Galson et al 1995; Warnecke et al 2008),
Smad3, STAT3, c-Myc (Warnecke et al 2008) are required specifically for HIF-1 activity
(Lisy and Peet 2008); whereas HIF-2 engages exclusive co-factor termed NFκB essential 
modulator (NEMO), which specifically enhances binding of HIF-2 to CBP/p300 (Bracken et
al 2005) and CITED-2, which was shown to be HIF-2-dependent (Wang et al 2005;
Aprelikova et al 2006).
Another distinction between -subunits involves a conserved iron response element
(IRE) identified at the 5’UTR of HIF-2, providing evidence that its translation depends on
iron availability (Sanchez et al 2007). Moreover, promoter analysis of the HIF-2-dependent
genes revealed that 90% of investigated genes contain putative ETS binding site which is
adjacent to HRE and directly interacts with HIF-2 (Aprelikova et al 2006). It was shown
that the knockdown of ETS family members, namely ETS-1 (Elvert et al 2003) and ELK-1
(Aprelikova et al 2006), reduced hypoxia-induced transcriptional activation of HIF-2-
dependent genes such as VEGFR-2 (Elvert et al 2003), CITED-2, EPO, PAI-1, WISP-2 and
insulin-like growth factor-binding protein (IGFBP)-3 (Aprelikova et al 2006; Hu et al 2007).
Another noted difference is HIF regulation upon cytokine stimulation. Recent
discoveries on monocyte/macrophage differentiation have revealed that HIF-1 is regulated
by Th1 cytokines (i.e. tumour necrosis factor (TNF)- and interleukin (IL)-1) which confer
the pro-inflammatory response, whereas HIF-2 is regulated by Th2 cytokines (i.e. IL-4, IL-
10) involved in the anti-inflammatory response (Takeda et al 2010). It is well-established that
HIF-1 mRNA, protein and HIF binding to HRE, is indeed induced by pro-inflammatory
cytokines including IL-1 and TNF- which was shown in different cell types (Hellwig-
Burgel et al 1999; Thornton et al 2000; Haddad and Land 2001; Hitchon et al 2002).
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Table 2.3 Major differences between the HIF- subunits
Characteristic HIF-1a HIF-2a HIF-3a Reference
Size (amino acids) 826 870 662 Source: PubMed
Molecular weight (kDa) 120 115 73 Gu et al 1998
mRNA stability in
hypoxia
Unstable Stable Stable Uchida et al 2006
Thrash-Bingham 1999
mRNA in hypoxia Decreased Unchanged Increased Ema et al 1997
Gu et al 1998
Protein in hypoxia Increased Increased Increased
or decreased
Jiang et al 1996
Makino et al 2002
Specific co-factors HNF4, Smad3,
STAT3, c-Myc
NEMO, CITED-2 - Warnecke et al 2008
Aprelikova et al 2006
Regulation by cytokines Th1 Th2 - Takeda et al 2010
Tissue distribution Ubiquitously
expressed
Mainly lungs, heart,
kidneys, liver
Mainly corneal
retina, brain, heart,
lung
Ema et al 1997
Makino et al 2001,
Makino et al 2002
Abbreviation used in the table: HNF4 - hepatic nuclear factor 4, Smad3 - mothers against
decapentaplegic homolog 3, STAT3 - signal transducer and activator of transcription 3, c-Myc, NEMO
- NFκB essential modulator, CITED-2 - CBP/p300-interacting modulator, Th1 cytokines - pro-
inflammatory cytokines, Th2 cytokines - anti-inflammatory cytokines, kDa - kilo Dalton.
The aforementioned studies indicate that to some extent HIF-1 and HIF-2 have
diverse roles due to differing tissue distribution, gene regulation, stability and co-factors´
engagement. However, some findings imply that these -subunits play completely opposing
functions. Striking evidence from studying tumour development showed that depending on
the type of cancer HIF-1 is anti-tumourigenic, whereas HIF-2 pro-tumourigenic, or vice
versa (Mandriota et al 2002; Sowter et al 2003; Raval et al 2005).
The clinical studies revealed that HIF isoforms are over-expressed in at least 19 types
of cancer and generally is associated with worse patient survival (Semenza 2010); however, it
is not always the case. As an example, HIF-1 over-expression in patients with brain, breast,
ovarian and bladder cancer is associated with a more aggressive tumour’s phenotype
(Semenza 2010), whereas HIF-2 over-expression correlates with a more aggressive tumour
phenotype and increased mortality of neuroblastomas patient (Lofstedt et al 2007). However,
low level or lack of HIF-2 in breast cancer (Blancher et al 2000) and colon cancer biopsy
samples (Imamura et al 2009) is associated with more aggressive tumours, advanced tumour
stage and poor prognosis. Another correlation study has shown that the increased expression
of HIF-1 in head and neck squamous carcinoma (Beasley et al 2002; Koukourakis et al
2002) and non-small cell lung cancer (Giatromanolaki et al 2001) is associated with
decreased patient mortality. Therefore, it can be concluded that the expression of particular
HIF- may be used as a prognostic marker of tumourigenesis, but it is cancer-specific.
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Experimental data revealed that HIF-1 and HIF-2 have unusual properties in
cancerogenesis. Pro-tumourigenic abilities of HIF-1 were shown by using HIF-1-/- mouse
embryonic stem cells which produced smaller tumours in subcutaneous xenografted
immunodeficient models, whereas over-expression of HIF-1 increased tumour growth (Ryan
et al 1998; Ryan et al 2000). Another study demonstrated that HIF-1 has anti-tumourigenic
and HIF-2 pro-tumourigenic roles, especially in VHL-defective RCC in which HIF-
subunits are constitutively expressed (Raval et al 2005). Inhibiting HIF-1 in RCC increased,
while over-expression decreased xenograft tumour mass. In contrast, it has been observed that
silencing HIF-2 reduced tumour growth in the nude mice and over-expression of HIF-2
promoted tumour growth in xenograft studies, implying that HIF-2steers the pro-
tumourigenic and anti-apoptotic responses in RCC (Kondo et al 2002; Raval et al 2005).
2.4 Oxygen sensors
Since the discovery of HIF transcription factors in 1992 (Semenza and Wang 1992), it
was believed that HIFs are the main oxygen sensors controlling the responses to hypoxia.
Almost a decade was needed for the view to be changed. Further investigation into the
regulation of HIF subunits conveyed a new idea of how sensing the drop in oxygen tension
works, replacing the primary role of HIF by a group of oxygen-dependent hydroxylases.
2.4.1 DISCOVERY OF HIF HYDROXYLASES
While investigating the oxygen-dependent HIF regulation, it was reported that
hydroxyprolines (Ivan et al 2001; Jaakkola et al 2001; Masson et al 2001) are approximately
100-fold more tightly bound by pVHL than non-hydroxylated prolines (Chan et al 2002),
accelerating the process of HIF protein ubiquitylation and degradation. In 2001, a conserved
family of oxygen-dependent HIF hydroxylases responsible for post-translational modification
of HIFs was identified (Bruick and McKnight 2001; Epstein et al 2001; Lando et al 2002a).
Since then it was accepted that these enzymes are the key factors upstream of HIFs
responding to fluctuations in oxygen levels and they became the main oxygen sensors.
The prolyl hydroxylase termed EGL-9 (an egg-laying deficiency nine-like protein) was
first described in C. elegans (Trent et al 1983) while screenings for 2-oxoglutarate (2-OG)-
dependent dioxygenase candidate. It was observed that C. elegans HIF (CeHIF) protein is
increased in nematode worms with a defect in the egl-9 gene. The hydroxylation of CeHIF
was confirmed by using recombinant EGL-9 in vitro (Epstein et al 2001). Also only one
prolyl hydroxylase, named Fatiga, was found in Drosophila melanogaster (D. melanogaster).
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It was shown that siRNA targeting Fatiga upregulates dmHIF- (also termed Similar), but not
dmHIF- (also known as Tango), and as a result induced hypoxia-responsive genes such as
LDH (Bruick and McKnight 2001; Lavista-Llanos et al 2002). Next, three human
isoenzymes, strikingly homologous to EGL-9, were identified by these groups by biochemical
purification of rabbit reticulocyte’s lysate and by sequence alignment with human genome
(Bruick and McKnight 2001; Epstein et al 2001; Ivan et al 2002). The existing alternative
designations include EGL nine homolog (EGLN)-2, -1, -3, HIF prolyl hydroxylase (HPH)-1, -
2, -3, or prolyl hydroxylase domain (PHD)-containing enzymes -1, -2, -3, respectively. The
latter name (PHD) is going to be used in this study.
The ability of prolyl hydroxylases to hydroxylate HIFs was found only a decade ago
(Epstein et al 2001), since when a vast amount of research has been carried out to scrutinise
this extended pathway. PHDs mediate trans-4-hydroxylation of -subunits at two specific
prolyl residues: Pro402 and Pro564 in HIF-1 (Bruick and McKnight 2001; Epstein et al
2001; Ivan et al 2001; Yu et al 2001) and Pro405 and Pro531 in HIF-2 (Chan et al 2002),
and only one Pro490 in HIF-3 (Maynard et al 2003) (Figure 2.2). Hydroxyprolines mediate
pVHL binding which targets HIF- protein for proteasomal degradation (Figure 2.3).
Apart from the three well-described orthologues of PHDs, one more namely proline 4-
hydroxylase (PH-4) was shown to suppress HIF activity through the same mechanism of
hydroxylation of prolyl residues in the ODD domain in HIF-1(Oehme et al 2002). PH-4 is
highly expressed in most organs (Oehme et al 2002), is upregulated by hypoxia and unlike the
other PHDs it is anchored in the endoplasmic reticulum membrane with its catalytic domain
located in the lumen rather than cytosol (Koivunen et al 2007).
In addition, an asparaginyl hydroxylase designated factor inhibiting HIF-1 (FIH-1) was
identified by a two-hybrid screen as a protein that interacts with and targets the C-TAD and as
a result inhibits HIF- transactivation (Mahon et al 2001). This oxygen-, 2-OG- and Fe2+-
dependent dioxygenase represents another level of HIF regulation by catalysing -carbon of a
single conserved asparaginyl residue (McNeill et al 2002) identified in human HIF-1 at
position Asn803 and in HIF-2 at position Asn851 (Lando et al 2002b). Hydroxyasparagine
prevents the association of the -subunit with the CH1 domain of the co-activators CBP and
p300, and thereby limits HIF- transactivity by hindering HIF-mediated gene transcription
(Mahon et al 2001; Hewitson et al 2002; Lando et al 2002a; Lando et al 2002b),
schematically depicted in Figure 2.3. In addition, FIH-1 does not co-localise with HIF-1 in
the nucleus in hypoxic conditions, which indicates that hydroxylation must occur prior to
nuclear entry (Metzen et al 2003; Stolze et al 2004).
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C. elegans, which consists of less than 1000 cells, receive oxygen by simple diffusion
from the air. D. melanogaster has a specialised system of tracheal tubes to conduct the
oxygen to all cells (Gorr et al 2006), whereas in mammals oxygen delivery system involves
much more complicated respiratory and circulatory systems. The vascular system supplies
oxygen and nutrients to approximately 1014 cells in an adult. The high conservation between
PHD and HIF isoforms in different species including human, mouse, fish, fly and worm,
indicates the importance of oxygen regulatory systems regardless of the mode of oxygen
extraction from air. The existence of the PHD-VHL-HIF pathway in C. elegans reveals that
an oxygen-sensitive mechanism existed before the evolution of a vascular system (Maynard et
al 2003). Interestingly, with evolution the HIF pathway became more complex in organisms
with greater oxygen requirements like vertebrates. A single prolyl hydroxylase EGL-9
evolved into at least three prolyl hydroxylases. Three genes have been shown to encode the -
subunits of HIF- containing one or two prolyl residues, each subjected to hydroxylation,
compared to a single CeHIF with a single prolyl residue (Pro621) in C. elegans (Epstein et al
2001). Moreover, complexity of the HIF system is paralleled by the increased importance of
the individual members, which with time became vital in physiology. Worms with deficiency
in CeHIF, vhl or egl-9 are viable with a normal phenotype (Jiang et al 2001). However,
biallelic inactivation of some members of the extended HIF system in mammals, including
hif-1 (Carmeliet et al 1998; Iyer et al 1998; Ryan et al 1998; Compernolle et al 2002), hif-
2(Tian et al 1998; Scortegagna et al 2003a), hif-1 (Yim et al 2006), vhl (Gnarra et al
1997) and phd-2 (Takeda et al 2006) leads to embryonic lethality.
2.4.2 DIFFERENCES BETWEEN HIF HYDROXYLASES
While assessing the expression pattern of PHDs it was demonstrated that the levels of
mRNA of HIF hydroxylases are widely distributed. The examination of mRNA level in
normal animals and human tissues revealed that PHD-1 is the most abundant in testis (Willam
et al 2006), PHD-2 is predominantly expressed in heart and adipose tissue, whereas the most
of PHD-3 is found in heart and placenta (Lieb et al 2002; Oehme et al 2002), which may
imply particular roles of PHDs. Protein studies using novel monoclonal antibodies have
shown that all PHD proteins are also widely distributed and overlap in most normal tissues
(Soilleux et al 2005), whereas in neoplastic tissues HIF hydroxylase expression is extremely
variable, with increased PHD-3, but unchanged or slightly decreased PHD-1 and PHD-2
levels (Soilleux et al 2005). In addition, PHDs are partitioned differently in nuclear and
cytoplasmic compartments; PHD-1 is predominantly expressed in cytoplasm (Soilleux et al
2005) or is exclusively expressed in nucleus depending on the cell type (Huang et al 2002;
Metzen et al 2003), PHD-2 is mainly expressed in the cytoplasm, but with the ability to
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migrate into the nucleus in hypoxia (Yasumoto et al 2009), whereas PHD-3 is homogenously
expressed in the nucleus and cytoplasm (Huang et al 2002; Metzen et al 2003; Soilleux et al
2005). FIH-1 is constitutively expressed in all cell types so far studied, exhibiting increased
staining in neoplastic tissue (mainly in RCC). FIH-1 is localised predominantly in the
cytoplasm under hypoxia and in the presence of hydroxylation inhibitors, including CoCl2 or
2-OG analogues (Stolze et al 2004; Soilleux et al 2005).
The mode of regulation of the hydroxylation reaction is well established; however, it
remains largely unknown how these enzymes are regulated. It was shown that PHD-1 and
FIH-1 are not altered by decreased oxygen tension, whereas both PHD-2 and PHD-3 mRNA
and protein levels are increased. It has been described that decreased oxygen tension has two
opposite effects on PHDs, it limits their enzymatic activity but stimulates their transcription
and translation (Epstein et al 2001; Berra et al 2003; Cioffi et al 2003; Del Peso et al 2003;
Metzen et al 2003; Marxsen et al 2004). The examination of PHD-2 (Metzen et al 2005) and
PHD-3 (Pescador et al 2005) gene promoters revealed that they contain HRE, therefore their
transcripts are strongly induced by hypoxia via HIF pathway. It was reported in a number of
cells in vitro that PHD-2 is solely regulated by HIF-1in hypoxia (Berra et al 2003; Appelhoff
et al 2004; Aprelikova et al 2004; Marxsen et al 2004), whereas PHD-3 is dependent on both
HIF-1 (Aprelikova et al 2004; Marxsen et al 2004) and HIF-2 (Huang et al 2002;
Appelhoff et al 2004; Aprelikova et al 2004; Marxsen et al 2004). Consequently it is believed
that PHD-2 and PHD-3 are involved in the negative feedback loop mechanism of HIFs and
high levels of these isoenzymes in hypoxia ensures oxygen-mediated HIF- degradation
observed during re-oxygenation.
In addition to oxygen-dependent regulation, some reports have shown that
transcription of PHD is altered by cytokines. It has been demonstrated that TGF-
significantly decreases both mRNA and protein level of PHD-2, resulting in HIF-1 protein
accumulation and increased HIF-1 binding to HRE. Conversely, inhibition of endogenous
production of bioactive TGF- increases PHD-2 expression and reduces HIF-1 and HIF
target gene, including VEGF (McMahon et al 2006). Also interferon (IFN) and to a lesser
extent IFN- significantly increases PHD-3 mRNA and protein level selectively in
endothelial cells, which is independent of HIF-1 (Gerber et al 2009).
It is important to add that PHDs and FIH-1 are able to hydroxylate also non-HIF
substrates. For instance, it has been demonstrated that PHD-1 and PHD-2 regulate NFB
pathway via hydroxylation of IKK (the kinase of an inhibitor of kappa B, IB) (Cummins et
al 2006). PHD-3 was shown to target a transcription factor, paired box (Pax)-2, for
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destruction (Yan et al 2011). Moreover, FIH-1 was reported to have plentiful of targets for
hydroxylation mainly ankyrin repeat domain-containing proteins, which account for
approximately 6% of all human protein (Cockman et al 2009). Some of the differences are
included in Table 2.4.
Table 2.4 Major differences between the HIF hydroxylases
Characteristic PHD-1 PHD-2 PHD-3 FIH-1
Size (amino acids) 407 426 239 348
Molecular weight (kDa) 43.6 46 27.3 40.6
Tissue distribution Testis Heart, adipose tissue Heart, placenta Ubiquitously
expressed
Intracellular
localisation
Cytoplasm
(Soilleux et al 2005)
Cytoplasm
(Soilleux et al 2005)
Nucleus in hypoxia
(Yasumoto et al 2009)
Cytoplasm and
Nucleus
(Soilleux et al 2005)
Cytoplasm
(Soilleux et al 2005)
Presence of HRE - HRE
(Metzen et al 2005)
HRE
(Pescador et al 2005)
-
mRNA in hypoxia Unchanged Induced Induced Unchanged
Protein in hypoxia Unchanged Induced Induced Unchanged
Preferences towards
HIF
HIF-2a
(Appelhoff et al 2004,
Takeda et al 2008,
Aragones et al 2008)
HIF-1a
(Berra et al 2003,
Hirsila et al 2003,
Appelhoff et al 2004)
HIF-2a
(Appelhoff et al 2004,
Takeda et al 2008,
Bishop et al 2008)
HIF-1a
(Koivunen et al 2004)
Interacting proteins Siah1/2
(Nakayama et al 2004)
FKBP38
(Barth et al 2007)
ATF-4, Siah2
(Koditz et al 2007,
Nakayama et al 2007)
Siah1
(Fukuba et al 2007)
Non-HIF substrates IKKb
(Cummins et al 2006)
IKKb
(Cummins et al 2006)
Pax2
(Yan et al 2011)
ARD
(Cockmann et al 2009)
Abbreviation used in the table: ARD - ankyrin repeat domain-containing proteins, ATF-4 - activating
transcription factor 4, IKK - inhibitor of NFB kinase beta, FKBP38 - FK506-binding protein 38,
HRE - hypoxia-responsive element, Pax2 - paired box 2, Siah1 - seven in absentia homologue 1.
The presence of at least three PHD isoenzymes raises an obvious question: what is
the role of the individual prolyl hydroxylases? Global knockout mice studies with deleted
genes encoding phds and fih-1 contributed to better understanding of the roles between HIF
hydroxylases (Table 2.5). It was demonstrated that PHD-2 is crucial during development
since phd2 knockout is embryonically lethal, whereas phd1-/- and phd3-/- mice are viable and
appear normal (Takeda et al 2006). Embryonic death in phd2-/- mice was proceeded by
placental dysfunction by poor labyrinth branching and heart defects. Systemic effect in the
embryo proper included significant global increase in HIF-1, VEGF and EPO protein
implying the role of PHD-2 in angiogenesis and the vascular system (Takeda et al 2006). It is
suggested that PHD-2 is the most important isoenzyme, since it is the most abundant in
different cells and is the key regulator of HIFs (Berra et al 2003). In addition, phylogenetic
analysis of domain structures revealed that PHD-2 is the ancestral form of EGL9 highlighting
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the importance of this isoform (Taylor 2001). The roles of remaining PHDs and FIH-1 have
been revealed only recently using conditional knockouts. A study by Aragones and colleagues
(2008) demonstrated that mice with phd1 deleted in skeletal muscles have decreased oxygen
consumption and are less tolerant to exercise. Therefore it is suggested that PHD-1
contributes to hypoxic adaptation of the muscles (Aragones et al 2008). Analysis of the
neuronal phenotype in phd3-/- mice revealed reduced apoptosis of neurons, implying that
PHD-3 is required for the development of nervous system (Bishop et al 2008). While FIH-1
was shown to be an essential regulator of metabolism, since fih1-/- mice exhibited reduced
body weight, elevated metabolic rate, hyperventilation and improved glucose and lipid
homeostasis (Zhang et al 2010).
Table 2.5 HIF hydroxylase knockout mice
Characteristic PHD-1 PHD-2 PHD-3 FIH-1
KO mice Viable
(Aragones et al 2008)
Lethal
(Takeda et al 2006)
Viable
(Bishop et al 2008)
Viable
(Zhang et al 2010)
KO phenotype Hypoxia tolerance of
muscles
Placental and heart
defects
Decreased neuronal
cells apoptosis
Enhanced metabolic
rate, reduced body
mass
General function Hypoxic adaptation Angiogenesis Sympathoadrenal
development
Metabolic adaptation
2.4.3 REGULATION OF HYDROXYLATION AND HIF HYDROXYLASES
Hydroxylation is an oxidative process that introduces a hydroxyl group (-OH) into an
organic compound catalysed by hydroxylases. These enzymes employ non-heme ferrous iron
(Fe2+) in the active binding site and create a complex with co-substrate, 2-OG (also called -
ketoglutarate), a substrate such as HIF-, and finally with the key substrate for hydroxylation,
dioxygen. One atom of oxygen is added to the C-H bond of HIF-, while the second atom
oxidises 2-OG and generates succinate releasing CO2 as a by-product (Figure 2.4).
The PHDs and FIH-1 activity is regulated by the availability of substrates, including
molecular oxygen, HIF and 2-OG, and by the presence of co-factors such as Fe2+ and
ascorbate (Ivan et al 2001; Hewitson et al 2002). Therefore any changes in these parameters
interfere with reactions catalysed by these enzymes. Like every iron-dependent enzyme,
hydroxylases bind Fe2+ which keeps the catalytic centre of the enzyme ready for substrate
binding. Therefore any molecules chelating Fe2+ (iron antagonists) such as desferrioxamine
(DFO) or dimetyloxaloylglycine (DMOG), CoCl2, Ni2+ ions, NO or ROS, oxidising Fe2+ to
Fe3+, act as PHDs/FIH-1 inhibitors.
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Ascorbate (also known as ascorbic acid or vitamin C) is also required for hydroxylation
by returning the ferric iron to its oxidised ferrous state after the reaction (PHD-Fe3+ back to
PHD-Fe2+). Ions such as Ni2+ and Co2+ block the entry of ascorbate into the cell, thus they
inhibit PHD activity by reducing intracellular ascorbate.
2-OG is an intermediate of the tricarboxilic acid (TCA) cycle and is an essential co-
substrate for PHDs and FIH-1 since it coordinates Fe2+ in the enzyme active site, hence a
competitive inhibition of hydroxylases may be triggered by 2-OG analogues. For instance,
excessive level of succinate produced during hydroxylation is inhibitory for PHDs. Other
antagonists of 2-OG acting via binding to the catalytic centre have inhibitory effects on PHDs
and include endogenous molecules such as TCA intermediates (fumarate, succinate and
oxaloacetate), by-products of glycolysis, e.g. pyruvate, and exogenous molecules such as
DMOG.
What is also important in the case of PHDs is the fact that PHDs are non-equilibrium
enzymes, i.e. they do not catalyse the reverse reaction. Therefore, it is believed that the
enzyme abundance is an important determinant of the rate of substrate hydroxylation
(Appelhoff et al 2004). In addition, hydroxylation of HIFs by PHDs is also influenced by
other enzymes or protein-binding partners. For instance, hydroxylation is facilitated by the
acetylation of an associated lysine residue (Lys532) in the ODD domain by acetyltransferase
ADP-ribosylation factor domain, ARD-1 (Jeong et al 2002). It was demonstrated that OS-9
(osteosarcoma protein 9), the protein product of a widely expressed gene, promotes PHD-
mediated hydroxylation of HIF-1 in an oxygen-dependent manner by binding to HIF-1 and
PHD-2 or PHD-3 (Baek et al 2005).
Figure 2.4 Product hydroxylation
In the presence of the co-substrate 2-oxoglutarate (2-OG) and co-factors (ascorbate and Fe2+), one atom
of oxygen is added to substrate (e.g. HIF) and the second one to 2-OG, producing hydroxyprotein,
succinate and releasing CO2.
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2.4.4 PREFERENCES OF HIF HYDROXYLASES TOWARDS -SUBUNITS
It is well-characterised that the relationship between HIFs and PHDs is bidirectional;
however, the contribution of each isoenzyme to the regulation of HIF-1 and HIF-2 remains
uncertain and it is still unclear whether PHDs have overlapping functions or act in a non-
redundant manner towards HIFs. It was shown in vitro that PHD-1 regulates HIF-2, PHD-2
controls HIF-1, whereas PHD-3 influences HIF-2(Appelhoff et al 2004). In addition, a
preference also does exist for FIH-1 with HIF-1 being more efficiently hydroxylated by
FIH-1 than HIF-2 (Koivunen et al 2004). It was demonstrated in vitro that this is possibly
due to a conserved alanine at position 804 in HIF-1, which forms a hydrogen bond
orientating asparagine into the active site of FIH-1, which is not present in HIF-2 that
contains valine in the equivalent position (Bracken et al 2006).
These preferences have been substantiated in in vivo studies, demonstrating that indeed
PHD-1 depletion in muscle cells increased HIF-2 (Aragones et al 2008), PHD-2 knockout in
adult mice led to HIF-1 stabilisation in murine liver and kidney (Takeda et al 2007),
whereas knockout of PHD-3 and PHD-1 led to HIF-2 accumulation in liver, but only when
both of them were depleted simultaneously (Takeda et al 2008).
From the available publications it is clear that PHDs have preference towards particular
HIF- subunits and more specifically towards hydroxylation of the definite prolyl residues. It
was reported that all PHDs hydroxylate peptides corresponding to Pro564, whereas peptide
containing Pro402 was hydroxylated only by PHD-1 and PHD-2 in HIF-1 (Hirsila et al
2003). Both prolyl residues of HIF-2, Pro405 and Pro531, were recognised and
hydroxylated by all three PHDs but with different efficacy (Hirsila et al 2003). According to
Appelhoff and colleagues PHD-2 was less active on HIF-2 than on HIF-1 (Appelhoff et al
2004). However, as stated by Chan and colleagues PHD-3 remains exclusively active on the
N-TAD, implying the catalytic ability towards Pro531 and Pro564 (Chan et al 2005).
In addition, it has been shown that hydroxylation of Pro402 is in general less effective
than Pro564 due to reduced enzyme affinity (Hirsila et al 2003) and hydroxylation of Pro564
occurs first and is required for hydroxylation of Pro402 (Chan et al 2005). As presented
above, the results regarding hydroxylation of specific prolines in HIF are not consistent.
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2.4.5 PHD-VHL-HIF PATHWAY AND SYSTEMIC HUMAN PHYSIOLOGY
The importance of the HIF mechanism in human physiology was learned mostly from
patients with RCC and by phenotyping haematology patients diagnosed with rare monogeneic
disease. Biallelic inactivation of VHL caused by vhl mutations in the gene were shown to be
implicated in human genetic diseases often referred as a VHL syndrome. The VHL disease is
a human hereditary cancer syndrome predisposing sufferers to highly angiogenic tumours
such as retinal and CNS hemangioblastomas, pheochromocytoma and clear cell renal cell
carcinoma (CCRCC), most common form of kidney cancer (Lonser et al 2003). In these
disorders patients demonstrate constitutively expressed HIF- protein irrespective of the
oxygen levels. The genes normally regulated by HIFs are abnormally high, including VEGF
and PDGF, which in turn leads to abnormal angiogenesis and tumourigenesis (Mandriota et al
2002; Khan et al 2011).
Polycythemia is a rare autosomal recessive disorder endemic to Chuvashia in Russia
(Ang et al 2002a) and to the Italian island of Ischia (Sergeyeva et al 1997; Perrotta et al
2006). Also known as erythrocytosis, it is characterised by persistent increase in the
hematocrit and red cell mass, which may cluster small capillaries in the brain leading to
headache and stroke. A number of mutations in the PHD-VHL-HIF pathway were described
for congenital polycythemia. A mutation in both alleles in the vhl gene was revealed (Ang et
al 2002b), and shown to reduce binding of pVHL to HIF-, thereby HIF- is stabilised and
pathologically activates HIF target genes (EPO, VEGF, GLUT-1, PAI-1) in those patients
(Ang et al 2002b; Gordeuk et al 2004). Next, heterozygosity for the mutation in egln1 which
encodes PHD-2 was identified and shown to diminish PHD-2 activity resulting in the
increased levels of EPO via HIF- (Percy et al 2007). In addition, a family with
erythrocytosis was screened for mutations in the hif-2 gene, the principal regulator of EPO.
A missense mutation was found (one copy of a hypermorfic allele encoding hif-2) and
demonstrated to impair HIF-2 hydroxylation and recognition by pVHL thereby stabilising
HIF-2 and inducing abnormal erythropoiesis (Percy et al 2008). Collectively, polycythaemia
can be caused by the mutations in the PHD2-VHL-HIF-2 axis, which is believed to hold a
critical role in maintaining the appropriate levels of EPO and erythrocyte production.
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2.5 Rheumatoid Arthritis (RA)
Rheumatism is a global phenomenon which refers to all disorders of the motor system,
including muscles and bones. There are over 100 types of arthritis entities, including RA,
osteoarthritis (OA), gout, systemic lupus erythematosus, ankylosing spondylitis, psoriasis and
Sjorgen’s syndrome, to name some of them.
OA is the most common degenerative arthritis which develops most frequently in
weight bearing joints or previously injured joints. The prevalence of OA increases with age
and the majority of 60-year olds suffer from OA to a different degree. OA is characterised by
joint soreness and swelling, fluid accumulation, bone spurs (osteophytes), breakdown of
cartilage and the presence of cartilage fragments in the joints (Figure 2.5).
http://www.bing.com/images/search?q=Osteoarthritis&view=detail&id=78
766A3D15BA71D73ED7463DD9E3EF4043B622FD&first=121&FORM=IDFRIR
Smolen JS and Steiner G Review Nature 2003
THERAPEUTIC STRATEGIES FOR RHEUMATOID ARTHRITIS
Figure 2.5 Comparison between healthy, RA and OA joints
(a) Healthy joints consist of a thin synovial membrane layer, which expands in RA (b) due to excessive
cell proliferation. In addition, there is an influx of various inflammatory cells, seen in figure, which
contribute to inflammation, excessive angiogenesis, and joint destruction. (c) In OA, there is thinned
cartilage with cartilage debris in the joint, bony projections, as well as accumulated synovial fluid.
RA, on the other hand, represents the most common chronic inflammatory arthritis.
RA appears usually in women than men and occurs generally in the 4th or 5th decade of life.
The prevalence of RA is 1% in the industrialised world and the incidence of RA appears to be
increasing worldwide. The clinical features of RA emerge symmetrically in joints in hands
and feet mainly, manifested as pain, stiffness, redness, heat and swelling of the affected joints,
leading to degeneration of cartilage and bone. Hypoperfusion and an incapacitated vascular
network induce both an engorgement of the capillaries that carry the blood away and an
increase in the diameter of the vessels that deliver blood, which result in erythema and ‘tissue
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heat’. Increased angiogenesis contributes to a constant supply of cytokines, growth factors,
and infiltrating effector cells facilitating inflammation, which together with progressive
degradation of the joints manifest in pain.
RA is a heterogeneous disease which affects every patient differently and the
symptoms vary from gradual progression or waxing and waning symptoms to rapid and
destructive disease involving also inflammation of other internal organs. Apart from
irreversible joint destruction in severe forms of RA, the systemic complications may
eventually lead to disability and premature death (Van Doornum et al 2006).
2.5.1 PATHOGENESIS OF RA
The aetiology and pathogenesis of RA is only partially understood and remains a
huge challenge for scientists; however, the interplay between environmental agents and
autoimmune reactions in individuals with genetic predispositions is being investigated. The
most common genetic risk factors associated with RA autoimmunity comprise the shared
epitope (SE) alleles of the human leukocyte antigen (HLA) gene. Over 80% of Caucasian RA
patients have SE conserved across the HLA-DR1 and HLA-DR4 haplotypes (0101, 0401,
0404 and 1402) (Stastny 1978), which are strongly associated with RA (Klareskog et al
2006). In addition, a polymorphism of protein tyrosine phosphatase N22 (PTPN22) has been
associated with susceptibility and severity of RA (Orozco et al 2006; Andersson et al 2008).
The organism answers to the antigen by producing antibodies. In autoimmune
diseases the immune system becomes misdirected and attacks the very organs it was designed
to protect using autoantibodies. There are several autoantibodies, which are proven to be
sufficiently sensitive, specific and predictive, thus clinically useful for both the diagnosis and
prognosis of RA. The most frequent autoantibody include IgM rheumatoid factors (RF) with
prevalence of approximately 82% (Agrawal et al 2007); however, RF is also detectable in up
to 10% of healthy individuals and in other systemic diseases (reviewed by Mewar and Wilson
2006). A great deal of interest is concentrated on antibodies to autoantigens modified by
citrullination (through deimination of arginine to citrulline). Anti-cyclic citrullinated peptide
antibodies (anti-CCP) have similar prevalence to RF of approximately 82% (Agrawal et al
2007); however, anti-CCP are rare (< 2%) in normal individuals and other inflammatory
conditions (Schellekens et al 2000; Hoffman et al 2005), making them the most specific
autoantibodies for RA.
Interestingly, anti-CCP antibodies are not only used in the diagnosis of RA, but were
also suggested to be involved in the pathogenesis of autoimmune arthritis. Accumulation of
citrullinated proteins is found at sites of inflammation, including inflamed joints (Vossenaar
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et al 2004). Moreover, collagen-induced arthritis (CIA) mice which were tolerised with a
citrulline-containing peptide exhibites reduced disease severity (Kuhn et al 2006). There is
accumulating evidence that the inflammation in RA is driven by anti-CCP autoantibodies
(Klareskog et al 2008).
Potentially there is a link between periodontitis (often associated with smoking) and
RA. Periodontitis is caused mainly by Porphyromonas gingivalis, which is known to
citrullinate human proteins such as -enolase, indicating the link between anti-citrullinated -
enolase peptide (CEP)-1 antibodies and autoimmunity (Lundberg et al 2010). Anti-CEP1
antibodies are present in approximately 40% of RA patients and are 97% disease-specific
(Lundberg et al 2008; Mahdi et al 2009).
Cigarette smoking history, which is the major known environmental risk factor for
RA, when combined with the presence of double copies of HLA-DR SE genes increases the
risk of RA 21-fold compared with the risk among non-smokers carrying no SE genes
(reviewed by Klareskog et al 2006). However, a single-nucleotide polymorphism (SNP)
found within the PTPN22 gene was reported to be a better predictor of RA than the HLA SE,
and in combination with anti-CCP antibodies gives a specificity of 100% for diagnosing RA
(Johansson et al 2006). This is a good illustration of the possible links between all three
factors contributing to onset of RA, including genes (PTPN22), autoimmunity (anti-CEP1)
and environment (smoking).
RA is caused by multiple pathogenetical processes combined together as described
above. To determine the risk of developing rheumatic autoimmunity, geoepidemiology study
is also performed on RA patients investigating the disease distribution across global regions
and ethnic groups and helps to understand genetic - environmental interactions. Ethnogenetic
susceptibility encircles lifestyle and environment, including socioeconomic status, exposure
to infectious agents (protective or pathogenic), pollutants, and vitamin D (dependent on
sunlight exposure). These studies have shown that there is a higher prevalence of RA in urban
compared to rural regions. Underdiagnosis could be a reason for higher RA incidence in
developing countries caused by lowered access to medical care, public awareness, low
medical expertise and unavailability of new diagnostic procedures and treatments. However,
according to the hygiene hypothesis, RA is rare in tropical and rural areas due to protective
mechanisms that are induced by endemic parasitic infections (Sub-Saharan Africa). On the
contrary, juvenile RA is strongly correlated with increased Mycoplasma pneumoniae
infections, which was shown in a Canadian cohort of young patients (Shapira et al 2010).
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RA is a very complex ailment which could be described as:
 autoimmune, which means that the immune system attacks the body itself. The
autoagression starts when non-specific antigen (or autoantigen) is presented to T helper
cells by APCs. This interaction initiates and activates effector immune responses.
Activated T cells are able to secrete mediators (cytokines), directly and indirectly
stimulating immune cells including B lymphocytes, which eventually become
plasmocytes producing autoantibodies (e.g. RF or anti-CCP).
 inflammatory, caused by infiltration of inflammatory cells (usually not found at the site of
tissue destruction) and production of an army of cytokines, growth factors, inflammatory
mediators by local and infiltrating cells.
 hypoxic, due to the hyperplastic intimal synovial lining and increased demand of oxygen
by proliferation of synoviocytes, accumulation of infiltrating cells, and due to
incapacitated vascular network.
 angiogenic, caused by excessive production of neovessels.
 chronic via self-perpetuating inflammation and enhanced angiogenesis and hypoxia; all
three processes contribute to pro-inflammatory cell ingress which produce pro-
inflammatory cytokines, responsibe for constant cell maturation and activation.
 degenerative, due to synovial invasion into cartilage and bone, triggering irreversible
destruction of the joints through the activity of proteases produced by synoviocytes and
other cell types, and also by increased ROS and RNS production which cause DNA
damage and cell death.
 systemic, since RA involves not only joints, but also contributes to co-morbidity via
affecting the organs of the cardiovascular, respiratory, neurologic and metabolic system.
2.5.2 TRANSFORMATION OF THE SYNOVIUM IN RA
The normal synovium encapsulates the joints and provides structural support,
produces lubricious synovial fluid and maintains joint homeostasis by rich vasculature, which
supplies the avascular articular cartilage with nutrients and oxygen. In the healthy joint, the
synovial lining consists of 1 – 3 cell-layers and lacks epithelial cells, a basement membrane
and tight junctions. It consists of type A or macrophage-like synoviocytes (MLS) and type B
or fibroblast-like synoviocytes (FLS), which build a thin synovial membrane in relatively
equal proportions. MLS express markers of hematopoietic origin, are derived from the bone
marrow and are vacuolated with well-developed Golgi apparatus indicating phagocytic
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activity. On the other hand, FLS are of mesenchymal origin with a highly developed
endoplasmic reticulum with prominent Golgi, but without phagocytic properties.
In inflammatory conditions such as RA, and to a lesser degree in OA, the synovium
transforms from a quiescent relatively acellular structure to a hyperplastic and invasive tissue
(Figure 2.5). The changes relate to both layers of the synovial tissue, including the intimal
lining and the sublining. MLS and FLS, the residents of the lining layer, expand their
population and the synovial membrane becomes multi-layered, approximately 20-cell-thick.
Activated MLS and FLS create so-called tissue swelling and together with osteoclasts, form
the forefront of the aggressive and destructive synovial membrane, termed ‘pannus tissue’,
that behaves like a locally invasive tumour which erodes cartilage and bone. The sublining
layer also enlarges due to cell infiltration and increased cell survival (Bartok and Firestein
2010). Dispersed RA synovium was shown to constitute approximately of 40% lymphocytes,
40% macrophages, 15% FLS and 5% other cells (Fionula Brennan, unpublished data).
2.5.3 FIBROBLAST-LIKE SYNOVIOCYTES ARE MAJOR RESIDENT CELLS IN RA SYNOVIUM
Fibroblasts used to be considered as rather passive residents in the body and purely
structural elements of tissues inhabiting distant anatomic regions such as synovium, skin,
periosteum, pleura, foetal lung and gingiva (Smith 2005). Regardless of localisation
fibroblasts have similar ultrastructure (Henrikson and Smith 1994) and nutritional
requirements, but exhibit heterogeneous phenotypes displaying various surface markers and
differences in their metabolic activities in distinct tissues. However, this opinion has been
replaced with the acknowledgement that fibroblasts are more dynamic and highly reactive
cells in physiological and pathological processes and exhibit biosynthetic activity (Muller-
Ladner et al 1996). In addition, fibroblasts can be frequent active players in autoimmune
diseases, where the connective tissue is susceptible to chronic inflammation such as human
orbital fibroblasts in Graves’ disease, and synovial fibroblasts in RA (Smith 2005).
The distinction between synovial fibroblasts and fibroblasts from other tissues
includes the ability to produce constituents of the synovial fluid including hyaluronan and
lubricin, and organise the extracellular matrix (ECM) components such as fibronectin,
laminin and collagen. RA FLS also support the co-compaction and maintenance of
macrophages derived from bone marrow. RA FLS have unique properties that distinguish
them from normal sublining resident fibroblasts such as expression of the adhesion molecule,
cadherin-11. Expression of cadherin-11 permits cell-cell communication sending cascade
signals to other FLS (paracrine effect), helps FLS to homoaggregate and to create synovial
architecture in vivo and in vitro. It was demonstrated that after 3 weeks in a 3-D extracellular
matrix (ECM) micromass culture FLS, but not dermal fibroblasts, migrate to the surface and
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recapitulate a synovial lining layer at the interface between the matrix and the fluid phase
(Kiener et al 2006). Mice that lack cadherin-11 develop normally, but without a defined
synovial intimal lining and they are also more resistant to joint inflammation, and destruction
in an arthritis model (Lee et al 2007a). In addition, it was demonstrated in vitro that FLS
cultured in a 3-D micromass not only spontaneously form a compact lining architecture, but
also produce lubricin and when stimulated with cytokines display hyperplastic properties
(Kiener et al 2010).
RA FLS appear elongated, sometimes oval with few cytoplasmic processes, large
pale nucleus and abundant rough endoplasmic reticulum indicating an active RNA
metabolism and protein synthesis. Cell activity is mirrored by the increased transcription of
disease-specific genes (Del Rey et al 2010) and spontaneous production of cytokines, growth
factors, proteoglycans, MMPs and prostaglandins. By the third passage of cultured FLS, the
production of factors gradually decreases, but can be restored by exposure of cells to
cytokines such as TNF- and IL-1(Rosengren et al 2007).
Cell division is uncommon in the healthy joint; therefore impaired apoptosis and
increased proliferation of synovial cells is one of the causes for cell accumulation in the RA
intimal lining. The altered morphology and modified genetic programme of FLS via
mutations and oncogenes inductions is well established and often referred to as tumour-like
transformations (Fassbender 1983) (Figure 2.6). Even though RA synovium is genotoxic,
which is characterised by high amounts of reactive nitrogen and oxygen species and thus
DNA damage, this cellular stress that normally kills cells is not accompanied by completed
apoptosis (Firestein et al 1995). Somatic mutations triggered by long-time exposure to
oxidative stress and inflammation, cause resistance to apoptosis and uncontrollable cell
proliferation. This includes activation of proto-oncogenes such as c-fos and c-myc (Dike and
Farmer 1988), and epigenetic changes deactivating tumour suppressors. For instance, it was
demonstrated that a reduction of a powerful tumour suppressor protein expression, namely
phosphatase and tensin homologue deleted from chromosome 10 (PTEN), which is involved
in cell cycle arrest and apoptosis, favours cell survival in RA (Pap et al 2000; Goberdhan and
Wilson 2003). Another tumour suppressor protein, p53 also called ‘the guardian of the
genome’, was shown to be increased in cells invading the cartilage, which should lead to cell
apoptosis (Firestein et al 1996; Seemayer et al 2003). However, the discovery of a somatic
mutation in the p53 gene explaines lack of apoptosis in RA synovium despite p53 induction
(Firestein et al 1997). It is important to note that the mutations in genes in FLS do not cause
RA; rather, they are triggered by the genotoxic environment present in the RA synovium and
potentially alter the natural history of the disease.
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The mechanisms regulating apoptosis of RA synoviocytes in vivo also include intrinsic
(mitochondrial mediated) and extrinsic pathways (death receptor mediated). The balance
between pro- and anti-apoptotic proteins is probably tilting more towards the latter. The
expression of anti-apoptotic proteins, including bcl-2 and mcl-2, is modestly increased in the
RA synovium compared to OA synovium (Firestein et al 1995; Matsumoto et al 1996).
However, one member of this family, the pro-apoptotic BNIP-3 protein is widely expressed in
both RA and OA synovium with minimal expression in normal tissue. The pro-apoptotic
action of BNIP-3 is probably inhibited by high levels of pro-survival factors such as TNF-
IL-15 and VEGF (Kammouni et al 2007). In addition, sumo-1 (sentrin-1) is highly expressed
in the synovial lining especially in the pannus (Franz et al 2000) and together with survivin
(Ahn et al 2010) protects synoviocytes from apoptosis.
Figure 2.6 The altered phenotype of RA FLS
During the inflammation synoviocytes are activated and play a pivotal role in the development and
maintenance of RA. This occurs through phenotypical and morphological changes in synovial
fibroblasts.
The evidence of an unusual aggressive behaviour of FLS comes from studies on the
severe combined immunodeficient mice (SCID) model (Geiler et al 1994; Muller-Ladner et al
1996). Briefly, human FLS and freshly isolated human cartilage were co-implanted in a
sponge under the kidney capsule of SCID mice, which resulted in FLS adhesion and invasion
into the implanted cartilage after 2 months. Histological assessment of the cartilage revealed
direct and indirect mechanisms of degradation, including FLS attachment to the underlying
cartilage via increased expression of adhesion molecules and destruction of bone by
producing proteases that digest the extracellular matrix, and the differentiation of
macrophages into osteoclasts through the expression of receptor activator of NFB ligand,
abbreviated RANKL (Takayanagi et al 2000; Nakano et al 2004).
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The FLS and MLS resident synovial lining cells are considered to be the extension of
the ‘professional’ immune system by producing immunomodulatory soluble mediators,
displaying various surface and intracellular receptors as depicted in Figure 2.7. All these
mediators contribute to the recruitment, activation and differentiation of immunocompetent
cells through direct or indirect contact (Smith 2005). FLS actively interplay with numerous
cells through cell-cell contact. For instance, FLS communicate with T cells via CD40, major
histocompatibility complex (MHC), SDF-1, ICAM-1 and fractalkine; with B cells via
VCAM-1, SDF-1 and B-cell attracting (BCA)-1 chemokine; with macrophages via
fractalkine; with endothelial cells via VEGF and IL-6; with mast cells via stem cell factor
(SCF); and with osteoclasts via RANKL. Moreover, adhesion molecules expressed by RA
FLS enable cells to attach and invade the tissue. Some of the most important adhesion
molecules are integrins, especially of the 1 subfamily (Rinaldi et al 1997), cadherins,
selectins (e.g. E-selectin), vascular adhesion molecule (VCAM)-1 and intercellular adhesion
molecule (ICAM)-1, which are all highly expressed by FLS (Kriegsmann et al 1995;
Ishikawa et al 1996).
RA synoviocytes can also interact with other cells by secreting diverse arrays of
soluble cytokines, chemokines, lipid mediators and growth factors. Most of the pro-
inflammatory cytokines are derived from macrophages. For instance, RA MLS secrete IL-1
and TNF- contributing largely to inflammation (Smith et al 1997). RA FLS from the lining
layer are the primary source of IL-6 (Hirano et al 1988), colony-stimulating factors (CSF),
which contribute to dendritic cells and macrophage maturation and activation, with a
particular role of granulocyte macrophage (GM)-CSF and macrophage (M)-CSF (Haworth et
al 1991). RA FLS produce also powerful chemoattractants, including IL-8, IL-16, monocyte
chemotactic protein (MCP)-1 and RANTES (regulated upon activation normal T cell
expressed and secreted), contributing to cell trafficking. By regulating the balance between
angiogenic and angiostatic molecules RA FLS are involved in synovial angiogenesis (Smith
2005). Studies in vitro showed that RA FLS contribute to the resistance of T cells to
apoptosis, which is prolonged by SDF-1 expression increased by co-culture of both cell types.
Also B cell survival is supported by FLS, which produce IL-6 and B cell-survival factor
(Korb et al 2009) and function like protective follicular dendritic cells (Lindhout et al 1999).
Interestingly, mediators which potentially can inhibit synovitis are also produced by
synovial fibroblasts. RA FLS are the major source of TGF- which suppresses protease and
pro-inflammatory cytokines. They also produce IL-1 receptor antagonist (IL-1Ra) which is a
natural protein competing with IL-1 for the IL-1 receptors; however, being mainly in the
intracellular form it is unable to interfere with IL-1 (Smith 2005).
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RA FLS are believed to be active players and no longer passive bystanders due to
their unique invasive properties and the production of prodigious amount of proteases, the
degradative enzymes, of which matrix metalloproteinases (MMPs) and cathepsins are
especially important. This contributes to tissue destruction and importantly to extracellular
matrix remodelling crucial for sprouting of new capillaries during angiogenesis (Huber et al
2006). Intriguingly, RA FLS are also able to migrate as was shown in in vitro studies. The
potential of RA FLS to migrate and spread the disease to unaffected joints, probably through
excessive and unstable neovessels, was also evaluated in vivo. Gelatin sponges with RA FLS,
OA FLS and normal dermal fibroblasts were implanted into SCID mice for 60 days, and then
the blood and tissue were collected to examine FLS migration. Indeed, it was reported that
RA FLS are able to transmigrate to the circulatory system and through the blood to the distant
tissues (e.g. spleen). These results suggest that RA FLS possibly can spread inflammation to
the other joints and organs as well (Lefevre et al 2009).
Figure 2.7 Involvement of FLS in RA
During inflammation, synoviocytes are activated and play a pivotal role in the development and
maintenance of RA. This occurs through release of different mediators, and signal exchange between
different cells in the affected joints. (A) In the synovial lining FLS interact with each other and also
communicate with MLS through direct cell-cell contact and through cytokines. (B) In the sublining
layer RA FLS interplay with T cells, B cells, macrophages, mast cells and endothelial cells. (C) RA
FLS directly contribute to the cartilage and bone degradation by producing MMPs and cathepsins, and
by inducing osteoclasts differentiation via RANKL (adapted from Noss and Brenner 2008).
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2.5.4 THE ROLE OF HYPOXIA IN RA
There is now considerable evidence that hypoxia is a feature of RA and contributes to
RA development. The oxygen diffusion limit in tissue is between 100 - 200µm (Gaber et al
2005; Bertout et al 2008), therefore in the proliferating synovium, the vasculature attempts to
grow together with the tissue. However, the vascular expansion is not sufficient, thus the
distance between FLS and the pre-existing blood vessels increases creating a hypoxic milieu.
Although new blood vessels are formed in excess, they are immature and leaky, because most
of them are not supported by pericytes (Kennedy et al 2010). This creates dysfunctional and
permeable vessels which facilitate cell influx to the joints.
The first evidence of the hypoxic nature of RA was described 40 years ago by
measuring the oxygen tension in more than 100 synovial fluids (SF) using a Clark-type
microelectrode. It was revealed that pO2 in RA SF is 26.5 mmHg (3.5% O2) and is
significantly lower than in traumatic exudates with 63 mmHg (8.3% O2) (Lund-Olesen 1970).
Low partial pressure of oxygen in SF was supported by decreased glucose levels and raised
carbon dioxide, lactate and acetate levels, which lead to a decreased synovial pH level as a
result of an anaerobic metabolism (Treuhaft and McCarty 1971). Lee and co-workers also
measured pO2 in RA SF using a gas analyser (Rapidlab 800 series) and have shown that pO2
is approximately 50 mmHg (7% O2). This technique, however, was different and the number
of samples was much lower (Lee et al 2007b).
Next, it was demonstrated that synovial tissue is hypoxic, as shown by direct
measurements of oxygen concentration using a gold microelectrode. It was reported that
oxygen tension in RA invasive tenosynovium is between 18 - 33 mmHg (2 - 4% O2), whereas
in non-RA tenosynovium it is between 69 - 89 mmHg (9 - 12% O2) (Sivakumar et al 2008).
This was confirmed using a different method, with a Licox probe placed in the synovial tissue
under direct visualisation just before the biopsy, showing that RA synovial tissue oxygen is
22.5 mmHg (3% O2); however, with a greater range than previously reported (3 - 54 mmHg
equal 0.4 - 7% O2) (Ng et al 2010). Moreover, it has been shown that the oxygen tension in
the joints correlates inversely with macroscopic synovitis (Ng et al 2010). In addition, studies
on an adjuvant induced arthritis (AIA) rat model using pimonidazole (hypoxyprobe-1), which
binds only to cells subjected to a low oxygen concentration, revealed that hypoxic areas
include synovium, pannus, bone marrow and articular cartilage chondrocytes (Peters et al
2004). Last but not least, since HIF is considered to be a hypoxia marker, and it has been
demonstrated to be increased in RA tissue (Hollander et al 2001; Giatromanolaki et al 2003;
Sivakumar et al 2008), it is another evidence for RA environment to be hypoxic.
Hypoxia is an intermediary process in RA taking part in a complex interplay between
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angiogenesis and inflammation (Figure 2.8). Hypoxia modulates pro-inflammatory mediators
via regulation of transcription factors, such as HIF, NFB and AP-1. NFB is a transcription
factor crucial in inflammation and highly activated in RA (Han et al 1998). NFB is also
involved in cell survival by regulating number of genes such as COX-2, IL-6, IL-8 and
ICAM-1 and thus it may contribute to cell survival and proliferation and eventually decreases
oxygen tension via NFB. In addition to controlling inflammation, hypoxia promotes
angiogenesis through increased release of pro-angiogenic molecules such as VEGF or MMPs
(Paleolog et al 1998; Sivakumar et al 2008). In turn, newly formed blood vessels provide
oxygen and nutrients for cells, further enhancing proliferation and expansion of the synovium
thus hypoxic environment. Moreover, neovessels enable infiltration of pro-inflammatory cells
into the joints increasing inflammation, and as a consequence, inflammatory cells trigger
angiogenesis via NFB, which regulates for instance growth factors and MMPs.
Figure 2.8 Cross-talk between inflammation-hypoxia-angiogenesis in RA
Inflamed synovial membrane, excessive angiogenesis, and a hypoxic microenvironment are some of
the main features of RA affected joints. The vicious circle of the responses is mediated by the direct
and indirect interplay between inflammation, hypoxia and angiogenesis via the production of number
of mediators depicted in the scheme.
2.5.5 IMPLICATIONS OF HIF EXPRESSION IN RA
One of the first studies done on HIF in RA has shown that HIF-1 is highly
expressed in the inflamed RA tissue overlapping with regions of massive macrophage
infiltration (Hollander et al 2001). Further analysis revealed that HIF-1 is expressed mainly
in the RA synovial sublining layer by fibroblasts, macrophages, plasma cells, lymphocytic
perivascular aggregations and also by blood vessels (Hitchon et al 2002; Giatromanolaki et al
2003; Brouwer et al 2009). HIF-2, on the other hand, was predominantly expressed in the
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RA synovial lining layer and in cell infiltrates (Giatromanolaki et al 2003; Sivakumar et al
2008). It was observed in another study using immunohistochemistry (IHC), that HIF-1 is
significantly increased in biopsy samples from patients with RA and OA, compared to healthy
controls (Hollander et al 2001; Giatromanolaki et al 2003). The presence of increased HIF
proteins in RA tissue and differences in the cell distribution, could imply that HIF- subunits
play several and maybe distinct roles in the RA synovium.
It has been demonstrated that HIFs play a pivotal role in the development and
function of a number of cell types relevant to RA. Deletion of HIF-1 in myeloid cells, such
as macrophages and neutrophils, impaired myeloid cell aggregation, motility, invasiveness
and bacterial killing and therefore crippling the innate immune system in a passively induced
arthritis model. Conversely, constitutive expression of HIF-1 through loss of vhl led to
increased acute inflammation (Cramer et al 2003). Deletion of HIF-1 in endothelial cells
interrupted an autocrine loop of VEGF-R2 expression, thus endothelial cell migration to
hypoxic areas was impaired, which is necessary during angiogenesis in wound healing (Tang
et al 2004). It has been demonstrated that loss of HIF-1 in thymocytes led to decreased
apoptosis, whereas thymocyte over-expression of HIF-1 (through vhl gene deletion)
increased caspase 8-mediated apoptosis (Biju et al 2004). HIF-1-/- chimeric mice (with
bypassed embryonic lethality by RAG-2 system) resulted in a dramatic defect of B
lymphocyte development, a reduced production of bone marrow B cells, which was
compensated by proliferation of autoimmune reactive B cells (Kojima et al 2002). In addition,
over-expression of HIF-1 in osteoblasts (by vhl deletion or using PHD inhibitors such as
DFO and L-mimosine) increased bone regeneration and vascularity (Wan et al 2008). HIF-1
affects chondrocyte differentiation by increasing cell apoptosis, leading to shorter limbs in
mice lacking HIF-1 (Schipani et al 2001). On the other hand, HIF-2 has been reported to
be essential for hypoxic induction of the human articular chondrocyte phenotype (Lafont et al
2007; Thoms and Murphy 2010) and to be involved in ossification of chondrocytes (Saito et
al 2010; Yang et al 2010).
In RA pathophysiology there is a strong link between decreased oxygen tension, an
active HIF pathway and the aggressive phenotype of RA synovial cells. As mentioned earlier,
the first evidence of the role of HIF-1 in joint inflammation was provided by Cramer and
colleagues, who showed that HIF-1 elimination in the myeloid lineage, including
neutrophils and macrophages reduced joint swelling, pannus formation, synovial infiltration,
and subsequently cartilage destruction (Cramer et al 2003). It has been reported that HIFs
directly contribute to joint inflammation, cell recruitment, cell migration, angiogenesis, and
cartilage destruction, which accelerates and perpetuates RA.
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It has been shown that HIFs contribute to the recruitment and accumulation of
monocytes, T cells and B cells into the RA synovium via the highly potent chemotactic and
angiogenic factor SDF-1 (CXCL12) and its receptor CXCR4 (Blades et al 2002). It has been
demonstrated by IHC that SDF-1 is expressed by FLS and is co-expressed with HIF-1 in the
RA synovium and contains HRE (Hitchon et al 2002). It has been shown that SDF-1 is HIF-
1-regulated in FLS, whereas in endothelial cells it is HIF-1 and HIF-2-regulated
(Ceradini et al 2004). In addition, SDF-1 receptor, CXCR4, is HIF-1-dependent (Staller et
al 2003). HIFs also contribute to angiogenesis and therefore the development and
perpetuation of RA. Promotion of neovascularisation balanced by the expression of
angiogenic and angiostatic mediators may be the most important role of HIFs in the
pathogenesis of RA. Angiogenesis consists of multiple steps, including endothelial cell
migration, activation, maturation, and local rearrangement of the basal membrane and
extracellular matrix. Several hundred direct and indirect HIF target genes have been identified
and many of these genes encode proteins involved in all those steps of vascular development
and homeostasis (Mole et al 2009; Xia and Kung 2009; Rey and Semenza 2010). For
instance, it has been reported that HIF-1 mediates the expression of a number of angiogenic
factors, such as VEGF and its receptors VEGFR-1 and VEGFR-2/KDR, angiopoietins
(ANGPT) and the ANGPT receptor Tie-2, which have also been shown to be upregulated in
RA (Paleolog 2002; Takeda et al 2004). Some other genes including VEGF, ANGPT1, basic
fibroblast growth factor (bFGF), are HIF-2-dependent (Tian et al 1997; Elvert et al 2003).
Over-expression studies performed on endothelial cells have revealed that HIF-1 and HIF-
2 promote cell migration and tubular organisation, pointing towards complementary
functions, and additive effects of HIF subunits in angiogenic regulation (Ben-Shoshan et al
2008). Although hypoxia and HIF promote cell survival it also induces apoptosis and cell
cycle arrest. For instance, a direct regulation of pro-apoptotic genes, including BNIP-3, is
HIF-1-mediated and cyclin D regulating cell cycle arrest is HIF-2-dependent in RCC (Raval
et al 2005). Another molecule, tumour suppressor p53, is involved in regulating apoptosis
possibly via HIF-1. It has been shown that in hypoxia activated and stabilised HIF-1
competes with murine double minute (Mdm)-2 for binding to p53 and when HIF-1 binds to
Mdm2, p53 is not targeted for ubiquitination and thus accumulates and decreases apoptosis.
Hence increased HIF-1 in RA may partly explain elevated p53 and better survival of cells
(Chen et al 2003).
Warburg’s effect described in the 20s says that rapidly growing tumours switch to
glycolysis leading to acidification by lactic acid production, which occurs even if the oxygen
is plentiful. This effect was also reported in RA. Decreased glucose levels and increased
carbon dioxide, lactate and acetate levels, which lead to decreased synovial pH level
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(acidosis), were also reported in RA possibly as a result of an anaerobic metabolism (Treuhaft
and McCarty 1971; Ahlqvist 1984). It has been shown in other cell lines that CA9, which
regulates intracellular pH and a number of enzymes involved in glycolysis, such as GLUT-1
and ENO-1 are HIF-1-regulated (Patiar and Harris 2006).
Another possible role of HIF in RA is its involvement, however indirect, in the
pannus formation, invasion and cartilage destruction. It has been reported that HIFs regulate
MMPs indirectly via ETS-1, a transcription factor required for MMPs induction (Wernert et
al 1994). ETS-1 has been shown to be co-expressed with HIF-1 in rheumatoid infiltrate and
pannus in the AIA rat model (Peters et al 2004) and to be induced by HIF-1 (Oikawa et al
2001). In addition, it has been revealed that an ETS-1 binding site in the promoter located
next to the HRE is required for HIF-2-dependent genes (Aprelikova et al 2006).
As described above, HIFs regulate a number of genes relevant to RA, but HIFs
themselves are induced by inflammatory factors, such as ROS (e.g. H2O2) (Goyal et al 2004)
or RNS (e.g. NO) (Sandau et al 2001), which are created in RA milieu by the respiratory
burst of macrophages, neutrophils and natural killer cells. It was shown that HIF-1 is
stabilised by pro-inflammatory cytokines which are increased in RA such as TNF- and IL-
1. It was demonstrated that transforming growth factor (TGF)- (Berse et al 1999), IL-1
and TNF- increase HIF-1 mRNA in RA fibroblasts and IL-1 also increases HIF-1
binding to HRE (Thornton et al 2000; Westra et al 2007).
Of note, in the context of RA, the synovium is both hypoxic and inflamed with
elevated levels of cytokines. Many of the stimuli that induce HIFs in normoxia are known to
activate a number of other transcription factors such as NFB. Hence most probably HIFs are
regulated simultaneously by both, decreased oxygen tension and pro-inflammatory cytokines.
Indeed, it has been shown that HIF-1 is further augmented in fibroblasts stimulated with IL-
1, TNF- and TGF- in hypoxic conditions (Hitchon et al 2002). Apart from that it has been
reported that both HIF-1 and NFB may share target genes, such as VEGF. Moreover, it has
been demonstrated that both HIF-1 and PHD-1 promoters contain NFB-binding sites
(Minet et al 1999) and PHD-1 is able to hydroxylate a member of the NFB pathway, namely
IKK (Cummins et al 2006). Therefore, there is growing evidence disclosing the cross-talk
between HIFs and NFB. The HIF and NFB pathways probably represent an important
convergence point in RA, integrating cellular responses to lowered oxygen tension and to
inflammatory cytokines.
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3 MATERIALS AND METHODS
All reagents used in this study are described in Table 3.13, and all apparatus is
outlined in Table 3.15.
3.1 Biological material and cell culture
3.1.1 CELL TYPES
Human synovial tissue samples were obtained from RA patients undergoing
tenosynovectomy (Royal Free Hospital, London UK) who met the American College of
Rheumatology/European League Against Rheumatism 2010 criteria for RA (Aletaha et al
2010). Full ethical approval was granted for the project (Local Ethics Research Committee
EC2003-64). RA fibroblast-like synoviocytes (RA FLS) derived from 19 patients with a
diagnosis of advanced stage of RA were the main cell type used in this study (Table 3.1). RA
FLS were isolated as described in the subsequent Section. In addition, FLS derived from 4
osteoarthritis (OA) patients who underwent knee or hip replacement surgery were a gift from
Dr David Ahern (Kennedy Institute of Rheumatology, Imperial College; ethics reference
number: 07/H0706/81). Pre-operative informed consent was obtained in all cases. As RA FLS
and OA FLS are a limited resource, some studies, including optimisation, were carried out on
normal human dermal fibroblasts (NHDF) purchased from Lonza (Walkersville, MD, USA)
and cultured as for RA and OA fibroblasts (described below).
Table 3.1 Demographic data of RA patients
The table summarises the gender, age and RA duration of the patients, whose biopsy samples
were used in the study.
Mean Range
Gender (female/male) 16/3 -
Age (years) 56.3 32 - 77
Duration of RA (years) 12.8 5 - 30
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3.1.2 ISOLATION OF RA FLS FROM RA TISSUE
Synovial tissue obtained from RA patients was digested as previously described
(Brennan et al 1989a; Sivakumar et al 2008). The RA tissue was dissociated mechanically
and digested enzymatically with 1g/L collagenase A (Roche, Burgess Hill, UK) and 0.15g/L
DNase (Sigma-Aldrich, Poole, UK). After the incubation with digesting solution for
approximately 1 hour at 37°C, the reaction was stopped by adding complete medium, namely
Dulbecco’s Modified Eagle’s Medium (DMEM, BioWhittaker, Cambrex Bio Science,
Belgium), containing 4.5g/L glucose, 2mM L-glutamine, supplemented with 100U/mL
penicillin and 100g/mL streptomycin (BioWhittaker, Cambrex Bio Science, Verviers,
Belgium), enriched with 10% heat-inactivated foetal bovine serum (FBS, BioSera, Sussex,
UK). The disaggregated cells were filtered through a sterile nylon cell strainer to obtain a
single cell suspension and spun down at 200 x g for 10 minutes. The pellet was re-suspended
in complete medium; cells were counted using trypan blue and Hawksley chamber (Improved
Neubauer, Lancing, Sussex, UK), and plated at 1 x 106 per 75cm2 flask (T-75). After
overnight incubation, non-adherent cells were removed by changing the medium to allow
eventual overgrowth of FLS. Cells were cultured for approximately 3 weeks before they were
used in experiments.
3.1.3 CELL CULTURE
RA FLS, OA FLS and NHDF were cultured in complete DMEM. The cells were
cultivated in T-75 flasks in 10mL of medium, kept in a humidified atmosphere of 5% CO2 at
37°C and the medium was fully replaced three times per week. Experiments were carried out
in tissue culture dishes (64cm2), ‘Easy Grip’ tissue culture dishes (20cm2), 48-well
(90mm2/well) or 96-well (30mm2/well) plates. Cells were passaged 1:2 or 1:3 depending on
their growth rate. When cells were confluent, waste media was removed and cell monolayer
was washed with 5mL of sterile phosphate-buffered saline (PBS; 10mM phosphate, 137mM
NaCl, 2.7mM KCl, pH 7.5). 3mL of trypsin-ethylenediaminetetraacetic acid (EDTA) (0.25%
trypsin-EDTA 1 x, Gibco, Invitrogen, Paisley, UK) was added to a T-75 flask, gently
agitated, then 1.5mL of trypsin was removed and the cells were placed in the incubator at
37°C. After 5 minutes, cells were aspirated using a pipette to break up any large clumps and
transferred into a 50mL falcon tube containing complete medium to deactivate the trypsin.
Cells were spun for 5 minutes at 200 x g, supernatant was discarded, complete medium was
added and cells were transferred to a fresh flask or plate for culture usually at the
concentration 1 x 104 cells per 1cm2 (Table 3.2).
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Table 3.2 Experimental set-up
The table comprises information about the size of dishes/plates, cell-seeding number and the amount of
medium used in the subsequent experiments. All the dishes and plates were purchased from Becton
Dickinson (Falcon, Leuven, Belgium).
Experiment Q-PCR Western blot HIF-1 ELISA TransAM assay MTT assay
Circumference of well 20cm2 20cm2 64cm2 64cm2 90mm2/well
Number of cells per well 2 x 105 2 x 105 8 x 105 8 x 105 1 x 104
Medium 2.5mL 2.5mL 5mL 5mL 200µL
Lysis buffer 300µL 150µL 250µL 6mL 250µL
RA FLS (Figure 3.1a) and OA FLS (Figure 3.1b) were used for the experiments at
passage 3 when there was a relatively homogenous population of FLS and only until passage
6, to ensure a minimal change in phenotype with repeated passageing (Zimmermann et al
2001; Neumann et al 2010). NHDF (Figure 3.1c) were purchased at the stage of passage 1
and were used up to passage 15 (according to the manufacturer’s instructions).
FLS can be isolated from RA synovial tissue and can be cultured for several months.
After the enzymatic digestion of the RA tissue, cells are present in a single cell suspension
and grow in a tissue culture dish. The non-adherent cells are removed leaving the two major
cell populations, including MLS and FLS. The macrophage-like phagocytic cells are
terminally differentiated with low proliferation ability and survive only a few weeks in
culture. After 3 – 4 passages FLS are the dominant cell type creating a relatively homogenous
population with a doubling time of 5 – 7 days (Rosengren et al 2007).
(c)(b)(a)
Figure 3.1 Types of fibroblasts used in the study
Fibroblasts used in the study: (a) RA FLS, (b) OA FLS and (c) NHDF.
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Prior to each experiment, cells were starved in serum-free medium for 24 hours in
order to synchronise cell cycles. The next day, the medium was changed into complete
DMEM and various procedures were carried out. Transfection experiments were conducted in
Opti-MEM medium (Gibco Invitrogen, Paisley, UK). For optimisation experiments,
fibroblasts were cultured at different oxygen tensions by setting up the incubator (Incubator
Galaxy R CO2 for cell culture in hypoxic conditions) to 1%, 3%, 5% or 10% O2 for different
times. Having only two hypoxic incubators, cell cultures at different oxygen tensions were not
run simultaneously. Parallel time-courses were performed in the Digital CO2 Incubator 6500
with 21% O2. Cells were also treated with DMOG (dimethyloxaloylglycine) for different time
points with an equivalent volume of DMSO (dimethyl sulphoxide) used as a vehicle control
for comparison with DMOG. Supernatants from cell cultures were aspirated and frozen at -
20°C for future ELISA and AngioKit assay. Monolayers of cells were washed with 1 x PBS
and lysed to obtain protein or RNA depending on the experiment.
3.2 RNA/DNA studies
3.2.1 RNA ISOLATION
RNA was isolated using Total RNA kit E.Z.N.A.™ EaZy Nucleic Acid Isolation
(VWR, Batavia, IL, USA). For RNA isolation, cells were cultured in 20cm2 plates at ~80%
confluence. Cells were washed with 1 x PBS, homogenised using 300µL of provided TRK
lysis buffer with addition of -mercaptoethanol and RNA was isolated following the
manufacturer’s procedure. Cells were scraped, mixed by pipetting, vortexed thoroughly with
300L 70% ethanol and spun using HiBind®RNA Spin Column at 10,000 x g for 1 minute.
Genomic DNA contamination was removed on-column using RNase-free DNase I Set (VWR,
Batavia, IL, USA), incubating RNA samples for 15 minutes at room temperature with 75µL
of buffer containing DNase. The enzyme activity was stopped using RNA Wash Buffer I,
followed by washing with RNA Wash Buffer II containing ethanol. RNA was eluted with
50µL nuclease-free water, in which RNases were inactivated using 0.1% DEPC
(diethylpyrocarbonate)-treated water. RNA samples were stored at -70C.
The concentration of RNA was measured using a spectrophotometer (Eppendorf AG,
Hamburg, Germany) measuring the absorbance (Abs) at the wavelength 260nm and counted
using the following formula: Abs260 x 40 x dilution factor = (µg/mL) of RNA (40 - a
conversion factor for RNA). The purity of RNA was evaluated by the ratio of the absorbance
read at 260nm and 280nm (Abs260/Abs280). This ratio provides an estimation of
contaminants that absorb the ultraviolet (UV) light, such as protein. The RNA sample was
considered pure when the Abs260/Abs280 ratio was 1.8 - 2.
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3.2.1.1 Agarose Gel Electrophoresis (RNA integrity)
Total RNA integrity was estimated by fractionating 1µg of samples on a native 1.5%
agarose gel in TAE buffer (40mM Tris, glacial acetic acid, 1mM EDTA) with SYBR® Green
Safe DNA gel stain (Invitrogen, Paisley, UK) diluted 1:10,000. 4 x native agarose gel loading
buffer (60% glycerol, 0.09% xylene cyanol, 0.09% bromophenol blue) was added to the RNA
samples to a final concentration 1 x. The electrophoresis was run for 30 minutes at 130V and
the picture of samples separation was taken while the gel was visualised using UV
transilluminator (Upland, CA, USA). Figure 3.2 illustrates an example of RNA integrity
assessment for 6 RNA samples. In eukaryotic samples intact total RNA run on agarose gel
has sharp, clear 28S and 18S ribosomal RNA (rRNA) bands. If the 28S rRNA band is
approximately twice as intense as the 18S rRNA band, it is a good indication that the RNA is
intact. Although RNA secondary structure alters its migration pattern and it does not migrate
according to its true size, RNA samples were run beside 1kb Plus DNA ladder (12,000bp -
100bp; Invitrogen, Paisley, UK) just as a reference point.
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Figure 3.2 Agarose gel electrophoresis to test RNA integrity
An example of agarose gel analysis of RNA samples depicting 28S and 18S rRNA units. 2L aliquots
of RNA samples (1 - 6) were mixed with 10L DEPC water and 4L loading buffer. 12L of the
mixture was loaded onto an 1.5% agarose gel stained with SYBR® Green gel stain next to the 1kb
DNA ladder (M=marker, 10µL) and the samples were separated by electrophoresis.
3.2.2 REVERSE TRANSCRIPTION
Reverse transcription polymerase chain reaction (RT-PCR) is a widely used
technique, which enables determination of the abundance of specific RNA molecules within a
cell or tissue as a measure of gene expression. Reverse transcription is a step where
complementary DNA (cDNA), a template for PCR, is synthesised from a RNA sample and is
catalysed by reverse transcriptase. The purified 500ng of RNA was used with 1µL of random
primers (Invitrogen, Paisley, UK) and DEPC-treated water to a total volume of 12µL (Table
3.3). The mixture was incubated at 72C for 10 minutes and then placed on ice for 5 minutes.
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Table 3.3 The amount of reagents used in the first step of reverse transcription
Reagent Concentration Final concentration Volume
RNA (X) 500ng XµL
DEPC H2O (Y) Y=12µL-1µL-Xl
Random primers 50ng/µL 4.2ng/µL 1µL
Final volume 12µL
A master mix containing RT buffer, RNasin (Ribonuclease Inhibitor to preserve RNA
integrity), dNTPs (deoxyribonucleotide triphosphates) including a mixture of dATP, dGTP,
dCTP, dTTP, M-MLV Reverse Transcriptase (all purchased from Promega, Southhampton,
UK) and DEPC water was prepared, and 8µL was added to each sample (Table 3.4).
Table 3.4 The amount of reagents used in the second step of reverse transcription
Reagent Concentration Final concentration Volume
RNA + Random primers 12µL
RT buffer 5 x 1 x 4µL
DEPC H2O 1.5µL
RNasin 40u 2u 1µL
dNTPs 10mM 0.5mM 1µL
Reverse transcriptase 200u/µL 100u/reaction 0.5µL
Final volume 20µL
Samples were incubated in T Gradient Thermoblock (Biometra, Thistle Scientific,
UK) at 25C for 10 minutes, 42C for 60 minutes, followed by a denaturing step at 70ºC for
15 minutes and 5 minutes on ice to keep cDNA single stranded. Products of RT-PCR could be
then amplified and analysed using PCR or quantitative PCR (Q-PCR).
3.2.3 PCR
Polymerase chain reaction (PCR) itself is a process used to amplify specific fraction
of a DNA molecule. As the name implies, DNA polymerase replicates cDNA and generated
DNA, an amplicon, is used as a template for another replication being exponentially amplified
with cycle numbers. PCR involves the following three steps: denaturation, annealing and
elongation. First DNA is denatured, converting double stranded (ds)DNA molecules to single
stranded (ss)DNA. The primers are then annealed to the complementary regions of ssDNA
and elongated by adding dNTPs. In this study, PCR was performed on RNA samples to detect
DNA contamination and on cDNA to replicate a number of genes of interest (Table 3.6). The
reaction mix was prepared as shown in Table 3.5, where 24µL of master mix was added to
1µL of each RNA or cDNA specimen and the reaction was performed as described below.
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Table 3.5 The amount of reagents used in PCR reactions
Reagent Concentration Final concentration Volume
PCR buffer 10 x 1 x 2.5µL
dNTPs 10mM 200µM 0.5µL
Forward primer 6.25µM 125nM 0.5µL
Reverse primer 6.25µM 125nM 0.5µL
MgCl2 50mM 1.5mM 0.75µL
Taq polymerase 5u/µL 0.02u/reaction 0.1µL
H2O 19.15µL
RNA or cDNA 1µL
Final volume 25µL
All PCR reactions were carried out in a T3 Thermocycler (Biometra, Thistle
Scientific, UK) with the following steps:
Initial denaturation 94°C 5 minutes
Cycles (37 x) I step denaturation 94°C 35 seconds
II step annealing 60°C 35 seconds
III step elongation 72°C 45 seconds
Final step 72°C 5 minutes
3.2.3.1 Agarose Gel Electrophoresis (PCR products)
PCR using primers for GAPDH (glyceraldehyde 3-phosphate dehydrogenase) was
performed to assess genomic DNA contamination of each RNA sample before analysis of the
gene of interest expression. 1L of each RNA sample, 1L cDNA (positive control) or 1L
water (negative control) were added to the master mix prepared as shown in Table 3.5 and
PCR was performed in the thermocycler, following native agarose gel electrophoresis (Figure
3.3). Lack of bands in lanes 2 – 8 suggest that these samples were free of DNA contamination
(or at least DNA was undetectable). The presence of a weak band in lane 1 means that this
sample was slightly contaminated with DNA and thus additional DNase-treatment was carried
out.
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Figure 3.3 Agarose gel electrophoresis to test DNA contamination of RNA samples
An example of agarose gel analysis of DNA contamination by performing PCR using primers
for GAPDH. Master mix containing RNA (1 – 8), cDNA (positive control) or water (negative
control) was prepared as described in Table 3.5 and PCR was performed. 15µL of samples
were mixed with 5µL of gel loading buffer and 15µL of the mixture was loaded onto an 1.5%
agarose gel next to the 1kb DNA ladder (M=marker, 10µL) and the samples were separated
by electrophoresis. Size of GAPDH product is 671bp.
Before gene expression analysis by quantitative PCR (Q-PCR), standard PCR was
performed as described in Section 3.2.3, using primers sets included in Table 3.6. Amplified
products were run on an agarose gel next to 1kb DNA ladder to confirm that designed primers
give single a band of expected size. A typical example is shown in Figure 3.4.
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Figure 3.4 Agarose gel electrophoresis to test PCR products
An example of agarose gel analysis of PCR products. Master mix containing cDNA sample or
H2O (negative control) was prepared as described in Table 3.5 using primers shown in Table
3.6 and PCR was performed. 15µL of PCR samples were mixed with 5µL of gel loading
buffer and 15µL of the mixture was loaded onto an 1.5% agarose gel next to the 1kb DNA
ladder (M=marker, 10µL) and the samples were separated by electrophoresis. Sizes of
selected products are ARP 131bp, FIH-1 115bp, 18S rRNA 152bp, HIF-1 194bp, PTEN
213bp and COX-2 273bp.
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3.2.3.2 Primer Design
To achieve reproducible results and quality Q-PCR assays, it is fundamental to have
sensitive and specific primers detecting only the gene of interest (Table 3.6). Some of the
parameters for designing primers include the optimal length of primers, which should range
between 18 – 22bp (base pairs), that is long enough to be specific and short enough to bind
easily to the template during the annealing step. Another parameter is a melting temperature
(Tm), which estimates DNA – DNA hybrid stability and Tm between 52 – 58ºC generally
produces the best results. In addition, primer pair should have closely matched Tm to
miximise PCR product yield. The GC content of the sequence, which should be 40 – 60% of
the total number of bases, enables calculations of primer’s Tm and also determines the
annealing temperature.
PubMed data base was used to find DNA and mRNA sequences of genes of interest
and Spidey programme (http://www.ncbi.nlm.nih.gov/spidey/) was used to align mRNA to
genomic sequence. Primer3 software (http://frodo.wi.mit.edu/) was used to design primers,
which were then cross-checked with the NCBI database to ensure that the primers detect only
a specific gene. Primers were designed with an amplicon size ranging from 100 – 250bp. The
primers sequences were ordered and synthesised by Eurofins MWG Operon (Ebersberg,
Germany). Finally, PCR efficiency of the primers was measured as described in Section
3.2.4.1 on page 78.
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Table 3.6 Sequences of primers used in the study and expected product sizes
Gene Forward sequence Reverse sequence Product size (bp)
18S RNA gtaacccgttgaacccca ccatccaatcggtagtagcg 152
ACTB ggggtgttgaaggtctcaaa ggcatcctcaccctgaagta 183
ARP cgacctggaagtccaactac atctgctgcatctgcttg 115
ATP5G3 ggatttgccttgtctgaagc cgtacattcccatgacacca 188
TBP tgcctccagaatatgcctct caatggttttcaagctttcca 203
GAPDH atgaggtccaccaccctgtt catggagaaggctggggctc 671
HIF-1 cacctctggacttgcctttc ggctgcatctcgagactttt 194
HIF-2 ccttcaagacaaggtctgca ttcatccgtttccacatcaa 190
HIF-3 cattggacacagcatctttgat gtaggccctcatatgtccagag 223
HIF-3#2 ctggctatagtcccgatgac gctcagcaaggtgtggatgc 100
HIF-34#1 atgcactgcctccccacctc ggcaaggaaggagacagttc 70
HIF-34#2 tccccacctcaacaccagct gggcaaggaaggagacagttc 61
PHD-1 cagctagcatcaggacagaaa cagaggcaaagtcagaagca 174
PHD-2 gcacgacaccgggaagtt ccagcttcccgttacagt 178
PHD-3 ttgggatgccaagctaca cgtgtgggttcctacgatct 125
FIH-1 caatgtactggtggcatcacatag ggccactttctgatgagctt 131
VEGF cttgccttgctgctctacct ctgcatggtgatgttggact 282
ANGPTL-4 ccacttgggaccaggatcac cggaagtactggccgttgag 115
GLUT-1 tggcatggcgggttgt ccagggtagctgctccagc 63
CA9 gctgtcaccagcgtcgcgt ccagtctcggctacctctgct 100
ENO-1 gcaagaaactgaacgtcacagaac caacggcaccagctttgc 137
BNIP-3 gatatgggattggtcaagtcgg cgctcgtgttcctcatgct 101
HO-1 ccttcttcaccttccccaac tggcctcttctatcaccctc 116
COX-2 tgtatgccacaatctggctg gaaggggatgccagtgatag 273
uPAR aacgacaccttccacttc ttgcagctgtaacactgg 109
PAI1 tctttggtgaagggtctgct ctgggtttctcctcctgttg 184
PTEN attcccagtcagaggcgctat gaacttgtcttcccgtcgtgt 213
MMP-1 cacatctgacctacaggattga tccaggtccatcaaaaggag 200
MMP-2 caagtggtccgtgtgaagtatg atacttcttgtcgcggtcgt 333
MMP-14 tgtttgtcttcaaggagcgc gagcagcatcaatcttgtcg 258
FGFR3 agatcgcagacttcgggct atccacttcacgggcagc 87
Ephrin-A1 ccatacatgtgcagctgaatgac cagcgtctgccacagagtga 74
Ephrin-A3 cactctcccccagttcaccat cgctgatgctcttctcaagct 103
IL-1 gtcattcgctcccacattct acttcttgccccctttgaat 105
IL-8 gttccactgtgccttggttt gcttccacatgtcctcacaa 95
Bax ctgacggcaacttcaactgg tcttggatccagcccaacag 159
Bcl-2 tcgccctgtggatgactga cagagacagccaggagaaatca 133
Caspase3 cagtgttctccatggatacctttatt ctggttttcggtgggtgt 75
Survivin agccagatgacgaccccata caagggttaattcttcaaactgctt 92
XIAP caatatggagactcagcagttgga gcactattttcaagataaaagccgtt 85
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3.2.4 Q-PCR
In contrast to standard PCR and semi-quantitative product analysis on agarose gels,
Q-PCR is a fluorescence-based PCR technique which allows for relative or absolute
quantification of specific mRNA species in the real-time. Amplification and detection occur
simultaneously and fluorescence intensity, which correlates with the increasing PCR
products, is monitored with a sensitive camera in each tube during the reaction (Wong and
Medrano 2005).
Three main phases are distinguished in the Q-PCR reaction: exponential, linear and
plateau, where the latter is characteristic for traditional PCR detection (Figure 3.5a). Q-PCR
is a kinetic approach where amplification occurs exponentially, that is a doubling of
amplicons takes place every cycle. During first few cycles the amount of products is too small
to be detected. The point at where the fluorescence crosses the detection limit of the detector
is called cycle threshold (Ct). Ct is set by the user and is represented by the red horizontal line
in Figure 3.5b. The Ct value is a representative value of the amount of examined molecules
present at the beginning of the reaction read for many parallel samples and is used for
calculating fold change in gene expression. The more copies of gene of interest are at the
beginning of the reaction, the lesser cycles are needed for fluorescence to exceed Ct value.
In this study SYBR® Green (Sigma-Aldrich, Poole, UK) was used for the Q-PCR.
SYBR® Green is one of the most common fluorescent chemistry used in Q-PCR, which when
intercalated in the minor groove of dsDNA fluoresces 1,000-fold more intensely. As more
double stranded amplicons are produced, the SYBR® Green dye signal increases. Although it
is a relatively inexpensive fluorescent dye, it is more prone to mistakes than other types of
real-time chemistry. A limitation of this method is that SYBR® Green recognises and binds
any dsDNA, also unspecific sequences of the Q-PCR reaction, such as primer-dimers, which
occur when amplifying low copy number transcripts.
To assess if the correct fragments were amplified, a melting curve analysis was
performed at the end of Q-PCR. The melting temperature is a characteristic of dsDNA
dissociation during heating, which depends on its base composition. When the temperature is
raised by a fraction of a degree, the decrease in SYBR® Green fluorescence is measured. All
PCR products for a particular primer pair should have the same melting temperature unless
there is contamination, mispriming or primer-dimers. The graph depicting melting curve of
FIH-1 product pin-point the temperature of dissociation equal 82°C meaning that 50% of PCR
products are dissociated (Figure 3.5c), fortunately corresponding to a specific DNA fragment.
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Figure 3.5 Representative graphs of Q-PCR analysis
FIH-1 gene expression represented by amplification curves in (a) a linear view, which depict
the increase in fluorescence in real-time divided into three phases: exponential, linear and
plateau; and (b) a logarithmic view of the kinetics of the same reaction. (c) Melting curve
shows the dissociation kinetics of the amplified FIH-1 products. Coloured lines represent
tested samples (every sample in triplicate); black line represents the blank control (water); red
horizontal line indicates the cycle threshold at 0.05.
Briefly, the preparation of Q-PCR is as follow, first cDNA generated by RT-PCR was
diluted 5 times with nuclease-free water, then 3µL of the sample was added to 10µL of Q-
PCR master mix containing SYBR® Green, forward and reverse primers (Table 3.6) and
nuclease-free water to a total volume of 13µL (Table 3.7). Three replicate reactions were run
for each cDNA sample.
Table 3.7 The amount of reagents used in Q-PCR reactions
Reagent Concentration Final concentration Volume
cDNA 3µL
SYBR® Green 2 x 1 x 6.25l
Forward primer 6.25µM 120nM 0.25l
Reverse primer 6.25µM 120nM 0.25l
Nuclease-free H2O 3.25l
Final volume 13l
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Samples were then placed on the thermocycler Rotor-Gene™ 6000 Multiplexing
System (Corbett Life Science, Sydney, Australia) and the reaction started as follows:
Pre-incubation 50°C 2 minutes
Initial denaturation 95°C 5 minutes
Cycles (40 x) I step denaturation 95°C 10 seconds
II step annealing 60°C 15 seconds
III step elongation 72°C 20 seconds
Melt 70 - 99°C hold 5 seconds on each step
Q-PCR does not require the running of standard curve, but is based on an endogenous
control, a housekeeping gene also called a reference control (e.g. 18S rRNA; arginine-rich
protein, ARP or TATA-box-binding protein, TBP). The relative fold change gene expression
was calculated automatically using the programme Rotor-Gene™ 6000 Software 1.7 (Corbett
Life Science, Sydney, Australia) or manually in an Excel sheet using a comparative Ct
method (2-∆∆Ct model) described by Livak (Livak and Schmittgen 2001). Ct values of the
reference control were used to normalise each sample for the amount of added template by
subtracting it from Ct values of target gene. These values were then further normalised to a
calibrator treatment (untreated samples or time zero control - t0) and the fold change was
calculated using 2-∆∆Ct model mathematical model.
delta Ct (dCt) value = Ct(target gene) -Ct (housekeeping gene)
delta delta Ct (ddCt; Ct) = deltaCt sample –deltaCt calibrator
fold change gene expression = 2-Ct
3.2.4.1 Primer validation
Theoretically the amount of products doubles with every cycle, until the efficiency of
reaction starts to decline caused by consumption of precursor reagents. However, practically
the kinetics of PCR is not ideal, meaning that the PCR product concentration does not double
after every cycle as expected. During Q-PCR, regardless of the primary amount of the
template, after certain number of cycles, the reaction efficiency is lower due to the usage of
primers, nucleotides, decrease in polymerase activity and the competition between primers
and products for the template and the final amount of products is similar in the plateau phase.
In order to use the 2-∆∆Ct model to analyse the Q-PCR results the amplification
efficiency of the primers, both for the housekeeping gene and the target gene, needs to be
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equal. A validation assay to monitor the difference in amplification efficiency for the primers
was therefore always performed prior to quantitative PCR analysis (Livak and Schmittgen
2001). A dilution series was prepared from a cDNA template and the average Ct was then
calculated from the triplicate for each gene. Ct values are shown on a logarithmic scale with
even spacing of the reactions with the threshold (Ct) shown as red line (Figure 3.6a). More
diluted samples have higher Ct values indicating they crossed the threshold later.
In addition, the software creates a plot of the log cDNA dilutions versus Ct values to
determine the exponential amplification and efficiency of a reaction (Figure 3.6b). The slope
(‘M’) of a reaction is calculated as the change in Ct divided by the change in log input (e.g.
copy number). A 100% efficient amplification means a doubling of amplification product in
each cycle resulting in an ‘M’ value of -3.322, an amplification factor of 2 and a reaction
efficiency of 1. The slope and reaction efficiency was automatically calculated and is
displayed in the standard curve window (Figure 3.6b).
Given an ‘M’ value of -3.322, the calculations are as follows:
Amplification value: 10(-1/-3.322)=2
Reaction efficiency: [10(-1/-3.322)]-1=1
An ‘M’ value lower than -3.322 gives a lower than 100% reaction efficiency, which
means that optimisation steps like primers, probe, MgCl2 or SYBR® Green concentrations
should be improved, or cycle times increased. An ‘M’ value higher than -3.322 signifies that
the reaction is more than 100% efficient. This could be caused by a disproportionate digestion
of probe compared to the amplicons produced. The set of primers was validated when the
reaction slope value was between -3.522 and -3.14, with the reaction efficiency between 92%
and 108%. If values were outside this range, primers were re-designed and validated again.
Correlation coefficient (R) and square root of correlation coefficient (R^2 or R2) are
automatically calculated and shown in the standard curve window. R2 value is more useful in
determining correlation and means the percentage of the data consistent with the statistical
hypothesis. A good R2 value is around 0.99 and if the R2 value is too low, it means that the
given standards cannot be easily fit onto a line of best fit (Figure 3.6a).
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Figure 3.6 Primer validation via generation of a standard curve
Validation of a primer set for FIH-1. (a) Kinetics of cDNA dilution series depicted on a
logarithmic scale. (b) Standard curve plotted as serial dilutions of cDNA versus Ct values.
Analysis of primers is shown in the window with R-value (correlation coefficient) and R^2-
value (R2 - square root of correlation coefficient), which indicate the percentage of the data
consistent with the statistical hypothesis, M (slope), B (intercept in the formula describing the
relation between two variables y=Mx+B) and reaction efficiency.
3.2.4.2 Housekeeping gene validation
Housekeeping gene expression fluctuates according to tissues and treatments
(Caradec et al 2010). Therefore before any experiment it was important to precisely
determine stable housekeeping genes to normalise Q-PCR results for each condition. To
evaluate valid housekeeping genes ensuring reliable results 5 genes were tested, namely small
ribosomal subunit RNA (18S RNA), ATP synthase, H+ transporting, mitochondrial F0
complex, subunit C3 (ATP5G3), TATA-box-binding protein (TBP), -actin (ACTB) and
arginine-rich protein (ARP). For the study, three experimental settings, namely normoxia,
hypoxia and DMOG were examined and the results are shown in Table 3.8.
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Table 3.8 Comparison of gene expression using different housekeeping genes
RA FLS were incubated in normoxic (21% O2) or hypoxic (1% O2) conditions or with 1mM
DMOG for 24 hours. RNA was isolated, cDNA was generated and Q-PCR performed using 5
different housekeeping genes (n=1). Fold change in gene expression was calculated against
each of the housekeeping genes (18S RNA, ATP5G3, TBP, ACTB, ARP).
Gene Condition
Housekeeping gene
18S RNA ATP5G3 TBP ACTB ARP
HIF-1
Hypoxia 0.81 0.59 0.58 0.52 0.57
DMOG 0.3 0.22 0.2 0.21 0.21
HIF-2
Hypoxia 0.96 0.7 0.69 0.62 0.67
DMOG 1.64 1.18 1.09 1.13 1.12
ANGPTL-4
Hypoxia 4.97 3.66 3.56 3.23 3.49
DMOG 16.27 11.64 10.82 11.14 11.11
BNIP-3
Hypoxia 5.4 3.97 3.87 3.51 3.79
DMOG 7.35 5.25 4.89 5.03 5.02
CA9
Hypoxia 21.07 15.5 15.09 13.68 14.8
DMOG 102.54 73.35 68.2 70.2 70.04
ENO-1
Hypoxia 2.54 1.87 1.82 1.65 1.78
DMOG 2.94 2.1 1.95 2.01 2
GLUT-1
Hypoxia 5.7 4.19 4.08 3.7 4
DMOG 31.93 22.84 21.24 21.86 21.81
VEGF
Hypoxia 5.35 3.94 3.83 3.47 3.76
DMOG 12.18 8.71 8.1 8.34 8.32
To assess the agreement between housekeeping genes used in the study Bland-
Altman statistical test was applied using two housekeeping genes to measure the same gene
and at the same scale of measurement (Ct values or fold change). Comparing 2 housekeeping
genes at a time (18S RNA versus ATP5G3, 18S RNA versus TBP, 18S RNA versus ACTB,
18S RNA versus ARP) indicated that using any of the housekeeping gene gave similar results
(R2=0.1071, p=0.2159 for 18S RNA versus ATP5G3; R2=0.1031, p=0.2252 for 18S RNA
versus TBP; R2=0.1014, p=0.2294 for 18S RNA versus ACTB; R2=0.09487, p=0.2458 for
18S RNA versus ARP). One representative graph analysing 18S RNA versus ARP is shown
in Figure 3.7. In subsequent studies 18S RNA was used as a housekeeping gene.
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Figure 3.7 Example of a Bland-Altman plot
3.2.5 PCR ARRAY
The PCR array system is one of the newest tools to analyse the expression of a focused
panel of genes using for instance SYBR® Green-based real-time PCR. Each PCR array
profiles simultaneously a collection of disease- or pathway-specific genes, generating single,
gene-specific amplicons and preventing the co-amplification of non-specific products.
To profile the expression of 84 genes involved in angiogenesis (Table 3.9), the Human
Angiogenesis RT2 Profiler™ PCR Array (Tebu-Bio, Peterborough, UK) was used. The array
includes growth factors and their receptors, chemokines and cytokines, matrix molecules
(proteases and their inhibitors), adhesion molecules, as well as transcription factors. cDNA
prepared as described in Section 3.2.2 was mixed with nuclease-free water and RT2 PCR
Master Mix (Tebu-Bio, Peterborough, UK), and aliquoted to the 96-well plate coated with a
set of optimised primers. The reaction was performed using ABI Prism 7700 Sequence
Detector (Applied Biosystems, Warrington, UK) and the real-time PCR cycling programme
(Software Detection System1.9.1) with the following steps:
Pre-incubation 50°C 2 minutes
Initial denaturation 95°C 10 minutes
Cycles (40 x) I step denaturation 95°C 15 seconds
II step annealing 60°C 1 minute
III step elongation 72°C 20 seconds
The fold change in gene expression was calculated using PCR array data analysis
software provided by the company, based on the comparative Ct method (2-∆∆Ct model)
normalised to the expression of 5 housekeeping genes (B2M: Beta-2-microglobulin, HPRT1:
Hypoxanthine phosphoribosyltransferase 1, RPL13A: Ribosomal protein L13a, GAPDH:
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Glyceraldehyde-3-phosphate dehydrogenase, ACTB: Actin, beta). The relative levels of
genomic DNA contamination were evaluated by the built-in RNA quality controls.
Table 3.9 Genes included on the angiogenesis PCR array
A list of 84 genes included on the Human Angiogenesis RT² Profiler™ PCR Array.
RefSeq Symbol Gene Name Description Function
NM_005163 AKT1 PKB/PRKBA V-akt murine thymoma viraloncogene homolog 1
Transcription
factor
NM_001146 ANGPT1 AGP1/AGPT Angiopoietin 1 Angiogenesis
NM_001147 ANGPT2 AGPT2/ANG2 Angiopoietin 2 Angiogenesis
NM_014495 ANGPTL3 ANGPT5 Angiopoietin-like 3 Adhesion molecule
NM_016109 ANGPTL4 ANGPTL2/ARP4 Angiopoietin-like 4 Angiogenesis
NM_001150 ANPEP CD13/LAP1
Alanyl (membrane)
aminopeptidase
(aminopeptidase N,
aminopeptidase M,
microsomal aminopeptidase,
CD13, p150)
Angiogenesis
NM_001702 BAI1 BAI1 Brain-specific angiogenesisinhibitor 1 Adhesion molecule
NM_002986 CCL11 SCYA11 Chemokine (C-C motif)ligand 11 Chemokine
NM_002982 CCL2 GDCF-2/GDCF-2 HC11
Chemokine (C-C motif)
ligand 2 Chemokine
NM_001795 CDH5 7B4
Cadherin 5, type 2, VE-
cadherin (vascular
epithelium)
Adhesion molecule
NM_030582 COL18A1 KNO Collagen, type XVIII, alpha1 Adhesion molecule
NM_000091 COL4A3 TUMSTATIN Collagen, type IV, alpha 3(Goodpasture antigen) Adhesion molecule
NM_001511 CXCL1 GRO1/GROa
Chemokine (C-X-C motif)
ligand 1 (melanoma growth
stimulating activity, alpha)
Chemokine
NM_001565 CXCL10 C7/IFI10 Chemokine (C-X-C motif)ligand 10 Chemokine
NM_002090 CXCL3 CINC-2b/GRO3 Chemokine (C-X-C motif)ligand 3 Chemokine
NM_002994 CXCL5 ENA-78/SCYB5 Chemokine (C-X-C motif)ligand 5 Chemokine
NM_002993 CXCL6 CKA-3/GCP-2
Chemokine (C-X-C motif)
ligand 6 (granulocyte
chemotactic protein 2)
Chemokine
NM_002416 CXCL9 CMK/Humig Chemokine (C-X-C motif)ligand 9 Chemokine
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NM_001953 ECGF1 MNGIE/PDECGF
Endothelial cell growth
factor 1 (platelet-derived) Angiogenesis
NM_001400 EDG1 CHEDG1/D1S3362
Endothelial differentiation,
sphingolipid G-protein-
coupled receptor, 1
Adhesion molecule
NM_182685 EFNA1 B61/ECKLG Ephrin-A1 Growth factor
NM_004952 EFNA3 EFL2/EPLG3 Ephrin-A3 Growth factor
NM_004093 EFNB2 EPLG5/HTKL Ephrin-B2 Growth factor
NM_001963 EGF URG Epidermal growth factor(beta-urogastrone) Growth factor
NM_000118 ENG CD105/END Endoglin (Osler-Rendu-Weber syndrome 1) Adhesion molecule
NM_004444 EPHB4 HTK/MYK1 EPH receptor B4 Growth factorreceptor
NM_001432 EREG ER Epiregulin Angiogenesis
NM_000800 FGF1 AFGF/ECGF Fibroblast growth factor 1(acidic) Angiogenesis
NM_002006 FGF2 BFGF/FGFB Fibroblast growth factor 2(basic) Angiogenesis
NM_000142 FGFR3 ACH/CEK2
Fibroblast growth factor
receptor 3 (achondroplasia,
thanatophoric dwarfism)
Growth factor
receptor
NM_004469 FIGF VEGF-D/VEGFD
C-fos induced growth factor
(vascular endothelial growth
factor D)
Angiogenesis
NM_002019 FLT1 FLT/VEGFR1
Fms-related tyrosine kinase
1 (vascular endothelial
growth factor/vascular
permeability factor receptor)
Angiogenesis
receptor
NM_021973 HAND2 DHAND2/Hed Heart and neural crestderivatives expressed 2
Transcription
factor
NM_000601 HGF F-TCF/HGFB
Hepatocyte growth factor
(hepapoietin A; scatter
factor)
Growth factor
NM_001530 HIF1A HIF-1alpha/HIF1-ALPHA
Hypoxia-inducible factor 1,
alpha subunit (basic helix-
loop-helix transcription
factor)
Transcription
factor
NM_006665 HPSE HPA/HPR1 Heparanase Transcriptionfactor
NM_002165 ID1 ID
Inhibitor of DNA binding 1,
dominant negative helix-
loop-helix protein
Transcription
factor
NM_002167 ID3 HEIR-1
Inhibitor of DNA binding 3,
dominant negative helix-
loop-helix protein
Transcription
factor
NM_024013 IFNA1 IFL/IFN Interferon, alpha 1 Cytokine
NM_002176 IFNB1 IFB/IFF Interferon, beta 1, fibroblast Cytokine
NM_000619 IFNG IFG/IFI Interferon, gamma Cytokine
NM_000618 IGF1 IGFI Insulin-like growth factor 1(somatomedin C) Growth factor
NM_000576 IL1B IL-1/IL1-BETA Interleukin 1, beta Cytokine
NM_000600 IL6 BSF2/HGF Interleukin 6 (interferon,beta 2) Cytokine
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NM_000584 IL8 3-10C/AMCF-I Interleukin 8 Adhesion molecule
NM_002210 ITGAV CD51/MSK8
Integrin, alpha V
(vitronectin receptor, alpha
polypeptide, antigen CD51)
Adhesion molecule
NM_000212 ITGB3 CD61/GP3A
Integrin, beta 3 (platelet
glycoprotein IIIa, antigen
CD61)
Adhesion molecule
NM_000214 JAG1 AGS/AHD Jagged 1 (Alagillesyndrome) Angiogenesis
NM_002253 KDR FLK1/VEGFR
Kinase insert domain
receptor (a type III receptor
tyrosine kinase)
Angiogenesis
NM_005560 LAMA5 KIAA1907 Laminin, alpha 5 Angiogenesis
NM_007015 LECT1 BRICD3/CHM-I Leukocyte cell derivedchemotaxin 1 Chemokine
NM_000230 LEP OB/OBS Leptin (obesity homolog,mouse) Cytokine
NM_002391 MDK MK/NEGF2 Midkine (neurite growth-promoting factor 2) Growth factor
NM_004530 MMP2 CLG4/CLG4A
Matrix metallopeptidase 2
(gelatinase A, 72kDa
gelatinase, 72kDa type IV
collagenase)
Matrix
NM_004994 MMP9 CLG4B/GELB
Matrix metallopeptidase 9
(gelatinase B, 92kDa
gelatinase, 92kDa type IV
collagenase)
Matrix
NM_004557 NOTCH4 INT3/NOTCH3 Notch homolog 4(Drosophila)
Transcription
factor
NM_003873 NRP1
DKFZp686A031
34/DKFZp781F1
414
Neuropilin 1 Angiogenesisreceptor
NM_003872 NRP2 NP2/NPN2 Neuropilin 2 Angiogenesisreceptor
NM_002607 PDGFA PDGF-A/PDGF1 Platelet-derived growthfactor alpha polypeptide Growth factor
NM_000442 PECAM1 CD31/PECAM-1
Platelet/endothelial cell
adhesion molecule (CD31
antigen)
Adhesion molecule
NM_002619 PF4 CXCL4/SCYB4 Platelet factor 4 (chemokine(C-X-C motif) ligand 4) Chemokine
NM_002632 PGF PLGF/PlGF-2
Placental growth factor,
vascular endothelial growth
factor-related protein
Angiogenesis
NM_002658 PLAU ATF/UPA Plasminogen activator,urokinase Matrix
NM_000301 PLG DKFZp779M0222 Plasminogen Growth factor
NM_020405 PLXDC1 TEM3/TEM7 Plexin domain containing 1 Angiogenesis
NM_021935 PROK2 BV8/MIT1 Prokineticin 2 Growth factor
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NM_000962 PTGS1 COX1/COX3
Prostaglandin-endoperoxide
synthase 1 (prostaglandin
G/H synthase and
cyclooxygenase)
Transcription
factor
NM_002615 SERPINF1 EPC-1/PEDF
Serpin peptidase inhibitor,
clade F (alpha-2
antiplasmin, pigment
epithelium derived factor),
member 1
Growth factor
NM_021972 SPHK1 SPHK Sphingosine kinase 1 Transcriptionfactor
NM_015136 STAB1 CLEVER-1/FEEL-1 Stabilin 1 Angiogenesis
NM_000459 TEK CD202B/TIE-2
TEK tyrosine kinase,
endothelial (venous
malformations, multiple
cutaneous and mucosal)
Growth factor
receptor
NM_003236 TGFA TFGA Transforming growth factor,alpha Growth factor
NM_000660 TGFB1 CED/DPD1
Transforming growth factor,
beta 1 (Camurati-
Engelmann disease)
Growth factor
NM_003238 TGFB2 TGF-beta2 Transforming growth factor,beta 2 Growth factor
NM_004612 TGFBR1 ACVRLK4/ALK-5
Transforming growth factor,
beta receptor I (activin A
receptor type II-like kinase,
53kDa)
Growth factor
receptor
NM_003246 THBS1 THBS/TSP Thrombospondin 1 Adhesion molecule
NM_003247 THBS2 TSP2 Thrombospondin 2 Adhesion molecule
NM_003254 TIMP1 CLGI/EPA TIMP metallopeptidaseinhibitor 1 Matrix
NM_003255 TIMP2 CSC-21K TIMP metallopeptidaseinhibitor 2 Matrix
NM_000362 TIMP3 HSMRK222/K222
TIMP metallopeptidase
inhibitor 3 (Sorsby fundus
dystrophy,
pseudoinflammatory)
Matrix
NM_000594 TNF DIF/TNF-alpha
Tumour necrosis factor
(TNF superfamily, member
2)
Cytokine
NM_006291 TNFAIP2 B94 Tumour necrosis factor,alpha-induced protein 2 Cytokine
NM_003376 VEGF VEGFA/VPF Vascular endothelial growthfactor Angiogenesis
NM_005429 VEGFC Flt4-L/VRP Vascular endothelial growthfactor C Angiogenesis
NM_004048 B2M - Beta-2-microglobulin Housekeeping
NM_000194 HPRT1 HGPRT/HPRT Hypoxanthinephosphoribosyltransferase 1 Housekeeping
NM_012423 RPL13A - Ribosomal protein L13a Housekeeping
NM_002046 GAPDH G3PD/ GAPD/MGC88685
Glyceraldehyde-3-
phosphate dehydrogenase Housekeeping
NM_001101 ACTB PS1TP5BP1 Actin, beta Housekeeping
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3.3 Protein studies
Protein concentration of HIF-1, ANGPTL-4, CA9 and VEGF was measured by
Enzyme-Linked Immunoadsorbent Assay (ELISA) using kits listed in Table 3.14. HIF-
1HIF-2, HIF-3, GLUT-1, BNIP-3, CA9, PHDs, FIH-1 and -tubulin proteins were
visualised by western blotting. HIF-1 and HIF-2 activity levels were measured by
analysing nuclear extracts in a DNA binding assay (TransAM assay).
3.3.1 MEASUREMENT OF PROTEIN CONCENTRATION
Prior to every experiment, in order to use the same amount of protein, total protein
concentration was assessed using a colourimetric bicinchoninic acid (BCA) assay. The
purple-coloured reaction product of this assay is formed by the chelation of two molecules of
BCA with one cuprous ion, which allows detection and quantification of the total protein.
Total cellular protein extract was diluted ten times in urea/SDS lysis buffer (western
blot), HIF lysis buffer (ELISA) or complete lysis buffer (TransAM) and assayed alongside a
series of dilutions of a common protein such as bovine serum albumin (BSA; PAA
Laboratories, Pasching, Austria) used with known concentrations of a broad working range
(25 - 2,000µg/mL). After adding BCA solution prepared by mixing two substrates (A + B) 1
in 50, the plate was incubated at 37ºC for 30 minutes and measured at 540nm on a MultiScan
Ascent Reader (Thermo Fisher Scientific, Basingstoke, UK). Followed the subtraction of the
respective lysis buffers which act as blanks, the concentration of each unknown sample was
determined automatically based on the standard curve using Ascent Software.
3.3.2 VEGF, ANGPTL-4, CA9 AND HIF-1 ELISA
ELISA is an enzyme immunoassay for antigen/protein measurements. In brief, this
method uses a capturing antibody bound to a polystyrene well in a 96-well plate to which the
protein to be measured is added. An immune complex consisting of capturing antibody and
protein is then recognised by detecting antibody conjugated to biotin with a strong affinity for
streptavidin-conjugated to horseradish peroxidase (HRP) enzyme. Colourimetric reaction with
a stable substrate (e.g. 3,3´,5,5´-tetramethylbenzidine, TMB) enables visualisation and
measurement of the captured protein concentration using spectrophotometer.
In detail, after coating the plate with 100L of the capturing antibody, the plate was
sealed and left to incubate overnight at 4°C. The following day, after washing 3 times with
the wash buffer PBST (0.05% Tween20 in 1 x PBS) and blotting the plate against paper
towels, the plate was blocked for unspecific binding with 300L of the blocking buffer (as
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indicated in Table 3.10) for 2 hours at room temperature. 100L of the protein samples,
respective standards or blanks (respective buffers), were loaded per well in duplicates or
triplicates and were incubated for 2 hours at room temperature or overnight at 4°C. Next,
100L of biotinylated detecting antibody was added for 1 hour followed by 100L of
streptavidin-HRP in 1:200 dilution added for 20 minutes. Washing was repeated after each
step until this point. 100L of TMB:H2O2 (1:1) substrate (KPL, Gaithersburg, MD, USA) was
added, and TMB being oxidised during the enzymatic degradation of H2O2 by HRP generated
blue solution. After approximately 20 minutes the reaction was stopped with 50L of acid
solution (2N H2SO4) and the blue product turned into yellow. The optical density (OD) was
measured at 450nm using a MultiScan Ascent Reader creating a standard curve based on
known concentrations of serially diluted recombinant proteins and using the Ascent Software
the concentration of the protein was extrapolated automatically (Table 3.10).
Proteins measured in this study were (1) secreted proteins measured in cell culture
supernatant, collected after each experiment carried out as described in Section 3.1.3, page 67
(VEGF or ANGPTL-4 ELISA), (2) a nuclear protein in the whole cell extract (HIF-
1ELISA), or (3) membrane-bound protein in the form of cytoplasmic fractions collected
during nuclear extraction for TransAM as described in Section 3.3.4 (CA9 ELISA).
VEGF and ANGPTL-4 protein secretion was evaluated by ELISA in supernatants
using monoclonal mouse anti-human VEGF IgG2B and biotinylated goat anti-human VEGF
IgG, and monoclonal goat anti-human ANGPTL-4 antibody and biotinylated goat anti-human
ANGPTL-4 IgG. Recombinant human VEGF protein (Sf21-derived) and recombinant human
ANGPTL-4 protein was used to produce standard curves (31 - 10,000pg/mL and 1.25 -
80ng/mL, respectively). Using monoclonal mouse anti-human CA9 antibody, membrane-
bound CA9 protein was measured in the cytoplasmic fractions, followed by biotinylated goat
anti-human CA9. The standard curve was created from a serial dilutions ranged between
31.25 - 2,000pg/mL. Samples for HIF-1 ELISA were prepared as follows: cells washed with
1mL ice cold 1 x PBS were solubilised with 250µL HIF lysis buffer (50mM Tris (pH 7.4),
300mM NaCl, 10% glycerol, 3mM EDTA, 1mM MgCl2, 20mM -glycerophosphate, 20mM
NaF, 1% Triton X-100, 25µg/mL leupeptin, 25µg/mL pepstatin, 3µg/mL aprotinin), scraped,
aspirated and spun at 2,000 x g for 5 minutes and either used immediately or stored at -20°C.
HIF-1 was measured in the cell extracts loaded into plate covered with mouse anti-human
HIF-1antibody, followed by a biotinylated goat anti-human HIF-1 antibody with the
standard curve using recombinant human HIF-1 ranged between 125 - 8,000pg/mL.
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Table 3.10 Specifications of ELISAs used in the study
Details of ELISAs used in the study, including final concentration of capturing and detecting
antibodies, ranges of standard curves and the concentration of milk used in the blocking
buffer. DuoSet® kits for ANGPTL-4, CA9, HIF-1 (Table 3.14), VEGF capturing antibody
and human recombinant VEGF 165 were purchased from R&D Systems (Abingdon, UK).
Protein Capturing Ab Blocking buffer Standard curve Detecting Ab
VEGF 1µg/mL 2% BSA in PBS 31 - 10,000pg/mL 200ng/mL
ANGPTL-4 0.8µg/mL 1% BSA in PBS 1.25 - 80ng/mL 400ng/mL
CA9 4µg/mL 1% BSA in PBS 31.25 - 2,000pg/mL 200ng/mL
HIF-1 4µg/mL 5% BSA in PBS 125 – 8,000pg/mL 400ng/mL
Abbreviations: Ab – antibody.
3.3.3 WESTERN BLOTTING
Sodium Dodecyl Sulphate Polyacrylamide Gel Electrophoresis (SDS-PAGE)
separates proteins according to their size. Negatively charged SDS-coated proteins migrate in
polyacrylamide gel towards the lower positive anode. The gel consists of the stacking gel to
concentrate the applied samples first, and the separating gel to separate the proteins based on
size. Following gel electrophoresis, the proteins can be analysed by western blotting by
transferring them from the polyacrylamide gel to a polyvinylidene fluoride (PVDF)
membrane. Proteins bind to the surface of the membrane and become accessible for
immunodetection by monoclonal or polyclonal primary antibody, which is then recognised by
HRP-conjugated secondary antibody. Adding a substrate, which is oxidased by HRP, enables
the visualisation of protein by exposing the membrane to the autoradiography film.
In details, total cellular protein extracts for western blot analysis was prepared on ice
using 150l of denaturating lysis buffer (8M urea, 1% SDS, 1% glycerol and 10mM Tris (pH
6.8), 0.5mM protease inhibitors cocktail (Sigma-Aldrich, Poole, UK), 1mM DTT) per 20cm2
plate. Cells were washed with 1 x PBS, lysed, scraped off the dish, aspirated into Eppendorfs,
sonicated for 10 minutes (Ultrasonic bath, Grant, Cambridge, England) and frozen in -20°C.
5µL aliquot of each lysate was measured for total protein concentration (as described in
Section 3.3.1) to adjust the samples to contain the same protein concentration of 50 - 80µg by
adding 4 x loading buffer (250mM Tris/HCl/SDS pH 6.8, 20% glycerol, 20mM DTT, 4%
SDS, 0.01% bromophenol blue and distilled H2O). The samples were boiled for 5 minutes to
denature proteins, spun and loaded onto 4 - 12% Bis-Tris NuPAGE® Ready Gels (Invitrogen,
Paisley, UK). The electrophoresis was performed in 1 x MOPS (3-N-morpholino propane
sulfonic acid)/SDS running buffer (Invitrogen, Paisley, UK) at 120V for 1 hour. A pre-stained
protein standard Full-Range Rainbow Marker (12,000 - 225,000Da; Amersham, GE
Healthcare, UK) was run on each gel to assess protein molecular weight.
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Following the electrophoresis gel was equilibrated in the ice-cold transfer buffer
(20% methanol, 10mM Tris base, and 100mM glycine) for 10 minutes. The membrane was
activated in methanol for 20 seconds, in distilled water for 2 minutes and finally the in cold
transfer buffer for 10 minutes. The proteins were transferred onto the Immobilon-P transfer
membrane (filter type: PVDF, Millipore) in the transfer buffer using the Bio-Rad system
(Bio-Rad, Hemel Hempstead, UK) at 100V for 90 minutes at 4°C. The membrane was
blocked in the blocking buffer (0.1% Tween20/1 x PBS/5% semi-skimmed milk) for one hour
at room temperature. Proteins were detected with monoclonal or polyclonal antibody
reconstituted in blocking buffer and incubated overnight at 4°C (Table 3.11). After the
washing step with PBS/0.1% Tween20 (or TBS/0.1% Tween20 for FIH-1), membranes were
incubated for another hour with rabbit anti-mouse (RAM) or swine anti-rabbit (SAR)
polyclonal immunoglobins conjugated with HRP (Dako Cytomation, Glostrup, Denmark)
diluted in the blocking buffer (as indicated in Table 3.11). The constitutively expressed -
tubulin was used as an internal control to verify equal loading. Binding of the antibodies was
visualised using enhanced chemiluminescence system, ECL Plus, which produces a more
intense light emission of longer duration (GE Healthcare, Amersham, UK).
Table 3.11 Details of antibodies used for western blotting
A list of antibodies used in the study. According to manufacturer (Abcam, Cambridge, UK) polyclonal
anti-HIF-3 antibody was observed to give band at 72kDa, but it was also predicted to cross-react with
several HIF-3 splice variants - 42, 50, 60, 68kDa; however, the identity of lower bands was uncertain.
Abbreviations: 1ºAb – primary antibody, 2ºAb – secondary antibody, Mo – monoclonal, Po –
polyclonal, RAM – rabbit-anti mouse, SAR - swine anti-rabbit antibody (Dako, Glostrup, Denmark).
1ºAb Company 1ºAb dilution 2ºAb 2ºAb dilution Size (kDa)
MoAb anti-HIF-1 Becton Dickinson, Oxford,
UK
1:500 RAM 1:4000 120
MoAb anti-EPAS-1
(HIF-2)
Santa Cruz Biotechnology,
Heidelberg, Germany
1:250 RAM 1:3000 115
MoAb anti--tubulin Sigma-Aldrich, Poole, UK 1:5000 RAM 1:10000 50
PoAb anti-PHD-1 Abcam, Cambridge, UK 1:1000 SAR 1:3000 43.6
PoAb anti-PHD-2 Abcam, Cambridge, UK 1:1000 SAR 1:4000 46
MoAb anti-PHD-3 A gift from Prof Christofer
Pugh (Oxford, UK)
1:25 RAM 1:3000 27.3
PoAb anti-FIH-1 Abcam, Cambridge, UK 1:1000 SAR 1:3000 40.6
MoAb anti-BNIP-3 Abcam, Cambridge, UK 1:1000 RAM 1:4000 30
PoAb anti-GLUT-1 Alpha Diagnostic Intl, San
Antonio, USA
1:500 SAR 1:4000 40 - 80
PoAb anti-CA9 Abcam, Cambridge, UK 1:1000 SAR 1:4000 54, 58
PoAb anti-HIF-3 Abcam, Cambridge, UK 1:1000 SAR 1:3000 72
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3.3.4 DNA BINDING ASSAY
To detect and quantify ability of HIF- to bind to HRE TransAM kit (Active Motif,
Rixensart, Belgium), a high-throughput ELISA-based assay, was used (Table 3.14). Wells
coated with immobilised oligonucleotides enclosing conserved HRE from erythropoietin gene
(5’-TACGTGCT-3’), bind specifically an epitope on HIF- dimers present in the nuclear
extracts, which is then recognised by the primary anti-HIF- antibody. This step is followed
by HRP-conjugated secondary antibody, which provides sensitive colourimetric readout
quantified by spectrophotometer. In order to monitor specificity of the assay a competition
binding was performed by adding wild-type or mutated oligonucleotides to the wells prior the
addition of the nuclear extract. Wild-type consensus oligonucleotides prevent HIF from
binding to HRE and conversely, mutated oligos do not have an effect on HIF binding.
Cells were seeded onto tissue culture dishes (64cm2) and treated as described in
Section 3.1.3. Nuclear extracts were then isolated as follows: cell monolayer was first washed
and then scraped off the dish with 6mL of the ice cold 1 x PIB/PBS buffer (125mM NaF,
250mM -glycerophosphate, 250mM para-nitrophenyl phosphate, 25mM NaVO3 diluted in 1
x PBS), transferred into the pre-chilled 15mL tube and spun at 300 x g for 5 minutes at 4°C.
Pellet was resuspended in 1.2mL ice-cold hypotonic buffer (20mM HEPES pH7.5, 5mM
NaF, 10µM Na2MoO4, 0.1mM EDTA) by gentle pipetting and transferred into an pre-chilled
Eppendorf. Cells were allowed to swell on ice for 15 minutes. Next, 70l of 10% NP-40
(IGEPAL) was added to the final concentration of 0.5% and tube was vortexed vigorously for
10 seconds followed by centrifugation at 4,000 x g for 30 seconds at 4°C. Supernatant
containing cytoplasmic fraction was aspirated and transferred into the pre-chilled Eppendorf
and stored at -80°C for subsequent CA9 ELISA. Pellet was resuspended in 50µL of the
complete lysis buffer (lysis buffer plus 1mM DTT and 10mM protease inhibitor cocktail
provided by the manufacturer), rocked on ice on the shaking platform for 30 minutes and
centrifuged at 14,000 x g for 10 minutes at 4°C. Nuclear extract was measured for total
protein concentration using BCA assay and stored at -80°C.
10µg of nuclear extracts were added to a 96-well plate containing 40µL of the
complete binding buffer with positive and negative controls, or blank (complete binding
buffer). Following 1 hour incubation at room temperature and washing step, 100µL of the
mouse monoclonal antibody against either HIF-1 (provided by the manufacturer) or HIF-2
(Santa Cruz, Heidelberg, Germany) at the concentration 0.25mg/mL (diluted in the antibody
binding buffer), were added and incubated for an another hour gently agitating. After washing
step, 100µL of anti-mouse HRP-conjugated IgG (0.4mg/mL) followed by 100µL of
developing solution and 100µL of stop solution provided colourimetric readout at 450nm.
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3.4 Transfection with short interfering RNA (siRNA)
RNA interference is a powerful method for sequence-specific gene silencing at the
post-transcriptional level. A double stranded RNA (dsRNA) is introduced to the cell, cleaved
by a ribonuclease known as a Dicer, into short 21 - 25 nucleotides called short interfering
RNAs (siRNAs). Then siRNA forms an RNA-induced silencing complex (RISC) with protein
components, which binds to the complementary transcript by pairing interactions between the
siRNA antisense strand and the mRNA and by cleaving it, RISC promotes mRNA
degradation and thus gene silencing.
In details, 2.5 x 105 cells were seeded in the ‘Easy Grip’ tissue culture dish with
2.5mL serum-free medium and cultured overnight. The knockdown studies were performed
by transfecting cells in approximately 80% confluency with siRNA targeting specific gene
(Table 3.12) with lipid-mediated transfection (lipofection). First, 5µL of lipofectamine
(cationic lipids) and nucleic acids (at calculated concentration, usually 10nM) were each
diluted in 250µL of Opti-MEM I Reduced Serum Medium (Invitrogen, Paisley, UK) and
incubated for 5 minutes. Then diluted siRNA and lipofectamine reagent were mixed gently
together (500µL in total) and incubated for 20 minutes at room temperature while siRNA-
liposomes complexes had been formed. Such complexes were added to plate containing cells
and 2mL of Opti-MEM, and mixed gently by rocking the plate back and forth. Liposomes
easily merge with cell membrane, since they both are made of phospholipid bilayer, and
release siRNA into the cell. Cells were incubated for 5 hours at 37°C, then medium was
changed into fresh complete medium and cells rested overnight followed by culture in
indicated conditions. Gene knockdown was assayed using different techniques. After titration
experiments of different siRNA final concentration of siRNA when added to cells was 10nM.
Table 3.12 Sequences of siRNA used in the study
A list of siRNA sense sequences. siRNA were purchased from MWG (Heidelberg, Germany),
apart from siLuc purchased from Dharmacon (Thermo Fisher Scientific, Cramlington, UK)
and siHIF-3 obtained from Santa Cruz (Heidelberg, Germany).
siRNA Sense sequence
siHIF-1  5’ [agcaguaggaauuggaacauu]RNA [tt]DNA 3’
siHIF-1  5’ [cugaugaccagcaacuuga]RNA [tt]DNA 3’
siHIF-2  5’ [gcgacagcuggaguaugaauu]RNA [tt]DNA 3’
siHIF-2  5’ [cagcaucuuugauagcagu]RNA [tt]DNA 3’
siPHD-1 #1 5’ [ggacagaaagguguccaagtt]RNA [tt]DNA 3’
siPHD-1 #2 5’ [caugcagggcacguaauaguc]RNA [tt]DNA 3’
siPHD-2 #1 5’ [gaagcugggcagcuacaaaat]RNA [tt]DNA 3’
siPHD-2 #2 5’ [caaauggagauggaagaugug]RNA [tt]DNA 3’
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siPHD-3 #1 5’ [ggagaggucuaaggcaaugtt]RNA [tt]DNA 3’
siPHD-3 #2 5’ [ggagaggucuaaggcaaugtt]RNA [tt]DNA 3’
siFIH-1 #1 5’ [caguugcgcaguuauagcuuc]RNA [tt]DNA 3’
siFIH-1 #2 5’ [gaugcuuggagaggccuu]RNA [tt]DNA 3’
scrambled HIF-1 5’ [gaugaguaugacgaacaugau]RNA [tt]DNA 3’
scrambled HIF-2 5’ [ggguuauggcucggaaucaaatt]RNA [tt]DNA 3’
siLuc 5’ [cguacgcggaauacuucga]RNA [tt]DNA 3’
For visual assessment of the siRNA uptake chemically labelled oligonucleotides with
6-FAM fluorophores (6-carboxyfluorescein, siGlo Green, Dharmacon, Cramlington, UK)
with FITC filter (with absorption/emission of 494nm/520nm) were used. Nuclear localisation
and fluorescent ability of siGlo enables to monitor relative efficiency of siRNA delivery of
co-transfected cells. RA FLS were transfected with either siGlo alone at the concentration of
10nM (Figure 3.8a) or with functional siRNAs, siLuc or siHIF-1 at the total concentration
of siRNAs of 20nM (Figure 3.8b,c). To visualise the delivery efficiency of siRNA, the cells
were monitored using Nikon TE2000-U Ultraview confocal microscope (Nikon, UK),
identifying transfected cells and demonstrating optimised delivery with the efficiency of
approximately 90% in each combination.
(a)
(c)
(b)
Figure 3.8 Visual assessment of siRNA uptake by RA FLS
RA FLS were transfected with either (a) siGlo alone (10nM) or (b) siGlo in combination with
siLuc or (c) siHIF-1 (final concentration of siRNA 20nM). Following 24-hour incubation,
the cell transfection was captured using fluorescent microscope (objectives x4).
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3.5 Cell proliferation assay/cytotoxicity (MTT assay)
MTT assay is a standard non-radioactive colourimetric assay for measuring cellular
growth and cytotoxicity. Living cells are able to reduce yellow 3-(4,5-Dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide, MTT (Roche, Burgess Hill, UK) to purple formazan, which
is then solubilised by the SDS solution (Roche, Burgess Hill, UK) added to dissolve insoluble
crystals. The absorbance is measured by a spectrophotometer. The reduction of MTT takes
place only when mitochondrial reductase enzymes are active and therefore the colourimetric
conversion can be directly related to the number of viable cells.
Cells were seeded onto the 48-well plate (90mm2/well) in triplicates (1 x 104
cells/well) and transfected with siRNA as described in Section 3.4. Supernatants were
aspirated 24 hours post-transfection, 250µL of 10% MTT/DMEM (final concentration of
MTT was 0.5mg/mL) was added and the plate was placed back in the incubator for 4 hours.
Crystals were observed as early as one hour after adding 10% MTT (Figure 3.9). Next, 250µL
of solubiliser was added and left overnight. The next day duplicates from each well (2 x
200µL) were transferred into 96-well plate and the absorbance was measured at 540nm
wavelength on a MultiScan Ascent Reader.
To confirm that reagents used in the transfection procedure (lipofectamine and
siRNAs) are not cytotoxic and do not influence cell proliferation, MTT assay was applied on
transfected RA FLS exposed to normoxia for 24, 48 and 72 hours, demonstrating that
transfection conditions and reagents used in these experiments did not have a significant
effect on the overall survival of RA FLS (Figure 3.9).
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Figure 3.9 Transfection and siRNA cytotoxicity
RA FLS were transfected with either siLuc, siHIF-1, siHIF-2siPHD-1, siPHD-2, siPHD-3
and siFIH-1 at a concentration of 10nM and exposed for 24, 48 and 72 hours to normoxia
(21% oxygen) followed by MTT assay protocol. (a) RA FLS with formazan crystals in the
cytoplasm of viable cells before solubilisation. (b) The colourimetric changes in transfected
cells were read at 540nm using a spectrophotometer (n=1).
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3.6 Angiogenesis assay
To measure angiogenesis in vitro, AngioKit was used (TCS Cell Works,
Buckingham, UK). Each well on a 24-well plate coated with growing human endothelial cells
and dermoblasts (as a support) was treated with or without human recombinant VEGF
(5ng/mL), as a positive or negative control, or with conditioned supernatants. Supernatants
from siRNA-transfected cell cultures were concentrated using Vivaspin 4 spin columns
(Sartorius, Epsom, UK) at the speed 3,500 x g for 60 minutes. The columns, with molecular
weight cut-off value of 5kDa, were used to remove any factors which would interfere with the
subsequent functional assay such as free radicals or changes in pH. The protein fraction was
resuspended 1:2 in the provided medium. Medium was changed at day 1, 4, 7 and 9. On day
11, expression of CD-31 (PECAM-1, platelet endothelial cell adhesion molecule-1) was
visualised by staining with mouse anti-human CD-31 antibody (TCS Cell Works, UK),
followed by goat anti-mouse IgG alkaline phosphate and nitrophenol phosphate, and the
absorbance was measured at 405nm using MultiScan Ascent Reader. Subsequently, insoluble
substrate, 5-bromo-4-chloro-3-indolyl phosphate/nitroblue tetrazolium (TCS Cell Works, UK)
was added to visualise the tubules. Wells were washed and air-dried before being captured
using a microscope linked to a camera.
In the meantime, to ensure no loss of VEGF, VEGF ELISA was performed as
described in Section 3.3.2, on supernatants before and after spinning as well as the flow-
through.
Each condition was repeated on 3 wells and 3 pictures were taken from each well,
giving in total 9 pictures per condition. Angiogenesis assay results were scored using
AngioSys Image Analysis Software (TCS Cell Works, UK), which provided the quantitative
measurement of tubule development. The analysis included 5 parameters such as total tubule
number, total tubule length, mean tubule length, number of junctions and field area, which is
occupied by the CD-31-positive tubules compared to the whole area. The values given in the
final experimental report were then plotted onto graphs and statistical analysis was performed.
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3.7 Chemical components and equipment
3.7.1 CHEMICALS
Table 3.13 Reagents used in the study
Reagent Company details Application
Collagenase A from Clostridium
histolyticum
Roche, Burgess Hill, UK Tissue digestion
DNase type IV from bovine pancreas Sigma-Aldrich, Poole, UK Tissue digestion
DMEM
PAA Laboratories, Somerset,
UK
Tissue culture
Penicillin-streptomycin
BioWhittaker, Cambrex Bio
Science, Verviers, Belgium
Tissue culture
FBS (foetal bovine serum) BioSera, Sussex, UK Tissue culture
DMOG (Dimethyloxalylglycine)
Frontier Scientific, Logan, UT,
USA
Tissue culture
DMSO (Dimethyl sulfoxide) Sigma-Aldrich, Poole, UK Tissue culture
0.25% Trypsin-EDTA 1x Gibco, Invitrogen, Paisley, UK Cells subculture
Opti-MEM I Reduced Serum Medium
1 x
Gibco, Invitrogen, Paisley, UK
siRNA
transfection
Lipofectamine2000 Invitrogen, Paisley, UK
siRNA
transfection
siControl Non-Targeting #2 (siLuc)
Dharmacon, Thermo Fisher
Scientific, Cramlington, UK
siRNA
transfection
Short interfering RNA sets MWG, Ebersberg, Germany
siRNA
transfection
siGLO® Green Transfection Indicator
(siGlo)
Dharmacon, Thermo Fisher
Scientific, Chicago, ILL, USA
siRNA
transfection
M-MLV Reverse Transcriptase, RNase
H (-), Point Mutant, purified from E.coli
strain (200units/µL)
Promega, Southampton, UK
Reverse
transcription
RNasin® Plus RNase Inhibitor
(10,000units)
Promega, Southampton, UK
Reverse
transcription
Random primers 300µg (3µg/µL) Invitrogen, Paisley, UK
Reverse
transcription
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dNTPs (set of dATP, dCTP, dGTP,
dTTP 40µmol each)
Promega, Southampton, UK
Reverse
transcription and
PCR
Taq DNA polymerase recombinant
(500U= 5U/µL)
Invitrogen, Paisley, UK PCR
SYBR® Green Safe DNA gel stain Invitrogen, Paisley, UK PCR
1kb Plus DNA ladder (12,000bp –
100bp)
Invitrogen, Paisley, UK PCR
SYBR® Green JumpStart™ Taq Ready
MIX™
Sigma-Aldrich, Poole, UK Q-PCR
Primer sets MWG, Ebersberg, Germany Q-PCR
Bovine serum albumin (BSA)
PAA Laboratories, Pasching,
Austria
ELISA, western
blot
TMB Microwell Peroxidase Substrate
System
KPL, Gaithersburg, MD, USA ELISA
DTT (DL-Dithiotreitol) Sigma-Aldrich, Poole, UK western blot
Protease inhibitor coctail Sigma-Aldrich, Poole, UK western blot
Full Range Rainbow™ Recombinant
Protein Molecular Weight Marker
GE Healthcare, Amersham,
UK
western blot
NuPAGE® 4-12% Bis-Tris Gel 1mmx10 Invitrogen, Paisley, UK western blot
NuPAGE® MOPS/SDS running buffer
(20x)
Invitrogen, Paisley, UK western blot
ECL Plus™ Western Blotting Detection
System
Amersham, GE Healthcare,
UK
western blot
Re-blot Plus Strong Solution (10 x) Chemicon, Temecula, USA western blot
Human Angiogenesis RT2 Profiler™
PCR Arrays
TebuBio, Peterborough, UK PCR Array
RT2 Real-Time™ SYBR® Green/Rox
PCR master mix
TebuBio, Peterborough, UK PCR Array
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3.7.2 KITS
Table 3.14 Details of the kits used in the study
Kit Company details Technique
Total RNA kit E.Z.N.A.™ EaZy
Nucleic Acid Isolation Kit
VWR, Batavia, IL, USA RNA isolation
RNase-free DNase I Set VWR, Batavia, IL, USA DNA digestion
Pierce® BCA Protein Assay Kit
Thermo Scientific, Pierce
Biotechnology, IL, USA
assessment of protein
concentration
TransAM™ HIF- binding assay
Active Motif, Rixensart,
Belgium
HIF-binding assay
DuoSet® IC intracellular
human/mouse total HIF-1
ELISA
R&D Systems, Abingdon,
UK
HIF-1 ELISA
DuoSet® ELISA human
ANGPTL 4
R&D Systems, Abingdon,
UK
ANGPTL-4 ELISA
DuoSet® ELISA human CA9
R&D Systems, Abingdon,
UK
CA9 ELISA
Cell proliferation Kit I (MTT) Roche, Burgess Hill, UK
cytotoxicity/cell
proliferation
AngioKit
TCS Cell Works,
Buckingham, UK
angiogenesis assay
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3.7.3 MECHANICAL DEVICES
Table 3.15 The apparatus used in the study
Apparatus Company details Technique
Laminar Flow Hood, Heraeus, Hera
Safe
Thermo Electron Corporation,
Germany
cell culture
Digital CO2 Incubator 6500 Napco, Hong Kong cell culture
Incubator Galaxy R CO2 for cell
culture in hypoxic conditions (Nr
300-2453)
Wolf Laboratories, York, UK cell culture
Centrifuge 5415D Eppendorf AG, Hamburg, Germany cell culture
Multi-function Centrifuge 2028R Napco, CA, USA cell culture
Hawksley BS748, cell counting
chamber
Improved Neubauer, Sussex, UK cell counting
ELISA Plate Reader, Multiskan
Ascent
Thermo Labsystems, Finland ELISA
Eppendorf AG, BioPhotometer Hamburg, Germany RNA measurement
T Gradient Thermoblock Biometra, Thistle Scientific, UK Reverse transcription
T3 Thermocycler Biometra, Thistle Scientific, UK PCR
Horizontal Gel Electrophoresis
Apparatus, Horizon®11,40
Life Technologies™, Gibco BRL,
Gaithersburg, MD, USA
PCR –electrophoresis
UV Transilluminator M-20, UVP
BioDoc-It™System
Upland, California, USA
PCR –
electrophoresis
Rotor-Gene™6000 Multiplexing
System (thermocycler)
Corbett Life Science, Sydney,
Australia
Q-PCR
Ultrasonic bath XB2 Grant, Cambridge, UK
western blot –
sonicating samples
Techne Dri-block DB-2A (heating
block) Model FDB02AD
Cambridge, UK
western blot - boiling
samples
X Cell Sure Lock™, Novex Mini-
Cell
Invitrogen, Paisley, UK
western blot -
electrophoresis
Western blot equipment
Bio-Rad Laboratories, Hemel
Hempsted, UK
western blot -
transfer
Hypercassette™ Amersham, Life Science, UK western blot
Fuji Medical X-ray Film, Super RX Fujifilm Corporation, Tokyo, Japan western blot
Nikon TE2000-U Ultraview confocal
microscope
Nikon, UK
Transfection
efficiency
Vivaspin 4 spin colums Sartorius, Epsom, UK angiogenesis assay
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3.8 Statistical analysis
Graph Pad Prism 5.02 software package (Graph Pad Software, La Jolla, CA, USA)
was used in the analyses of the data. To evaluate the effects of the stimuli (hypoxia and
DMOG) and siRNA transfection on gene expression, analysis of variance (ANOVA),
followed by a Bonferroni’s Multiple Comparison Test was used if there were more than two
groups to compare, or student t-test was applied if two groups were analysed. Results are
expressed as the mean ± standard error of the mean (SEM) as indicated. P values less than
0.05 were considered significant (*p<0.05, **p <0.01, ***p≤0.001). 
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4 Fibroblast Responses Mediated By Hypoxia: Relative Roles
Of HIF Isoforms
4.1 Introduction
Hypoxia, defined as deprivation of adequate oxygen supply in the tissue/organ, is a
pathological condition, occurring in many diseases, but can be also part of normal physiology,
for example during physical exercises. Importantly, hypoxia is also a feature of rheumatoid
arthritis (RA), and is thought to contribute to the development and maintenance of RA
(Taylor and Sivakumar 2005; Biniecka et al 2010; Ng et al 2010). Fibroblast-like
synoviocytes (FLS), which are the major cell type in RA synovium, are likely to be exposed
to significant hypoxia by being at the invading edge of the pannus. It has been shown that RA
FLS respond to decreased oxygen tension by regulating genes involved in angiogenesis
(VEGF), apoptosis (bcl-2), migration (SDF-1) and invasion (MMPs), to name some of them.
Cells respond to hypoxia by expressing proteins that facilitate survival and adaptation
to decreased oxygen tension. The adaptive response is mainly mediated by a transcriptional
complex termed hypoxia-inducible factor (HIF). HIF heterodimers are composed of two
different subunits, inducible HIF- and constitutively expressed HIF- present in the nucleus
(Wang et al 1995; Wang and Semenza 1995; Salceda and Caro 1997). Hypoxia has little
effect on HIF- mRNA, thus HIF regulation occurs mainly at the post-translational level
(Wiesener and Maxwell 2003). The activity of -subunits is induced by hypoxia in most cell
systems and is associated with the protein stabilisation via the ODD domain which is the
target of specific HIF prolyl hydroxylase domain (PHD)-containing enzymes (Bruick and
McKnight 2001; Epstein et al 2001) and via the C-TAD targeted by factor inhibiting HIF-1
(FIH-1) which controls HIF transcriptional activity (Lando et al 2002a; McNeill et al 2002).
Regulation of HIF-dependent gene expression occurs in hypoxia, which decreases the
enzymatic activity of PHDs and FIH-1. The HIF target gene activation requires -subunit
accumulation in the cytoplasm, translocation into the nucleus, dimerisation with HIF-1
subunit and binding with co-activators. The whole complex binds to the hypoxia-responsive
element (HRE) in the target gene and initiates transcription of an army of genes (Wang, Jiang
et al 1995).
One of the most intriguing questions is the presence of 3 subunits of HIF- (HIF-1,
-2 and -3) and their functional roles. The amino acid sequence in critical regions is
strikingly similar with a high homology between HIF-1 and HIF-2 at the domains involved
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in heterodimerisation, DNA binding HIF degradation and transactivation (Ema et al 1999).
However, although there are many similarities between HIF-1 and HIF-2, there is growing
evidence revealing differences, including effects on tumour growth and identification of
unique target genes (Hu et al 2003; Warnecke et al 2004; Raval et al 2005). This implies that
the HIF isoforms have distinct biological roles in different cell types. This chapter is devoted
to HIF-1 and HIF-2, whereas HIF-3 is described separately in Chapter 6 (page 199). The
majority of research has been done on HIF-1 and HIF-2, showing their fundamental role as
mediators of transcriptional responses to hypoxia.
Synovial hypoxia affects the gene/protein expression in RA, particularly in terms of
angiogenesis, inflammation, long-term growth and matrix degradation. The panel of genes
regulated by HIF-1 and HIF-2 in RA FLS has not yet been investigated, therefore the main
aim of this part of the study was to characterise the roles of HIF- in RA FLS by examining
genes relevant to RA and classification of their HIF isoform-dependence. To distinguish
between the roles of HIF-1 and HIF-2, an RNA interference-based approach was used. In
addition, other fibroblasts, including OA FLS and normal human dermal fibroblasts (NHDF),
were examined by identification of hypoxia-mediated gene and protein expression profiles.
4.2 Objectives
The present chapter consists of 2 complementary parts related to genes regulated by
hypoxia in RA with the following objectives:
(1) To analyse the profile of hypoxia-mediated gene and protein expression in RA FLS,
and to compare this profile with OA FLS and NHDF
(2) To investigate the roles of HIF-1 and HIF-2 in RA FLS by studying the HIF
isoform-dependence of the genes identified in Objective 1
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4.3 Results
To investigate the mechanism by which HIFs regulate genes in RA FLS, the effect of
hypoxia and the hypoxia mimetic DMOG (dimethyloxalylglycine), an inhibitor of PHDs and
FIH-1, on gene expression was assessed. Messenger RNA (mRNA) levels were determined
by Q-PCR, protein levels were assessed by western blot and ELISA, and HIF activation was
examined using DNA binding assay.
4.3.1 CHARACTERISATION OF HIF- TRANSLATION IN RA FLS
To establish the conditions for subsequent studies, hypoxia- and DMOG-induced
changes in HIF-1 and HIF-2 were first assessed at the protein level, as it has been
extensively published that HIF- is regulated post-translationally by hypoxia in various cell
types. FLS were cultured in hypoxia (1% O2) (Figure 4.1a) or treated with 1mM DMOG
(Figure 4.1b) for the indicated time points with parallel time-courses at 21% O2, as a control.
The time-course experiment illustrated in Figure 4.1 was performed to validate the
experimental conditions, and has shown that the stabilisation of both HIF- isoforms was
observed as early as 1 hour under hypoxic conditions (1% O2) and in response to DMOG, and
that the peak induction was observed between 2 and 6 hours. Thereafter HIF-1 slightly
decreased and remained unchanged, whereas HIF-2 was minimal or undetectable at later
time points. DMOG seemed to be a stronger stabiliser of both -subunits than 1% O2 in most
cases.
Interestingly, in most experiments conducted on RA FLS HIF-1 but not HIF-2
was detectable in normoxia, different from patient to patient, probably due to spontaneous
production of cytokines by these cells, which has been shown to contribute to HIF-1
stabilisation (Thornton et al 2000; Hitchon et al 2002). HIF-1 ELISA confirmed the protein
expression at indicated time points, which did not change over time (not shown), showing in
addition that the normoxic levels of HIF-1 were detected in pg/mL in the cell extracts (more
specifically pg per cell number according to the protocol used in this study). As no HIF-2
ELISA is available, it was not possible to quantify HIF-2 using this method.
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Figure 4.1 Stabilisation of HIF- proteins in RA FLS by hypoxia and DMOG
RA FLS were exposed to either (a) hypoxia (1% O2) or (b) 1mM DMOG for the time periods indicated.
Normoxia (21% O2) was used as control. HIF-1 and HIF-2 protein was assessed by western blot,
with -tubulin shown as a loading control (n=1).
To support the use of 1% O2 as the level of oxygen tension to mimic hypoxia, RA
FLS were cultured in a range of oxygen tensions (1 - 21% O2) for 6 and 24 hours. Some
stabilisation of HIF-1 protein in RA FLS was seen to occur at 5% O2, increased at 3% O2,
and was maximal at 1% O2. HIF-2 has shown a very similar to HIF-1pattern of protein
accumulation with 1% O2 at 6-hour time point inducing the strongest stabilisation as seen in
Figure 4.2.
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Figure 4.2 Stabilisation of HIF- proteins in a range of oxygen concentrations
RA FLS were exposed to 1, 3, 5, 10 and 21% O2 for either 6 or 24 hours. HIF-1 and HIF-2 protein
was assessed by western blot with -tubulin shown as a loading control (n=1).
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The TransAM HIF-1 colourimetric DNA binding assay from Active Motif was used
to detect and quantify HIF activation, providing information about the degree of HIF-/HIF-
1β dimer formation, nuclear translocation and the subsequent DNA binding as a response to 
various stimuli. 1% O2 induced maximal HIF-1 and HIF-2 protein binding to HRE, not
surprisingly since 1% O2 induced the strongest stabilisation of HIF- protein in RA FLS as
shown in Figure 4.1 and Figure 4.2. HIF binding to HRE correlated with the amount of
stabilised protein. Figure 4.3a illustrates that already at 5% O2 HIF-1 has shown 45% of the
activity seen with 1% O2, and that 3% O2 closely resembled HIF-1 activity (76%) at 1% O2.
In contrast, in the case of HIF-2 binding to HRE, 5% O2 was equivalent to 32% and 3% O2
was equivalent to 55% of the activity represented at 1% O2 (Figure 4.3b). This suggests that
HIF-1 is more sensitive to oxygen changes and is activated at higher oxygen tension,
compared to HIF-2.
Specificity of HIF binding to HRE was confirmed by competition experiments, by
adding mutated or wild-type oligonucleotides to the wells before adding nuclear extracts.
Addition of 20pmol per well of wild-type competitor oligonucleotides together with nuclear
extract from a sample serving as the positive control (1% O2) prevented HIFs binding to HRE
resulting in decreased signal, whereas addition of mutated oligonucleotides had no effect on
DNA binding (Figure 4.3).
HIF-1
21 10 5 3 1 wt mut
0.0
0.5
1.0
1.5
oxygen tension (% O2)
1% O2
H
IF
bi
nd
in
g
to
H
R
E
Ab
s4
50
nm
HIF-2
21 10 5 3 1 wt mut
0.0
0.5
1.0
1.5
oxygen tension (% O2)
1% O2
H
IF
bi
nd
in
g
to
H
R
E
A
bs
45
0n
m
(a) (b)
Figure 4.3 1% O2 induces maximal HIF binding to HRE in RA FLS
RA FLS were exposed to 1 - 21% O2 for 24 hours. DNA binding of (a) HIF-1 and (b) HIF-2 was
assessed in nuclear extracts by TransAM assay and depicted as optical density measured at 450nm.
Specificity of binding was confirmed using mutated (mut) and wild-type (wt) oligonucleotides. Dashed
lines represent HIFs binding to HRE under normoxic conditions (21% O2). Data are mean ± SEM
(n=1).
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4.3.2 CHARACTERISATION OF HIF- TRANSCRIPTION IN RA FLS
HIFs are traditionally considered to be regulated at the level of protein stability by
PHDs. To examine HIF- mRNA levels in hypoxic conditions, fibroblasts were cultured in
normoxia (21% O2), hypoxia (1% O2) or 1mM DMOG at different time points and Q-PCR
was performed. Hypoxia appeared to downregulate both HIF-1 and HIF-2 mRNA
expression in a time-dependent manner. DMOG treatment also decreased HIF-1 mRNA
(Figure 4.4a), whereas HIF-2 seemed unchanged or increased after DMOG treatment
(Figure 4.4b). These time-course graphs represent one experiment; however, the effect
described above was noticed also in a subsequent series of experiments at 24 hours for HIF-
1 (Figure 4.4c) and HIF-2 (Figure 4.4d).
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Figure 4.4 Effect of hypoxia and DMOG on HIF- mRNA levels in RA FLS
RA FLS were exposed to either hypoxia (1% O2) or 1mM DMOG for the time periods indicated. (a)
HIF-1 and (b) HIF-2 mRNA was measured by Q-PCR, and normalised to normoxia (21% O2) at t0.
Data are mean ± SEM from a representative experiment. (c) HIF-1 and (d) HIF-2 mRNA after 24
hours exposure to either hypoxia (1% O2) or 1mM DMOG measured by Q-PCR. Data are mean ± SEM
from 12 - 14 independent experiments and normalised to normoxia (21% O2). Dashed lines indicate
normoxic expression and solid lines designate the mean; the data were analysed by unpaired t-test: ***
p<0.001.
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4.3.3 GENES REGULATED BY HYPOXIA AND DMOG IN RA FLS
Before proceeding to the next part of the project, which aimed to investigate the
effects of HIF-1 and/or HIF-2 knockdown on genes relevant to RA, the panel of genes
regulated by hypoxia and DMOG in RA FLS was determined.
Studies from the Kennedy Institute of Rheumatology (KIR) and from other research
groups have been demonstrating genes regulated in RA, expressed by FLS and/or modulated
by hypoxia. It has been shown that vascular endothelial growth factor (VEGF) is increased in
RA serum (Paleolog, Young et al. 1998) and VEGF secretion is augmented by hypoxia in RA
FLS (Hitchon et al 2002). Another angiogenic molecule, namely angiopoietin like-4 protein
(ANGPTL-4) was detected in stromal FLS within the inflamed synovium in CIA (Hermann et
al 2005) and was also increased by hypoxia in RA FLS (Del Rey et al 2010). Ephrin receptors
and ligands involved in angiogenesis were present in RA (Romanovsky et al 2006) and
ephrin-A3 was increased in FLS (Del Rey et al 2010). In addition, it has been shown that
carbonic anhydrase (CA) 9 (Del Rey et al 2010), cyclooxygenase (COX)-2 (Demasi et al
2004), heme oxygenase (HO)-1 (Muz et al 2008) are upregulated in RA FLS. Enolase (ENO)-
1 has been demonstrated to be one of the most common targets for citrullination in RA
(Lundberg et al 2008). Interleukin (IL)-8 (Ahn et al 2008; Sivakumar et al 2008) and IL-1
(Buchan et al 1988) were augmented in RA FLS in response to hypoxia. Also some of the
matrix metalloproteinases (MMPs), including MMP-1, MMP-3, MMP-9 (Sivakumar et al
2008), MMP-2 and MMP-14 (Akhavani et al 2009) have been reported as being hypoxia-
responsive in RA FLS. A pro-apoptotic gene, bcl2/adenovirus E1B 19 kDa protein-interacting
protein 3 (BNIP-3) was widely expressed in RA synovium and was increased in RA FLS
(Kammouni et al 2007). Survivin (Bokarewa et al 2005) and B-cell lymphoma 2 (bcl-2)
(Giatromanolaki, Sivridis et al. 2003) belong to the group of genes regulating different stages
of apoptosis and are modified in RA. In contrast, to my knowledge glucose transporter-1
(GLUT-1), bcl-2-associated X protein (bax), caspase-3, X-linked inhibitor of apoptosis
protein (XIAP), fibroblast growth factor receptor (FGFR) 3, plasminogen activator inhibitor 1
(PAI1) and urokinase plasminogen activator receptor (uPAR) have not been shown to date to
be hypoxia-dependent in RA or more specifically in RA FLS.
Human RA FLS were cultured for 24 hours under hypoxic conditions (1% O2) or in
the presence of 1mM DMOG, and the expression of genes relevant to RA was assessed using
Q-PCR, western blot and ELISA. Both hypoxia and DMOG increased the transcription of
various genes, responsible for angiogenesis, metabolism, and apoptosis, and in most cases
DMOG was a stronger inducer than hypoxia at the same time point, resulting in a fold change
of >30 for expression of ANGPTL-4, CA9, GLUT-1 and VEGF. CA9 was the most inducible
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gene in RA FLS and was upregulated approximately 20-fold in hypoxia, and 90-fold in
DMOG-treated cells (Table 4.1). COX-2 and PAI1 were also augmented in both conditions;
however, they were not further investigated due to lack of HIF-dependence in RA FLS.
Table 4.1 Genes regulated by hypoxia and DMOG in RA FLS
RA FLS were exposed to either hypoxia (1% O2) or 1mM DMOG for 24 hours. Gene expression was
measured by Q-PCR and normalised to normoxia (21% O2). Data are mean ± SEM from the indicated
number of experiments (n).
Gene Function Hypoxia DMOG n
Hypoxia/DMOG
ANGPTL-4 angiogenesis 5.9±0.8 55.9±12.9 16/13
BNIP-3 apoptosis 5.3±0.6 12.1±2.8 15/12
CA9 pH regulation 19.4±4.5 91.9±35.1 15/11
COX-2 inflammation 5.9±5.1 11.0±4.3 7/3
ENO-1 metabolism 2.1±0.2 2.9±0.4 13/11
Ephrin-A3 angiogenesis 5.7±3.4 16.1±5.9 10/7
GLUT-1 metabolism 6.7±1.2 41.9±9.3 15/15
PAI1 migration 6.1±3.9 4.5±0.6 5/5
VEGF angiogenesis 6.6±1.1 30.8±10.6 16/13
The analysis of the expression of a range of other genes after hypoxic stimulation
revealed that genes such as FGF receptor (FGFR)-3, IL-8, HO-1, MMP-1 and PTEN were not
much altered by hypoxia but responded only to DMOG (Table 4.2).
Table 4.2 Genes altered by DMOG in RA FLS
RA FLS were exposed to either hypoxia (1% O2) or 1mM DMOG for 24 hours. Gene expression was
measured by Q-PCR and normalised to normoxia (21% O2). Data are mean ± SEM from the indicated
number of experiments (n).
Gene Function Hypoxia DMOG n
Hypoxia/DMOG
FGFR3 angiogenesis 1.2±0.1 5.7±2.0 14/11
IL-8 migration 1.8±0.1 8.6±2.4 6/7
HO-1 inflammation 0.9±0.4 3.0±1.5 8/7
MMP-1 invasion 0.7±0.2 4.2±3.4 6/5
PTEN apoptosis 1.7±0.3 3.0±0.2 5/4
The third group contains some of the assayed genes that were not altered by either
hypoxia or DMOG, including ephrin-A1, IL-1, MMP-2, uPAR and the apoptotic genes, such
as caspase-3, survivin and XIAP, or seemed to be reduced in these conditions: bax, bcl-2 and
MMP-14 (Table 4.3). Nonetheless, these genes were not further investigated in this study.
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Table 4.3 Genes unaffected by hypoxia or DMOG in RA FLS
RA FLS were exposed to either hypoxia (1% O2) or 1mM DMOG for 24 hours. Gene expression was
measured by Q-PCR and normalised to normoxia (21% O2). Data are mean ± SEM from indicated
number of experiments (n).
Gene Function Hypoxia DMOG n
Hypoxia/DMOG
Bax apoptosis 0.8±0.1 0.5±0.1 3/3
Bcl-2 apoptosis 0.4±0.1 0.3±0.1 6/6
Caspase-3 apoptosis 0.9±0.2 1.5±0.3 3/3
Ephrin-A1 angiogenesis 1.6±0.7 1.5±0.3 3/3
IL-1b inflammation 1.1±0.3 0.5±0.1 5/4
MMP-2 invasion 1.0±0.2 1.0±0.2 6/5
MMP-14 invasion 0.5±0.1 0.6±0.2 6/4
Survivin apoptosis 1.2±0.6 0.8±0.3 4/3
uPAR migration 0.9±0.1 1.8±0.4 5/5
XIAP apoptosis 0.6±0.1 1.3±0.2 3/3
To scrutinise the expression of genes highly upregulated by hypoxia and DMOG in
RA FLS, a time-course study shown below was carried out and and the values from a single
experiment diverge slightly from the results shown in Table 4.1. In this particular experiment,
ANGPTL-4 seems to be the most profoundly hypoxia-induced gene, being increased steadily
with time up to 13-fold (Figure 4.5a); however, after DMOG treatment ANGPTL-4
expression increased rapidly by 40-fold within the first 6 hours and remained at a high level
thereafter (Figure 4.6a). BNIP-3 and CA9 expression was gradually upregulated in hypoxia
reaching 6- and 10-fold change, respectively, after 24 hours (Figure 4.5b and c) and in
DMOG-treated cells reaching 18-fold and as high as 260-fold change, respectively (Figure
4.6b and c). ENO-1 is a gene, whose expression was slightly upregulated in hypoxia and
DMOG compared to other genes, yet still this change was consistent (Figure 4.5d and Figure
4.6d). GLUT-1 expression in hypoxia peaked at 6 hours by 7.5-fold and then remained
unchanged (Figure 4.5e), whereas DMOG induced gradual and high increase of GLUT-1
mRNA up to 50-fold (Figure 4.6e). VEGF time-course expression was progressively
upregulated by hypoxia with 9-fold change (Figure 4.5f) and more rapidly in DMOG,
reaching 40-fold change as soon as 6 hours, and was further increased by 75-fold after 24
hours (Figure 4.6f).
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Figure 4.5 Time-course of hypoxia-induced gene expression: ANGPTL-4, BNIP-3
CA9, ENO-1, GLUT-1 and VEGF
RA FLS were exposed to 1% O2 for the time periods indicated. mRNA was measured by Q-PCR and
normalised to normoxia (21% O2) at t0. Data are mean ± SEM (n=1).
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Figure 4.6 Time-course of DMOG-induced gene expression: ANGPTL-4, BNIP-3
CA9, ENO-1, GLUT-1 and VEGF
RA FLS were exposed to 1mM DMOG for the time periods indicated. Gene expression was measured
by Q-PCR and normalised to normoxia (21% O2) at t0. Data are mean ± SEM (n=1).
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To investigate whether the gene increase induced by hypoxia and DMOG is
paralleled by protein expression, ELISA and western blot was performed. ANGPTL-4, CA9
and VEGF secretion by the RA FLS into media was also observed after hypoxia and DMOG
treatment. As shown in Table 4.4, following incubation at 1% O2, ANGPTL-4 concentration
increased 2-fold to a mean concentration of 25.9ng/mL (ranging from 2 to 58ng/mL), and
approximately 4-fold in the presence of 1mM DMOG to a mean concentration of 42.4ng/mL
(ranging from 9 to 119ng/mL), as compared to basal secretion level in normoxia after 24
hours with a mean of 11.2ng/mL (ranging from 1.7 to 47ng/mL). CA9 concentration
increased 12-fold to a mean concentration of 908.7pg/mL (ranging from 158 to 1984pg/mL),
and approximately 22-fold in the presence of 1mM DMOG to a mean concentration of
1636pg/mL (ranging from 124 to 2300pg/mL), as compared to basal secretion level in
normoxia with a mean of 73.8pg/mL (ranging from 41 to 198pg/mL). VEGF concentration
increased 2.6-fold to a mean concentration of 825.3pg/mL (ranging from 124 to 1595pg/mL),
and approximately 11-fold in the presence of 1mM DMOG to a mean concentration of
3466pg/mL (ranging from 946 to 6709pg/mL), as compared to basal secretion level in
normoxia with a mean of 314.6pg/mL (ranging from 113 to 811pg/mL).
Table 4.4 ANGPTL-4, CA9 and VEGF secretion is induced by hypoxia and
DMOG
RA FLS were exposed to 1% O2 (hypoxia) or 1mM DMOG for 24 hours. Protein levels of ANGPTL-4,
CA9 and VEGF were measured by ELISA. Data are mean ± SEM from the indicated number of
experiments (n). Data were analysed by 1-way ANOVA versus normoxia: * p<0.05, ** p<0.01,
***p<0.001.
Gene Units Normoxia Hypoxia DMOG n
N/H/D
ANGPTL-4 ng/mL 11.2±2.1 25.9±3.9* 42.4±15.4** 23/22/7
CA9 pg/mL 73.8±25.2 908.7±169.0* 1636.1±364.2** 6/10/5
VEGF pg/mL 314.6±30.4 825.3±97.6* 3466.4±476.8*** 31/23/14
Abbreviations: N – Normoxia, H – Hypoxia, D – DMOG.
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An increase in BNIP-3, CA9 and GLUT-1 protein level was observed in both hypoxia
and DMOG-treated cells after 24 hours of incubation (Figure 4.7).
Figure 4.7 Stabilisation of HIF is paralleled by the induction of BNIP-3, CA9 and
GLUT-1 protein in RA FLS
RA FLS were cultured in normoxia (21% O2), hypoxia (1% O2) or 1mM DMOG for 24 hours. HIF-1,
HIF-2, BNIP-3, CA9 and GLUT-1 proteins were assessed by western blot, with -tubulin as a
loading control showed from a single experiment.
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4.3.4 HIF- DEPLETION IN RA FLS
RA fibroblasts were transfected with siRNA targeting HIF-1 or HIF-2,
successfully used in human chondrocytes at the KIR (Lafont et al 2007), with luciferase
siRNA designed to knockdown firefly luciferase, therefore serving as a control. Lipofection
was followed by cell culture in hypoxia (1% O2) or in the presence of DMOG, which is the 2-
OG analogue inhibiting PHDs and FIH-1. siRNA acts in a similar way to microRNA
(miRNA), which is able to inhibit translation by affecting mRNA levels, thus it is imperative
to monitor siRNA-induced knockdown at both protein and mRNA level. To determine the
silencing effects of HIF- knockdown, mRNA levels of HIFs were first analysed using Q-
PCR (for HIF-1 and HIF-2), protein levels by western blotting (for HIF-1 and HIF-2)
and ELISA (for HIF-1 only), and then HIFs activity by DNA binding assay (for both HIF-
1 and HIF-2).
To control siRNA specificity, two sets of siRNA (Table 3.12, page 92) targeting
different regions of the HIF-1 and HIF-2 transcripts were used, and both sets were seen to
reduce the gene transcription to similar levels (>70%; not shown). The sets of siRNA, namely
siHIF-1#1 and siHIF-2#1, were used in the subsequent experiments.
In order to validate RA FLS transfection, different controls and various
concentrations of siRNA were used. Non-transfected cells were compared with cells
transfected with siRNA against luciferase. Each control and specific knockdown was related
to mock control (lipofectamine without siRNA). Additionally, siRNA targeting HIF-2
served as a specific negative control for HIF-1, and vice versa. HIF-1 was specifically
knocked down by 79% with 10nM siHIF-1 and there were no significant effects of negative
controls (siLuc or HIF-2) on HIF-1 mRNA (Figure 4.8a). HIF-2 mRNA was knocked
down by 84% with 10nM siHIF-2 (Figure 4.8b). Transfection and knockdown of HIFs was
considered successful, as it is generally accepted that required inhibition of transcription
needs to be more than 70%. However, 100nM siLuc had an inhibitory effect on HIF-1 and
HIF-2 mRNA levels and also the off-target effect was seen on HIF-2 mRNA expression
triggered by siHIF-1 concentration of 50nM and above (Figure 4.8). In my future studies,
10nM concentration of siRNA was used in order to exclude off-target effects, as it is believed
that using low concentrations (between 5 and 20nM) of a highly specific siRNA appears to
minimise non-specific changes in other than target gene expression.
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Figure 4.8 Optimisation of HIF- knockdown
RA FLS were transfected with siHIF-1, siHIF-2 siLuc with different concentrations of siRNA,
including 10, 50 and 100nM, or with lipofectamine alone, or the cells were left untreated. (a) HIF-1
and (b) HIF-2 mRNA levels were measured by Q-PCR and normalised to mock-transfected cells
(indicated by dashed lines). Data are mean ± SEM from 3 - 7 experiments and were analysed by 1-way
ANOVA versus mock-transfected cells: * p<0.05, *** p<0.001.
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After validation of HIF- knockdown under normoxic conditions, cells were
transfected and harvested after 6 and 24 hours of treatment with hypoxia or DMOG.
Successful knockdown of both HIF-1 and HIF-2 at the mRNA level in hypoxia and
DMOG at 6 hours (Figure 4.9) and 24 hours (Figure 4.10) was achieved. Note that, in the 6-
hour experiment, HIF knockdown in DMOG condition was performed only once.
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Figure 4.9 HIFs mRNA knockdown followed by 6-hour hypoxia or DMOG
RA FLS were transfected with siLuc, siHIF-1 or siHIF-2 (10nM). (a) HIF-1 and (b) HIF-2
mRNA levels were measured by Q-PCR after exposure for 6 hours to normoxia (21% O2), hypoxia
(1% O2) or 1mM DMOG, and normalised to mock-transfected cells exposed to normoxia. Data are
mean ± SEM from 3 experiments and were analysed by 1-way ANOVA versus matched siLuc:
*p<0.05, ** p<0.001.
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Figure 4.10 HIFs mRNA knockdown followed by 24-hour hypoxia or DMOG
RA FLS were transfected with siLuc, siHIF-1 or siHIF-2 (10nM). (a) HIF-1 and (b) HIF-2
mRNA levels were measured by Q-PCR after exposure for 24 hours to normoxia (21% O2), hypoxia
(1% O2) or 1mM DMOG, and normalised to mock-transfected cells exposed to normoxia. Data are
mean ± SEM from 3 experiments and were analysed by 1-way ANOVA versus matched siLuc:
*p<0.05, ** p<0.001, *** p<0.001.
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Both HIF-1 and HIF-2 protein levels, undetectable under normoxia in most cases,
were upregulated by hypoxia and DMOG in RA FLS. Clearly translation of both proteins was
inhibited by respective siRNA when assayed by western blot at 6 hours of treatment (Figure
4.11) as well as after 24 hours of treatment (Figure 4.12). The knockdown effect was
maintained for up to 72 hours post-transfection (data not shown).
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Figure 4.11 Knockdown of HIF- protein followed by 6-hour hypoxia and DMOG
stimulation
RA FLS were transfected with siLuc, siHIF-1 or siHIF-2 (10nM). A representative western blot of
HIF-1 and HIF-2 protein assessed after the exposure for 6 hours to normoxia (21% O2), hypoxia
(1% O2) or 1mM DMOG. -Tubulin is shown as a loading control.
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Figure 4.12 Knockdown of HIF- protein followed by 24-hour hypoxia and DMOG
stimulation
RA FLS were transfected with siLuc, siHIF-1 or siHIF-2 (10nM). A representative western blot of
HIF-1 and HIF-2 protein assessed after the exposure for 24 hours to normoxia (21% O2), hypoxia
(1% O2) or 1mM DMOG. -Tubulin is shown as a loading control.
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Additionally, knockdown of HIF-1 protein was confirmed using an available HIF-1
ELISA, showing the presence of HIF-1 protein under normoxia with the average
concentration of 105pg/mL and a significant decrease in protein translation by 34% in
normoxia following siRNA targeting HIF-1 (not shown). Hypoxia increased HIF-1 protein
level 2.3-fold to concentrations ranging from 144 to 432pg/mL (mean 236pg/mL). DMOG
treatment upregulated HIF-1 protein to the mean concentration of 328pg/mL (range 280 to
411pg/mL), which is a mean fold increase of 3. siHIF-1-treated cells produced less HIF-1
protein, which was decreased by 73% in hypoxia and DMOG conditions versus respective
siLuc controls, down to the normoxic basal concentration of the protein (Figure 4.13a).
In a separate experiment the cells had already very high levels of normoxic HIF-1
protein and responded to hypoxia increasing HIF-1 from 540 to 1602pg/mL. Hypoxia-
induced HIF-1 protein level was reduced by 92% to 127.5pg/mL by siRNA targeting HIF-
1 far below the normoxic levels. Importantly, knocking down HIF-2 had no effect on HIF-
1 protein level (Figure 4.13b). In addition, a titration experiment showed that the lowest
siRNA concentration of HIF-1 (10nM) delivered the best knockdown (data not shown).
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Figure 4.13 Silencing HIF-1 protein in response to hypoxia and DMOG
(a) RA FLS were transfected with either siLuc or siHIF-1 (10nM), or lipofectamine alone (“mock”)
and HIF-1 protein was assessed by ELISA after exposure to hypoxia (1% O2) or 1mM DMOG for 24
hours. Data are mean ± SEM from 3 experiments and were analysed by 1-way ANOVA versus siLuc:
*** p<0.001. (b) RA FLS were transfected with siLuc, siHIF-1 siHIF-2 (10nM), or lipofectamine
alone (“mock”) and HIF-1 protein was assessed by ELISA after exposure to hypoxia (1% O2) for 24
hours. Data are mean ± SEM from a single experiment. Dashed lines show protein levels under
normoxic conditions.
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To investigate whether targeting HIF- transcription in hypoxia- or DMOG-mediated
induction of HIF- protein is paralleled by changes in HIF binding to DNA, nuclear extracts
from knockdown experiments were added to the wells pre-coated with oligonucleotides
containing HRE. HIF-1 ability to bind to DNA increased the signal 3.3-fold when RA FLS
were incubated for 24 hours in hypoxia (1% O2) compared to normoxia and decreased by
87% using siHIF-1Figure 4.14a HIF-1 binding to HRE after DMOG treatment was 8.5-
fold higher than vehicle control (DMSO) and was reduced by 72% with siHIF-1 compared
to siLuc control in response to DMOG (Figure 4.14b). The tendency of the increase ability of
HIF-1 to bind to DNA was noticed when siRNA targeting HIF-2 were used; however, it was
not statistically significant (Figure 4.14).
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Figure 4.14 Reduction in HIF-1 activation with siHIF-1 followed by hypoxia and
DMOG
RA FLS were transfected with siLuc, siHIF-1 siHIF-2 (10nM), or lipofectamine alone (“mock”).
HIF-1 protein binding to HRE was assessed in nuclear extracts by TransAM assay after exposure to
either (a) hypoxia (1% O2) or (b) 1mM DMOG for 24 hours. Dashed lines show response using siLuc.
Specificity of binding was confirmed using mutated and wild-type oligonucleotides. Data are mean ±
SEM from 3 experiments and were analysed by 1-way ANOVA versus siLuc: ns=not significant,
*p<0.05, ** p<0.001, *** p<0.001.
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In parallel to HIF-1 knockdown experiment, HIF-2 depletion was assessed in a
similar way. HIF-2 binding to HRE in hypoxia (1% O2) was increased approximately 7.5-fold
compared to normoxia and decreased by 79% using siHIF-2. Interestingly, HIF-1
depletion had a significant effect on HIF-2, actually increasing its binding to HRE by 66%
compared to siLuc in hypoxia-treated cells (Figure 4.15a. HIF-2 binding to HRE after
DMOG treatment increased 3.6-fold compared to vehicle control (DMSO) and was reduced
by 69% with siHIF-2 compared to siLuc control in DMOG, and again HIF-1 knockdown
increased the ability of HIF-2 binding to HRE by 20% when compared to siLuc in response to
DMOG (Figure 4.15b).
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Figure 4.15 Reduction in HIF-2 activation with siHIF-2 followed by hypoxia and
DMOG
RA FLS were transfected with siLuc, siHIF-1, siHIF-2 (10nM), or lipofectamine alone (“mock”).
HIF-2 protein binding to HRE was assessed in nuclear extracts by TransAM assay after exposure to
either (a) hypoxia (1% O2) or (b) 1mM DMOG for 24 hours. Dashed lines show response using siLuc.
Specificity of binding was confirmed using mutated and wild-type oligonucleotides. Data are mean ±
SEM from 3 experiments and were analysed by 1-way ANOVA versus respective siLuc: * p<0.05,
***p<0.001.
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4.3.5 IDENTIFICATION OF GENES REGULATED BY HIF-1 OR HIF-2 IN RA FLS
Some of the main features of RA include angiogenesis, inflammation and hyperplasia
which eventually lead to decreased oxygen tension. It is believed that HIF-1 and HIF-2 play a
pivotal role in activation of stress-response proteins in RA, since the state of decreased
oxygen levels in RA (Lund-Olesen 1970) and increased HIFs protein expression was reported
in RA (Hitchon et al 2002; Giatromanolaki et al 2003). HIF-1 and HIF-2 have possibly
distinct effects on cell biology although they have very similar structure. Moreover HIF- can
act in completely opposite ways as shown by the action of both -subunits on tumour
development (Sowter et al 2003). Short interfering RNA (siRNA) technique gives not only
direct silencing effects on targeted gene, but also enables investigation of downstream effects
such as HIF-regulated genes. Most of the genes, whose expression have been examined and
shown to be strongly increased by hypoxia or DMOG in RA FLS included in Table 4.1 are
potentially HIF- dependent. Therefore siRNA-based approach was used to investigate which
HIF- subunit is responsible for the regulation of which gene.
Expression of ANGPTL-4 was recently discovered to be strongly upregulated in RA
FLS after hypoxic stimulation (Del Rey et al 2010). Thus ANGPTL-4 was measured after
silencing -subunits. The mRNA level of ANGPTL-4 was significantly decreased in hypoxia
by siHIF-1and siHIF-by 55% and 31%, respectively. In the presence of DMOG, siHIF-
1 and siHIF-2 reduced ANGPTL-4 mRNA by 77% and 32%, respectively (Figure 4.16).
Figure 4.16 HIF-1 and HIF-2 regulate ANGPTL-4 mRNA in RA FLS
RA FLS were transfected with siLuc, siHIF-1 siHIF-2 (10nM) or lipofectamine alone (“mock”) and
subsequently exposed to normoxia (21% O2), hypoxia (1% O2) or 1mM DMOG for 24 hours.
ANGPTL-4 mRNA levels were assessed by Q-PCR and normalised to normoxia. Data are mean ±
SEM (n=6) and were analysed by 1-way ANOVA versus respective siLuc: * p<0.05, *** p<0.001.
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ANGPTL-4 mRNA knockdown was further confirmed at the protein level using
ELISA. Both siHIF-1 and siHIF-2 decreased ANGPTL-4 secretion by approximately 42%
and 48%, respectively. However, DMOG-induced ANGPTL-4 protein was decreased
significantly by 53% only by siRNA targeting HIF-1 (Figure 4.17).
Figure 4.17 HIF-1 and HIF-2 regulate ANGPTL-4 protein in RA FLS
RA FLS were transfected with either siLuc or siHIF-1 siHIF-2 (10nM) or lipofectamine alone
(“mock”) and subsequently exposed for 24 hours to either normoxia (21% O2) or hypoxia (1% O2), or
1mM DMOG to measure ANGPTL-4 protein by ELISA. Dashed line indicates ANGPTL-4 levels
under normoxic conditions. Data are mean ± SEM from 8 experiments for hypoxic conditions and 2
experiments for DMOG-treated cells and were analysed by 1-way ANOVA versus respective siLuc:
ns=not significant, *** p<0.001.
VEGF, which is one of the well-known and broadly investigated HIF- target genes,
was also investigated at the mRNA and protein level after silencing HIFs. Results below
indicate that transcription of VEGF gene was significantly downregulated by both siHIF-1
and siHIF-2in RA FLS, by 48% and 58%, respectively. DMOG-induced VEGF was
reduced by siHIF-1 and siHIF-2, however with a predominance of siHIF-1 being reduced
by 69%, and by 46% using siRNA targeting HIF-2 (Figure 4.18).
Data showing mRNA levels of VEGF after HIF knockdown paralleled protein data,
revealing predominance of HIF-2 under hypoxia and HIF-1 after DMOG treatment in VEGF
regulation. Hypoxia-induced VEGF secretion was inhibited significantly by both siHIF-
1and siHIF-2, by 40% and 82%, respectively. VEGF production after DMOG stimulation
was reduced by 69% with siHIF-1 and by 53% using siHIF-2 (Figure 4.19).
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Figure 4.18 HIF-1 and HIF-2 regulate VEGF mRNA in RA FLS
RA FLS were transfected with either siLuc or siHIF-1 or siHIF-2 (10nM) and subsequently exposed
for 24 hours to normoxia (21% O2), hypoxia (1% O2) or 1mM DMOG. VEGF mRNA levels were
assessed by Q-PCR and normalised to normoxia. Data are mean ± SEM from 4 - 6 experiments and
were analysed by 1-way ANOVA versus respective siLuc: * p<0.05, ** p<0.01, *** p<0.001.
Figure 4.19 HIF-1 and HIF-2 regulate VEGF protein in RA FLS
RA FLS were transfected with either siLuc or siHIF-1 or siHIF-2 (10nM) and subsequently exposed
to normoxia (21% O2), hypoxia (1% O2) or 1mM DMOG for 24 hours to measure VEGF protein by
ELISA. Dashed line indicates VEGF levels under normoxic conditions. Data are mean ± SEM from 4 -
11 experiments and were analysed by 1-way ANOVA versus siLuc: *** p<0.001.
In addition to its role in stimulating expression of angiogenic growth factors in
hypoxic RA FLS, HIFs play important role in glycolysis by regulating one of the most
important metabolic genes, namely GLUT-1, investigated previously in various cell types
(Aprelikova et al 2006; Lafont et al 2007). As shown in Figure 4.20, it could be concluded
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that HIF-1 is required for the expression of GLUT-1 in both hypoxia- and DMOG-treated
cells, since siHIF-1 reduced GLUT-1 mRNA level by 69% and 63%, respectively.
Figure 4.20 GLUT-1 gene expression is HIF-1-dependent in RA FLS
RA FLS were transfected with either siLuc or siHIF-1 or siHIF-2 (10nM) and subsequently exposed
for 24 hours to normoxia (21% O2), hypoxia (1% O2) or 1mM DMOG. GLUT-1 mRNA levels were
assessed by Q-PCR and normalised to normoxia. Data are mean ± SEM from 4 experiments and were
analysed by 1-way ANOVA versus matched siLuc: ns=not significant, * p<0.05, ** p<0.01.
As seen in Figure 4.21, HIF-1 was also implicated in GLUT-1 protein regulation.
Normoxic level of GLUT-1 was shown previously in Figure 4.7.
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Figure 4.21 GLUT-1 protein is HIF-1-dependent in RA FLS
RA FLS were transfected with either siLuc or siHIF-1 or siHIF-2 (10nM), or lipofectamine alone
(“mock”), and subsequently exposed to either hypoxia (1% O2) or 1mM DMOG for 24 hours. GLUT-1
protein levels were assessed by western blot with -tubulin as a loading control and are shown from a
representative experiment.
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CA9, a transmembrane protein whose expression is strongly induced by hypoxia in a
variety of solid tumours (Wykoff et al 2000; Hu et al 2003; Raval et al 2005; Wang et al
2005), was seen to be increased also in RA FLS exposed to hypoxia (Del Rey et al 2010) and
DMOG (Table 4.1 and Figure 4.7). CA9 was strongly HIF-1-dependent and was reduced by
76% and 82% in hypoxia and after DMOG treatment, respectively (Figure 4.22).
Figure 4.22 CA9 gene expression is HIF-1-dependent in RA FLS
RA FLS were transfected with siLuc, siHIF-1 or siHIF-2 (10nM) and exposed to normoxia (21%
O2), hypoxia (1% O2) or 1mM DMOG for 24 hours. CA9 mRNA level was assessed by Q-PCR and
normalised to normoxia. Data are mean ± SEM (n=4) and were analysed by 1-way ANOVA versus
matched siLuc: ns=not significant, * p<0.05, ** p<0.01.
Protein data showed that CA9 was regulated predominantly by HIF-1. Hypoxia- and
DMOG-induced CA9 concentration measured in cytoplasmic fractions by ELISA was
reduced by 64% and 96%, respectively, without significant influence of siHIF-2 (Figure
4.23a). CA9 protein measured in the whole-cell extract was also primarily regulated by HIF-1
(Figure 4.23b). Normoxic level of CA9 protein was shown previously in Figure 4.7.
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Figure 4.23 CA9 protein is HIF-1-dependent in RA FLS
RA FLS were transfected with siLuc, siHIF-1 siHIF-2 (10nM), a combination of siHIF-1 plus
siHIF-2 or lipofectamine alone (“mock”) and subsequently exposed to either hypoxia (1% O2) or
1mM DMOG for 24 hours. (a) CA9 protein levels assessed by ELISA in cytoplasmic fractions. Dashed
line indicates CA9 levels under normoxic conditions. Data are mean ± SEM (n=1) analysed by 1-way
ANOVA versus siLuc: *** p<0.001. (b) A representative CA9 blot with -tubulin as a loading control.
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It was reported by others that a pro-apoptotic gene, namely BNIP-3, is increased by
hypoxia in RA FLS (Kammouni et al 2007) and is HIF-1-dependent in RCC (Raval et al
2005). BNIP-3 regulation was confirmed in this study to be highly hypoxia and DMOG
inducible and demonstrated for the first time to be a HIF-1 target gene in RA FLS. BNIP-3
was decreased at the mRNA level by siHIF-1 by 61% and 56% in hypoxia and DMOG,
respectively (Figure 4.25a). Decrease in mRNA level after silencing HIF-1 was paralleled
by protein levels of BNIP-3 (Figure 4.24b).
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Figure 4.24 BNIP-3 expression is HIF-1-dependent in RA FLS
RA FLS were transfected with either siLuc or siHIF-1 or siHIF-2 (10nM), or lipofectamine alone
(“mock”), and subsequently exposed for 24 hours to either normoxia (21% O2) hypoxia (1% O2) or
1mM DMOG. (a) BNIP-3 mRNA levels were assessed by Q-PCR. Data are mean ± SEM from 3 - 4
experiments and were analysed by 1-way ANOVA versus respective siLuc: ns=not significant,
*p<0.05, ** p<0.01. (b) Representative BNIP-3 western blot with -tubulin shown as a loading
control.
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It was shown in other cell types that enolase-1 (ENO-1), known also as -enolase, is
regulated by both HIF- (Semenza et al 1994; Koizume et al 2008). However, results from
the experiment conducted on synovial fibroblasts demonstrated specific responsiveness to
HIF-1 but not HIF-2. Hypoxia- and DMOG-induced ENO-1 mRNA was diminished by
siRNA targeting HIF-1by 60% and 55%, respectively (Figure 4.25a).
Ephrin receptors and ligands belong to a big family of proteins which are believed to
be implicated in angiogenesis (Romanovsky et al 2006). In our system only ephrin-A3 (Table
4.1), and not ephrin-A1 (Table 4.3), responded to hypoxia and DMOG. In addition, ephrin-A3
regulation was decreased specifically by siRNA targeting HIF-1 by 74% and 71% in
hypoxia- and DMOG-treated cells, respectively (Figure 4.25b).
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Figure 4.25 ENO-1 and ephrin-A3 expression is HIF-1-dependent in RA FLS
RA FLS were transfected with either siHIF-1 or siHIF-2 and subsequently exposed to normoxia
(21% O2), hypoxia (1% O2) or 1mM DMOG for 24 hours. (a) ENO-1 and (b) ephrin-A3 mRNA levels
were assessed by Q-PCR and normalised to normoxia. Data are mean ± SEM from 3 - 5 experiments
and were analysed by 1-way ANOVA versus respective siLuc: ns=not significant, * p<0.05, ** p<0.01.
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4.3.6 COMPARISON OF DIFFERENT FIBROBLASTS
Next, it was of interest to examine how arthritic fibroblasts (RA FLS, OA FLS) and
non-arthritic fibroblasts (NHDF) respond to hypoxia. Therefore the protein levels of these
cells cultured in normoxia, hypoxia and DMOG were compared at the 24-hour time point
using a western blot technique. As shown in Figure 4.26 all fibroblasts responded to hypoxia
and DMOG by stabilising HIF-1 and HIF-2 proteins. Interestingly, HIF-1 protein was
detected in normoxia in arthritic cells (RA and OA FLS) but not in healthy dermal fibroblasts,
NHDF. HIF-2 protein level in OA FLS and NHDF was hardly detectable compared to RA
FLS, which clearly upregulated HIF-2 in hypoxia- and DMOG-treated cells. In addition,
two well established hypoxia/HIF-responsive genes, namely BNIP-3 and GLUT-1, were
strongly induced by hypoxia and DMOG in all three cell lines.
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Figure 4.26 The protein profile of hypoxic markers in RA, OA FLS and NHDF
RA FLS, OA FLS and NHDF were cultured in normoxia (N, 21% O2), hypoxia (H, 1% O2) or 1mM
DMOG (D) for 24 hours. Western blot from one experiment is showing a protein profile of hypoxic
markers (HIF-1, HIF-2, BNIP-3 and GLUT-1) in these cells with -tubulin as a loading control.
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Hypoxia and DMOG time-course studies in NHDF have shown that healthy
fibroblasts responded to hypoxia and DMOG in a similar way to arthritic RA FLS. HIF-1
and HIF-2 together with a HIF-1 target protein, GLUT-1, were clearly stabilised in a time-
dependent manner in both hypoxia- (Figure 4.27a) and DMOG-treated cells (Figure 4.27b). In
addition, Q-PCR analysis from 3 separate experiments has shown that genes such as
ANGPTL-4, BNIP-3, CA9, GLUT-1 and VEGF were upregulated 29-, 6-, 14-, 3- and 6-fold,
respectively, in hypoxic conditions after 24-hour incubation (data not shown).
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Figure 4.27 Time-course study of HIF- stabilisation and GLUT-1 protein in NHDF
NHDF were exposed for 24 hours to either (a) hypoxia (1% O2) or (b) 1mM DMOG for indicated time
points. A single western blot shows HIF-1, HIF-2 and GLUT-1 proteins detected by specific
antibodies with -tubulin used as a loading control.
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4.4 Discussion
Tissue hypoxia results from an inadequate supply of oxygen, with resultant effects on
biological functions. Since arthritic synovium is characterised by an altered proliferative
response of cells and thus hyperplasia, which leads to an increased distance from pre-existing
blood vessels, it is not surprising that hypoxia has been characterised as one of the main
features of RA (Hollander et al 2001; Taylor and Sivakumar 2005; Kennedy et al 2010). The
hypoxic microenvironment was demonstrated in RA synovial fluid for the first time in 1970
(Lund-Olesen 1970) and then confirmed in synovial tissue revealing that oxygen tension is
lower in RA joints comparing to healthy joints (Sivakumar et al 2008; Ng et al 2010). HIF-1
was described in the inflamed synovium and shown positive correlation with synovitis in AIA
rat model (Peters et al 2004) as well as in humans (Brouwer et al 2009). More specifically,
HIF-1 as a hypoxia marker is indeed expressed in RA synovium, primarily in the synovial
sub-lining layer, macrophages and vascular endothelial cells (Hollander et al 2001; Hitchon et
al 2002; Brouwer et al 2009), whereas HIF-2 is mainly localised around lymphocytic
perivascular aggregates (Giatromanolaki et al 2003). Distinct cell expression suggests that
HIF- isoforms may play different roles in RA. In addition, immunohistochemical (IHC)
staining demonstrated that FLS, which were used in this study, also express both HIF-
subunits (Hitchon et al 2002; Giatromanolaki et al 2003; Sivakumar et al 2008).
Oxygen-dependent regulation of HIF- degradation and activity of HIF-1 and HIF-2
occurs mainly at the post-translational level, since hypoxia does not increase HIF- mRNA
(Wiesener and Maxwell 2003). In the presence of oxygen, HIF- protein levels are decreased
by enzymatic hydroxylation of critical amino residues, which is accomplished by two distinct
families of hydroxylases (PHDs and FIH-1), whose mechanisms of action are discussed in
more detail in Chapter 5 (page 142). Under conditions where oxygen is limiting, HIF-
subunits accumulate and activate the transcription of HRE-containing genes. As part of my
study, the expression of HIFs was evaluated at both mRNA and protein level in RA FLS.
Although it was shown that inflamed tissue oxygen tension is between 2 - 4% O2
compared to 9 - 12% O2 in healthy RA tenosynovium (Sivakumar et al 2008), 1% O2 was
used in this study to mimic hypoxia. This was due to the fact that stabilisation of HIF-
protein, as well as HIF binding to HRE was maximal at 1% O2, although it occurred already
at 3 - 5% O2. HIF- protein accumulation in hypoxic conditions was time-dependent and the
peak induction of HIF-1 and HIF-2 was observed between 2 and 6 hours of hypoxia (1%
O2), then slightly decreased and remained unchanged thereafter, which indicates that
stabilisation and nuclear translocation occurs rapidly in hypoxic synovial cells. HIF-2 has a
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similar expression pattern to HIF-1 and its peak induction was early between 2 and 4 hours
of hypoxia. Note that in most of the experiments performed in this study it was difficult to
detect HIF-2 protein, which could have been caused by either not high enough the affinity of
the antibody to the protein or that HIF-2 is less abundant in RA FLS. In addition,
interestingly, stabilisation of HIF-1 was sometimes observed in normoxia in RA FLS,
meaning that HIF-1 is present even though its upstream oxygen-dependent regulators, PHDs
and FIH-1, are active. This could be the effect of oxygen-independent mechanisms via for
instance cytokines, which are augmented in RA and spontaneously secreted in cultured RA
FLS (Brennan et al 1989b), and which can also stabilise HIF-1 (Hitchon et al 2002). In
contrast to HIF-1, HIF-2 protein was not detected under normoxic conditions in RA FLS at
all. This is consistent with pro-inflammatory cytokines having a stabilising effect on HIF-1,
but not HIF-2, in contrast to anti-inflammatory cytokines which regulate HIF-2 (Takeda et
al 2010), which are less abundant in RA.
DMOG, which is a 2-OG analogue, stabilises HIF- via inhibition of PHDs and FIH-
1, and was therefore used in this study. Among many available stabilisers of HIF- protein,
DMOG was chosen for comparison with hypoxia, as a striking concordance between gene
pattern induced by hypoxia and 2mM DMOG was reported in MCF7 and Hep3B cells
(Elvidge et al 2006). Although mimicking hypoxia DMOG does not activate HIF-1 and
HIF-2 in RA FLS to the same extent. A concentration of 1mM DMOG was much stronger
stabiliser of HIF- than hypoxia. These results can be probably explained by the fact that
hypoxia decreases only PHDs activity, whereas DMOG is able to inhibit both PHDs and FIH-
1, an effect which can therefore be mirrored by the HIF- protein level. Unfortunately,
DMOG is not specific and inhibits also procollagen hydroxylases (prolyl- and lysyl-
hydroxylases), decreasing the stability of the collagen triple helix (Myllyharju 2003). More
recently it was shown that DMOG decreased type II collagen alpha 1 (COL2A1) in cultured
chondrocytes in vivo and impaired post-translational processing leading to accumulation of
type II collagen via negative feedback loop (Gelse et al 2008).
In keeping with others, the time-related increment in HIF- proteins was not
observed at the mRNA level, which means that indeed HIF- is regulated predominantly at
the post-translational level under hypoxic conditions (Wenger et al 1998; Wiesener and
Maxwell 2003). HIF-1 and HIF-2 transcription was decreased by hypoxia in RA FLS.
DMOG, although mimicking hypoxia, induced a more profound decrease of HIF-1
compared to hypoxia. In contrast, HIF-2 mRNA was upregulated in my system after DMOG
treatment. Interestingly, as shown by others HIF-2 mRNA is also upregulated by hypoxia in
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vivo in lung epithelial cells (Uchida et al 2004) and in pulmonary arteries (Chen et al 2006).
Similar results have been reported previously using another inhibitor of PHDs and FIH-1, a
Fe2+ chelator 2,2’dipyridyl (DP), which also slightly increased HIF-2 mRNA, whereas it had
no or moderate reducing effect on HIF-1 mRNA (Warnecke et al 2008). These results
suggest that both -subunits are differentially regulated by DMOG at the mRNA level, which
possibly has further implications in HIF-dependent gene regulation.
An observed phenomenon of HIF- mRNA downregulation with simultaneous HIF-
protein upregulation under hypoxic conditions could be explained by the intriguing, naturally
existing antisense transcript (aHIF), which by recognising homologous sequences in HIF-1
destabilises its mRNA (Thrash-Bingham and Tartof 1999). It has been shown by Dr Helene
Larsen in our group that indeed aHIF is upregulated by hypoxia in RA FLS, with the highest
levels after 6 hours followed by its declining after 24 hours. DMOG increased aHIF by 46-
fold and subsequently decreased HIF-1 mRNA (Dr Helene Larsen, unpublished data).
Moreover, aHIF is a HIF-1-dependent gene, since it contains HRE and its expression is
abrogated by siHIF-1, thus it is possibly implicated in negative feedback loop of HIF
pathway. Another compelling evidence of HIF-1 complex regulation was recently
discovered, with description of at least 4 non-coding microRNAs (miRNAs), which is
important in regulation of gene expression. miRNA were significantly upregulated by
hypoxia in MCF7 cells and at least one of them, namely hsa-miR210 was HIF-1-dependent
(Camps et al 2008). Transcript levels of HIF-2 decreased slower and later than HIF-1
mRNA or remained unchanged in hypoxia in RA FLS, whereas HIF-1 mRNA begins to
decrease after 4 - 6 hours of hypoxia, what is probably due to the presence of aHIF. There is
no aHIF or miRNA discovered yet which regulate HIF-2; however, CITED-2, which is a
competitor for the transcriptional co-activator CBP/p300 perhaps negatively regulates HIF-2
level and is clearly HIF-2-dependent (Aprelikova et al 2006; Hu et al 2007). This suggests
that there is probably another mechanism, not only in DMOG-treated cells but also in hypoxic
conditions, regulating HIF-2 synthesis, distinct from HIF-1.
In healthy individuals synovial membrane consisting of synovial fibroblasts is in
charge of joint homeostasis. In RA expansion of the synovial tissue and increased but
weakened angiogenesis finally leads to insufficient joint oxygenation. It has been
demonstrated that hypoxia stimulates genes involved in many aspects of RA progression such
as (i) angiogenesis induced by angiogenic growth factors (VEGF, ANGPTL-4, ephrin-A3),
which increase the delivery of oxygen, (ii) anaerobic metabolism provoked by enhanced
glucose transport and expression of glycolytic enzymes (GLUT-1, ENO-1), (iii) increased
proliferation and inhibited apoptosis by the regulation of BNIP-3, (iv) migration and invasion
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of cells to adjacent cartilage and bone (IL-8, PAI1, MMPs), (v) pH regulation contributing to
cell survival via CA9 expression, and (vi) inflammation involved in disease progression and
perpetuation (COX-2, HO-1, IL-1). Adaptation to these adverse conditions is triggered by
induction of HIFs which modulate gene transcription. In order to understand and treat
diseases in which hypoxia is involved scrutinising the difference between HIF-1 and HIF-2
is critical. Therefore, to validate the premise of the study it was of interest to investigate these
genes and provide further insight into the consequences of silencing HIF- subunits in RA
FLS using siRNA approach thus to identify their roles.
Both HIF- were successfully silenced in RA FLS at the mRNA and protein level,
significantly reducing their binding to DNA. To prove that specific -subunit is targeted with
specific siRNA, two sets of oligos were used, which gave similar results. However, the
transregulation between HIF-1 and HIF-2 cannot be excluded. Silencing HIF-1 in
hypoxia and DMOG-treated cells significantly increased HIF-2binding to HRE and knocking
down HIF-2 probably also increases HIF-1 binding to HRE (data not statistically
significant). This reciprocal interaction between HIF- subunits was shown previously by
others, when HIF-1 over-expression inhibited HIF-2 expression and vice versa in RCC
(Raval et al 2005; Warnecke et al 2008) and silencing HIF-1 resulted in HIF-2 protein
increase and vice versa in MCF-7 cells (Carroll and Ashcroft 2006). Therefore, it is difficult
to distinguish the role of individual isoforms and to answer the question if the inhibitory
results were direct or indirect using only siRNA technique. In addition, DMOG stabilised
HIF-1 so profoundly that it was never fully reduced by siRNA and the protein band was
shifted, whereas HIF-2 protein was clearly silenced by siHIF-2 in DMOG-treated cell.
In this study, only hypoxia-regulated genes with functional HIF--dependent
regulation have been discussed below. All of these genes were more upregulated in the
presence of DMOG than hypoxia, resembling HIF- proteins response possibly due to the
fact that under hypoxia FIH-1 is still active and able to hydroxylate HIF-, whereas DMOG
inhibits all PHDs and FIH-1 (Mahon et al 2001; Metzen et al 2003). The other group of genes
involved in inflammation (HO-1 and COX-2), migration (PAI1, uPAR and MMPs) or
apoptosis (bax, bcl-2, caspase-3, survivin, XIAP, PTEN), were been described in detail in this
report since not enough experiments were performed to verify speculation of their HIF-
dependence or simply they were not regulated by hypoxia and/or DMOG.
RA belongs to a group of angiogenic diseases characterised by increased new blood
vessels formation. It is believed that angiogenesis contributes to RA development and
increased angiogenesis in RA joints, augmented level of VEGF in synovial fluids, one of the
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most potent stimulator of physiological and pathological angiogenesis, correlates with
severity of the disease (Brouwer et al 2009; Kennedy et al 2010). It was shown that VEGF is
increased by hypoxia (Shweiki, Itin et al 1992), that promoter region of VEGF contains HRE
(Wang and Semenza 1993) and it is therefore regulated by HIF-1 and/or HIF-2 depending
on the cell type (Sowter et al 2003; Raval et al 2005; Carroll and Ashcroft 2006; Lafont et al
2007; Koizume et al 2008). In RA synovium it was demonstrated that VEGF expression
appears to closely resemble that of HIF-2 (Sivakumar et al 2008). In this study both HIF-1
and HIF-2 were implicated in VEGF regulation with HIF-2 prevalence under hypoxia, and
HIF-1 dominance after DMOG treatment in RA FLS. Regulation of VEGF by both HIFs is
not surprising, because it was already shown in endothelial cells suggesting for the first time
that HIF-1 and HIF-2 may have common contribution to vasculogenesis, having additive
effects on cytokine expression, cell migration and tubule formation capacity (Ben-Shoshan et
al 2008). However, in terms of VEGF, its regulation is intricate, hence VEGF promoter
encompasses four transcription factors such as AP-1, AP-2, HIF and Sp1 (Tsuji et al 2007),
and is modulated by other factors such as cytokines (TGF-, TNF-, IL-1), serum (Hitchon
et al 2002), or indirectly by the mutations of PTEN, VHL, p53. Interestingly, these factors
also increase HIF-1 (Blancher et al 2000) implying convergence of the HIF pathway and
VEGF expression at different levels and not only in hypoxic conditions.
There is growing evidence suggesting that ANGPTL-4 could be a new therapeutic
target in the regulation of angiogenesis, next to VEGF. However, ANGPTL-4 role has not
been fully elucidated and the function of this putative pro-angiogenic factor appears to be
controversial. In vitro studies revealed that recombinant ANGPTL-4 inhibited proliferation
and tubule formation of endothelial cells. Moreover, in vivo studies demonstrated that
addition of ANGPTL-4 protein inhibited VEGF-induced angiogenesis suppressing tumour
growth (Ito et al 2003). However, studies performed on RA revealed that ANGPTL-4 is
localised in synovial fibroblasts by in situ hybridisation, it is one of the most highly expressed
mRNA early in CIA and is highly increased by hypoxia in RA FLS (Del Rey et al 2010). It
was shown that in the CIA model ANGPTL-4 promotes angiogenesis by improving
endothelial survival and formation of tubule-like structures (Hermann et al 2005). I have
shown that the induction of ANGPTL-4 mRNA level was strikingly increased by hypoxia and
even more by DMOG in RA FLS. Consistently with results performed in other cell types,
including Hep3B, HepG2 and HeLa (Warnecke et al 2008), the analysis of HIF-dependence
in RA FLS revealed that ANGPTL-4 was regulated by both HIF-1 and HIF-2, with the
predominance of HIF-1 in hypoxia.
In hypoxic milieu of joints, due to enhanced cell proliferation of RA FLS and other
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cell types, the cells must adjust cellular metabolism appropriately with limited sources of
oxygen and glucose. Glucose serves as a ‘metabolic fuel’ and ‘structural precursor’ of
extracellular matrix biomolecules, which enters the cells via glucose transporters. Hypoxic
cells rely strongly on glycolysis to produce ATP (high energy substrate), which is accelerated
through induction of glucose availability facilitated by glucose transporters. Thus, although
oxygen is decreased, uncontrolled growth and proliferation of cells is maintained, because a
steady source of metabolic energy is delivered. Therefore, another gene analysed in this study
was GLUT-1, which is a sensing apparatus working via HIF-dependent mechanism and
promoting anaerobic glycolysis when aerobic processes are repressed. The GLUT-1
expression and HIF-dependence analysis demonstrated that GLUT-1 is induced by hypoxia
and is preferentially activated by HIF-1 in RA FLS, which was clearly concordant with the
study performed on RCC lines and chondrocytes (Lafont et al 2007; Khan et al 2011).
Inhibition of glycolysis via HIF-1 inactivation could be a good candidate to target RA FLS
metabolism and thus survival. However, this approach would be complicated because glucose
provides energy also to the brain cells, therefore targeting GLUT-1 would have to be cell and
tissue specific.
To neutralise pH by regulating hydrogen ion (H+) flux, cells developed a system via
carbonic anhydrase (CA), a zinc metalloenzyme. CA9 catalyses the reversible hydration of
CO2 diffused from oxygenated areas to carbonic acid, bicarbonate and hydrogen ions. CA9
enables cells to survive in such conditions by maintaining the acid-base balance, thus it may
contribute indirectly to cell apoptosis and/or growth (Chia et al 2001). In addition, striking
localisation of CA9 expression in regions of necrosis and the correlation between pattern of
oxygenation and expression of CA9 was demonstrated (Wykoff et al 2000). It was
demonstrated that RA is associated with low glucose concentration and high lactate levels
which acidify the milieu and lower pH (Treuhaft and McCarty 1971). CA9 was one of the
most hypoxia-inducible genes in RA FLS shown in my study and also by others (Del Rey et
al 2010). CA9 protein was increased at the mRNA level and at the protein level in the whole
cell lysate and in cytoplasmic fraction. It was reported that CA9 contains functional HRE
close to gene transcriptional start site (Wykoff et al 2000; Kaluz et al 2002; Hu et al 2003;
Raval et al 2005; Wang et al 2005). Therefore consistently with others (Kaluz et al 2002;
Raval et al 2005) CA9 was regulated by hypoxia and was predominantly regulated by HIF-1
also in RA FLS. CA9 is already being used as a biomarker in various cancers revealing
hypoxic regions and maybe could become a target as well. However, modulation of CA9
expression in order to gain clinical importance is more complex, since apart from hypoxia cell
density and serum also regulate the protein (Kaluz et al 2002).
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One of the main therapeutic goals in RA is to limit the proliferation of RA FLS, since
synovial fibroblasts are no longer exposed to normal pro-apoptotic mechanisms and exhibit
resistance to apoptosis, which leads to synovial hyperplasia. It seems that HIF-1 which is
important in cell growth as well as apoptosis, induces anti-apoptotic mediators outweighing
pro-apoptotic factors in RA. It was demonstrated previously that a member of the Bcl-2
family, namely BNIP-3, which contains functional HRE (Bruick 2000), is upregulated by
HIF-1 in monocytes, endothelial cells and tumour cells (Hu et al 2003; Greijer et al 2005;
Raval et al 2005). It was reported that BNIP-3 is widely expressed in RA synovium and is
especially prominent in synovial fibroblasts from the lining layer, and that mRNA and protein
level is increased by hypoxia (Kammouni et al 2007). Therefore, HIF-dependence of BNIP-3
was investigated next in RA FLS. In this study BNIP-3 was notably increased by hypoxia and
even further in the presence of DMOG and was clearly a HIF-1 target gene. Interestingly, it
was previously described in RCC4 that HIF-2 has the opposite effect on BNIP-3 (Raval et al
2005). Also in RA FLS, silencing HIF-2 in hypoxia, led to increased BNIP-3 transcription
(although it was not significant) and translation (note that western blot was performed only
once). Targeting HIF- and therefore BNIP-3 would be a perilous target for RA therapy,
because BNIP-3 reduction might actually increase cell proliferation. In addition, BNIP-3 is
localised to the mitochondria, a site where numerous cell death regulatory pathways
converge, which could switch on unwanted cascades of events. Therefore in order to inhibit
proliferation by induction of apoptosis other targets should be investigated.
Another gene relevant to RA and investigated in this study was enolase-1 (ENO-1),
known also as -enolase. ENO-1 is widely expressed and exhibits many distinct functions.
ENO-1 is well-known glycolytic enzyme which regulate cell growth, differentiation and
facilitates muscle repair via increasing plasmin generation (Lopez-Alemany et al 2005).
ENO-1 is an interesting protein in autoimmune and inflammatory diseases, including RA.
Lundberg and colleagues established that citrullinated enolase protein (CEP)-1 is one of the
most important autoantigens present in RA synovial fluid and antibodies against CEP-1
(detected using ELISA) are successfully used in the diagnosis of RA (Lundberg et al 2008).
Thus, it would be advantageous to target ENO-1 via HIF- in the case of RA, since it is one
of the most common targets for citrullination, hence induction of the autoantibodies
production. ENO-1 is probably differently modulated by HIF- isoforms in different cell
types. For instance, ENO-1 was firstly identified as a HIF-1 target gene (Semenza et al
1994), whereas it was demonstrated that ENO-1 can be activated also by HIF-2 under
various conditions, irrespective of promoter binding. Interestingly, it was reported that both
HIFs bind to ENO-1 enhancer, but only silencing HIF-1 reduced ENO-1 expression,
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whereas silencing HIF-2 upregulated ENO-1 expression in ovarian cancer cells (Koizume et
al 2008). In the case of RA FLS targeting HIF-1 with siRNA, but not HIF-2 attenuated
hypoxia-induced ENO-1 transcription. It would not be as straightforward to target ENO-1 via
HIF pathway, due to ubiquitous expression of ENO-1 and condition-dependent regulation.
Last but not least, ephrin-A3 was investigated in this study. It belongs to a novel
family of genes, Eph receptors and ephrin ligands, which are involved in the pathogenesis of
RA via the induction of angiogenesis and inflammation (Romanovsky et al 2006). The family
consists of 16 Eph receptors and 8 ligands, all further divided into A and B subclasses
expressed widely in cells (Wilkinson 2000). It was shown that for example ephrin-A1 and its
receptor EphA2 mediate TNF--induced vascularisation by regulating migration of
endothelial cells (Pandey et al 1995) and that ephrin-B2 and EphB4 are also involved in
inflammatory angiogenesis (Yuan et al 2000). In addition, an in vivo model of systemic
inflammation revealed that downregulation of EphA3 occurred simultaneously with
upregulation of ephrin-A3 ligand (Ivanov et al 2005). However, not much is known about this
particular ephrin-A3 ligand in RA FLS, part from the fact that it is upregulated by hypoxia in
RA FLS (Del Rey et al 2010). I have demonstrated ephrin-A3 expression and its HIF-
dependence revealing that it is inducible by hypoxia and DMOG and it is clearly a HIF-1
target gene.
For the practical and therapeutical purpose it was of interest to inspect in what way
fibroblasts from other sources behave in hypoxic environment. Therefore, fibroblasts isolated
from OA tissue as well as normal human dermal fibroblasts (NHDF) were used for
comparison with RA FLS to investigate the HIF signalling pathway in arthritic and non-
arthritic cells. It was reported formerly that although OA is classified as non-inflammatory
synovitis, some OA patients demonstrate evidence of angiogenesis and inflammation.
Approximately 60% of OA patients exhibit synovial proliferation compared to 90% of RA
patients (Lee et al 2007b). OA is also characterised by highly vascularised synovium
(Giatromanolaki et al 2003) and inflammation (Haywood et al 2003). OA is manifested by
higher pO2 than RA as measured in synovial fluids (Lund-Olesen 1970) and possibly
therefore HIF-1 staining of OA synovial tissue is weaker than of RA (Hitchon et al 2002;
Brouwer et al 2009). However, inconsistently, one report described that staining of synovial
stromal cells revealed very strong and comparable patterns of HIF-1 and HIF-2 expression
in both OA and RA (Giatromanolaki et al 2003). In my study, OA FLS as well as NHDF
responded to hypoxia in a similar way to RA FLS, stabilising HIF proteins and HIF target
genes, thus implying that they use the common HIF pathway. One of the major differences
between these cell types was substantial HIF-1 stabilisation in hypoxia and greater
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stabilisation of HIF-2 in hypoxia and DMOG in RA FLS compared to OA FLS and NHDF.
What is more, HIF-1 protein was present in normoxia in RA FLS and OA FLS, but not in
NHDF. This phenomenon could be explained by the fact that HIF-1 was shown to be also
stabilised in an oxygen-independent manner by cytokines, which are spontaneously expressed
by these cells (Brennan et al 1989b). In addition, BNIP-3 and GLUT-1 proteins were
similarly increased in RA FLS and OA FLS. Interestingly, NHDF responded to hypoxia and
DMOG by stabilising HIF-, BNIP-3 and GLUT-1 proteins and augmenting transcription of
a plethora of HIF-dependent genes, indicating that healthy, non-arthritic cells respond in a
similar manner to arthritic cells.
In summary, RA FLS respond to changes in oxygen tension by upregulating the
expression of a range of genes, involved in angiogenesis, apoptosis and metabolism. These
responses require HIF-1 and HIF-2 in a gene-specific manner. The next chapter aimed to
study events upstream of HIF, namely regulation of PHDs and FIH-1, and their involvement
in HIF-dependent gene expression.
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5 Regulation Of Hypoxia Responses Upstream Of HIF: The
Role For PHDs And FIH-1 In RA FLS
5.1 Introduction
The low partial pressure of oxygen present in RA synovium is likely to affect cellular
responses via the ‘master regulator’ which is the HIF transcription factor. The family of HIFs
is regulated predominantly at the level of protein stability in an oxygen-dependent manner
mainly by the group of hydroxylases. Since prolyl hydroxylase domain (PHD)-containing
enzymes (PHD1-3) and factor inhibiting HIF-1 (FIH-1) were identified, they have achieved
the status of oxygen sensors by being able to sense first the slightest fluctuations in oxygen
concentration (Bruick and McKnight 2001; Epstein et al 2001; Lando et al 2002a). They have
been characterised as dioxygenases governed by O2, 2-oxoglutarate (2-OG), iron (Fe2+) and
ascorbic acid. These enzymes hydroxylate different amino acid residues, prolyl or asparaginyl
respectively, which differentially influence HIF- subunits. PHD affects protein
accumulation, through hydroxylation of Pro402 and Pro564 in human HIF-1, and Pro405
and Pro531 in human HIF-2, which leads to polyubiquitination of -subunits by von Hippel
Lindau (pVHL) tumour suppressor protein complex, and proteolytic destruction by E3
ubiquitin ligase/26S proteasome (Maxwell et al 1999; Ivan et al 2001). FIH-1 affects HIF-
transactivation through hydroxylation of Asn803 in HIF-1 and Asn851 in HIF-2 which
blocks the binding of the transcriptional co-activators p300/CBP to -subunits (Lando et al
2002a; McNeill et al 2002). Thus, when the oxygen level drops, HIF- subunits accumulate
and activate transcription of HRE-containing genes facilitating adaptation to hypoxia.
The PHD isoforms and FIH-1 have wide and overlapping distribution in healthy
tissues. Predominantly localised in cytoplasmic compartments, they are mainly expressed by
epithelial and stromal cells (Soilleux et al 2005). Differing roles of HIF hydroxylases was
proven by knockout studies. PHD-1 seems to be implicated in inflammation (Cummins et al
2006) and in metabolic adaptation of muscles (Aragones et al 2008), PHD-2 is the only
hydroxylase, whose biallelic knockout led to embryonic lethality due to placental defects
(Takeda et al 2006) and abnormal angiogenesis (Takeda et al 2007; Minamishima et al 2008),
PHD-3 is involved in neurological development (Bishop et al 2008), whereas FIH-1 seems to
play an important role in metabolism (Zhang et al 2010).
Although it is well established that PHDs and FIH-1 control stability and activity of
HIFs, and thereby induce adaptations to hypoxia, it remains largely unknown how these
enzymes are regulated in RA. Since only PHD-2 and PHD-3 contain HRE, therefore they are
Chapter 5
143
themselves hypoxia-inducible and HIF--dependent genes (Metzen et al 2005; Pescador et al
2005), and in contrast to PHD-1 and FIH-1, they are implicated in the negative feedback loop
mechanism of the HIF pathway.
The data described in Chapter 4 (page 102) highlighted the HIF isoform dependence
of genes involved in angiogenesis and metabolism in RA FLS. The work described in the
current chapter aimed to dissect out expression profile, HIF--dependence, preferences
towards HIF- and differing roles of PHD isoforms and FIH-1 in the hypoxia-mediated
adaptive responses of FLS from RA. In addition, some responses were compared with
osteoarthritis (OA) FLS and a healthy cell type, normal human dermal fibroblasts (NHDF).
5.2 Objectives
The studies presented in Chapter 4 (page 102) addressed the relative roles of HIF-1
and HIF-2 in regulating the responses of RA FLS to hypoxia and DMOG. In order to further
dissect out the molecular events in the HIF pathway, the next step was to investigate the
upstream regulators of HIF hydroxylases (PHDs and FIH-1). This chapter consists of 3 parts
with the following objectives:
(1) To examine the profile of PHDs and FIH-1 gene and protein expression in RA FLS in
hypoxic conditions and their HIF--dependence
(2) To analyse the roles of PHDs and FIH-1 in RA FLS by studying the effect of
hydroxylase depletion on HIFs and HIF--dependent genes identified in Chapter 4
(page 102) in arthritic and non-arthritic cells
(3) To compare the roles of PHDs and FIH-1 in RA FLS and fibroblasts from other
sources, in particular OA FLS and NHDF, on tubule formation
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5.3 Results
To fully understand the HIF pathway, it is indispensable to investigate the mechanism
by which HIFs themselves are regulated. The major oxygen-dependent HIF regulation occurs
via the ODD domain and the C-TAD in the -subunit, which is the target of the specific
hydroxylases, including prolyl hydroxylases (PHDs) and an asparaginyl hydroxylase (FIH-1).
These dioxygenases are believed to be the main oxygen sensors by the ability to respond to
changes in cell oxygenation and acting through enzymatic hydroxylation of the critical HIF
prolyl and asparaginyl residues, respectively. However, in hypoxia PHDs and FIH-1 activity
decreases, which leads to HIF- protein accumulation, translocation to the nucleus,
dimerisation with HIF-1 and HRE, resulting in the transcriptional activation of target genes.
There is not much known about HIF hydroxylases regulation in RA FLS, therefore in
the first part of this study the effect of hypoxia and DMOG on PHDs and FIH-1 expression as
well as their HIF-dependence was assessed in RA FLS. Protein levels were assessed by
western blot, ELISA and TransAM assay, whereas mRNA levels were determined by Q-PCR.
5.3.1 CHARACTERISATION OF PHDS AND FIH-1 EXPRESSION IN RA FLS
To investigate the regulation of FIH-1 and different isoforms of PHD in RA FLS,
cells were exposed to different conditions for 24 hours followed by Q-PCR and western blot
analysis. Hypoxia (1% O2) and 1mM DMOG upregulated both PHD-2 and PHD-3 expression
compared to normoxia and exerted a stronger effect on PHD-3 mRNA than on PHD-2 mRNA
levels. In contrast, hypoxia and DMOG failed to elicit any effect on either PHD-1 or FIH-1
mRNA expression in RA FLS over the period of 24 hours. Data are summarised in Table 5.1
indicating the number of independent experiments.
Table 5.1 PHD and FIH-1 mRNA expression in response to hypoxia and DMOG in
RA FLS
RA FLS were exposed to either hypoxia (1% O2) or 1mM DMOG for 24 hours. Gene expression was
measured by Q-PCR and normalised to normoxia (21% O2). Data are mean ± SEM from the number of
experiments indicated (n). Data were analysed by 1-way ANOVA versus normoxia: ** p<0.01,
***p<0.001.
Gene Activity Hypoxia DMOG n
Hypoxia/DMOG
PHD-1 Prolyl hydroxylase 0.8±0.1 1.2±0.1 15/13
PHD-2 Prolyl hydroxylase 2.3±0.2*** 6.8±1.0*** 15/13
PHD-3 Prolyl hydroxylase 18.8±5.2** 340.7±72.7*** 16/13
FIH-1 Asparaginyl hydroxylase 1.1±0.1 1.3±0.1 15/14
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PHDs and FIH-1 transcription in response to hypoxia and DMOG was paralleled by
translation of these genes. PHD-2 was present in normoxic cells and was increased modestly
by hypoxia and DMOG, whereas PHD-3 protein was only detected in response to DMOG.
Levels of FIH-1 and PHD-1 protein were unchanged and paralleled mRNA data (Figure 5.1).
Normoxia Hypoxia DMOG
PHD-2
PHD-3
a-tubulin
FIH-1
PHD-143.6kDa
46kDa
27.3kDa
40.6kDa
50kDa
Figure 5.1 PHD and FIH-1 protein expression in normoxia, hypoxia and DMOG
RA FLS were cultured in normoxia (21% O2), hypoxia (1% O2) or 1mM DMOG for 24 hours. PHD-1,
PHD-2, PHD-3 and FIH-1 proteins were assessed by western blot with -tubulin shown as a loading
control.
The observation that PHD-3 protein was detectable only in DMOG-treated cells can
be explained by the fact that PHD-3 mRNA was the least abundant hydroxylase in RA FLS
compared to PHD-1, PHD-2 and FIH-1. Study of Ct values used for Q-PCR analysis (at a
constant Ct threshold of 0.05) substantiated the abundance of PHDs and FIH-1 showing that
Ct values in normoxia for PHD-1, PHD-2, PHD-3 and FIH-1 were 21.6 ± 0.2, 19.3 ± 0.2, 25.9
± 0.3 and 20.2 ± 0.3, respectively (mean ± SEM, n≥11), where higher Ct value indicates less 
abundance of RNA/cDNA. Although PHD-3 had the lowest endogenous expression, it was
the most hypoxia-responsive hydroxylase, with mRNA being increased approximately 40-
fold. By comparison, PHD-2 expression was increased just 4-fold relative to normoxia in this
particular experiment, whereas PHD-1 and FIH-1 levels were unchanged (Figure 5.2). Note
that these values were from one representative experiment, therefore the fold increase of
PHD-2 and PHD-3 in hypoxia was different than in Table 5.1.
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Figure 5.2 Total expression of PHDs and FIH-1 mRNA in RA FLS
RA FLS were cultured in normoxia (21% O2) and hypoxia (1% O2) for 24 hours. Gene expression was
measured by Q-PCR. Numbers indicate the mean ± SEM of the fold change relative to PHD-3 level in
normoxia (set as 1) from a representative experiment.
Time-course experiments were performed to examine how the expression of
hydroxylases was changed with time under hypoxia and hypoxia-mimetic conditions. RA
FLS were cultured in hypoxia (1% O2) or treated with 1mM DMOG for the indicated time
points with parallel time-courses in normoxia (21% O2) as a control. The results confirmed
that PHD-1 (Figure 5.3a) and FIH-1 (Figure 5.3d) were not changed in hypoxia and in
response to DMOG (Figure 5.4a and Figure 5.4d). PHD-2 was slightly, but consistently
upregulated approximately 2-fold by hypoxia (Figure 5.3b) and much more strongly by
DMOG, peaking at 4 hours and staying at the level of 4.5-fold increase for the following 20
hours (Figure 5.4b). Changes in PHD-3 mRNA were clear from the early time points and
were constantly increasing under hypoxia up to 8-fold (Figure 5.3c), and in DMOG
conditions by more than 200-fold without reaching the peak induction (Figure 5.4c). DMOG
seemed to induce rapid increase of PHD-2 and PHD-3 compared to hypoxic induction, with
changes in expression seen within first 1 – 3 hours.
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Figure 5.3 Time-course of hypoxia-induced PHD and FIH-1 mRNA in RA FLS
RA FLS were exposed to 1% O2 for the time periods indicated. Gene expression was measured by Q-
PCR and normalised to normoxia (21% O2) at t0. Data are mean ± SEM (n=1).
Since only PHD-2 and PHD-3 mRNA increased in hypoxia, and PHD-3 protein was
detectable only in response to DMOG, the time-course of protein expression by western blot
of these two hydroxylases was performed in DMOG-treated cells. PHD-2 protein expression
was already high in normoxic conditions, therefore the protein increase after DMOG
treatment was not so evident but still visible, whereas PHD-3 protein appeared at 4 hours and
peaked at the 16-hour time point (Figure 5.5).
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Figure 5.4 Time-course of DMOG-induced PHD and FIH-1 mRNA in RA FLS
RA FLS were exposed to 1mM DMOG for the time points indicated. Gene expression was measured
by Q-PCR and normalised to normoxia (21% O2) at t0. Data are mean ± SEM (n=1).
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Figure 5.5 Time-course of PHD-2 and -3 protein expression in DMOG-treated FLS
RA FLS were exposed to 1mM DMOG for the time periods indicated. Normoxia (21% O2) was used as
control. PHD-2 and PHD-3 protein was assessed by western blot with -tubulin as a loading control
shown by single time-course experiment.
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In addition to the above time-course experiment, RA FLS were cultured in a range of
oxygen tensions (1 - 21% O2) for 6 and 24 hours to assess how oxygen concentration
influences PHDs and FIH-1 expression. As seen in Figure 5.6, some stabilisation of PHD-2
protein in RA FLS was seen to occur at 1% O2 after 6 and 24 hours incubation. A shadow of
PHD-3 protein was detectable only at 1% O2 of hypoxia at the earlier time point (6 hours),
whereas PHD-1 and FIH-1 protein was unchanged throughout the range of oxygen tensions.
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Figure 5.6 PHDs and FIH-1 protein expression under different oxygen tensions
RA FLS were exposed to 1, 3, 5, 10 and 21% O2 for either 6 or 24 hours. PHD-1, PHD-2, PHD-3 and
FIH-1 protein was assessed by western blot with -tubulin shown as a loading control (n=1).
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5.3.2 HIF--DEPENDENCE OF PHDS AND FIH-1 IN RA FLS
It was reported that PHD-2 and PHD-3 contain HRE (Metzen et al 2005; Pescador et
al 2005), therefore they are themselves HIF target genes (Aprelikova et al 2004; Marxsen et
al 2004). In this part of the project, cells were cultured in normoxia, hypoxia or DMOG and
the pattern of gene and protein expression of PHDs and FIH-1 after HIF-1 and HIF-2
knockdown was investigated in RA FLS (as described in Chapter 4. From the results
illustrated below, it can be concluded that PHD-1 (Figure 5.7a) and FIH-1 (Figure 5.7d) were
not regulated by HIF-. Silencing HIF-1 resulted in downregulation of PHD-2 in normoxia,
3-fold hypoxic induction was inhibited to normoxic levels, whereas in the presence of DMOG
the 7.6-fold increase was ablated by 64% relative to normoxic levels (Figure 5.7b). Basal
level of PHD-3 was reduced by siHIF-1 by 60% and by siHIF-2 by 51%. Hypoxia induced
a mean of 29-fold increase of PHD-3 mRNA with a strong inactivation driven by siRNA
specific for HIF-1 by 54%, and for HIF-2 by 28%. In response to DMOG, 475-fold
induction PHD-3 mRNA was decreased using siHIF-1 by 84% (Figure 5.7c).
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Figure 5.7 PHD-2 and PHD-3 expression is HIF-dependent
RA FLS were transfected with either siLuc or siHIF-1 or siHIF-2 (10nM) and subsequently exposed
to normoxia (21% O2), hypoxia (1% O2) or 1mM DMOG for 24 hours. PHDs and FIH-1 mRNA levels
were assessed by Q-PCR and normalised to normoxic mock control. Data are mean ± SEM (n≥4) and 
were analysed by 1-way ANOVA versus appropriate siLuc: ns=not significant, *p<0.05, ***p<0.001.
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Hypoxia- and DMOG-induced PHD-2, and DMOG-induced PHD-3 protein
expression was decreased using HIF-1 siRNA, whereas PHD-1 and FIH-1 protein level was
not changed at all (Figure 5.8a). HIF-1-dependence of PHD-2 and PHD-3 was shown more
clearly in Figure 5.8b with cells from a different experiment. Consistently with Q-PCR data
there was no visible effect on PHD-3 protein after silencing HIF-2 in DMOG-treated cells;
however, double knockdown of HIF-1 and HIF-2 seemed to have slightly stronger effect
on PHD-3, but not on PHD-2 protein.
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Figure 5.8 PHD-2 and PHD-3 protein expression is HIF-dependent
(a) RA FLS were transfected with siLuc, siHIF-1or siHIF-2 (10nM), and subsequently exposed to
normoxia (21% O2), hypoxia (1% O2) or 1mM DMOG for 24 hours. PHD-1, PHD-2, PHD-3 and FIH-1
protein levels were assessed by western blot with -tubulin as loading control and shown from a one
experiment. (b) RA FLS were transfected with siLuc, siHIF-1, siHIF-2 (10nM), both siHIF-1 plus
siHIF-2 (20nM in total) or lipofectamine alone (“mock”), and cultured with 1mM DMOG for 24
hours. A representative western blot shows PHD-2 and PHD-3 proteins and -tubulin as a loading
control.
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5.3.3 PHD AND FIH-1 DEPLETION IN RA FLS
It is believed that PHDs and FIH-1 are the first molecules that respond to oxygen
changes, regulating HIF- availability and therefore contributing to regulation of hypoxic
responses in cells. Fibroblasts were transfected with siRNA targeting PHD-1, PHD-2, PHD-3,
FIH-1, and with luciferase siRNA as a control, subsequently exposed to normoxia, hypoxia or
DMOG followed by assessing knockdown efficiency. Two sets of siRNA for each
hydroxylase were used (Table 3.12, page 92) and since the knockdown results were similar in
each case (data not shown), siRNAs #1 were used. To determine the silencing effects of
PHDs and FIH-1 knockdown, mRNA and protein levels of HIF- were analysed using Q-
PCR, western blotting, ELISA or DNA binding assay. This was followed by examination of
HIF- target gene expression at the RNA level and at the protein level, where available.
PHD-1 mRNA was significantly knocked down by 56%, 79% and 63% in normoxia,
hypoxia and DMOG compared to appropriate siLuc control, respectively (Figure 5.9a). PHD-
2 mRNA was silenced by 61% in normoxia, 2-fold upregulation by hypoxia was reduced by
70% and 3.5-fold induction was down by 58% in DMOG-treated cells (Figure 5.9b). PHD-3
was significantly knocked down by 77% in normoxia, 8-fold hypoxic increase was
diminished by 66% and 240-fold DMOG-induction was reduced by 74% (Figure 5.9c).
Significance was not reached for PHD-3 knockdown in DMOG-treated cells due to high
variations between the patients. In addition, PHD-3 mRNA was significantly upregulated 4.2-
fold and 1.8-fold by silencing PHD-2 in normoxia and hypoxia, respectively. FIH-1 was the
easiest hydroxylase to knockdown with a significant decline of mRNA by 85%, 85% and 74%
in normoxia, hypoxia and DMOG, respectively (Figure 5.9d).
Knockdown of PHD-2, PHD-3 and FIH-1 was also confirmed at the protein level.
PHD-2 protein was present in normoxia, increased by hypoxia and further in DMOG-treated
cells and was efficiently knocked down in all these conditions (Figure 5.10b). PHD-3 protein
was completely abolished by siPHD-3, which was visible only in DMOG-treated cells (Figure
5.10c). FIH-1, a non-hypoxia regulated hydroxylase, was also shown to be effectively
reduced by siRNA in normoxia, hypoxia and DMOG (Figure 5.10d). Although efficient
knockdown of PHD-1 was achieved at the mRNA level (Figure 5.9a), western blot shown no
changes at the protein level (Figure 5.10a).
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Figure 5.9 PHD and FIH-1 mRNA knockdown in RA FLS
RA FLS were transfected with siLuc, siPHD-1, siPHD-2, siPHD-3 or siFIH-1 (10nM) and
subsequently exposed to normoxia (21% O2), hypoxia (1% O2) or 1mM DMOG for 24 hours. (a) PHD-
1, (b) PHD-2, (c) PHD-3 and (d) FIH-1 mRNA levels were assessed by Q-PCR and normalised to
normoxia (mock control). Data are mean ± SEM from minimum 3 experiments and were analysed by
1-way ANOVA versus appropriate siLuc: * p<0.05, ** p<0.01, *** p<0.001.
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Figure 5.10 PHD and FIH-1 protein knockdown in RA FLS
RA FLS were transfected with siRNA targeting luciferase, PHD-1, PHD-2, PHD-3, FIH-1 (10nM) or
lipofectamine alone (“mock”) and subsequently exposed to normoxia (21% O2), hypoxia (1% O2),
1mM DMOG or hypoxia/DMOG for 24 hours. (a) PHD-1, (b) PHD-2, (c) PHD-3 and (d) FIH-1 protein
level was assessed by western blot with -tubulin as a loading control.
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5.3.4 ROLES OF PHDS AND FIH-1 IN RA FLS
The next step was to determine the effect of PHD and FIH-1 knockdown on HIF-
protein stabilisation. To do this, PHD-1, PHD-2, PHD-3 and FIH-1 were silenced using
siRNA and HIF- protein level was assessed by western blot, revealing that PHD-2
knockdown in normoxic conditions stabilised HIF-1 and also HIF-2 protein, but to a lesser
extent, with no visible HIF increase after silencing PHD-1, PHD-3 or FIH-1 (Figure 5.11).
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Figure 5.11 PHD-2 knockdown stabilises HIF- protein in RA FLS
RA FLS were transfected with siLuc, siPHD-1-3, siFIH-1 (10nM) or lipofectamine alone (“mock”) and
subsequently cultured in normoxia (21% O2) for 24 hours. A representative western blot shows HIF-1
and HIF-2 protein levels with -tubulin shown as a loading control.
To examine the combined effect of silencing PHDs, double and triple knockdown
was performed. As seen in Figure 5.12, double knockdown (siPHD-2 plus either siPHD-1 or
siPHD-3) or even triple knockdown did not further affect HIF- stabilisation compared to
siPHD-2 alone, with consistently accumulated HIF-1 and HIF-2 after PHD-2 knockdown.
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Figure 5.12 PHD-2 is the major regulator of HIF- protein in normoxia in RA FLS
RA FLS were transfected with siLuc, siPHD-1-3, siFIH-1 (10nM), or PHDs in all combinations and
cultured in normoxia (21% O2) for 24 hours. DMOG-stimulated cells served as a positive control. A
representative western blot shows HIF-1 and HIF-2 proteins with -tubulin as a loading control.
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PHD-2 was the most difficult prolyl hydroxylase to silence in RA FLS, which was
consistent with the observation noticed by Berra and colleagues (Berra et al 2003). In order to
validate PHD-2 knockdown and its effect on HIF- proteins, various concentrations of
siRNA against PHD-2 were used, with non-transfected cells compared with cells transfected
with siRNA against luciferase. Although PHD-2 protein was only partially abrogated, HIF-1
was stabilised with as low a siPHD-2 concentration as 1nM. In this particular experiment no
effect on HIF-2 stabilisation was visible. Additionally, hypoxia- and DMOG-treated cells
served as the positive controls for both HIF- proteins stabilisation (Figure 5.13). In future
studies, 10nM concentration of siRNA for PHD-2 knockdown was used in order to minimise
off-target effects.
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Figure 5.13 Titration of PHD-2 siRNA oligonucleotides and HIF- stability
RA FLS were transfected with either siLuc (10nM) or siPHD-2 at indicated concentration of siRNA
and subsequently exposed to normoxia (21% O2), hypoxia (1% O2) or 1mM DMOG for 24 hours.
PHD-2, HIF-1 and HIF-2 protein levels were assessed by western blot from a single experiment
with -tubulin shown as a loading control.
To substantiate the effect of PHD-2 knockdown on HIF ability to bind to HRE, RA
FLS were transfected as above and the TransAM assay was performed. Hypoxia and DMOG-
treated cells, which activates HIF served as the positive controls due to the fact that only
when the transcription factor is activated, it is then translocated to the nucleus where it binds
to the HRE sequence. Consistently with protein data, DMOG induced even stronger HIF-1
and HIF-2 activation. Silencing PHD-2 increased HIF-1 binding to HRE to the levels
comparable to those of the hypoxic positive controls (Figure 5.14a). HIF-2 binding to HRE
was also significantly enhanced, but to a lesser extent (Figure 5.14b).
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Figure 5.14 PHD-2 knockdown increases HIF binding to HRE in normoxia
RA FLS were transfected with either siLuc or siPHD-2 (10nM), or lipofectamine alone (“mock”) and
cultured in normoxia (21% O2) for 24 hours. Hypoxia- (1% O2) and DMOG-treated cells were used as
controls. (a) HIF-1 and (b) HIF-2 binding to HRE was assessed in nuclear extracts by TransAM assay.
Dashed lines represent response to normoxic mock control. Data are mean ± SEM from 3 experiments
and were analysed by 1-way ANOVA versus siLuc: ns=not significant, ** p<0.01, *** p<0.001.
After corroboration of the effect of PHD-2 knockdown on HIF- subunits, cells were
transfected with siPHD-2 under normoxic conditions and further analysed for downstream
effects on HIF-regulated genes. Expression of HIF- target genes was significantly
upregulated in RA FLS after silencing the PHD-2 isoenzyme, including the mRNA levels of
ANGPTL-4, BNIP-3, CA9, ENO-1, ephrin-A3, GLUT-1 and VEGF, which were significantly
increased 3.7-, 3.1-, 13.4-, 1.4-, 4.6- , 4.1- and 2.1-fold, respectively (Figure 5.15).
Figure 5.15 PHD-2 knockdown increases the mRNA levels of HIF--dependent genes
in normoxia in RA FLS
RA FLS were transfected with either siLuc or siPHD-2 (10nM), or lipofectamine alone (“mock”) and
subsequently exposed to normoxia (21% O2) or hypoxia (1% O2) for 24 hours. ANGPTL-4, BNIP-3,
CA9, ENO-1, ephrin-A3, GLUT-1 and VEGF mRNA levels were assessed by Q-PCR and normalised
to normoxic mock control (dashed line). Data are mean ± SEM from 9 experiments and were analysed
by 1-way ANOVA versus siLuc: *p<0.05, ** p<0.01, *** p<0.001.
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To assess the consequences of PHD-2 knockdown under normoxic conditions, ELISA
was conducted where available. In a representative experiment ANGPTL-4 release was
increased 4.7-fold by siPHD-2 from 4ng/mL to 18.8ng/mL (Figure 5.16a), CA9 protein
expression was enhanced 59-fold from 40pg/mL to 2350pg/mL comparing to siLuc (Figure
5.18b) and VEGF protein followed that pattern, being induced approximately 3-fold from
427pg/mL to 1300pg/mL (Figure 5.16c). The increase in these proteins after silencing PHD-2
was similar to levels observed when cells were exposed to hypoxia in the same experiment.
Further experiments confirmed that BNIP-3 and GLUT-1 proteins were upregulated by
siPHD-2 without any visible changes after siPHD-3 in normoxia (Figure 5.17).
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Figure 5.16 PHD-2 knockdown increases HIF--dependent protein induction in
normoxia in RA FLS
RA FLS were transfected with either siLuc or siPHD-2 (10nM), or lipofectamine alone (mock, U) and
subsequently exposed to normoxia (21% O2) or hypoxia (1% O2) for 24 hours. ANGPTL-4, CA9 and
VEGF proteins were assessed by ELISA. Data are mean ± SEM (n=1).
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Figure 5.17 PHD-2 knockdown induces BNIP-3 and GLUT-1 proteins in normoxia in
RA FLS
RA FLS were transfected with either siLuc or siPHD-2, or siPHD-3 (10nM) and cultured in normoxia
(21% O2) for 24 hours. A representative western blot showing PHD-2, HIF-1, BNIP-3 and GLUT-1
proteins with -tubulin as a loading control.
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To examine that other HIF hydroxylases do not control HIF- target genes, FIH-1
and PHDs alone or in different combinations were knocked down in normoxia with DMOG-
treated cells as a positive control. From Figure 5.18 it could be concluded that PHD-2 was the
main regulator of HIF-dependent genes with no additional effect of PHD-1 or PHD-3 when
co-silenced.
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Figure 5.18 PHD-2 is the main regulator of HIF- and its downstream genes in
normoxia in RA FLS
RA FLS were transfected with siLuc, siPHD-1, siPHD-2, siPHD-3, siFIH-1 (10nM), or in indicated
combinations (total siRNA concentration of double and triple knockdown was 20nM and 30mM,
respectively) and subsequently cultured in normoxia (21% O2) for 24 hours. DMOG-stimulated cells
served as a positive control. ANGPTL-4, BNIP-3, CA9, ENO-1 and VEGF mRNA levels were
assessed by Q-PCR and normalised to normoxic mock control (shown by dashed line). Data are mean ±
SEM (n=1).
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The role of PHD-2 as a key prolyl hydroxylase was confirmed at the protein level of a
representative gene, showing that GLUT-1 protein was increased by siPHD-2 and was not
affected by silencing any other hydroxylases, which corresponded with messenger RNA
levels of GLUT-1 (Figure 5.19).
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Figure 5.19 PHD-2 knockdown in RA FLS increases GLUT-1 mRNA and protein in
normoxia
RA FLS were transfected with siLuc, siPHD-1, siPHD-2, siPHD-3, siFIH-1 (10nM), or in indicated
combinations (total siRNA concentration of double and triple knockdown was 20nM and 30nM,
respectively) and subsequently cultured for 24 hours in normoxia (21% O2). DMOG-stimulated cells
served as a positive control. (a) Expression of GLUT-1 was assayed using Q-PCR and data are mean ±
SEM (n=1). (b) A representative western blot shows PHD-2 and GLUT-1 protein levels with -tubulin
as a loading control.
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To verify that PHD-2 indeed acts via HIF- regulation, double knockdown of PHD-2
and HIF-1 or HIF-2 in normoxia was performed. By silencing PHD-2, upregulation in
transcription of the genes of interest was anticipated to increase as seen on Figure 5.18. By
using siPHD-2 together with siHIF-1, siPHD-2-mediated increase in BNIP-3 (Figure 5.20a),
CA9 (Figure 5.20b), ENO-1 (Figure 5.20c), ephrin-A3 (Figure 5.20d) and GLUT-1 (Figure
5.20e) was attenuated with expression returning to control levels or even below. In addition,
this experiment confirmed the HIF-1 isoform specificity of BNIP-3, CA9, ENO-1 and
GLUT-1. Furthermore, these data identified ephrin-A3 as another HIF-1-dependent gene.
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Figure 5.20 PHD-2 and HIF-1 double knockdown abolishes the upregulation of
BNIP-3, CA9, ENO-1, ephrin-A3 and GLUT-1 induced by siPHD-2
RA FLS were transfected with siLuc, siPHD-2, siHIF-1, siHIF-2 (10nM), or PHD-2 in combination
with HIF-1 or HIF-2 siRNA (20nM in total) and subsequently cultured in normoxia (21% O2) for 24
hours. (a) BNIP-3, (b) CA9, (c) ENO-1, (d) ephrin-A3 and (e) GLUT-1 mRNA levels were assessed by
Q-PCR and normalised to normoxic mock control (dashed line). Data are mean ± SEM (n=2).
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However, the siPHD-2-induced increase in ANGPTL-4 mRNA (Figure 5.21a), VEGF
mRNA (Figure 5.21b) and PHD-3 mRNA (Figure 5.21c) could be abrogated by either siHIF-
1 or siHIF-2, also confirming the dual HIF- isoform specificity of ANGPTL-4 (Figure
4.16), VEGF (Figure 4.18) and PHD-3 (Figure 5.7c), which was shown previously.
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Figure 5.21 PHD-2 and HIF-1 or HIF-2 double knockdown abolishes siPHD-2-
induced ANGPTL-4, VEGF and PHD-3
RA FLS were transfected with siLuc, siPHD-2, siHIF-1, siHIF-2 (10nM), PHD-2 ± HIF-1 or HIF-
2siRNA (20nM in total) and subsequently cultured in normoxia (21% O2) for 24 hours. (a)
ANGPTL-4, (b) VEGF and (c) PHD-3 mRNA levels were assessed by Q-PCR and normalised to
normoxic mock control (dashed line). Data are mean ± SEM from two experiments.
While validating PHD-2 knockdown in normoxia and hypoxia, it became apparent
that silencing PHD-2 in hypoxia further stabilised HIF-1 protein and had a more visible
effect on HIF-2 protein accumulation (Figure 5.22).
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Figure 5.22 PHD-2 knockdown stabilises HIF- proteins in normoxia and even
further in hypoxia
RA FLS were transfected with either siLuc or siPHD-2 (10nM) and subsequently exposed to either
normoxia (21% O2) or hypoxia (1% O2) for 24 hours. PHD-2, HIF-1 and HIF-2 protein levels were
assessed by western blot from a single experiment with -tubulin as a loading control.
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Results in Figure 5.23 from Q-PCR analyses have shown that silencing PHD-2 in
hypoxia further elevated mRNA levels of HIF-regulated genes, namely ANGPTL-4, BNIP-3,
CA9, ephrin-A3, GLUT-1 and VEGF.
Figure 5.23 PHD-2 knockdown stabilises HIF--dependent genes in normoxia and
even further in hypoxia
RA FLS were transfected with either siLuc or siPHD-2 (10nM) and subsequently exposed to either
normoxia (21% O2) or hypoxia (1% O2) for 24 hours. ANGPTL-4, BNIP-3, CA9, ephrin-A3, GLUT-1
and VEGF mRNA levels were assessed by Q-PCR and normalised to normoxia (dashed line). Data are
mean ± SEM (n= 5 - 10) analysed by 1-way ANOVA versus siLuc in hypoxia: * p<0.05, *** p<0.001.
The effect on mRNA was paralleled by protein levels of ANGPTL-4 and VEGF
measured by ELISA. ANGPTL-4 release was increased further by siPHD-2 in hypoxia from
28ng/mL to 37ng/mL (Figure 5.24a), whereas VEGF protein secretion was induced from
1000pg/mL to 1600pg/mL comparing siLuc to siPHD-2 in hypoxia (Figure 5.24b).
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Figure 5.24 Silencing PHD-2 in hypoxia further increases ANGPTL-4 and VEGF
secretion by RA FLS
RA FLS were transfected with either siLuc or siPHD-2 (10nM) and exposed to normoxia (21% O2;
dashed line) or hypoxia (1% O2) for 24 hours. ANGPTL-4 (a, n=6) and VEGF (b, n=6) secretion was
assessed by ELISA. Data represent mean ± SEM analysed by 1-way ANOVA versus siLuc: *p<0.05.
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Having analysed the effects of PHD-2 knockdown in RA FLS, subsequent studies
addressed the roles of other HIF hydroxylases. As described earlier (Section 5.3.4),
knockdown of PHD-3 did not increase HIF protein levels in RA FLS, as was seen using
siPHD-2. To investigate whether targeting PHD-3 transcription in normoxia regulates HIF
DNA binding in RA FLS, nuclear extracts from knockdown experiments were assayed.
Interestingly, siPHD-3 did not change HIF-1 binding abilities (Figure 5.25a), or if anything
induced a slight reduction, whereas HIF-2 binding to HRE was significantly increased 2-fold
when compared to siLuc (Figure 5.25b).
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Figure 5.25 PHD-3 knockdown increases HIF-2 binding to HRE in normoxia in FLS
RA FLS were transfected with either siLuc or siPHD-3 (10nM), or lipofectamine alone (“mock”). (a)
HIF-1 and (b) HIF-2 binding to HRE was assessed in nuclear extracts by TransAM assay after
exposure for 24 hours to normoxia (21% O2), hypoxia (1% O2) or 1mM DMOG. Data are mean ± SEM
from 3 experiments and were analysed by 1-way ANOVA versus siLuc: ns=not significant, * p<0.05,
** p<0.01, *** p<0.001. Dashed lines indicate response using mock control.
ELISA confirmed a decrease in HIF-1 protein from 1412pg/mL to 516pg/mL. In the
same experiment, siPHD-2 increased HIF-1 protein to 2047pg/mL (Figure 5.26). For the
reason that PHD-3 was undetectable in normoxia no western blot was performed.
Figure 5.26 PHD-3 knockdown decreases HIF-1 protein in normoxia in RA FLS
RA FLS were transfected with siLuc, siPHD-2 or siPHD-3 (10nM), and were subsequently cultured in
normoxia (21% O2) for 24 hours. HIF-1 protein level was assessed by ELISA. Data are mean ± SEM
(n=1). The dashed line shows protein levels in mock-transfected cells.
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Additionally, PHD-3 knockdown effect in normoxia was examined by the mRNA
level of HIF- target genes. ANGPTL-4, BNIP-3, CA9, GLUT-1 and VEGF were slightly but
significantly downregulated by silencing PHD-3 in RA FLS, whereas changes in ENO-1 and
ephrin-A3 were not significant (Figure 5.27).
Figure 5.27 PHD-3 knockdown decreases transcription of HIF--dependent genes in
normoxia in RA FLS
RA FLS were transfected with either siLuc or siPHD-3 (10nM), or lipofectamine alone (“mock”) and
subsequently exposed to normoxia (21% O2) for 24 hours. ANGPTL-4, BNIP-3, CA9, ENO-1, ephrin-
A3, GLUT-1 and VEGF mRNA levels were assessed by Q-PCR and normalised to normoxic mock
control. Data are mean ± SEM from 9 experiments and were analysed by 1-way ANOVA versus siLuc:
ns=not significant, * p<0.05, ** p<0.01, *** p<0.001.
Next, two concentrations of siRNA against PHD-2 and PHD-3 were used for
comparison (10nM and 25nM) and western blot was performed. PHD-2 reduction had
stabilising effect on HIF-1 and its target genes, including BNIP-3 and GLUT-1. In contrast
to PHD-2, it seemed that silencing PHD-3 decreased HIF-1 protein and therefore as a
consequence BNIP-3 and GLUT-1 proteins were reduced using both concentrations of siRNA
(Figure 5.28).
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Figure 5.28 PHD-3 knockdown decreases HIF-1 protein and HIF--dependent
genes in RA FLS
RA FLS were transfected with siLuc, siPHD-2 or siPHD-3 at the concentration of 10nM or 25nM, and
subsequently cultured in normoxia (21% O2) for 24 hours. Hypoxia (1% O2) is shown as a positive
control. PHD-2, HIF-1, HIF-2, BNIP-3 and GLUT-1 protein levels were assessed by western blot
from a single experiment with -tubulin as a loading control.
Unlike the effect of PHD-2 or PHD-3 knockdown, silencing PHD-1 (Figure 5.29a)
and FIH-1 (Figure 5.29b) did not elicit any significant effect on either HIF- proteins (Figure
5.11 and Figure 5.12) or HIF- target genes (Figure 5.29). Nevertheless, the role of FIH-1
was further investigated due to the fact that in some cell lines FIH-1 does regulate HIFs and
HIF target genes (Dayan et al 2006; Khan et al 2011).
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Figure 5.29 PHD-1 and FIH-1 knockdown does not affect transcription of HIF--
dependent genes in RA FLS
RA FLS were transfected with siLuc, siPHD-1, siFIH-1 (10nM) or lipofectamine alone and cultured in
normoxia (21% O2) for 24 hours. ANGPTL-4, BNIP-3, CA9, ENO-1, GLUT-1 and VEGF mRNA
levels were assessed by Q-PCR and normalised to normoxia after silencing (a) PHD-1 and (b) FIH-1.
Data are mean ± SEM (n=5-9) analysed by 1-way ANOVA versus siLuc: all values not significant.
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Although no changes at the HIF- protein level was seen analysing western blot
(Figure 5.11 and Figure 5.12), more sensitive assay measuring HIF binding to DNA was used.
TransAM assay revealed that silencing FIH-1 in hypoxia- and DMOG-treated cells did not
have any additional effect on HIF-1 (Figure 5.30a) or HIF-2 (Figure 5.30b) ability to bind
to HRE in RA FLS.
HIF-1
siLuc siFIH-1 siLuc siFIH-1
0.0
0.2
0.4
0.6
0.8
1.0
Hypoxia DMOG
H
IF
bi
nd
in
g
to
H
R
E
A
bs
45
0n
m
HIF-2
siLuc siFIH-1 siLuc siFIH-1
0.0
0.2
0.4
0.6
0.8
1.0
Hypoxia DMOG
H
IF
bi
nd
in
g
to
H
R
E
Ab
s4
50
nm
(a) (b)
Figure 5.30 Silencing FIH-1 does not change HIF binding to HRE in RA FLS
RA FLS were transfected with either siLuc or siFIH-1 (10nM), or lipofectamine alone. (a) HIF-1 and
(b) HIF-2 protein binding to HRE was assessed in nuclear extracts by TransAM assay after exposure to
normoxia (21% O2), hypoxia (1% O2) or 1mM DMOG for 24 hours. Dashed line shows binding under
normoxia. Data are mean ± SEM (n=1).
It was reported in HeLa cells that simultaneous knockdown of PHD-2 and FIH-1
synergise in increasing the HIF-1 transcriptional activity in normoxia (Mazure et al 2004).
This was most likely due to dual inhibition of the N-TAD and the C-TAD activity via PHD-2
and FIH-1, respectively, which regulates HIF- protein at two levels, by stabilising the
protein and enabling the interaction between -subunit and co-factors, therefore inducing
HIFs transcriptional activity.
The work on FIH-1 activity was therefore continued. Single and double knockdown
was achieved in RA FLS, which is shown at the mRNA and protein level in the representative
experiment below. PHD-2 was knocked down by 57% by siPHD-2 and by 68% when silenced
together with FIH-1. Hypoxia-induced PHD-2 expression was reduced by 81%, and by 84%
when double-transfected (Figure 5.31a). FIH-1 mRNA was similarly decreased in hypoxia
and normoxia, and was knocked down by 92% by FIH-1 siRNA and approximately by 87%
when silenced together with PHD-2 (Figure 5.31b).
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Figure 5.31 PHD-2 and FIH-1 single and double knockdown in normoxia and
hypoxia in RA FLS
RA FLS were transfected with siLuc, siPHD-2, siFIH-1 (10nM), siPHD-2/siFIH-1 in combination
(20nM) or lipofectamine alone (“mock”) and subsequently exposed to either normoxia (21% O2) or
hypoxia (1% O2) for 24 hours. (a) PHD-2 and (b) FIH-1 mRNA levels were assessed by Q-PCR and
normalised to normoxic mock control. Data are mean ± SEM from a representative experiment.
PHD-2 and FIH-1 protein levels were also considerably reduced in normoxic and
hypoxic conditions, following either single or double knockdown. HIF-1 protein was
stabilised by silencing PHD-2 in normoxia and hypoxia, without any additional effects when
both PHD-2 and FIH-1 were silenced (Figure 5.32).
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Figure 5.32 Effect of PHD-2 and FIH-1 single and double knockdown on HIF-1
protein levels in RA FLS
RA FLS were transfected with siLuc, siPHD-2, siFIH-1 (10nM) or siPHD-2/siFIH-1 in combination
(20nM) and exposed to either normoxia (21% O2) or hypoxia (1% O2) for 24 hours. PHD-2, FIH-1 and
HIF-1 protein levels were assessed by western blot from a single experiment with -tubulin shown as
a loading control.
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To corroborate this effect on HIF- target genes, the experiment was repeated as
above and the mRNA levels of genes of interest were measured using Q-PCR. Figure 5.33
illustrates that ANGPTL-4, BNIP-3, CA9, ENO-1, GLUT-1 and VEGF genes paralleled the
HIF-1 protein, and were upregulated by siPHD-2 in normoxia, further enhanced in hypoxia
and without any additional effects after silencing FIH-1 in normoxia or hypoxia.
Figure 5.33 Effect of PHD-2 and FIH-1 single and double knockdown on HIF--
target genes in RA FLS
RA FLS were transfected with siLuc, siPHD-2, siFIH-1 (10nM), siPHD-2/siFIH-1 in combination
(20nM) or lipofectamine alone (mock) and subsequently exposed to either normoxia (21% O2) or
hypoxia (1% O2) for 24 hours. ANGPTL-4, BNIP-3, CA9, ENO-1, GLUT-1 and VEGF mRNA levels
were assessed by Q-PCR and normalised to normoxic mock control. Data are mean ± SEM (n=1).
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5.3.5 ROLE OF PHDS AND FIH-1 IN NHDF AND OA FLS
To my knowledge the role of HIF hydroxylases in normal human dermal fibroblasts
(NHDF) and in FLS from OA patients has not been investigated. As shown before, RA FLS,
OA FLS and NHDF responded to hypoxia and DMOG in a comparable way, stabilising HIF-
1, HIF-2, followed by BNIP-3 and GLUT-1 protein increase (Figure 4.26, page 130).
Therefore, the response of HIF hydroxylases to hypoxia and DMOG at the protein level in
these fibroblasts was next examined. PHD-2 noticeably increased in all cell types in response
to hypoxia and DMOG, with the most considerable rise in RA FLS. PHD-3 was hardly
detectable, but seemed to be induced by DMOG most noticeably in RA FLS compared to OA
FLS and NHDF. Consistently, PHD-1 and FIH-1 proteins were constitutively expressed and
unchanged in all three types of fibroblasts (Figure 5.34).
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Figure 5.34 The protein profile in RA FLS, OA FLS, NHDF in response to normoxia,
hypoxia and DMOG
RA FLS, OA FLS and NHDF were cultured in normoxia (N, 21% O2), hypoxia (H, 1% O2) or 1mM
DMOG (D) for 24 hours. One experiment of western blot is showing protein levels of PHD-1, PHD-2,
PHD-3 and FIH-1 with -tubulin as a loading control.
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According to the literature (Berra et al 2003) and my previous results carried out on
RA FLS (Figure 5.11 and Figure 5.12), PHD-2 plays a predominant role in the stabilisation of
HIF-1 and HIF-2, and thus HIF target gene regulation. To investigate whether this
response is cell type-specific, similar sets of experiments were repeated in FLS from OA
donors and NHDF.
Analogous treatment of cells revealed that OA FLS responded to PHD-2 reduction in
normoxia as was seen in RA FLS, stabilising HIF- and GLUT-1 protein comparable to
hypoxia (Figure 5.35a). In contrast, silencing PHD-2 in NHDF did not exhibit any responses
in normoxia, although they stabilised HIF pathway proteins very strongly in hypoxia and
DMOG (Figure 5.35b).
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Figure 5.35 PHD-2 knockdown in OA FLS, but not in NHDF, stabilises HIFs and
HIF-dependent gene expression
(a) OA FLS and (b) NHDF were transfected using either 10nM siLuc or siPHD-2, or lipofectamine
alone (“mock”) and cultured in normoxia (21% O2) or for comparison to either hypoxia (1% O2) or
1mM DMOG for 24 hours. Protein levels of PHD-2, HIF-1, HIF-2 and GLUT-1 were assessed by
western blot with -tubulin as a loading control.
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Further analysis revealed that knockdown of PHD-2 in normoxia by 85% (Figure
5.36a) significantly increased a panel of HIF-dependent genes in OA FLS (Figure 5.36b). The
same set of experiments carried out on NHDF confirmed that in these healthy, non-arthritic
fibroblasts, although PHD-2 was effectively silenced by 75% in normoxia (Figure 5.36a), no
effect on HIF-regulated genes was seen (Figure 5.36b).
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Figure 5.36 PHD-2 knockdown in OA FLS, but not in NHDF, increases HIF-
dependent gene expression
OA FLS (n=4) and NHDF (n=3) were transfected using either 10nM of siLuc or siPHD-2, or
lipofectamine alone (“mock”) and cultured in normoxia (21% O2) for 24 hours. (a) PHD-2 knockdown
at the mRNA level and subsequently the effect on gene expression, including (b) ANGPTL-4, BNIP-3,
CA9, ephrin-A3, GLUT-1, VEGF was assessed by Q-PCR. Data represent mean ± SEM from indicated
number of experiments. Values are expressed relative to 18S RNA and were normalised against
normoxic mock control (dashed line), using 2-Ct method. Data were analysed by 1-way ANOVA
versus siLuc: ns=not significant, *p<0.05, **p<0.01, ***p<0.001.
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To investigate whether the lack of effect of concurrent PHD-2 and FIH-1 knockdown
on HIF- and HIF target genes is cell-specific, non-arthritic cells (NHDF) were used in the
study. PHD-2 and FIH-1 single and double knockdown was achieved at the mRNA and
protein level. PHD-2 was knocked down in normoxia by 74% and 72% when silenced on its
own or together with FIH-1, respectively. Hypoxia-induced PHD-2 expression was reduced
by 68% when single transfected with siPHD-2 and by 65% when co-transfected with siFIH-1
(Figure 5.37a). FIH-1 mRNA was decreased similarly in normoxia and hypoxia, being
knocked down by 71% by siFIH-1, and by 73% when combined with siPHD-2 in normoxia,
and approximately by 78% by siFIH-1, and by 71% when co-transfected with siPHD-2 in
hypoxia (Figure 5.37b).
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Figure 5.37 PHD-2 and FIH-1 single and double knockdown in NHDF
NHDF were transfected with siLuc, siPHD-2, siFIH-1 (10nM), siPHD-2/siFIH-1 in combination
(20nM) or lipofectamine alone (“mock”) and subsequently exposed to either normoxia (21% O2) or
hypoxia (1% O2) for 24 hours. (a) PHD-2 and (b) FIH-1 mRNA levels were assessed by Q-PCR and
normalised to normoxia. Data are mean ± SEM (n=2).
Next, the protein response after double knockdown of PHD-2 and FIH-1 was
examined by western blot. Consistently with previous results, there was no effect on HIF-1
stabilisation and GLUT-1 protein in normoxia in NHDF after PHD-2 knockdown alone,
although the cells responded to hypoxia and DMOG by increasing PHD-2, HIF-1 and
GLUT-1 protein. Moreover, PHD-2 depletion in combination with siFIH-1 in NHDF also did
not exert any additional stabilising effect (Figure 5.38).
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Figure 5.38 Effect of PHD-2 and FIH-1 single and double knockdown on NHDF
NHDF were transfected with siLuc, siPHD-2, siFIH-1 (10nM), siPHD-2/siFIH-1 in combination (either
10nM+10nM or 5nM+5nM) or lipofectamine alone (“mock”) and exposed to normoxia (21% O2),
hypoxia (1% O2) or 1mM DMOG for 24 hours. Western blot from a single experiment shows PHD-2,
FIH-1, HIF-1 and GLUT-1 protein levels with -tubulin as a loading control.
To examine the downstream effect of PHD-2 and/or FIH-1 knockdown on HIF-
target genes, Q-PCR analysis on genes of interest was performed. In normoxia the expression
of HIF-dependent genes (ANGPTL-4, BNIP-3, CA9, ENO-1, GLUT-1 and VEGF) were not
altered by silencing PHD-2 or when the cells were co-transfected with siFIH-1. However,
since NHDF respond to hypoxia by stabilising HIF proteins (Figure 5.35), HIF regulated
genes were also increased in hypoxic conditions. Interestingly, the expression of these
transcripts seemed to be further increased after PHD-2 depletion in hypoxia, again with no
effect of silencing or co-silencing FIH-1 (Figure 5.39). It seemed that PHD-2 knockdown in
NHDF did not stabilise HIF-1 and thus did not increase HIF-dependent gene expression in
normoxia, although NHDF respond to hypoxia and DMOG inducing common HIF pathway.
Furthermore, FIH-1 is probably inactive in both RA FLS and NHDF in both normoxia and
hypoxia.
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Figure 5.39 Effect of PHD-2 and FIH-1 single and double knockdown on HIF--
dependent genes in NHDF
NHDF were transfected with siLuc, siPHD-2, siFIH-1 (10nM), siPHD-2/siFIH-1 in combination
(20nM) or lipofectamine alone and subsequently exposed to either normoxia (21% O2) or hypoxia (1%
O2) for 24 hours. ANGPTL-4, BNIP-3, CA9, ENO-1, GLUT-1 and VEGF mRNA levels were assessed
by Q-PCR and normalised to normoxia. Data are mean ± SEM (n=1).
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5.3.6 PHD-2 KNOCKDOWN SELECTIVELY INCREASES PRO-ANGIOGENIC ACTIVITY OF RA
AND OA FLS
To screen the effect of PHD-2 knockdown between RA FLS, OA FLS and NHDF on
genes involved in modulating angiogenesis, the Angiogenesis RT2Profiler™ PCR Array
(TebuBio, Peterborough, UK) was used (Table 3.13, page 96). The whole array of genes is
shown in Table 3.9 (page 83). Cells were transfected with siRNA targeting PHD-2, PHD-3 or
luciferase (used as a control sample), harvested after 24-hour culture in normoxia, RNA was
isolated and cDNA was transcribed, which then was used as a template in SYBR Green-based
Q-PCR.
The PCR array was performed on RA FLS from four different patients, OA FLS from
two different patients and once on healthy NHDF. The analysis was completed with the
software provided and performed using Excel and the 2-Ct method to calculate the fold
change in gene expression, which was achieved by normalising the data to the average of five
housekeeping genes. A 2-fold induction or reduction was used as cut-off when evaluating the
changes on the PCR array.
Data from individual patients were also expressed as scatter plot of 2-Ct values (Ct
value of housekeeping genes subtracted from gene of interest) for siLuc versus siPHD-2.
Solid line represents no change, thus genes whose expression increased with PHD-2
knockdown are above the solid line, and genes whose expression decreased with PHD-2 are
below the solid line. Dashed lines indicate ≥2-fold increase and ≥2-fold decrease, 
respectively. In addition, scatter plot represents the abundance of investigated genes, meaning
that genes closest to the bottom left-hand corner of the graph are expressed at low levels, with
very high Ct values, whereas genes located close to top right-hand corner are those highly
abundant with low Ct values. Statistical analyses were performed comparing dCt values and
analysed using student t-test.
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The array carried on RA FLS resulted in altered expression of five genes by siPHD-2.
In a representative patient, PHD-2 knockdown increased significantly transcripts for leptin
(LEP; 17.5-fold), ephrin-A3 (EFNA3; 4.3-fold), ANGPTL-4 (3.6-fold), epidermal growth
factor (EGF; 2.7-fold) and VEGF (2.2-fold). Silencing PHD-2 also significantly decreased
placental growth factor (PGF; -2.5-fold; Figure 5.40).
Figure 5.40 Gene expression changes on a PCR array after silencing PHD-2 in
normoxia in RA FLS
RA FLS were transfected with 10nM siRNA against luciferase or PHD-2 and cultured in normoxic
conditions for 24 hours. The scattered plot represents values of 2-Ct for target gene (siPHD-2) against
control (siLuc) from one patient. Solid line indicates no change; dashed lines indicate 2-fold increase
and 2-fold decrease. Only genes which increased or decreased by 2-fold or more are annotated.
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Next, OA FLS were transfected with siPHD-2 and array including the same panel of
angiogenic genes was performed. As seen in Figure 5.41, OA FLS from a representative
patient induced the same group of genes as RA FLS, including leptin (3.6-fold), ANGPTL-4
(3.4-fold), ephrin-A3 (2.8-fold), and VEGF (2.5-fold) plus an extra gene, chemokine ligand 9
(CXCL9; 2.6-fold). In addition, 6 genes were significantly decreased by siPHD-2 knockdown,
namely chemokine ligand 3 (CXCL3; -8-fold), heart and neural crest derivatives 2 (HAND2;
-3.8-fold), C-fos induced growth factor (FlGF; -2.7-fold), angiopoietin 1 (ANGPT1; -2.3-
fold), interleukin 8 (IL8; -2.3-fold) and stabilin 1 (STAB1; -2.0-fold).
Figure 5.41 Gene expression changes on a PCR array after silencing PHD-2 in
normoxia in OA FLS
OA FLS were transfected with 10nM siRNA against luciferase or PHD-2 and cultured in normoxic
conditions for 24 hours. The scattered plot represents values of 2-Ct for target gene (siPHD-2) against
control (siLuc) from one patient. Solid line indicates no change; dashed lines indicate 2-fold increase
and 2-fold decrease. Only genes which increased or decreased by 2-fold or more are annotated.
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To verify the lack of siPHD-2 effect on NHDF, the same approach as described above
was used, revealing that none of the genes changed in RA or OA FLS were altered in these
cells. However, four other genes were changed in response to siPHD-2, two upregulated and
two downregulated. This group included kinase insert domain receptor (KDR also known as
VEGF-R2; 2.2-fold), collagen type IV alpha 3 (COL4A3; 2.0-fold), thrombospondin 1
(THBS1; -3.7-fold) and plasminogen activator urokinase (PLAU; -2.3-fold) (Figure 5.42).
Figure 5.42 Gene expression changes on a PCR array after silencing PHD-2 in
normoxia in NHDF
NHDF were transfected with 10nM siRNA against luciferase or PHD-2 and cultured in normoxic
conditions for 24 hours. The scattered plot represents values of 2-Ct for target gene (siPHD-2) against
control (siLuc) from one experiment. Solid line indicates no change; dashed lines indicate 2-fold
increase and 2-fold decrease. Only genes which increased or decreased by 2-fold or more are
annotated.
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These experiments were repeated few times in cells from other RA and OA patients
and the genes which were altered in all three cell types were compiled together, in order to
compare their relative expression. Using 2-fold induction or reduction in expression as cut-off
it was confirmed that ANGPTL-4, ephrin-A3, leptin, PGF and VEGF were increased in RA
and OA FLS, but not in NHDF (Figure 5.43).
Figure 5.43 A summary of genes affected after silencing PHD-2 in normoxia in RA
FLS, OA FLS and NHDF
RA FLS (n=4), OA FLS (n=2) and NHDF (n=1) were transfected with 10nM siRNA against luciferase
and PHD-2 and cultured in normoxic conditions for 24 hours (dashed line). A 2-fold induction or
reduction in expression was used as cut-off in the evaluation of the data. The values represent mean ±
SEM from indicated number of experiments. Data were analysed using t-test comparing dCt values
(siLuc versus gene of interest); *p<0.05, **p<0.01.
A
N
G
PT
1
A
N
G
PT
L4
C
X
C
L3
C
X
C
L9
EF
N
A
3
Fl
G
F
H
A
N
D
2
LE
P
ST
A
B
1
V
EG
FA EG
F
PG
F
C
O
L4
A
3
K
D
R
PL
A
U
TH
B
S1
-10
-5
0
5
10
15
RA FLS
OA FLS
NHDF
**
*
* **
*
*
*
* *
*
**
*
*
**
**
*
Fo
ld
ch
an
ge
ve
rs
us
si
L
uc
Chapter 5
181
To compare the effect of PHD-2 knockdown with that of PHD-3 knockdown on
genes involved in modulating angiogenesis, PCR array was used to screen RA FLS. Silencing
PHD-3 in normoxia led to significant upregulation of six genes encoding interleukin-8 (IL8;
5.8-fold), interleukin-1 (IL1B; 3.9-fold), epiregulin (EREG; 3.3-fold), fibroblast-growth
factor receptor 3 (FGFR3; 3.0-fold), chemokine (C-C motif) ligand 11 (CCL11; 2.6-fold),
ephrin-A1 (EFNA1; 2.4-fold) and downregulation of one gene, namely cadherin 5 (CDH5; -
5.9-fold) as shown in Figure 5.44 from one representative experiment.
Figure 5.44 Gene expression changes on a PCR array after silencing PHD-3 in
normoxia in RA FLS
RA FLS were transfected with 10nM siRNA against luciferase or PHD-3 and cultured in normoxic
conditions for 24 hours. The scattered plot represents values of 2-Ct for target gene (siPHD-3) against
control (siLuc) from one patient. Solid line indicates no change; dashed lines indicate 2-fold increase
and 2-fold decrease. Only genes which increased or decreased by 2-fold or more are annotated.
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When results from four experiments performed on RA FLS were pooled and the
silencing effect of PHD-2 and PHD-3 was compared, it was apparent that expression of genes
upregulated by siPHD-2 in RA FLS, including ANGPTL-4 (3.0-fold), ephrin-A3 (3.6-fold),
leptin (10.0-fold) and VEGF (2.0-fold), was moderately but consistently reduced by siPHD-3
(below 2-fold cut-off). The data were consistent with Q-PCR results showing that the same
genes are changed by both PHD-2 and PHD-3 in the opposite way. In addition, it seemed that
genes, which were increased by siPHD-3, including IL-1 (2.4-fold), EREG (2.6-fold),
ephrin-A1 (2.5-fold), IL-8 (3.3-fold) and FGFR3 (3.4-fold) were also decreased by siPHD-2
(Figure 5.45).
Figure 5.45 Silencing PHD-2 and PHD-3 in normoxia has differing and opposing
roles on gene regulation in RA FLS
RA FLS were transfected with 10nM siRNA against luciferase, PHD-2 or PHD-3 and cultured in
normoxic conditions for 24 hours (dashed line). A 2-fold induction or reduction in expression was used
as cut-off in the evaluation of the data. The values represent mean ± SEM (n=4). Data were analysed
using t-test comparing dCt values (gene of interest minus housekeeping gene): * p<0.05, ** p<0.01,
*** p<0.001.
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Three genes which were increased on the PCR array after silencing PHD-3 were
further validated by Q-PCR. The expression of IL-1, IL-8 and FGFR3 were indeed
upregulated by siPHD-3, and interestingly were also downregulated by siPHD-2 in normoxia
in RA FLS (Figure 5.46a). HIF-dependence of these genes revealed that IL-1 and IL-8
seemed to be induced by siHIF-1 in hypoxia, whereas FGFR3 was increased by siHIF-1 in
normoxia and hypoxia (Figure 5.46b). This was in contrast to the genes shown so far in
Chapter 4 (page 102), which were downregulated by siRNA targeting HIF-. In terms of their
responsiveness to hypoxia, IL-8 was increased by both hypoxia and DMOG (Table 4.1),
FGFR3 was not altered by hypoxia but was increased by DMOG (Table 4.2), whereas IL-1
mRNA level seemed not be regulated by hypoxia but downregulated by DMOG (Table 4.3).
These results suggest that among PHD/HIF-regulated genes, some genes can be hypoxia-
independent but still HIF-dependent, suggesting indirect regulation of the gene.
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Figure 5.46 Validation of siPHD-3-regulated genes in RA FLS
RA FLS were transfected using 10nM of siRNA targeting luciferase, (a) targeting PHD-2 and PHD-3,
or (b) targeting HIF-1 and HIF-2 and cultured in normoxia (21% O2) or hypoxia (1% O2) for 24
hours indicated number of times (n). Q-PCR was performed using primers for IL-1, IL-8 and FGFR3
(Table 3.6 page 75) and analysed using 2-Ct method. Values are expressed relative to 18S RNA and
were normalised against normoxic mock controls. Data were analysed by 1-way ANOVA versus siLuc:
ns=not significant, *p<0.05, **p<0.01, ***p<0.001.
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5.3.7 INDUCTION OF PRO-ANGIOGENIC ACTIVITY BY SIPHD-2 BY ARTHRITIC
FIBROBLASTS (RA AND OA), BUT NOT BY NON-ARTHRITIC FIBROBLASTS (NHDF)
An in vitro angiogenesis assay (AngioKit, TCS Cell Works, Buckingham, UK) was
performed to further elucidate the role of PHD-2 and PHD-3 in tubule formation (Table 3.14,
page 98). Supernatants from knockdown experiments with siPHD-2, siPHD-3 or siLuc (used
as a control) carried out on RA FLS, OA FLS and NHDF were added onto pre-seeded human
endothelial cells, following co-culture for 11 days and staining of the tubules with anti-CD-31
(PECAM-1) antibody.
A marked pro-angiogenic effect after silencing PHD-2 in RA and OA FLS was
observed by the stable staining of CD-31, showing increased tubule formation (Figure 5.47).
Measurement of CD-31 expression based on the soluble p-nitrophenol phosphate substrate
generation corroborated the above results, showing that siPHD-2 in normoxia, but not PHD-3,
significantly increased the expression of CD-31 (Figure 5.48a), when the supernatants from
RA FLS and OA FLS were used, with no effect of supernatants from NHDF cultures.
This was paralleled by the scoring of the stained tubules when analysed using
AngioSys Programme (TCS Cell Works, Buckingham, UK). CD-31-positive tubules formed
after adding supernatants from siPHD-2-treated RA and OA FLS covered 13% and 10% of
the total field area, respectively, compared to siLuc controls (~5.8%), whereas in case of
NHDF CD-31-positive tubules covered approximately 6% of the area in all three conditions
(Figure 5.48b). Similarly, number of junctions increased from ~46 (per high power field x4)
in siLuc controls to 137 and 90, after adding supernatants from siPHD-2-treated RA and OA
FLS, respectively. Number of junctions from NHDF was approximately 40 and was
unchanged regardless of supernatant treatment (Figure 5.48c). In addition, number of tubules
formed by endothelial cells after culture with supernatants rose from 137 to 289 comparing
siLuc-treated and siPHD-2-treated RA FLS, and with media from OA FLS increased from
121 to 205, respectively, with no significant effects of NHDF conditioned media (Figure
5.48d). Total tubule length was increased by supernatants from RA FLS after silencing PHD-
2 compared to siLuc, increasing from 5118 to 8566pixels (per field). Supernatants from
siPHD-2-treated OA FLS also contributed significantly to increase in total tubule length from
4674 to 7606pixels when siLuc- was compared to siPHD-2-treated cells. Supernatants from
transfected NHDF failed to elicit any angiogenic response with unchanged length of tubules
of approximately 5800pixels (Figure 5.48e).
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Figure 5.47 RA FLS and OA FLS transfected with siPHD-2 induces tubule
formation
RA FLS, OA FLS and NHDF were transfected using 10nM of siRNA targeting luciferase, PHD-2 or
PHD-3 and were cultured in normoxia for 24 hours. Supernatants from these cultures, centrifugally
concentrated and resuspended in a fresh medium, were applied on pre-seeded human endothelial cells
at day 1, 4, 7 and 9, following staining for CD-31 (PECAM-1) on day 11. Representative images show
morphology of the tubules from wells treated with medium only (U, untreated), VEGF (5ng/mL) or
conditioned media from RA FLS, OA FLS or NHDF (the black bar represents 100µm; objective
magnification x4).
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Figure 5.48 RA and OA FLS transfected with siPHD-2 exert pro-angiogenic activity
RA FLS (n=4), OA FLS (n=2) and NHDF (n=1) were transfected with 10nM siRNA targeting
luciferase, PHD-2 or PHD-3 and were cultured in normoxia (21% O2) for 24 hours. Supernatants from
these cultures, centrifugally concentrated and resuspended in a fresh medium, with appropriate
controls: medium (U, untreated), VEGF (5ng/mL), were applied on pre-seeded human endothelial cells
at day 1, 4,7 and 9, following staining for CD-31 (PECAM-1) on day 11. Analysis includes: (a) soluble
expression of CD-31 quantified by colorimetric assay and AngioSys evaluation of tubule formation by
measuring (b) % of field area covered by CD-31-positive tubules, (c) number of junctions, (d) number
of tubules, and (e) total tubule length. Values were analysed by 1-way ANOVA versus siLuc: ns=not
significant, *p<0.05, **p<0.01, ***p<0.001.
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5.4 Discussion
Hypoxia and the HIF pathway are critical during mammalian embryogenesis and are
further implicated in a number of pathological conditions, including RA. The RA synovium,
which is characterised by an altered proliferative response of the residing cells leading to
expansion of the synovial tissue mass, exhibits a significant decrease in oxygen tension
(Lund-Olesen 1970; Sivakumar et al 2008). Induction of HIFs described in Chapter 4 (page
102) facilitates adaptation to these stressful conditions via modulation of gene transcription.
Although our knowledge about the HIF mechanism is constantly growing, this pathway is not
fully understood due to its high complexity. In order to understand and treat diseases in which
HIF is involved, scrutinising the upstream and downstream events is crucial. It is well
established that oxygen-dependent regulation of HIFs is under the notoriously tight control of
a family of dioxygeneses, including three members of prolyl hydroxylases (PHD-1-3) and one
asparaginyl hydroxylase (FIH-1). One of the most intriguing questions is the role of
individual PHD isoenzymes mediating the HIF:VHL binding (Epstein et al 2001; Jaakkola et
al 2001) and FIH-1 controlling HIF:CBP/p300 interaction (Lando et al 2002a; Lando et al
2002b; McNeill et al 2002).
Studies on the distribution of PHDs and FIH-1 using monoclonal antibodies have
revealed wide and overlapping expression in normal tissues (Soilleux et al 2005). Apart from
reports showing PHDs/FIH-1 expression in non-immortalised fibroblast and mouse
embryonic fibroblasts (Berra et al 2003; Vengellur et al 2003), there is no report so far
examining their expression in RA FLS. FLS represent key resident cell type in RA synovium
and display an abnormal phenotype, contributing to inflammation and tissue destruction in
RA (Muller-Ladner et al 1996; Del Rey et al 2009; Lefevre et al 2009). Divergence between
the gene expression pattern in synovial fibroblasts from healthy and RA individuals supports
the concept of acquired changes (Del Rey et al 2010). The functions of PHDs and FIH-1 have
not yet been investigated in RA; therefore an siRNA-based approach was used. It was also of
interest to compare the expression of dioxygenases in other inflammatory synovial fibroblasts
(from OA tissue) and healthy, non-inflammatory fibroblasts as this has not been investigated
yet. The study was therefore extended to OA FLS and normal human dermal fibroblasts
(NHDF) in order to examine whether hypoxia-mediated responses are cell-specific.
In this study, the expression of PHDs and FIH-1 was first evaluated at both mRNA
and protein level in RA FLS. Q-PCR analysis of the relative amount of these hydroxylases in
normoxia, based on Ct values and assuming that amplification efficiency of the primers for
the housekeeping gene and the gene of interest is equal, demonstrated that PHD-1, PHD-2
and FIH-1 mRNA levels were high and comparable, whereas PHD-3 mRNA was the least
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abundant (i.e. PHD-2 > FIH-1 > PHD-1 > PHD-3). Protein analysis in normoxia illustrated
that PHD-2 endogenous expression was the highest, PHD-1 and FIH-1 were constitutively
expressed in RA FLS, but to a lesser degree, while PHD-3 protein was undetectable in
normoxia (i.e. PHD-2 > PHD-1 > FIH-1 > PHD-3).
While investigating HIF hydroxylase expression in hypoxia it became apparent that
PHD-2 and PHD-3 mRNA and protein levels were upregulated by hypoxia and further by the
hypoxia-mimetic DMOG, whereas PHD-1 and FIH-1 were not altered in RA FLS in any
conditions. Monitoring mRNA changes revealed that PHD-2 and PHD-3 rose steadily with
time at 1% O2, whereas DMOG seemed to act instantly, over-riding hypoxic induction of
these genes during the first 1 - 3 hours of treatment and inducing more significant mRNA
increment. These changes were paralleled at the protein level, showing consistent
upregulation of PHD-2 in hypoxia and after DMOG treatment, although the changes were
small due to the already high endogenous level of this hydroxylase. PHD-3 was detected only
in DMOG-treated cells, appearing at 4 hours in the time-course study, when HIF-1
stabilisation was maximal. Although PHD-3 mRNA was extremely hypoxia-sensitive, the
protein was still not detectable in hypoxia. This could be explained by the lowest abundance
of PHD-3 compared to other oxygenases and probably by the fact that hypoxia increases E3
ligase Siah2, which is responsible at least partially for proteasomal degradation of PHD-3
(Nakayama and Ronai 2004). Studies were also extended to OA FLS and NHDF and have
shown that HIF hydroxylases were very similarly expressed to RA FLS, with PHD-2 and
PHD-3 responding to hypoxia and DMOG and unchanged high endogenous levels of PHD-1
and FIH-1.
The report demonstrating the presence of HRE in the promoter sites of PHD-2 and
PHD-3 (Metzen et al 2005; Pescador et al 2005) indicates that these dioxygenases are
hypoxia/HIF-responsive genes (Vengellur et al 2003; Aprelikova et al 2004; Marxsen et al
2004; Forooghian et al 2007). Investigation of HIF-dependence of PHD and FIH-1 revealed
that PHD-1 and FIH-1 are not regulated by any of the -subunits in RA FLS, whereas both
hypoxia- and DMOG-induced PHD-2 and PHD-3 were mediated by HIF-1 and HIF-2.
Interestingly, in normoxia and hypoxia siHIF-2 also affected PHD-3 mRNA expression,
which unfortunately could not be confirmed at the protein level, but which is in agreement
with previous reports (Aprelikova et al 2004; Marxsen et al 2004). For these reasons it is
suggested that HIF-1 is involved in PHD-2 and PHD-3 regulation, whereas HIF-2
modulates only PHD-3 expression. This implies that HIFs drive induction of enzymes
responsible for their degradation possibly when oxygen levels are restored.
To investigate the role of HIF hydroxylases in RA, all of them were silenced using
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specific siRNA in RA FLS resulting in unambiguous reduction of these enzymes at both
mRNA and protein level. The first effect of PHDs/FIH-1 knockdown was examined by
evaluating HIF- proteins, showing no effect on HIF- following knockdown of PHD-1 or
FIH-1. In the case of PHD-3, which is both HIF-1- and HIF-2-dependent, intriguingly,
silencing PHD-3 led to increased HIF-2 binding to HRE, but reduction in HIF-1 binding to
HRE. Surprisingly, although PHD-2 itself was regulated only by HIF-1, silencing PHD-2
stabilised both HIF-1 and also HIF-2 protein, but to lesser extent, which was also mirrored
by increased ability of HIF-1 and HIF-2 to bind to HRE. The response of RA FLS to PHD-2
knockdown was similar to hypoxic induction of cells, implying that it is the most important
HIF hydroxylase.
It was reported previously that PHD-2 is the most abundant enzyme, ubiquitously
expressed in all tested organs such as heart, brain, lung, liver, kidney and testis as reported in
rats (Koivunen et al 2004; Willam et al 2006) and different human tissues (Appelhoff et al
2004). It is postulated that PHD-2 is the most important HIF hydroxylase, since global
knockout of PHD-2, but not PHD-1, PHD-3 or FIH-1, was embryonically lethal with severe
placental and heart defects (Takeda et al 2006). Possibly because PHD-2 was the most
abundant dioxygenase, it was the most difficult to knockdown; however, already the lowest
concentration of siPHD-2, which only slightly reduced PHD-2 protein, had substantial
stabilising effect on HIF-1. In addition, double and triple knockdown of PHD-1 ± PHD-2 ±
PHD-3 exposed the stabilising effect of siPHD-2 on HIF-1 and HIF-2 proteins and HIF
target genes, which was not altered by the lack of other PHDs, thus leading to the conclusion
that PHD-2 is indeed the major player in regulating the HIF system in normoxia in RA FLS.
This is in agreement with reports published for a number of other cell types (Aprelikova et al
2004; Marxsen et al 2004; Forooghian et al 2007; Thoms and Murphy 2010).
In the case of PHD-3, attenuation of this enzyme by siRNA in normoxia in RA FLS
resulted in clear increase of HIF-2, but not of HIF-1 binding to HRE, also consistently with
others (Huang et al 2002; Appelhoff et al 2004; Aprelikova et al 2004; Chen et al 2006).
This effect has not been shown at the protein level, due to scarcity of both PHD-3 and HIF-2
proteins in RA FLS. However, interestingly, further analysis revealed that PHD-3 knockdown
in normoxia actually decreased HIF-1 protein stability and indeed when compared to siLuc
HIF-1 binding to HRE was modestly decreased by siPHD-3. These results suggest that
possibly in normal conditions PHD-3 positively regulates HIF-1.
From previous experiments it can be concluded that PHD-2 is having the highest
activity towards HIF-1, whereas PHD-3 towards HIF-2. These preferences were verified
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before in a number of immortalised and primary cell lines (Huang et al 2002; Berra et al
2003; D'Angelo et al 2003; Mazure et al 2004; Ginouves et al 2008; Thoms and Murphy
2010) and corroborated by in vivo studies. PHD-2 knockout in adult mice led to HIF-1
stabilisation in murine liver and kidney (Takeda et al 2007), whereas concurrent knockout of
PHD-1 and PHD-3 led to HIF-2 accumulation in liver, but only when both of them were
depleted simultaneously (Takeda et al 2008). Although all three PHDs hydroxylate HIF-
isoforms, it was reported previously that the individual PHDs preferences towards HIF-
exist and originate from favouring specific prolyl residues in the ODD domain (Hirsila et al
2003; Appelhoff et al 2004).
Scrutinising prolyl hydroxylation as an oxygen-dependent destruction signal of HIFs,
it was demonstrated that hydroxylation of only one proline is sufficient for pVHL binding and
partial HIF ubiquitylation, meaning that both sites function independently. When a single
proline was mutated, HIF protein was still targeted by PHD followed by VHL-E3 complex-
binding and ubiquitination, and thus HIF was partially stabilised, whereas a double mutant
was not ubiquitinated at all and was completely stabilised (Masson et al 2001). Chan and co-
workers, on the other hand, showed that both prolyl residues are not equally hydroxylated and
that hydroxylation of Pro564 occurs first, which is then required for hydroxylation of the
second proline, Pro402 (Chan et al 2005).
According to two reports, PHD-2 predominantly hydroxylates Pro402 in the N-TAD
and to a lesser degree Pro564 in the C-TAD of HIF-1On the other hand, PHD-3 is the main
hydroxylase targeting Pro564 and has no activity towards Pro402(Hirsila et al 2003;
Appelhoff et al 2004). Thus in RA FLS when PHD-2 was silenced, Pro402 and Pro564 were
no longer hydroxylated, and although the C-TAD prolyl residue 564 was possibly still
hydroxylated by PHD-3, it was not enough to degrade HIF-1 protein. In addition, my study
has shown that silencing PHD-2 in normoxia increased PHD-3 mRNA level (however maybe
not the enzyme activity), but it was still not sufficient to regulate HIF-1 protein. However,
PHD-3 knockdown led to HIF-1 protein degradation in RA FLS. This could be explained by
the presence of abundant PHD-2, which can sufficiently hydroxylate both Pro402 and Pro564
(Figure 5.49).
Note that PHD-1 is not taken into account in these schemes and expanations, due to
the fact that PHD-1 was not HIF-dependent in RA FLS and there was no effect of silencing
PHD-1 on HIF and/or HIF target genes. However, obviously PHD-1 should not be excluded
from the general picture as it possibly has a more discreet function in different conditions and
perhaps in different cell types.
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Figure 5.49 Schematic oxygen-dependent regulation of HIF-1 protein
HIF-1 contains Pro402 which is hydroxylated by PHD-2 and Pro564 which is hydroxylated by both
PHD-2 and PHD-3. In normoxia, both prolines are recognised and hydroxylated by PHD-2 and/or
PHD-3, which target HIF-1 to proteasomal degradation. In hypoxia, neither of the oxygenases are
active, thus prolyl residues are not hydroxylated and HIF-1 is stabilised. While silencing PHD-2
possibly only Pro564 is hydroxylated by PHD-3 (which is the least abundand) and therefore HIF-1 is
partially stabilised. On the other hand, PHD-3 knockdown leads to HIF-1 degradation, because both
Pro402 and Pro564 are still recognised by PHD-2 and hydroxylated and targeted for ubiquitination.
In the case of HIF-2, according to the literature, it can be concluded that all PHDs
hydroxylate both Pro405 and Pro531 in the ODD domain of HIF-2, with the highest affinity
and activity of PHD-3 towards both prolines (Hirsila et al 2003; Appelhoff et al 2004).
However, this could not fully explain results achieved in my study, which has shown that
HIF-2 was stabilised not only by PHD-3, but also by PHD-2.
When PHD-2 was silenced in RA FLS, HIF-2 protein was stabilised and HIF-2
binding to HRE was increased. It could be explained by the fact that Pro405 was no longer
hydroxylated by PHD-2 and that hydroxylation of Pro531 by PHD-3 resulted only in part in
degradation of HIF-2 protein with some remaining activity, probably without the additional
effect of siPHD-2 increasing PHD-3 mRNA (and maybe thus the activity of enzyme).
Interestingly, silencing PHD-3 was enough to increase HIF-2 binding to HRE, suggesting that
even though the single hydroxyproline Pro405 still retained an active site for VHL binding,
HIF-2 was partially stabilised. Another explanation could be that the effect of PHD-3
depletion on HIF-2 was indirect and was happening via decreased HIF-1 which then acted
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negatively on HIF-2 due to transregulation described earlier stabilising HIF-2.
Based on my data, PHD-2 seemed to predominantly hydroxylate Pro405, whereas
Pro531 is probably mainly hydroxylated by PHD-3 in HIF-2. If my results are true, then
PHD-2 and PHD-3 preferences towards prolines in HIF-2 are as shown in Figure 5.50.
Figure 5.50 Schematic oxygen-dependent regulation of HIF-2 protein
According to my data, HIF-2 contains Pro405 which is hydroxylated by PHD-2 and Pro531 which is
hydroxylated by PHD-3. In normoxia, both prolines are recognised and hydroxylated by PHD-2 or
PHD-3, which target HIF-2 to proteasomal degradation. In hypoxia, neither of the oxygenases are
active, thus prolines are not hydroxylated and HIF-2 is stabilised. Based on my results, when PHD-2
is silenced only Pro531 is hydroxylated by PHD-3, therefore HIF-2 is moderatly degraded. PHD-3
knockdown also retains HIF-2 binding to HRE, because hydroxyPro405 is not enough to degrade the
protein and thus it is partially stabilised.
Due to the fact that PHD-2 depletion protected HIF-1 and HIF-2 from degradation
in RA FLS, the downstream effect observed for HIF target genes was as anticipated. Indeed,
PHD-2 knockdown promoted transcription of angiogenic factors, such as ANGPTL-4, ephrin-
A3 and VEGF, together with markers of anaerobic metabolism active in hypoxic conditions,
like GLUT-1 and ENO-1, as well as survival markers, such as BNIP-3 and CA9. These
responses were paralleled by increased VEGF, ANGPTL-4, ephrin-A3, CA9, GLUT-1 and
BNIP-3 protein. Consequence of silencing PHD-2 in RA FLS closely resembled hypoxic
induction of HIFs and HIF-dependent genes, implying that PHD-2 knockdown on its own can
mimic the hypoxic milieu. HIF--dependence of downstream genes as well as PHD-2
regulatory effects on HIF-1 and HIF-2 were also confirmed by double knockdown. Thus,
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siPHD-2-driven induction of BNIP-3, CA9, ENO-1, ephrin-A3 and GLUT-1 mRNA was
decreased after concurrent knockdown of PHD-2 with HIF-1. Consistent with the HIF-
dependence of VEGF, ANGPTL-4 and PHD-3, both double knockdowns of PHD-2 with HIF-
1 or HIF-2 resulted in reduction of their expression. In summary, these data suggest that
PHD-2 plays the principal role in HIF- hydroxylation and that bidirectional HIF-PHD-2
interaction is involved in hypoxia-induced responses.
Similarly to conclusions regarding PHD-2, it was expected that since PHD-3
knockdown increased HIF-2 binding to DNA, it would be able to regulate HIF-2-dependent
genes, specifically ANGPTL-4 and VEGF. However, silencing PHD-3 did not increase their
expression. This is most likely because induction of HIF-2 alone is not sufficient to induce
transcription of these genes. As explained above, silencing PHD-3 did not protect HIF-1
from degradation, but even reduced the protein in concert with significant downregulation of
HIF-1-dependent genes such as CA9, BNIP-3, ENO-1, ephrin-A3 and GLUT-1. Even genes
which required both HIF-1 and HIF-2 (VEGF, ANGPTL-4) were decreased. There are
several possible explanations for this observation. Firstly, HIF-1 protein appeared to
actually be reduced by PHD-3 knockdown, which would account for the reduced expression
of target genes. This reduction could be due to the fact that PHD-2 is present at very high
levels without any competing influence of PHD-3 (in siPHD-3-treated cells) can more
efficiently maintain low HIF-1 levels. Additionally, there may be some transregulation
between HIF-1 and HIF-2. Taking into account the likelihood of negative transactivation
between HIF-1 and HIF-2 described in Chapter 4 (page 102) and in the literature (Raval et
al 2005; Carroll and Ashcroft 2006), the hypothesis would be that silencing PHD-3 increases
HIF-2 stability, which in turns decreases basal levels of HIF-1 and as a result decreases
HIF target genes which require HIF-1. In summary, PHD-3 role in normoxia might be
negligible due to its very low basal expression, but is not redundant.
Based on the literature it was proposed that HIF- is prone to feedback inhibition as a
result of the activity of PHD-2 and PHD-3, which are HIF--regulated genes themselves.
Silencing PHD-2 resulted in a significant increase in PHD-3 mRNA among other HIF target
genes, confirming that it is HIF/hypoxia-regulated gene. However, silencing PHD-3 did not
have the same effect on PHD-2, most likely due to the fact that PHD-3 knockdown did not
increase HIF-1 protein. On the basis of the findings that PHD-2 and PHD-3 reduction do not
stabilise HIFs to the same extent and act differently on HIF-dependent genes and also each
other, it can be concluded that these two isoenzymes have divergent roles, with PHD-2
negatively regulating HIF-1, whereas PHD-3 positively regulating HIF-1.
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HIF hydroxylases are oxygen-dependent and the affinity of PHDs for HIFs drops
dramatically when oxygen tension decreases, resulting in HIFs stabilisation (Koivunen et al
2004; Tuckerman et al 2004). However, consistently with others (Berra et al 2003; Ginouves
et al 2008; Thoms and Murphy 2010), it has been demonstrated in the present study that
silencing PHD-2 in hypoxia further stabilised HIF-1 and HIF-2 protein, as well as HIF
target genes in hypoxia. Therefore this implies that in decreased oxygen tension, (i) there is
some remaining activity of PHD-2 possibly due to the presence of non-respiratory oxygen
(Hagen et al 2003). (ii) It could be also related to PHD-2 localisation, which is mainly
cytoplasmic; however, in hypoxia it is the only prolyl hydroxylase which shuttles between
cytoplasm and nucleus, and thus affects HIF-1 stability and activity (Yasumoto et al 2009).
It is proposed that FIH-1 regulates HIF and HIF target genes at another level than
PHD, selectively hydroxylating asparagine on the C-TAD, thereby preventing recruitment of
co-factors to the -subunit inhibiting HIF- transcriptional activity (Lando et al 2002a;
McNeill et al 2002). Similar to PHD enzymes, FIH-1 requires oxygen to become active.
However, it was shown that even under hypoxia FIH-1 does not lose its activity; therefore it is
still able to regulate HIFs and hence HIF-responsive gene transcription (Koivunen et al 2004;
Dayan et al 2006; Khan et al 2011). Silencing FIH-1 in renal cancer cells (Khan et al 2011),
Hep3B and U-2OS cells (Stolze et al 2004) increased the expression of HIF transcriptional
targets such as GLUT-1, VEGF, BNIP-3 and CA9 in normoxia and hypoxia.
Certainly, data in this study have shown that HIF- proteins and HIF target genes are
more responsive to DMOG than to hypoxia suggesting that DMOG activates mechanisms
additional to those induced by hypoxia. This may be well due to the ability of DMOG to
inhibit FIH-1 as well as PHDs. However, the contribution of FIH-1 in HIF-mediated events
investigated in RA FLS using siRNA revealed that FIH-1 knockdown had no effect on either
HIF- proteins or HIF-dependent genes. Furthermore, it was reported in HeLa cells that
simultaneous knockdown of PHD-2 and FIH-1 synergise in increasing the HIF-1
transcriptional activity in normoxia (Mazure et al 2004). This was most likely due to dual
inhibition of the N-TAD and the C-TAD activity via PHD-2 and FIH-1, respectively.
However, effective single and double knockdown of PHD-2 and FIH-1 achieved in normoxic
and hypoxic conditions was yet without any additional effect in RA FLS and NHDF. In
addition, neither FIH-1 mRNA, nor protein was altered by hypoxia, DMOG and it was not
HIF--dependent. Due to complete lack of response to changes in FIH-1, it is therefore
postulated that FIH-1 may be inactive in RA FLS and NHDF, or it is possible that in these
conditions FIH-1 has a higher affinity towards alternative class of substrates containing the
ankyrin repeat domain (ARD), including IB (Cockman et al 2006) and Notch (Wilkins et
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al 2009), which account for 6% of the human proteosome (Cockman et al 2009).
To investigate the putative differences in hypoxia-sensitive pathways in other arthritic
and non-arthritic cells, the study was extended to fibroblasts isolated from OA tissue and
healthy fibroblasts isolated from adult skin, NHDF. Comparing protein levels involved in the
HIF mechanism between these cells exposed to hypoxia and DMOG, the results revealed that
all three cell types respond in a comparable way, upregulating HIF-1 and HIF-2 proteins,
HIF upstream regulators, PHD-2, PHD-3, and HIF target genes, BNIP-3 and GLUT-1. One of
the main differences between the cells was that HIF-1 was present in normoxia in RA FLS
and OA FLS, which could be a characteristic of diseased cells due to for instance pro-
inflammatory milieu in the joints. In these cells the HIF pathway might be already induced by
cytokines spontaneously produced by arthritic fibroblasts which stabilise HIF-1 in an
oxygen-independent manner.
Even though OA FLS and NHDF were able to respond to hypoxia and DMOG in a
similar way to RA FLS using the common HIF pathway, substantial differences between the
cells were noticed in normoxia. By creating hypoxic conditions after silencing PHD-2, NHDF
did not stabilise HIF- proteins and therefore did not alter HIF target genes, whereas OA FLS
responded as was seen in RA FLS inducing the HIF pathway, but to a lesser extent.
Next, the angiogenic genes regulated by PHD-2 in these cells were investigated
screening 84 putative candidates by PCR array. Silencing PHD-2 in RA FLS confirmed
induction of a number of pro-angiogenic genes shown earlier in the study, including
ANGPTL-4, ephrin-A3, VEGF, but also revealed induction of other genes such as epidermal
growth factor (EGF) and the most responsive gene in this assay, leptin. PGF transcript,
although it belongs to a group of pro-angiogenic genes, was decreased in RA FLS. OA FLS
responded in a similar way to RA FLS, inducing ANGPTL-4, ephrin-A3, VEGF and leptin,
but again to a lesser degree, and in addition chemokine ligand (CXCL)-9 was also induced.
Interestingly, a bigger group of transcripts were reduced after siPHD-2 in OA FLS, including
chemokine ligand (CXCL)-3, heart and neural crest derivatives (HAND)-2, C-fos induced
growth factor (FlGF), angiopoietin (ANGPT)-1, IL-8 and stabilin (STAB)-1. In contrast,
NHDF altered a distinct group of genes compared to RA FLS and OA FLS, increasing kinase
insert domain receptor (KDR), which is VEGF receptor 2, collagen type IV alpha 3
(COL4A3) and decreasing thrombospondin (THBS)-1 and plasminogen activator urokinase
(PLAU). Similarities and differences in three cell types are summarised in Figure 5.51.
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Figure 5.51 Summary of effects of PHD-2 knockdown in RA FLS, OA FLS and
NHDF
Compilation of genes altered in RA FLS, OA FLS, and NHDF after silencing PHD-2 in normoxia as
demonstrated by PCR array. Arrows ‘up’ represent genes upregulated by siPHD-2, whereas, arrows
‘down’ represent genes downregulated by siPHD-2.
Analysis of genes altered by PHD-3 depletion in RA FLS, revealed that PHD-3
knockdown decreased cadherin (CDH)-5 and increased pro-inflammatory cytokines such as
IL-1 or IL-8, chemokines (CXCL5), epiregulin (EREG), FGF receptor 3 (FGFR3) and
EFNA1 growth factor. In addition, it seemed that IL-1 IL-8 and FGFR3 belong to a group
of genes downregulated in hypoxia by HIF-1as oppose to a majority of genes upregulated
by HIF-1, often omitted in studies, but still very important. Interestingly, detailed analysis of
genes the most regulated by PHD-3 on this PCR array, namely IL-1 IL-8 and FGFR3,
revealed that these genes were reversely regulated by PHD-2 depletion. Moreover, angiogenic
factors, such as ANGPTL-4, VEGF, ephrin-A3 and leptin, which were increased by silencing
PHD-2 in RA FLS, were decreased by PHD-3 reduction in those cells. Therefore, according
to PCR array analysis, PHD-2 and PHD-3 may have non-redundant roles during
neovascularisation, since data included in this study revealed that they regulate different
group of genes and the common ones are regulated in the opposite way. Due to lack of time,
the profile of genes induced by silencing PHD-3 in OA FLS and NHDF was not investigated.
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Consequently, the functional assay testing the ability of conditioned media from cells
after silencing PHD-2 or PHD-3 to induce angiogenesis was used to test the hypothesis that
PHD-2 is implicated in angiogenesis. Supernatants from RA and OA FLS, but not from
NHDF, transfected with siPHD-2 were able to exert a pro-angiogenic effect on human
endothelial cells in that they formed tubule structures after co-culture, increasing the number
of junctions, number of tubules and tubule length, most likely via increased HIF target gene
expression. Conditioned media from siPHD-3-treated cells did not increase angiogenesis
significantly in these cell types, possibly due to opposite effect on powerfully pro-angiogenic
transcripts when compared to PHD-2.
It was reported formerly that although OA is classified as non-inflammatory
synovitis, some OA patients show evidence of angiogenesis and inflammation.
Approximately 60% of OA patients exhibit synovial proliferation, compared to 95% of RA
patients (Lee et al 2007b), what undoubtedly influences oxygen tension in joints. It has been
demonstrated that pO2 in synovial fluid averaged 43 mmHg and 26 mmHg in OA and RA
patients, respectively (Lund-Olesen 1970). Although OA patients demonstrate higher oxygen
tension than RA patients, it has been described that OA tissue expresses similar amounts of
HIF-1 and HIF-2 to RA tissue (Giatromanolaki et al 2003), possibly this is the reason why
they respond alike. Based on these results, fibroblasts from OA patients seem to exert a
similar effect to RA FLS, implying that these diseases have more in common than previously
believed.
Collectively, the aforementioned results suggest that PHD-2 regulates pro-angiogenic
responses in RA and OA via controlling HIF--dependent mechanisms and strongly pro-
angiogenic molecules, including VEGF and ANGPTL-4 (as seen in the in vitro angiogenesis
assay). These results make PHD-2 a promising object of research in angiogenesis therapy,
suggesting that targeting PHD-2 as a therapy could be specific for diseased/arthritic cells.
Presumably, over-expression of PHD-2 could decrease HIF- stability and activity, therefore
reduce angiogenesis. Regulating a specific upstream molecule such as PHD-2, which is
capable of controlling multiple angiogenic growth factors via HIF, could be a better and more
efficient choice for gene therapy targeting angiogenesis, than using antibodies against single
molecules like VEGF.
Moreover, in the future, it is important to further dissect out PHD-3-mediated
responses, since it seems that PHD-3 plays a ‘subtle’ role in regulating angiogenesis, but the
importance has not yet been accurately appraised. It would be of interest to investigate the
role of PHD-3 also in hypoxia, since it is one of the most hypoxia-responsive genes in RA
synovium.
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6 HIF-3 Expression In RA FLS
6.1 Introduction
The regulation of HIF-1 and HIF-2, and the involvement of these HIF isoforms in
the induction of hypoxia-dependent genes in RA FLS are described in Chapter 4 (page 102).
To complete the investigation of HIFs, it was essential to scrutinise the third -subunit. HIF-
3 was first discovered in mice and described as inhibitory PAS domain, IPAS (Gu et al
1998), and then was characterised in humans. HIF-3 was shown to be an active transcription
factor which dimerises with HIF-1 inducing HRE-driven transcription, but only when HIF-
3 and HIF-1 are over-expressed (Hara et al 2001). Moreover, HIF-3 is also able to reduce
HIF-1- and HIF-2-driven transcription, suggesting that HIF-3 competes with both -
subunits for recruitment of the -subunit, therefore abolishes hypoxia-induced HIF-
transactivation (Hara et al 2001; Makino et al 2001).
Similarly to HIF-1 and HIF-2, HIF-3 encloses the ODD domain with a single
prolyl residue, Pro490 that is hydroxylated by all PHDs and thus contributes to HIF-3
ubiquitination and proteasomal degradation (Hirsila et al 2003; Maynard et al 2003). HIF-3
protein stability decreases much slower than other -subunits with half-life of approximately
18 hours after DP (2,2’ dipyridyl) pre-stimulation (Tanaka et al 2009). In contrast to HIF-1
and HIF-2, HIF-3 is regulated at the mRNA by different molecular mechanisms, since
HIF-3 transcriptional regulation by hypoxia is subjected to the extensive alternative splicing.
In response to hypoxia HIF-3 transcript gives a rise to at least 7 splice variants (Figure 6.1)
(Pasanen et al 2010). HIF-34 is being the most studied variant of HIF-3 due to its
interesting anti-angiogenic functions (Jang et al 2005) and anti-tumourigenic activities
(Maynard et al 2007). However, there is a discrepancy in HIF-34 expression in hypoxia
HIF-34 which is either increased (Makino et al 2001; Makino et al 2002; Tanaka et al 2009)
or decreased (Maynard et al 2005) depending on the cell types used in the study.
It was reported that HIF-3 regulates HIF-1 and HIF-2 activity by competition for
HIF-1. In addition, the presence of a functional HRE in HIF-3 makes this molecule
potentially a HIF target gene. Indeed, it was shown that HIF-3variant (HIF-32 and HIF-
34 were regulated by HIF-1, but not by HIF-2 (Tanaka et al 2009; Pasanen et al 2010).
This implies that HIF-3 splice variants containing HRE are regulated by HIF thereby they
belong to the group of negative regulators of the HIF pathway, including PHD-2 and aHIF.
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Figure 6.1 Organisation of the HIF-3 locus
(a) Schematic representation of the HIF-3 locus. (b) Exons present in the subsequent splice variants.
(c) The structure of protein domains, including the basic helix-loop-helix (bHLH), the Per-ARNT-Sim
(PAS), the oxygen-dependent degradation (ODD) and the leucine zipper (LZIP) domain with the
indication of the number of amino acids in the encoded proteins (modified from Pasanen et al 2010).
6.2 Objectives
In order to complete HIF pathway research in RA FLS, the final step was to examine
the third and the least investigated of HIF- isoforms, namely HIF-3. This chapter presents
preliminary results related mainly to total HIF-3 and HIF-34 splice variant expression in
hypoxic conditions in RA FLS, as well as the effect of total HIF-3 knockdown. The
subsequent objectives were identified:
(1) To investigate total HIF-3 and HIF-34 splice variant expression in RA FLS in
hypoxic conditions, their HIF-- and PHD-dependence
(2) To examine the effect of HIF-3 depletion on HIFs and HIF- target genes
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6.3 Results
HIF-3 is the least investigated HIF- subunit and is thought to be controlled in a
different manner than HIF-1 and HIF-2, with regulation mainly at the transcriptional level,
giving rise to at least 7 splice variants described to date (Pasanen et al 2010). It was reported
that HIF-3 transcription is increased by hypoxia in RA FLS (Del Rey et al 2010). This part
of the work addressed the expression and role of HIF-3 in RA FLS. Firstly, the effect of
hypoxia and the hypoxia mimetic DMOG on total HIF-3 and on the HIF-34 variant was
assessed. Next, HIF-dependence and HIF-3 regulation by different PHD and FIH-1 was
examined. Finally, the effect of HIF-3 knockdown was carried out in RA synovial
fibroblasts. Q-PCR was applied throughout these studies determining mRNA levels of HIF-
3 and hypoxia/HIF-regulated genes. Unless otherwise indicated, primer sets #1 were used.
6.3.1 HYPOXIC AND HYPOXIA-MIMETIC INDUCTION OF HIF-3 AND HIF-34
Firstly, relative amounts of all HIF isoforms in RA FLS was compared using Q-PCR.
The relative amount of HIFs was assessed examining the Ct values. As shown in Figure 6.2
HIF-1 seemed to be the most abundant, followed by HIF-2 both were also downregulated
by hypoxia as shown in Figure 4.4 (page 107). The higher Ct value the lesser amount of RNA
is in the cell, therefore it could be concluded that both HIF-1 and HIF-3 mRNA levels were
similar and the least abundant. HIF-1 was not altered by hypoxia, whereas HIF-3 was the
only isoform whose mRNA was upregulated by hypoxia by 6-fold (Figure 6.2).
Figure 6.2 HIF abundance in RA FLS
RA FLS were exposed to either normoxia (21% O2) or hypoxia (1% O2) for 24 hours. HIF-1, HIF-2,
HIF-3 and HIF-1 mRNA was measured by Q-PCR. The numbers indicate the mean ± SEM of the
fold change relative to HIF-3 levels in normoxia (set as 1). Data are from a representative experiment.
Ct values for each gene in normoxia and hypoxia are indicated below the graph.
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To further investigate HIF-3 expression in RA FLS, cells were exposed to hypoxia
or DMOG for indicated time points. Q-PCR revealed that HIF-3 increased by hypoxia by 7-
fold (Figure 6.3a) and consistently, but to a lesser extent, by DMOG by 2.5-fold (Figure 6.3b)
after 24 hours of culture in these conditions.
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Figure 6.3 Time-course of hypoxia- and DMOG-induced HIF-3 mRNA expression
RA FLS were exposed to either hypoxia (1% O2) or 1mM DMOG for indicated time points. HIF-3
mRNA was measured by Q-PCR and normalised to normoxia (21% O2) at t0. Data are mean ± SEM
from a single experiment.
It was demonstrated that hypoxia induces alternative splicing of HIF-3 gene
(Makino et al 2002) resulting in the presence of at least 7 splice variants, and that all of them
respond rapidly to the oxygen changes (Pasanen et al 2010). Certain splicing arrangement
encodes a polypeptide that antagonises HRE-dependent gene expression, namely HIF-34,
which is proposed to be a negative regulator of the HIF pathway (Makino et al 2001).
Therefore the expression of the HIF-34 variant with that of total HIF-3 was compared in
RA FLS using two different sets of primers.
After exposing RA FLS to normoxia and hypoxia for 24 hours, the results revealed
that both total HIF-3 and HIF-34 were upregulated in response to hypoxia by 10-fold and
4.5-fold, respectively (Figure 6.4). Interestingly, it seemed that DMOG increased total HIF-
3 slightly less compared to hypoxia, inducing its expression by 6.4-fold (Figure 6.4a). In
contrast, HIF-34 expression in response to DMOG was higher than its hypoxic induction
and was increased by 7-fold (Figure 6.4b).
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Figure 6.4 HIF-3 and HIF-34 are upregulated by hypoxia and DMOG
RA FLS were exposed to either hypoxia (1% O2) or 1mM DMOG for 24 hours. (a) HIF-3 and (b)
HIF-34 mRNA was measured by Q-PCR using two sets of primers for each gene and normalised to
normoxia. Data are mean ± SEM from 6 - 14 experiments and were analysed by paired t-test: * p<0.05.
6.3.2 HIF-DEPENDENCE OF HIF-3 IN RA FLS
HIF-3 contains at least 5 putative HRE and thus it is a HIF-1 target gene (Tanaka
et al 2009; Pasanen et al 2010). To investigate the HIF--dependence of HIF-3 in RA FLS,
the cells were transfected with either HIF-1 or HIF-2 siRNA. As shown below HIF-3 was
regulated by silencing HIF-1and was reduced by 28%, 64% and 76% in normoxia, hypoxia
and DMOG, respectively (Figure 6.5a). HIF-34 was also decreased by siHIF-1 in
normoxia, hypoxia and DMOG by 53%, 60% and 77%, respectively (Figure 6.5b).
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Figure 6.5 Expression of HIF-3and HIF-34 is HIF-1-dependent in RA FLS
RA FLS were transfected with siLuc, siHIF-1, siHIF-2 or lipofectamine alone (mock) followed by
culture in normoxia (21% O2), hypoxia (1% O2) or 1mM DMOG for 24 hours. (a) HIF-3 and (b) HIF-
34 mRNA measured by Q-PCR and normalised to normoxia. Data are mean ± SEM (n= 3 – 7) and
were analysed by 1-way ANOVA versus normoxia: *p<0.05, ** p<0.01, *** p<0.001.
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6.3.3 HIF-3REGULATION BY PHDS AND FIH-1
The data presented above have shown that HIF-3 is a HIF-1 target gene, as has
been described for a number of genes in RA FLS (Chapter 4, page 102). HIF target genes
were upregulated following knockdown of PHD-2, the main upstream regulator of HIF
(Chapter 5, page 142). It was described that HIF-3 which contains the ODD domain is
hydroxylated by all three PHD isoenzymes (Hirsila et al 2003). Therefore, the next step was
to assess the effect of PHD and FIH-1 knockdown on HIF-3 expression. As shown in Figure
6.6, HIF-3 mRNA was significantly upregulated by silencing PHD-2, whereas interestingly
depletion of PHD-3 and FIH-1 seemed to decrease the amount of HIF-3 mRNA.
Figure 6.6 HIF-3 regulation by PHDs and FIH-1 in RA FLS
RA FLS were transfected with siRNA targeting luciferase, PHDs, FIH-1 or lipofectamine alone (mock
control) followed by culture in normoxia (21% O2) for 24 hours. HIF-3 was measured by Q-PCR and
normalised to normoxia (21% O2). Data are mean ± SEM from 5 experiments. Data were analysed by
1-way ANOVA versus normoxia: * p<0.05, ** p<0.01, *** p<0.001.
When double and triple knockdown of HIF hydroxylases was conducted in RA FLS,
the effect of silencing PHD-2 was the most evident, but slightly decreased by the
simultaneous presence of PHD-1 and/or PHD-3 siRNA (Figure 6.7). This result suggests that
PHD-2 is the major hydroxylase regulating HIF-3; however, other HIF hydroxylases are
also able to modulate HIF-3 mRNA level in RA FLS, but in the opposite manner.
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Figure 6.7 PHD-2 is the main regulator of HIF-3in RA FLS
RA FLS were transfected with siRNA targeting PHD-1, PHD-2, PHD-3 and FIH-1, separately or in
combination and cultured in normoxia (21% O2) for 24 hours. DMOG treatment served as a control.
HIF-3 mRNA was measured by Q-PCR and normalised to normoxia (21% O2). Data are mean ± SEM
(n=1).
Since HIF-3 behaved like one of the HIF target genes by being regulated by HIF-1
and HIF hydroxylases, the effect of siPHD-2 on HIF-3 and HIF-34 was examined also in
hypoxic conditions. As described in Figure 6.4, hypoxia was again less effective in terms of
upregulating the HIF-34 isoform than the total HIF-3 mRNA. Using two different sets of
primers for HIF-3 the results revealed that silencing PHD-2 increased HIF-3 mRNA level
in normoxia and enhanced the expression of HIF-3 even further in hypoxia (Figure 6.8a and
Figure 6.8b). Also using two sets of primers for HIF-34, PHD-2 depletion acted on this
splice variant in a similar way, increasing HIF-34 mRNA expression in normoxia and
augmenting it further in hypoxic conditions (Figure 6.8c and Figure 6.8d). For instance, using
HIF-3 #1 primer set, hypoxia induced 4.0-fold increase of HIF-3 mRNA level and PHD-2
depletion in hypoxia further increased this expression 12-fold (Figure 6.8a). Using HIF-34
#1 primers, hypoxia increased HIF-34 mRNA level 3.5-fold relative to normoxia and
siPHD-2 in hypoxia further upregulated this response 6.6-fold (Figure 6.8c).
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Figure 6.8 PHD-2 knockdown further induces HIF-3 and HIF-34 mRNA in
hypoxic conditions in RA FLS
RA FLS were transfected with siLuc, siPHD-2 or lipofectamine alone (mock control) followed by
exposure to normoxia (21% O2) or hypoxia (1% O2) for 24 hours. HIF-3 and HIF-34 mRNA was
measured by Q-PCR and normalised to normoxia. Data are mean ± SEM from 5 - 8 experiments and
were analysed by 1-way ANOVA versus matched siLuc: * p<0.05, ** p<0.01.
6.3.4 HIF-3 KNOCKDOWN IN RA FLS
It is suggested that HIF-3 might have its own target genes, since it is able to bind to
HIF-1 and induce the expression of HRE reporter gene (Gu et al 1998; Hara et al 2001). To
examine the putative HIF-3target genes siRNA transfection was performed on RA FLS
using three different concentrations of siRNA targeting total HIF-3 and followed by
exposing the cells to normoxic and hypoxic conditions. Total HIF-3 was reduced similarly
using 10nM, 20nM or 50nM by approximately 68% in normoxia and by 56% in hypoxia
(Figure 6.9a), whereas HIF-34 was decreased less efficiently, by 44% in normoxia and by
39% in hypoxia (Figure 6.9b).
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Figure 6.9 HIF-3 knockdown in RA FLS
RA FLS were transfected with 10nM, 20nM or 50nM of siRNA targeting total HIF-3 followed by
exposure to normoxia (21% O2) or hypoxia (1% O2) for 24 hours. (a) HIF-3 and (b) HIF-34 mRNA
level was measured by Q-PCR and normalised to normoxia. Data are mean ± SEM (n=1).
The next step was to assess the effect of HIF-3 knockdown on HIF and
hypoxia/HIF-regulated genes. As shown in Figure 6.10 HIF-1 and HIF-2 were slightly but
significantly (p<0.01 in both cases) downregulated by siHIF-3 in normoxia. HIF-1 and
HIF-2 mRNA level was downregulated by hypoxia as shown previously (Figure 4.4, page
107); however, HIF-3 knockdown had no additional effect on HIF-1 and HIF-2 levels in
hypoxia (Figure 6.10).
Figure 6.10 Effect of HIF-3 knockdown on HIF-1and HIF-2 mRNA
RA FLS were transfected with 10nM siRNA targeting HIF-3 or siLuc followed by exposure to
hypoxia (H, 1% O2) for 24 hours. HIF-1 and HIF-2 mRNA level was measured by Q-PCR and
normalised to normoxia (N, 21% O2; dashed line). Data are mean ± SEM (n=1).
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Effect of siHIF-3 on HIF- mRNA was followed by investigation HIF-regulated
genes. Reduction of HIF-dependent gene expression by siHIF-3 in normoxia was probably a
result of HIF-1 and HIF-2 mRNA decrease. The reduction observed with siHIF-3 was
statistically significant in all cases: ANGPTL-4 p<0.001, BNIP-3 p<0.001, CA9 p<0.001,
Ephrin-A3 p<0.01, GLUT-1 p<0.001, VEGF p<0.001. However, the hypoxic induction of
HIF target genes was not further altered by silencing HIF-3 just as seen for HIF- mRNA
levels (Figure 6.11).
Figure 6.11 Effect of HIF-3 knockdown on hypoxia-responsive genes
RA FLS were transfected with 10nM siRNA targeting HIF-3 or siLuc followed by exposure to
hypoxia (H, 1% O2) for 24 hours. ANGPTL-4, BNIP-3, CA9, ephrin-A3, GLUT-1 and VEGF mRNA
was measured by Q-PCR and normalised to normoxia (N, 21% O2; dashed line). Data are mean ± SEM
(n=1).
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6.4 Discussion
HIF-3 was first described in 1998 (Gu et al 1998), 6 years after the discovery of
HIF-1 (Semenza and Wang 1992). However, it has not been intensely investigated, with
only 17 publications so far, possibly because HIF-3 is more difficult to work with due to the
fact that the expression level is lower compared to other HIF- and also it undergoes
extensive alternative splicing. In addition, it was shown that HIF-3 is not as potent a
transcription factor as HIF-1 or HIF-2.
In contrast to HIF-1 and HIF-2, HIF-3 is regulated at the transcriptional level by
hypoxia. HIF-3 mRNA was increased in all rat organs at short time points, from 30 to 120
minutes (Heidbreder et al 2003) and after 3 days of hypoxia (Chen et al 2006). Increase in
HIF-3 mRNA was also observed in A549 human lung cancer cells (Li et al 2006), Caki-1
(RCC), Hep3B cells (Tanaka et al 2009) and in fobroblasts (Del Rey et al 2010). In this
study, RA FLS increased HIF-3 mRNA level significantly in response to hypoxia and to a
lesser extent to DMOG treatment. Consistently with others, it was confirmed that HIF-3 is
certainly regulated by hypoxia at mRNA level. In RA FLS HIF-3 mRNA had indeed the
highest Ct, next to HIF-1, which means that there was less RNA encoding HIF-3 than
other -subunits.
HIF-3 is unique among the HIF- subunits in that its primary gene transcript is
subject to vast differential splicing (Figure 6.1). Seven described splice variants utilise three
alternative transcription initiation sites, named exon 1a: HIF-32/4/9, 1b: HIF-37/8 and 1c:
HIF-31/10, resulting in diverse translational start sites (Pasanen et al 2010). All of the splice
variants were detected in various human tissues and cell lines and also interestingly, the
expression pattern of these variants was very distinct in foetal and adult tissues and was
particularly low in many cancer cell lines, indicating their putative roles in physiology and
pathophysiology (Maynard et al 2005; Pasanen et al 2010).
HIF-3variant 4 (HIF-34) has been the most studied variant, due to its recognised
inhibitory functions. Interestingly, the expression of the negative splice variants, human HIF-
34 or mouse IPAS, differ in hypoxia depending on the cell line and/or organism. For
instance, HIF-34 expression was decreased after 4 hours of hypoxia by 75% and 50% in
HepG2 and HEK293A cells, respectively (Maynard et al 2005). However, it was shown that
IPAS promoter was induced by hypoxia and was highly expressed in corneal retina, brain,
heart, lung and skeletal muscle (Makino et al 2001; Makino et al 2002). Similarly, HIF-34
was also increased in hypoxia in human Caki-1 and Hep3B cells (Tanaka et al 2009). It has
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been reported recently by Pasanen and colleagues that HIF-3which is initiated from exon
1a (together with variants 2 and 9)is induced 3.3-fold by hypoxia in Hep3B and HEK293A
cells cultured in 1% O2 for 24 hours (Pasanen et al 2010). In this study, HIF-34 was
increased 4-fold in the same conditions (1% O2, 24 hours) in RA FLS and HIF-34 was more
upregulated in DMOG-treated cells. This was different than total HIF-3, which increased
more in hypoxia than after DMOG treatment. These results suggests that HIF-34 responds to
DMOG differently than HIF-3 Hence hypoxia-mimicking DMOG which acts as a pan-
specific inhibitor of HIF hydroxylases thus maybe HIF-3 which does not contain the C-
TAD, is not affected by FIH-1.
The involvement of HIF-1 and HIF-2 in the hypoxic induction of HIF-3 was
studied next by means of siRNA. This approach was based on the fact that HIF-3 is induced
by hypoxia and it contains at least 5 putative HRE (Tanaka et al 2009). It was shown in Caki-
1 and in Hep3B cells that HIF-32 and HIF-34 are indeed HIF-1-dependent genes (Tanaka
et al 2009; Pasanen et al 2010). In this study, total HIF-3 and variant 4 expression induced
by hypoxia and DMOG in RA FLS was significantly downregulated by HIF-1 depletion,
and not by silencing HIF-2. This implies that HIF-3 splice variants containing HRE are
being regulated by hypoxia and HIF; therefore they possibly take part in a negative feedback
regulation of HIF pathway.
Some studies suggested that HIF-3 protein is not stabilised by hypoxia and the
HRE-driven transcription is unchanged when HIF-3 is over-expressed (Hara et al 2001).
The protein analysis by western blot performed in RA FLS did show no difference in HIF-3
levels in different treatment, including normoxia, hypoxia or DMOG. The rabbit polyclonal
antibody against total HIF-3 used in this study purchased from Abcam and successfully used
by others (Tanaka et al 2009), gave at least 4 bands, unidentified 42 kDa, 50 kDa, 68 kDa and
72 kDa, which are believed to correspond to variant 5 and 1, 2, 3. However, the conducted
western blots are doubtful and the conclusions could not have been drawn, because of the
abundance of unspecific bands. In addition, although HIF-3mRNA level was clearly
reduced, there was no decline of HIF-3 protein even after using three concentrations of
siRNA (10, 25 and 50nM).
One of th differences between -subunits is that HIF-3 contains only one prolyl
residue Pro490 that is hydroxylated by all PHDs, compared to two prolyl residues in HIF-1
and HIF-2 (Hirsila et al 2003). This is sufficient for the protein to be ubiquitinated by pVHL
and degraded by proteasome (Maynard et al 2003); however, this process lasts longer, with
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HIF-3 protein half-life of approximately 18 hours (Tanaka et al 2009) compared to 5
minutes for HIF-1 (Uchida et al 2004). It can be concluded that there must be another
mechanism regulating the abundance of the HIF-3 protein. It has been shown for the first
time in this study, that silencing PHD-2 in RA FLS increased the mRNA level of total HIF-
3 as well as HIF-34. In addition, knocking down PHD-2 in hypoxia further augmented
HIF-3 and HIF-34 expression, indicating that HIF-3 behaves like any other HIF-
regulated gene and indicating PHD-2 activity in hypoxia (Chapter 5, Figure 5.22, page 162).
Furthermore, reducing PHD-3 and FIH-1 led to significant decrease in HIF-3 mRNA level
in normoxia. My results are consitent with a report showing the positive correlation between
PHD-3 and HIF-3 (Chen et al 2006). Double and triple knockdown of PHD was carried out
in RA FLS, revealing that siPHD-1 and siPHD-3 slightly reduced the siPHD-2-induced HIF-
3 mRNA level. These results suggest that all HIF hydroxylases seem to regulate HIF-3;
however, PHD-2 might act in opposite way to PHD-1, PHD-3 and FIH-1.
None of the human HIF-3 variants is likely to be an efficient transcription factor
because of the lack of the C-TAD and in the case of HIF-34 also the N-TAD. A study on the
human kidney revealed that HIF-3 mRNA was co-expressed/co-localised with HIF-1 and
HIF-2 In addition, immunoprecipitation study and DNA binding analysis confirmed that
mouse IPAS binds to HIF-1 (ARNT) (Makino et al 2001). Some of the HIF-3 variants
were reported to inhibit HIF-1 and HIF-2 functions. HIF-34 was shown to bind both HIF-
1 and HIF-1, thus inhibiting HIF-1 activity in a dominant negative manner (Maynard et al
2005; Pasanen et al 2010). Moreover, it was reported that HIF-3 splice variants containing
the ODD domain enclose extra DNA binding elements (LZIP) and new protein-protein
interaction motifs (LXXLL) (Maynard et al 2005), meaning that HIF-3 may have different
binding partners than HIF-1 and HIF-2, therefore different target genes. To examine the
effect of HIF-3 on previously shown HIF-1- and HIF-2-dependent genes, siRNA was
used. Since siRNA was targeting total HIF-3 silencing effect was seen at both HIF-3 and
HIF-34 mRNA levels in normoxia and hypoxia, regardless of siRNA concentration.
Silencing total HIF-3 lowered both HIF-1 and HIF-2 mRNA levels in normoxia. This
effect was not observed in hypoxia, which could be due to over-riding effect of increased
HIF-1/HIF-2 stability and competition between them in binding to HIF-1. Only HIF-1
depletion reduced HIF-3 suggesting that HIF-1 and HIF-3 are involved in a negative
feedback loop mechanism.
In addition, reducing HIF-3 in normoxia had decreasing effect on HIF-regulated
genes, including ANGPTL-4, BNIP-3, CA9, ephrin-A3, GLUT-1 and VEGF, which occurred
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probably due to decreased HIF- mRNA levels. Although the experiment was performed
only once, it was in agreement with a report showing that silencing HIF-3 reduced
ANGPTL-4 in Caki-1 cells (Tanaka et al 2009). However, it was in contrast to another study
revealing that over-expression of HIF-34 decreased VEGF and GLUT-1 in VHL null 786-O
cells. Also in Hep2G and HEK293 cells (in which hypoxia reduced HIF-34) silencing HIF-
34 upregulated VEGF and GLUT-1 indicating negative correlation (Maynard et al 2007).
Interestingly, there were no changes in HIF-1 and HIF-2, suggesting that VEGF could be
driven by HIF-34 and not HIF-1 upregulation in hypoxia (Maynard et al 2005).
HIF-34 is being the most studied variant due to its interesting anti-angiogenic
functions (Jang et al 2005) and anti-tumourigenic properties (Maynard et al 2007). Some
studies suggested that mouse IPAS or human HIF-34 could be involved in a negative
regulation of angiogenesis. In mouse corneal which is naturally hypoxic, the angiogenesis no
longer occurs possibly due to high IPAS and low VEGF levels (Makino et al 2002). In
addition, HIF-34 inhibited hypoxia-induced VEGF expression and conditioned medium
collected from HEK293 after transfection with HIF-34 reduced endothelial cell migration
and tube formation (Jang et al 2005). HIF-34 is possibly of functional relevance in tumour
biology, since it was unravelled that re-expression of HIF-34 suppressed tumour growth in
the SCID mice (Maynard et al 2007). Moreover, the basal level of HIF-34 was shown to be
low in majority of RCC, which possibly enhances hypoxic gene induction in kidney tumours
contributing to tumourigenesis (Maynard et al 2005). Therefore, manipulation of HIF-3, and
especially variant 4 in solid tumours or in angiogenic diseases, including RA, seems to be an
attractive target in therapy.
In summary, HIF-3 is the lowest abundant HIF- subunit in RA FLS; however, the
only one which is clearly induced by hypoxia at the transcriptional level, increasing
alternative splicing of the gene. HIF-3 and the investigated variant HIF-34 are themselves
HIF-1 target genes also regulated by PHD-2, therefore at least total HIF-3 and HIF-3
variant 4 are involved in a negative feedback loop mechanism of the HIF pathway.
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7 CONCLUDING REMARKS
7.1 Discussion
Where hypoxic gradients exist and oxygen levels fluctuate dynamically, cells cope
with varying levels of oxygen via the hypoxia-inducible factor (HIF) pathway to adapt
organs, tissues and cells to the abnormal conditions, and to adjust the oxygen supply. It is
known that HIF plays a role in physiology and pathology, and the power of this small
molecule is very prominent, due to the fact that HIF controls more than 1% of all human
genes, thereby giving modern medicine a powerful tool.
A key hypoxia-regulated gene is VEGF, a potent pro-angiogenic molecule,
expression of which is altered in many diseases associated with angiogenesis and hypoxia,
including cancer and RA. Angiogenesis involves a succession of events controlled by
receptors and signalling molecules, many of which are also important in vasculogenesis, with
VEGF playing a particularly crucial role. Endothelial cells normally form a tight barrier
between the flowing blood and underlying tissue, as a consequence of interactions between
extracellular matrix proteins and adhesion molecules. Such interactions need to be overcome
prior to endothelial migration and new vessel formation. Angiogenesis thus involves
retraction of pericytes from the abluminal surface of capillaries, protease secretion by
activated endothelial cells to disrupt these cell-matrix interactions, degradation of the
extracellular matrix surrounding the pre-existing vessels, and then endothelial migration and
proliferation towards the angiogenic stimulus. A provisional matrix is laid down, consisting
of molecules such as fibrin and fibronectin. Cell adhesion molecules mediate interactions of
the endothelial cells in the newly formed sprout, as they adhere to one another and to the
matrix. Subsequently these endothelial sprouts differentiate into mature vessels, which
become stabilised and surrounded by pericytes. Finally lumen and capillary loop formation
and stabilisation of the mature vessels occurs (Carmeliet and Jain 2011).
Low oxygen concentration (hypoxia) is a known instigator of RA pathogenesis and it
is believed that HIFs together with other transcription factors such as NFB coordinate cell
behaviour and responsiveness to the hypoxic and inflamed milieu in RA, hence they have a
great impact on RA progression. The RA synovial tissue becomes hypoxic by the
hyperproliferative properties of cells inhabiting synovial membrane, namely FLS and MLS.
The demand for oxygen is increased by proliferation of synoviocytes, accumulation of
infiltrating cells and the incapacitated vascular network. Hypoxia and HIF in turn are thought
to promote new blood vessels formation, particularly through induction of VEGF (Sivakumar
et al 2008; Akhavani et al 2009), such that these new vessels reach distant cells supplying
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them with oxygen and nutrients, and moreover setting up the vicious circle of constant cell
infiltration, inflammation, hyperplasia and destruction. Despite the increased expression of
pro-angiogenic factors such as VEGF, a recent study documented the presence of immature
blood vessels in rheumatoid synovium with fewer pericytes (Kennedy et al 2010). Another
recent comparison of the staining patterns for CD-31 and the pericyte/smooth muscle cell
marker -smooth muscle cell actin (SMA) revealed a significant fraction of CD-31-positive
but SMA-negative cells in RA tissue (Izquierdo et al 2009). Thus in RA, increased blood
vessel formation may not necessarily result in improved perfusion/oxygenation, due to the
formation of unstable vessels with abnormal morphology, and might explain the apparent
paradox that while synovial blood vessel density is increased, hypoxia is nevertheless a
feature of RA.
There is a considerable evidence for the presence of HIF-1 protein in human RA
tissue demonstrated by IHC staining (Hollander et al 2001; Giatromanolaki et al 2003) and
more specifically in RA FLS, which appear to be one of the most important residing cells in
RA (Hitchon et al 2002; Ahn et al 2008). HIF-2 protein has also been shown in RA tissue
(Giatromanolaki et al 2003; Sivakumar et al 2008); however, to my knowledge HIF-2
protein expression particularly in RA FLS has been shown by western blot for the first time in
this study, although HIF-2 has been previously described using this approach. However,
there have been problems with detecting HIF-2 with commercially available antibodies,
probably due to lower abundance of this -isoform in RA FLS or differences between
patients, or simply because of low affinity/specificity of the antibody. The detection was
achievable most of the time perhaps because I have used more protein lysate than for usual
western blot (50 - 80µg/mL).
Given that both HIF-1 and HIF-2 are expressed by RA FLS, in my study one of
the first aims was to investigate effects of HIF knockdown on angiogenic genes relevant to
RA, searching for genes regulated differentially in RA FLS, as described in Chapter 4 (page
102). None of the investigated transcripts were solely regulated by HIF-2. However, my
results suggest the complementary involvement of both HIF-1 and HIF-2 in
neovascularisation during RA development through the regulation of VEGF and ANGPTL-4
by both -subunits. It was reported that indeed both HIF- isoforms act in concert to form
new blood vessels, both regulating VEGF, which is involved in all three stages of vascular
development (Ben-Shoshan et al 2008). Interestingly, HIF-1 and HIF-2 functions are
distinguished as shown by in vivo studies, suggesting that there is a potential involvement of
HIF-1 in vasculogenesis and angiogenesis, and HIF-2 in the last stage of blood vessel
formation, namely vascular remodelling (Peng et al 2000; Bernhardt et al 2006).
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As well as playing the role in regulation of pro-angiogenic genes, including VEGF
and ANGPTL-4 (which contributes to angiogenesis by increasing survival of endothelial
cells), HIF-1, but not HIF-2, was able to modulate transcripts of additional angiogenic
genes, such as ephrin-A3 and FGFR3. Ephrin-A3 is a ligand which binds to EphA receptors
displaying reciprocal signalling leading to increased cell migration, cell attachment, capillary
tube formation and finally tumour angiogenesis (Cheng et al 2002). FGFR3 is a receptor,
which through binding to a potent angiogenic molecule, fibroblast growth factor (FGF),
contributes to modulation of the vascular bed. HIF-1 is also involved in glycolysis by
regulating genes, such as GLUT-1 and ENO-1, cell apoptosis through BNIP-3, pH regulation
by inducing CA9 and also inflammatory responses by modulating pro-inflammatory
cytokines and chemokines such as IL-1 and IL-8.
The investigated HIF target genes represent most of the features of RA (angiogenesis,
synovitis), thus implying that HIF- expressed by FLS contributes to RA progression and
maintenance. By analysing the pattern of hypoxia-inducible genes assessed in RA FLS, it can
be concluded that there is a broader group of HIF-1-dependent genes, having a more general
role in many aspects of cell biology, and another group, which is regulated by both HIF-1
and HIF-2, suggesting concurrent roles of HIFs particularly in angiogenesis. A unique role
for HIF-2 in RA FLS has not been found; however, because HIF-2 regulates fewer genes
compared to HIF-1 (Aprelikova et al 2006; Warnecke et al 2008), wider genome screening
after silencing or over-expressing this isoform in RA FLS could yield more information.
The presence of three HIF- subunits raises an obvious question about their roles.
Whether HIF-1 and HIF-2 overlap by having individual roles but working together at the
same time or have completely diverse functions is controversial and has not been answered
yet. However, evidence to support both viewpoints exist. Some reports indicates that HIF-1
and HIF-2 have distinct roles, because they regulate exclusive genes, therefore they have
particular roles. Based on my results and on the literature it has been shown that regardless of
the number of HIF-1 and HIF-2 unique targets, a group of common target genes is always
present implying partially overlapping functions for HIF-subunits (Aprelikova et al 2006;
Warnecke et al 2008). Moreover, in some cell types, including RA FLS and RCC4 (Raval et
al 2005), there is a reciprocal relationship between HIF-1 and HIF-2 and HIFs are able to
negatively regulate each other, thus one subunit may affect unique gene expression of the
counterpart. Due to this suppressive interaction, it is not possible to say if the role of one
subunit in the adaptive response accounts for direct or indirect effect. In addition, it was
shown that HIF-2 does not take over HIF-1 functions when the other is inactive, and also
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HIF-1 is required for HIF-2 activity (Hu et al 2003). In some cases, like during new blood
vessel formation, HIF-1 and HIF-2 are essential for the same process but at different
stages, revealing functional redundancy. For instance, during embryonic and larval
development of zebrafish it was demonstrated that in some tissues such as the notochord the
expression of HIF-1 is replaced by that of HIF-2(Rojas et al 2007). Interestingly, it was
suggested that acquisition of aggressive tumour phenotype is not only caused by genetic
mutations, but through a step-wise selection process driven in part by hypoxia and a switch
from HIF-1 to HIF-2(Raval et al 2005). Since RA and cancers share number of
similarities, it is plausible that the transition between HIF isoforms is also happening during
the progression of RA, and that a switch from a HIF-1-dependent pro-apoptotic phenotype
to a more HIF-2-dependent ‘tumour-like’ proliferative phenotype might occur in RA.
As well as investigating the HIF-dependent responsiveness of hypoxia-induced genes,
the present work was also undertaken with the particular aim to study the HIF upstream
regulators, PHDs and FIH-1. To my knowledge, protein expression of HIF hydroxylases
which is described in Chapter 5 (page 142) is shown in RA FLS for the first time. The
hypoxia regulation of PHD-2 and PHD-3 and their HIF-dependence was also presented in RA
FLS for the first time, although it was shown before in non-immortalised and mouse
embryonic fibroblasts (Berra et al 2003; Vengellur et al 2003).
The differential contribution of PHD and FIH-1 in the HIF regulation in RA FLS was
studied next. The available literature demonstrates that although all HIF hydroxylases target
all HIF- subunits, the affinity for substrates is variable between these dioxygenases (Hirsila
et al 2003; Appelhoff et al 2004). This suggests that HIF hydroxylases roles may differ by
having preferences towards HIF and thus HIF target genes.
Specific knockdown of individual PHDs and FIH-1 was achieved and highlighted the
fact that PHD-2 is the main HIF hydroxylase in RA FLS. The results indicated that PHD-2
knockdown simulates hypoxic conditions, stabilising HIF- proteins, and also HIF-1 and
HIF-2 binding to HRE. As a result, silencing PHD-2 increased ANGPTL-4, CA9 and VEGF
secretion, and induced the mRNA expression of a number of hypoxia-responsive genes in a
HIF--dependent manner. Even double or triple knockdown of HIF hydroxylases had the
same stabilising effect on HIF proteins and HIF target genes as single knockdown of PHD-2.
According to the literature, recombinant PHD activity determined by 2-OG
decarboxylation assay (Hirsila et al 2003) and VHL capture assay (Tuckerman et al 2004)
manifest unusual sensitivity to hypoxia and lowered oxygen tension decreases PHD affinity
towards HIF (Koivunen et al 2004). However, one of the previously described, but not fully
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understood, phenomenons was the fact that PHD-2 depletion in hypoxia further increases
stabilisation of both HIF- proteins and HIF target genes (Berra et al 2003), which was also
shown in my study. One of the possible explanations of these findings could be the presence
of non-respiratory oxygen originating from hypoxia-induced HIF-dependent inducible nitric
oxide synthase (iNOS), which by releasing nitric oxide (NO) blocks oxygen consumption by
mitochondria, resulting in more oxygen available for PHDs (Hagen et al 2003). In addition, it
was demonstrated that chronic hypoxia increases the pool of prolyl hydroxylases and over-
activates PHD isoenzymes by inhibition of mitochondrial respiration, therefore triggering
HIF- desensitisation required to protect cells against death (Ginouves et al 2008). Moreover,
it was reported that hypoxia decreases microRNA 199a, which inhibits the repressor for PHD-
2 transcription, namely sirtuin 1, thus increases PHD-2 mRNA level (Rane et al 2009).
Following the notion that capacity for hydroxylation of native HIF-1 is oxygen-
dependent, which is compatible with HIF hydroxylases regulatory function, other
explanations are also likely. It was demonstrated that the N-TAD hydroxylated by PHDs and
the C-TAD targeted by FIH-1 have their own functions (Dayan et al 2006). Therefore, it
would be possible that silencing PHD-2 in normoxia activates the N-TAD genes because the
C-TAD is still active (and hydroxylated by FIH-1), whereas in hypoxia FIH-1 partially loses
its activity towards the C-TAD and together with siPHD-2 contributes to increased expression
of HIF and HIF target genes. Thus it is possible that the observed effect is not due to
increased activity of PHD-2 in hypoxia, but is accounted for the FIH-1 contribution. Although
FIH-1 knockdown studies performed at the beginning of the project did not reveal any
changes in the HIF pathways, the role of FIH-1 in directing the expression of endogenous HIF
targets in RA FLS was further investigated. It was reported previously that FIH-1 suppression
upregulates CA9 and GLUT-1, the two dominantly HIF-1-responsive genes (Stolze et al
2004). In addition, co-silencing of FIH-1 and PHD-2 has synergistic effect on the luciferase-
HRE assay activity similar to that obtained in hypoxia when HIF-1 was fully active (Dayan
et al 2006). It was therefore of interest to study the effect of FIH-1 knockdown in RA FLS
using a similar siRNA approach to that described previously and to compare FIH-1
suppression with concurrent knockdown of PHD-2 (Figure 7.1). However, my results showed
no such effect on CA9, GLUT-1, any other HIF-dependent gene expression or HIF proteins
themselves. Lack of FIH-1 activity in RA FLS is another question mark, which could be
explained by much higher affinity of FIH-1 to proteins containing ARD domain, present in
abundance in humans and enclosing approximately 6% of proteosome (Wilkins et al 2009).
FIH-1 could be also inactive in RA FLS due to for instance methylation of CpG islands.
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Figure 7.1 Regulation of N-TAD and C-TAD genes in different conditions
Domain structure of HIF- containing the prolyl (in the N-TAD lying within the ODD domain) and the
asparaginyl residues (within the C-TAD) involved in HIF regulation. The different conditions show the
possible explanation of increased PHD-2 activity in hypoxia. Normoxic conditions have usually no
detectable HIF- protein. By silencing PHD-2 or FIH-1, the N-TAD or the C-TAD activity is released,
increasing the pool of HIF-. The combination of siRNA targeting PHD-2 and FIH-1 mimics hypoxic
conditions, and are expected to be comparable to DMOG-treated cells.
Another interesting question is the specific role of PHDs in the physiology. It was
reported that depending on the tissue, PHD-1 is responsible mainly for hypoxic adaptations,
PHD-2 is predominantly implicated in angiogenesis, PHD-3 is involved primarily in neuron
development, and FIH-1 is important in metabolic adaptations (Table 2.5, page 47). There are
a number of lines of evidence showing specific PHD-2 involvement in vascular networking in
vivo and in vitro. First of all, conditional PHD-2 knockout in mice increased HIF-1, VEGF
and EPO in many organs, contributing to increased number and size of blood vessels, but also
augmented red blood cell production and hyperviscosity syndrome causing congestion of
circulation (Takeda et al 2007; Minamishima et al 2008). NIH3T3, a well-described
fibroblast cell line, with PHD-2-/- deletion implanted into Matrigel plugs and then into mice,
stimulated angiogenesis in wild-type mice increasing HIF protein and the expression of
angiogenic factors (Wu et al 2008). Injection of short hairpin PHD-2 in a model of mice
hindlimb ischemia promoted therapeutic revascularisation via induction of HIF-1 (Loinard
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et al 2009). In addition, conditioned medium from PHD2-/- vector-transfected fibroblasts
increased proliferation of endothelial cells (Takeda et al 2008; Wu et al 2008) and also
vascular smooth muscle cells survival regulating vascular remodelling via HIF-1 (Schultz et
al 2009). Angiogenesis and hypoxia are both features of RA, thus the role of PHD-2 in the
generation of new blood vessels in the context of RA was also tested in this study.
Applying supernatants from siPHD-2-transfected RA FLS onto pre-seeded
endothelial cells revealed that this conditioned medium was able to increase the expression of
CD-31 (PECAM-1) indicating increased neovascularisation. Next, to confirm that PHD-2 role
in angiogenesis is not specific only for RA FLS, fibroblasts from OA patients were used.
Supernatants from OA FLS treated analogously to RA FLS also triggered tubule formation,
but to a lesser degree than RA FLS.
Both RA and OA are inflammatory arthritides with different aetiology. Comparing
many different aspects of these disorders, a number of similarities could be listed, including a
pro-angiogenic and hypoxic phenotype (Table 7.1). For instance, the oxygen tension in RA
joint is approximately 26 mmHg (3.5% O2), in OA 43 mmHg (5.6% O2), and in non-RA
approximately 76 mmHg (10% O2) (Lund-Olesen 1970; Lee et al 2007b; Sivakumar et al
2008; Ng et al 2010). It was demonstrated by musculoskeletal ultrasonography that 95% of
RA and 60% of OA patients exhibit synovial proliferation, IL-8 levels were higher in RA
(1700 pg/mL) compared to OA synovial fluids (500pg/mL), and moreover RA tissue
exhibited higher myeloid cell infiltration (170 cells/mm3) compared to OA (12 cells/mm3)
(Lee et al 2007b). In addition, a study using Matrigel plugs soaked with fibroblasts and
engrafted into SCID mice for 7 days revealed increased myeloid cell infiltration in plugs with
RA FLS (1200 cells/field) compared to plugs with OA FLS (750 cells/field) or containing
normal fibroblasts (300 cells/field). In the same study, it was also shown by counting the
number of CD-31-positive blood vessels that the number of neovessels is higher in plugs with
RA FLS (14 vessels/field), lower with OA FLS (5 vessels/field), and hardly any using normal
fibroblasts (1 vessels/field) (Del Rey et al 2009). Macroscopic and microscopic studies on
vessel phenotype have shown that vasculature in RA is unstable and immature due to lower
recruitment of pericytes, whereas in OA it is stable and mature (Kennedy et al 2010). Also the
aggressive phenotype of fibroblasts was shown by co-injecting FLS and cartilage into the
sponge and implanting into the SCID mice in renal capsule, and next analysed by scoring
cartilage destruction histologically. RA FLS were more destructive (grade 2.4 and 2.3) than
OA FLS (grade 0.1 and 0.5) and healthy FLS (grade 0 and 0.2) (Muller-Ladner et al 1996;
Lefevre et al 2009). As demonstrated above, OA seems to respond in a similar way to RA,
but to lesser degree in all cases. OA is thus considered a milder inflammatory disease, but still
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with significant synovial angiogenesis, lymphoid aggregates and macrophage infiltration
indicating ongoing inflammation, contributing to joint destruction (Haywood et al 2003).
Table 7.1 Comparison of RA, OA with non-arthritic cells/tissues
Some characteristics of two types of arthritis (RA and OA) compared with healthy or non-arthritic
cells/tissues.
RA OA non-RA & non-OA Reference
Oxygen tension
in synovial fluid
~3.5% O2 ~5.6% O2 ~10% O2 Lund-Olesen 1970
Sivakumar et al 2008
Ng et al 2010
Synovial
proliferation
95% of patients 60% of patients No proliferation Lee et al 2007
Myeloid cell
infiltration
170 cells/mm3
1200 cells/field
12 cells/mm3
750 cells/field
-
300 cells/field
Lee et al 2007
Del Rey et al 2009
Increased
angiogenesis
14 vessels/field 5 vessels/field 1 vessel/field Del Rey et al 2009
Vessel phenotype Immature w/o
pericytes
Mature and stable Mature and stable Kennedy et al 2010
Cartilage
destruction by
synoviocytes
Severe (score 2.3) Mild (score 0.1 - 0.5) None (score 0 - 0.2) Muller-Ladner et al 1996
Lefevre et al 2009
The study was extended to healthy fibroblasts isolated from adult skin, which are
usually used for wound healing studies. Due to difficulties with achieving healthy synovial
tissue to isolate healthy synoviocytes, which would serve as the best control for this study,
NHDF were used as a surrogate. To investigate the ability to promote angiogenesis after
silencing PHD-2 by other fibroblasts, NHDF (non-arthritic cells) were compared with RA
FLS and OA FLS (arthritic cells). In this case, conditioned supernatants from NHDF did not
induce new tubule formation, revealing the differences between the arthritic and non-arthritic
cells. Possibly these findings are not that surprising since Table 7.1 indicates that healthy cells
usually do not trigger any response in different settings.
Interestingly, scrutinising the protein profile of these cell types in response to
hypoxia, it was clear that all of them are able to activate HIF pathway in hypoxia to similar
extent with differences in normoxic responses. For instance, PHD-2 depletion in NHDF in
normoxia did not stabilise HIF proteins and HIF target genes as was seen in RA FLS and OA
FLS. Moreover, when screening 84 genes involved in angiogenesis after silencing PHD-2,
arthritic fibroblasts (RA and OA FLS) had a specific angiogenic gene expression pattern in
common, increasing very potent pro-angiogenic genes, including VEGF, ANGPTL-4, leptin
and ephrin-A3, representing possibly a signature for pathological angiogenesis. Not
surprisingly, OA FLS increased these genes to a lesser degree, plus exhibited a number of
altered genes not changed in RA FLS. Galligan and colleagues reported that interestingly
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apart from mutual genes, 287 unique transcripts were showed to be significantly different
between RA and OA FLS. RA-characteristic genes belong to adaptive immune response and
OA-specific genes are involved mainly in extracellular matrix remodelling and fibrosis
(Galligan et al 2007). On the other hand, NHDF transfected with siPHD-2 augmented
angiogenic genes in normoxia, but responses were distinct from OA and RA FLS. Among
them were 2 pro-angiogenic genes, including KDR, known as VEGF receptor (VEGFR)-2, a
tyrosine kinase receptor mediating the majority of cellular responses to VEGF, and PLAU,
which is a serine protease involved in degradation of the extracellular matrix, and two
possessing anti-angiogenic activities, namely type IV collagen alpha 3 (Col4A3), which is the
major structural component of basement membranes and thrombospondin (THBS)-1, an
adhesive glycoprotein. However, as seen using in vitro tubule formation assay, these genes
were not enough to stimulate new blood vessel formation.
Summarising the role for PHD-2, it has been confirmed that PHD-2 is involved in the
angiogenic switch in RA and possibly OA. Continuing my investigation of the role of other
HIF hydroxylases, the results were less clear since depleting PHD-1, PHD-3 or FIH-1 did not
reveal any significant responses at first. However, subtle changes have been noticed after
PHD-3 reduction in RA FLS. It is believed that both PHD-2 and PHD-3 play a role in a
negative feedback loop mechanism in the HIF pathway, which is expected since they both
contain HRE and are HIF--dependent. As anticipated, silencing PHD-2 in normoxia
upregulated mRNA level of PHD-3; however, silencing PHD-3 did not exert similar effect on
PHD-2. Interestingly, PHD-3 depletion was responsible for the opposite regulation of HIF-1
causing its reduction, which resulted also in a decline of HIF target gene expression. In
addition, PCR array data has shown that most of the genes upregulated by silencing PHD-2
were downregulated by silencing PHD-3 and vice versa. These results would confirm my
previous observations, that PHD-2 depletion stabilised, whereas PHD-3 depletion decreased
HIF protein, followed by the respective response of HIF-dependent genes. In addition, a
group of angiogenic genes which was regulated by PHD-3 was different from PHD-2, but
apparently was not sufficient to induce tubule formation by endothelial cells when
conditioned medium was used. However, PHD-3 role in regulating these and other responses
may be more pronounced in hypoxia, since PHD-3 is one of the highly hypoxia-inducible
genes in RA FLS.
The current study revealed that arthritic cells have common way of responding to
hypoxia via increasing HIF and leading to augmented expression of target genes. The
identification of universal changes in the arthritic cells with altered PHD-2 expression and
major differences in non-arthritic cells gives the opportunity to design specific therapeutics.
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7.2 Future work
Viewed altogether, the data presented herein provide evidence of upstream and
downstream events following onset of hypoxia which is crucial to comprehend if required to
target in pathological hypoxia. The understanding of the major players creating the PHD-
VHL-HIF axis is constantly increasing; however, due to cell specificity and disease aetiology
this mechanism is very complex and ought to be further explored.
A limitation of this study was that all the data are derived from fibroblasts, a single
cell population. Although RA FLS are clearly involved in RA, it would be crucial to
investigate the interaction between different cell types that also influences RA pathogenesis.
In addition, most of my experiments only reflect a single time point (24-hour) that was
selected according to gene expression kinetics, to be able to study mRNA and protein changes
simultaneously. However, genes with different kinetics may be HIF-independent or secondary
signalling of HIF could be induced, which are therefore underrepresented in this study. In
addition, another common factor which may change or modify gene expression profiles in
response to hypoxia or normoxia is the presence of serum in cell culture. All the experiments
in this study were performed on cells with serum after serum-starvation overnight. However,
preliminary data on the influence of serum and its absence did not indicate any differences in
HIF signalling in RA FLS. To complement this study, some of the aspects could be further
studied, as described below.
7.2.1 INVESTIGATION OF POSSIBLE INTERACTION BETWEEN HIF-1 AND HIF-2
It has been demonstrated in this study that silencing HIF-1 downregulated HIF-2 in
normoxia at the mRNA level. However, mRNA level or even protein level of HIF does not
guarantee the transcriptional activity of these factors. TranAM assay, which is a better way to
investigate HIF activity through its binding to DNA, was performed, revealing that silencing
HIF-1 increased HIF-2 binding activity in hypoxia and DMOG, and vice versa. These
findings suggest a level of transregulation between the HIF isoforms, but this needs to be
confirmed by increasing the number of experiments. In addition, over-expression studies to
confirm this phenomenon should be also performed, especially because HIF is actually
upregulated in RA joints.
7.2.2 ROLES OF HIF-1 AND HIF-2 IN RA FLS
The principal aim of my study was to compare the genes regulated by HIF-1 and
HIF-2 in RA FLS, and in particular to find a unique role for HIF-2 by finding an exclusive
HIF-2-dependent gene. Genes such as ENO-1, uPAR and PAI-1, which were reported by
others to be HIF-2-regulated, were either HIF-1targets (ENO-1) or not regulated by hypoxia
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(uPAR), or regulated by hypoxia in a HIF-independent manner (PAI-1). Performing
microarray analysis of cells transfected with siHIF-2 would help to find distinctive targets
and other functions for HIF-2 in RA FLS apart from angiogenesis. If other angiogenic
molecules are significant for particular stages of new blood vessel formation, it would be of
interest to investigate if the preference between HIF-1 and HIF-2 exist towards these
angiogenic genes of specific stage. Due to time limitations, PCR array analysis following
HIF-1 and/or HIF-2 knockdown was not performed, but this could have yielded invaluable
information about HIF isoform specificity. Further investigations using endothelial cell-based
assays (such as AngioKit, or endothelial proliferation and migration assays), antibody arrays
(to measure protein expression) or indeed PCR arrays encompassing other gene groups (for
instance apoptotic genes) would clarify whether HIF-1 and HIF-2 have different or
overlapping roles in RA FLS in terms of induction of angiogenesis and survival genes, and
functional responses in terms of modulating endothelial responses.
7.2.3 FUNCTION OF HIF HYDROXYLASES IN RA FLS
My studies have highlighted a predominant role for PHD-2 in RA FLS. However, the
research using PCR array and AngioKit comparing three different types of fibroblasts has not
provided fully comprehensive data, in part due to low number of samples (4 for RA FLS, 2
for OA FLS and 1 for NHDF). Also the appropriate control for this study would be fibroblasts
from healthy synovial tissue and not dermal fibroblasts, ideally with matched passage
number. These studies would therefore need to be repeated. Moreover, as discussed earlier,
further investigations using endothelial cell-based assays (such as endothelial proliferation,
apoptosis and migration assays), antibody arrays or indeed PCR arrays encompassing other
gene groups (for instance apoptosis genes) would be of interest. To confirm the effect of
PHD-2 in controlling angiogenesis, over-expression study would be useful.
Studies on distribution of PHD and FIH-1 using monoclonal antibodies revealed wide
and overlapping expression in normal tissues and highly variable expression in neoplastic
tissues, where PHDs expression was generally decreased and FIH-1 staining increased,
especially in renal cell carcinomas (Soilleux et al 2005). Increased HIF protein detection in
tumours was demonstrated in at least 19 cancers studied so far and summarised by Semenza
(Semenza 2010). Therefore it would be interesting to perform IHC staining for HIF
hydroxylases of total RA synovial tissue and compare it to the healthy synovial tissue, which
has not yet been shown. HIF-1 and HIF-2 staining demonstrated increased expression in
the synovial tissue from RA patients, much higher than in healthy control (Hollander et al
2001; Giatromanolaki et al 2003); therefore, it would be expected that PHD-2 would be
downregulated, whereas according to my results and hypothesis PHD-3 would be increased.
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7.2.4 FIH-1 ACTIVITY STUDIES
Hydroxylation by FIH-1 could be measured by antibody against Asn-OH. This would
give an answer if FIH-1 is active in RA FLS and how hydroxylation activity is changing in
normoxia, hypoxia and DMOG. In addition, since all of my experiments were performed in
1% O2 and FIH-1 is apparently more resistant to reduced oxygen concentrations than PHDs
(Koivunen et al 2004), thus it would be imperative to continue examining the role of FIH-1 in
more severe conditions. If FIH-1 is indeed inactive in RA FLS it would be interesting to
examine the epigenetics to investigate whether for instance FIH-1 is for instance methylated
using gene-specific methylation analysis by PCR.
7.2.5 INVESTIGATION OF THE ROLE OF PHD-3 IN RA FLS
This study has shown that silencing PHD-3 does not induce tubule formation and that
PHD-3 depletion in RA FLS in normoxia actually decreased HIF-1 protein. Therefore my
hypothesis is that PHD-3 is not involved in the negative feedback loop mechanism of HIF
pathway, but positively regulates HIF-1. My suggestion is in contrast to a study, showing
that short hairpin PHD-3 injected into femoral ligation mice model had potential to rebuild
vascularisation of the limb through regulation of HIF-1 (Loinard et al 2009). To confirm
that my results are correct in that silencing PHD-3 downregulated HIF-1protein, western
blot and TransAM assays should be repeated together with functional assays.
My results revealed a group of angiogenic genes regulated after silencing PHD-3,
including FGFR3, IL-1 and IL-8. HIF-dependence analysis has shown that these genes
upregulated by siPHD-3 in normoxia were also upregulated by siHIF-1, suggesting that
these genes are downregulated by hypoxia. The group of genes downregulated by hypoxia in
RA FLS are in the minority (approximately 15%; Del Rey et al 2010) and have been in
general less extensively investigated. It would be interesting to inspect if more genes which
are downregulated by hypoxia/HIF-1 are also positively regulated by PHD-3. In addition, to
corroborate the fact that PHD-3 is not regulating angiogenesis mediated by RA FLS, or is
involved in the opposite effect, the tubule formation assay should be also performed again.
It would be of interest to investigate further the role of PHD-3, examining other PHD-
3-regulated genes, and maybe considering HIF-independent pathways. There are transcription
factors responding to hypoxia in various cell types such as HIF-3, ATF-4, Erg-1, NFB,
C/EBPbeta, ETS-1 and many more, which were activated by hypoxia in macrophages
(Elbarghati et al 2008). The aim would be to investigate the expression of transcription
factors in RA FLS silenced with PHD-3 siRNA, using for instance PCR array for
transcription factors.
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7.2.6 NON-HYPOXIC REGULATION OF HIF HYDROXYLASES IN RA FLS
Results presented in this thesis have described the hypoxic regulation of HIF
hydroxylation, with significant induction of PHD-2 and PHD-3, which is in agreement with
the literature (Epstein et al 2001; Berra et al 2003; Appelhoff et al 2004). Since the RA
milieu is not only hypoxic but also inflamed, I would propose to investigate cytokine-
mediated regulation of HIF upstream regulators in RA FLS, using some of the highly
expressed cytokines in RA tissue, including TGF-, TNF-, IL-1, IL-6, bFGF (Brennan et
al 1989b; Brennan et al 1990). It was shown in other cell types that PHD-2 is decreased by
TGF- (McMahon et al 2006) and PHD-3 is increased by IFN- (Gerber et al 2009). My
preliminary results revealed that PHD-2 and PHD-3 mRNA are increased by TGF-
stimulation, and that PHD-3 additionally responded to bFGF, whereas PHD-1 and FIH-1
mRNA levels were not affected by any of the cytokines (data not shown). These findings
need to be repeated and confirmed at the mRNA and protein level, and in combination with
IHC staining proposed already above (Section 7.2.3). This would hopefully clarify possible
links between hypoxia and inflammation. Understanding the regulation of HIF hydroxylases
by inflammatory cytokines would therefore contribute to understanding other mechanisms
regulating PHDs in inflammation-mediated events in RA.
7.2.7 ROLE OF HIF-3 IN RA FLS
HIF-1is subjected to a number of autonegative feedback inhibition during hypoxia.
The third -subunit, namely HIF-3, was shown to be one such antagonist (Hara et al 2001).
HIF-3 undergoes extensive alternative splicing in hypoxia and some variants of HIF-3 (e.g.
HIF-34) compete with HIF- subunits for HIF-1 dimerisation decreasing HIF-1 and HIF-2
activity by blocking it from active complex formation (Maynard et al 2007). The initial
results on HIF-3 and HIF-34 were described in Chapter 6 (page 199) showing its hypoxia
inducibility, HIF-1-dependence, and preliminary data on silencing HIF-3. During
knockdown studies of HIF hydroxylases it became apparent that PHD-2 negatively regulated
HIF-3, which was likely since it behaves as HIF target gene. Interestingly, it seemed that
PHD-3 and FIH-1, and perhaps also PHD-1, regulated HIF-3 positively. However, all results
in this study concerned mRNA and not protein levels, due to poor quality of the HIF-3
antibody, therefore it would be required to use new more specific antibody.
To answer the question if HIF-3 and/or HIF-34 compete with HIF-1 and/or HIF-
2 for binding to HIF-1, chromatin immunoprecipitation (ChIP) analysis could be
performed. ChIP is a method used to determine the interaction between DNA and DNA-
binding protein, which occurs inside the nucleus of living cell. The immunoprecipitation is
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performed on the cell lysate with an antibody that targets protein of interest, followed by
purification and separation of the DNA-protein/antibody complexes to identify and quantify
DNA by PCR.
It was shown that in contrast to other -subunits, HIF-3 is present under normoxic
conditions in various organs (Li et al 2006; Pasanen et al 2010), being the only -subunit
increased by hypoxia at the mRNA level. It was reported that HIF-3 can be also regulated in
an oxygen-independent manner by insulin, 2-DP (Jang et al 2005; Heidbreder et al 2007) and
also by ROS (Li et al 2006). In addition, HIF-3 does not contain the C-TAD, which suggests
that HIF-3 functions are regulated in a different way than HIF-1 and HIF-2. Since RA
milieu is inflamed, I have tentatively examined HIF-3 regulation by cytokines. My
preliminary data revealed that total HIF-3 mRNA level seemed to be upregulated by bFGF
and downregulated by TGF-, with no effect of IL-1 or TNF-; however, more research is
required to prove alternative regulation of HIF-3.
7.3 Therapeutic implications
Since RA contributes to significant impairment of the quality of life, there has been
considerable research into mechanisms of RA pathogenesis and also significant progress in
RA treatment. My research described in this thesis contributes to an understanding of the
mechanisms of action of HIF, which play a prominent role in RA. The role of HIF in FLS
biology demonstrated in this study, together with the literature about specific involvement of
FLS in the initiation and perpetuation of RA via inhibited apoptosis, increased migratory,
invasive and destructive abilities (Huber et al 2006), suggests that these key residing cells
could be a promising target in normalisation of the RA pathogenesis. In addition, direct
inhibition of HIF could lead to more efficient reduction of arthritis than for instance anti-
VEGF, because it would target not only angiogenesis but also other crucial processes of RA
pathogenesis.
The past decade has yielded striking evidence that HIF is a promising target in many
therapies. There are different ways to modulate the HIF pathway depending on the
oxygenation state, for instance it can be induced in HIF-deficient diseases or inhibited in
disorders in which HIF expression is abundant. Activation of the HIF pathway and thus
inducing HIF-mediated protective mechanisms might be of therapeutic value by (1)
promoting new blood vessels formation to restore the oxygen supply after an existing blood
vessel has been blocked, which would find application in vascular ailments for instance in
ischemia, (2) inducing cytoprotection and cell survival in wound healing or tissue damage, (3)
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increasing new oxygen-carrying red blood cells and factors utilising iron in anaemia, (4)
mediating lipid catabolism by leptin induction to reduce adipose tissue, to treat metabolic
disorders such as obesity, and (5) activating hypoxia tolerance needed in organ preservation
and transplantation. In contrast, in diseases with insufficient oxygen tension, where hypoxia
arises mainly due to uncontrolled proliferation of cells and/or by impaired vasculature, the
HIF pathway is constantly active. Activated HIF is able to trigger excessive angiogenesis in
angiogenic diseases, including solid tumours, diabetic retinopathy, atherosclerosis or RA,
thereby HIF inhibition would be essential.
If the HIF pathway is to be targeted in RA or any other HIF-related disease, many
aspects of HIF expression and regulation should be considered carefully in the first place.
Before manipulating the HIF pathway using different approaches, HIF induction, signalling,
cross-talk, isoforms specificity and stability should be scrutinised, as well as deciding which
cells would be the best to target. Answering which HIF- isoform(s) to de/activate is crucial
especially if transregulation exists between HIF-1 and HIF-2 Regulating the same genes
but in the opposite way may differentially contribute to progression or regression of the
disease, which is evidently demonstrated in cancer (Raval et al 2005).
In agreement with published data showing the importance of PHD-2 in HIF-1
regulation, my results also imply that PHD-2 is the major hydroxylase responsible for HIF
stabilisation in RA. However, it is now becoming apparent that PHDs may also hydroxylate
targets other than HIFs, including members of the NFB pathway and complement pathway
proteins (Cummins et al 2006; Yan et al 2011). Therefore PHD-2 turns out to be a new
possible target, for instance in RA FLS, but with certain cautiousness.
An fascinating evidence demonstrated that endothelial PHD-2 haplodeficiency in
mice increased tumour oxygenation via blood vessel normalisation, leading to reduction in
malignancy in vitro and in vivo, without changing the number of blood vessels (Mazzone et al
2009). Normalisation of vascularisation in RA would be the perfect outcome for RA, since it
was shown that blood vessels are leaky, unstable and immature (Kennedy et al 2010). I would
suggest performing similar studies to Mazzone and colleagues, using PHD-2+/- mice and
inducing arthritis (CIA or AIA) to investigate the results. It could be expected that
normalisation of vessels would not allow RA to progress through maintaining more stable
vasculature thus regulating the oxygen tension, decreasing cell influx and inflammation.
Hopefully heterozygosity in endothelial cells would also normalise RA FLS and other cell
functions and behaviour by regulating RA milieu, and as a result would contribute to the
reduction in cartilage and bone destruction in this model.
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